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Cardiovascular disease (CVD) is ranked as the leading cause of death world wide, 
responsible for 17.1 million deaths globally each year. Such numbers are often difficult 
to comprehend. A coronary even occurs every 25 seconds and CVD kills one person 
every 34 seconds. 35 people under 65 years of age die prematurely every day due to 
CVD. The incidence of CVD has declined in recent years due to a better understanding 
of the pathology, implementation of lipid lowering therapy, new drug regimens and 
advances in acute surgical intervention. The disease burden has a great financial 
impact on global healthcare systems and major economic consequences for world 
economies. This text reviews the epidemiology, development, risk factors, diagnosis 
and treatment of ischemic heart disease.
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Cardiovascular disease is ranked as the leading cause of death world wide. According to the
World Heart Federation, cardiovascular disease is responsible for 17.1 million deaths global‐
ly each year. A staggering 82% of these deaths actually occur in the developing world. Such
numbers are often difficult to comprehend. The gravity of the situation is enhanced when
portrayed as the following: A coronary even occurs every 25 seconds and CHD kills one
person every 34 seconds in the United States of America alone. 35 people under the age of 65
die prematurely in the United Kingdom every day due to cardiovascular disease (12,500
deaths per annum). Although the leading killer, the incidence of cardiovascular disease has
declined in recent years due to a better understanding of the pathological mechanisms in‐
volved and development of targeted therapeutics; along with the implementation of lipid
lowering therapy such as statins and new drug regimens including low molecular weight
heparin and antiplatelet drugs such as glycoprotein IIb/IIIa receptor inhibitors. Recent ad‐
vances in acute surgical intervention have also improved mortality, especially with the ad‐
vent of drug eluting stents and minimally invasive coronary artery bypass grafting, along
with improvements in cardioplegia and a systemic hypothermic environment.
The disease burden has a great financial impact on global healthcare systems and major eco‐
nomic consequences for world economies. Cardiovascular disease cost the UK healthcare
system £14.4 billion (€16.7 billion; $22.8 billion) in 2006. Hospital care for patients with car‐
diovascular disease accounts for approximately 70% of the cost with 20% spent on pharma‐
cological agents. The total cost should include non-healthcare costs such as production
losses in the workforce and informal care of people with the disease. Production loss is esti‐
mated to cost the UK economy £8.2 billion in 2006 (55% due to death and 45% due to ill‐
ness). Informal care cost the UK economy £8.0 billion in 2006. Overall cardiovascular disease
is estimated to cost the UK economy £30.7 billion per annum.
This text firstly introduces the heart and circulation and the development and anatomy of
the coronary arteries before introducing the all encompassing umbrella of cardiovascular
disease and the Pathobiology of ischemic heart disease (IHD). The epidemiological burden
of Ischemic heart disease is described on a global scale; followed by risk factors, diagnostic
modalities and treatment regimens for IHD. The next chapter describes the deleterious ef‐
fects of congenital heart diseases and the role of myocardial ischemia in these conditions,
detailing the pathogenesis, diagnosis and treatment options before tacking strategies for
prevention. Chapter three demonstrates the gender disparity in sudden cardiac death
(SCD). SCD occurs predominantly in women often without previous symptoms or history of
CVD. The mechanisms surrounding SCD are detailed followed by identification of those at
risk and potential treatment strategies such as implantable cardioverter-defibrillators for
high risk subjects. Chapter four reports on the significance of endothelial function and its
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ness). Informal care cost the UK economy £8.0 billion in 2006. Overall cardiovascular disease
is estimated to cost the UK economy £30.7 billion per annum.
This text firstly introduces the heart and circulation and the development and anatomy of
the coronary arteries before introducing the all encompassing umbrella of cardiovascular
disease and the Pathobiology of ischemic heart disease (IHD). The epidemiological burden
of Ischemic heart disease is described on a global scale; followed by risk factors, diagnostic
modalities and treatment regimens for IHD. The next chapter describes the deleterious ef‐
fects of congenital heart diseases and the role of myocardial ischemia in these conditions,
detailing the pathogenesis, diagnosis and treatment options before tacking strategies for
prevention. Chapter three demonstrates the gender disparity in sudden cardiac death
(SCD). SCD occurs predominantly in women often without previous symptoms or history of
CVD. The mechanisms surrounding SCD are detailed followed by identification of those at
risk and potential treatment strategies such as implantable cardioverter-defibrillators for
high risk subjects. Chapter four reports on the significance of endothelial function and its
relationship to silent myocardial ischemia, especially in patients with concomitant diabetes
mellitus. Damage to the endothelium is considered to be the initiation of the atherothrom‐
botic episode; be it chemically induced by reduction in nitric oxide, oxidative stress or in‐
flammation or by mechanical sheer stress and hemodynamic disruption. This is followed by
the presentation of clinical findings in sixty patients with CHD and type II diabetes Mellitus
compared to sixty eight patients with CHD but no evidence of diabetes. Using Holter ECG
monitoring, echocardiography, vascular Doppler ultrasound, the vascular responses be‐
tween those with and those without diabetes were measured. Furthermore, cerebrovascular
reactivity testing was also assessed. Patients with CHD and concomitant diabetes demon‐
strate reduced endothelium-dependent vasodilation compared to those CHD patients with‐
out CHD. As mentioned above, the economic cost of CHD is crippling healthcare budgets
and contributes to loss of business revenue and national reduction in gross domestic prod‐
uct. Chapter five from experts at the Centers for Disease Control and Prevention, USA sur‐
veyed inpatient admissions between 2006-8. Some 41,546 claims were made for a primary
diagnosis of acute myocardial infarction (46% ST segment elevation MI; STEMI). The associ‐
ated costs are highest in males than females and a geographical variation was observed.
STEMI costs were higher than non-STEMI costs and costs were highest in those undergoing
surgical revascularisation by primary coronary intervention or coronary artery bypass graft‐
ing. These data could be used to model more cost-effective AMI intervention programs. The
next chapter details the biochemical tests available for the detection and diagnosis of cardiac
ischemia. There are a plethora of candidate biomarkers however very few have made the
transition to use in the clinical setting. Biomarkers up stream of the cardiac troponins may
serve as sensitive tests, but at the cost of specificity thus reducing the overall diagnostic effi‐
ciency of the test. Malondialdehyde low-density lipoprotein, Myeloperoxidase, whole blood
choline, and free fatty acids are described. The FDA cleared Ischemia Modified Albumin
assay is described in detail including its clinical utility not only in acute chest pain but in
those patients without acute coronary syndrome. Lastly, with the advent of sensitive cardiac
troponin tests, the ischemia vs necrosis debate is challenged once again. Chapter seven dis‐
cusses the role of uric acid (the end product of purine metabolism) as a risk factor for the
development of CVD. Similarly, the role of magnesium and the hypomagnesaemic state and
its relationship in the development of clinical disorders such as diabetes, hypertension, athe‐
rosclerosis and acute coronary syndrome are discussed in the subsequent chapter. Chapter
nine investigates the process of ‘self-eating’ or autophagy, detailing the intracellular signal‐
ling control mechanisms and its role in the maintenance of normal myocardial tissue and its
cardioprotective effect during ischemia in the hypoxic myocardium. The understanding of
autophagy may lead to possible therapeutic targets for IHD. The penultimate chapter is con‐
cerned with progenitor and stem cell engineering as a possible intervention to treat IHD.
This is of great interest given recent advances in understanding progenitor cell biology but
also poses many considerable challenges in transferring from laboratory based science into a
clinical reality. The chapter reviews recent progress in progenitor and stem cell engineering,
including cell sources, scaffold free tissue construct, myocardial tissue generation using de‐
cellularised native tissue, porous scaffolding and biosynthetic polymers. The final chapter of
this text discuses the role of fatty acid imaging, in which fatty acid tracers labelled with the
radioisotope of iodine, 123-I is used in single positron emission computer tomography
(SPECT) imaging. An overview of myocardial fatty acid metabolism is given, along with de‐
scription of the iodine-labelled tracers and their myocardial tissue kinetics. This is followed
by the clinical utility of the tracer in imaging post acute myocardial infarction, in those with
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stable chronic coronary artery disease, risk stratification and the assessment of myocardial
tissue viability and probably most importantly, prediction of functional recovery. Further‐
more, its role in chronic kidney disease is discussed in light of the high prevalence of CHD
in this unique population.
David C. Gaze
Dept of Chemical Pathology Clinical Blood Sciences,
St George’s Healthcare NHS Trust
London, United Kingdom
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1. Introduction
“The heart has its reasons which reason knows not.” Blaise Pascal (1623-1662)
The heart is the vital organ that tirelessly pumps oxygenated blood from the lungs to the organs
and peripheral tissues via the circulatory system. In return, deoxygenated blood is returned
via the heart and the pulmonary circulation to the lungs to expel waste carbon dioxide (figure
1). The average human heart beats approximately 72 beats per minute totalling around 2.5
billion beats in a 66-year lifespan. The human heart weighs 250-300g in females and 300-350g
in males. The heart is located in the mediastinum of the thorax, anterior to the vertebrae and
posterior to the sternum. Archosaurs (crocodilians and birds) as well as Mammalia species show
complete separation of the heart into two pumping units comprised of four distinct chambers.
The myogenic musculature of the heart is supplied by the coronary arteries and the entire
organ is held within the pericardial sac.
1.1. Development and anatomy of the coronary arteries
As with any organ, the heart requires its own supply of blood for continued functioning. The
supply of blood to the myocardium occurs via the coronary artery circuit (figure 2). Their name
is derived from the Latin ‘Corona’, meaning crown as the main vessels encircle the interven‐
tricular and atrioventricular grooves.
The arterial tree has two main compartments; firstly, the main arteries (table 1) and ramifica‐
tions on the surface of the myocardium, known as the extramural coronary system. Secondly,
the branches of the surface vessels which penetrate deep into the myocardial tissues are known
as the intramural coronary system.
© 2013 Gaze; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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The extramural coronary system is formed from two main arteries. The left coronary artery
(LCA) and the right coronary artery (RCA). A third vessel exists in up to 50% of the population
and is known as the conus artery. The diameters of the vessels are given in table 1. The
intramural coronary system is a complex vascular network containing the main intramural
branches which have region specific distribution patterns. The ventricular branches arise at
right angles from the subepicardial arteries taking an endocardial route. An important
component of the intramural system is the collateral or anastomotic arterial system. These
vessels have a characteristic corkscrew appearance. They are present at birth and do not differ
in distribution by age or gender. In the normal heart they are 20-350 μm in diameter.
Figure 1. Anterior view of the human heart with blood vessels identified
Ischemic Heart Disease2
Figure 2. Coronary artery anatomy. a) Left coronary artery and b) Right coronary artery. A, atrial branch; AM, acute
marginal artery; AVCx, atrioventricular groove branch of circumflex; AVN, atrioventricular node artery; CB, conus
branch; D, diagonal branch of LAD; LAC, left atrial circumflex; LAD, left anterior descending; LAO 30° left anterior obli‐
que projection; LAT, left lateral projection; LMS, left main stem; LV, left ventricular branches; MCx, main circumflex; PD,
posterior descending; PLCx, posterior circumflex branch (obtuse marginal); RA, right atrial branch; RAO, 30o right an‐
terior oblique projection; RV, right ventricular branch; S, septal perforating arteries; SN, sinus node artery.
Introduction to Ischemic Heart Disease
http://dx.doi.org/10.5772/55248
3
The extramural coronary system is formed from two main arteries. The left coronary artery
(LCA) and the right coronary artery (RCA). A third vessel exists in up to 50% of the population
and is known as the conus artery. The diameters of the vessels are given in table 1. The
intramural coronary system is a complex vascular network containing the main intramural
branches which have region specific distribution patterns. The ventricular branches arise at
right angles from the subepicardial arteries taking an endocardial route. An important
component of the intramural system is the collateral or anastomotic arterial system. These
vessels have a characteristic corkscrew appearance. They are present at birth and do not differ
in distribution by age or gender. In the normal heart they are 20-350 μm in diameter.
Figure 1. Anterior view of the human heart with blood vessels identified
Ischemic Heart Disease2
Figure 2. Coronary artery anatomy. a) Left coronary artery and b) Right coronary artery. A, atrial branch; AM, acute
marginal artery; AVCx, atrioventricular groove branch of circumflex; AVN, atrioventricular node artery; CB, conus
branch; D, diagonal branch of LAD; LAC, left atrial circumflex; LAD, left anterior descending; LAO 30° left anterior obli‐
que projection; LAT, left lateral projection; LMS, left main stem; LV, left ventricular branches; MCx, main circumflex; PD,
posterior descending; PLCx, posterior circumflex branch (obtuse marginal); RA, right atrial branch; RAO, 30o right an‐
terior oblique projection; RV, right ventricular branch; S, septal perforating arteries; SN, sinus node artery.
Introduction to Ischemic Heart Disease
http://dx.doi.org/10.5772/55248
3
Vessel Median Diameter (range) in mm
LEFT CORONARY ARTERY (LCA) 4 (2.5-5.5)
Left anterior descending 3.6 (2-5)
DG diagonal 2 (0.5-2.5)
LCX circumflex 3 (1.5-5)
LMG marginal 2.2 (1-3)
RIGHT CORONARY ARTERY (RCA) 3.2 (1.5-5.5)
RMG marginal 1.7 (1-2.5)
PD posterior descending 2.1 (1-3)
THIRD CORONARY ARTERY ‘conus artery’ 1.1 (0.7-2)
Septal branches anterior from LCX 1 (0.5-2.5)
Septal branches posterior from PD 0.7 (0.3-0.9)
From ascending LAD 0.4 (0.3-0.7)
Table 1. The major coronary arteries.
The primitive embryonic heart is nourished via lacunar or intertrabeclar spaces, forming a net-
like structure separating bundles of muscle fibres. Further evolutionary development results
in endothelial budding. Originally this was thought to derive from the coronary sinus and
aorta, forming superficial veins and arteries which penetrate into the myocardial tissue joining
the lacunar spaces. It was then demonstrated in chick-quail chimaeras that the vessels were
derived from the proepicardium structure common to the embryo and undergo a transition
from epithelial to mesenchymal tissue. Mouse studies refute this, suggesting that the proepi‐
cardium gives rise to myocardial stroma and vascular smooth muscle but not coronary artery
endothelial cells. Using clonal and histological analysis in the mouse, Red-Horse and collea‐
gues (Red-Horse et al. 2010) demonstrate that coronary arteries are formed by developmental
reprogramming of venous cells, arising from angiogenic sprouts of the sinus venosus which
returns blood to the embryonic heart. The understanding of angiogenesis in the myocardium
may in future lead to more natural methods to stimulate vascular growth and engineering
coronary bypass grafts rather than transplanting veins to revascularize damaged myocardium.
2. Cardiovascular disease
A variety of diseases affect the primary functioning of the heart. Cardiovascular disease (CVD)
is the collective name for diseases of the heart and blood vessels of the circulatory system. An
atlas of types of cardiovascular diseases in the heart and in the circulation are given in table 2.
International efforts have been implemented to classify and code the different types of ischemic
heart diseases. A number of notable indexing databases such as the International Classification
of Diseases database, Disease Database eMedicine and MeSH databases have produced
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Vessel Median Diameter (range) in mm
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RMG marginal 1.7 (1-2.5)
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THIRD CORONARY ARTERY ‘conus artery’ 1.1 (0.7-2)
Septal branches anterior from LCX 1 (0.5-2.5)
Septal branches posterior from PD 0.7 (0.3-0.9)
From ascending LAD 0.4 (0.3-0.7)
Table 1. The major coronary arteries.
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Table 2. Atlas of cardiovascular diseases of the heart and circulatory system.
Ischemic Heart Disease6
Classification system Code
International Classification of Diseases (ICD-9)
World Health Organisation,
Geneva, Switzerland
410 Acute Myocardial infarction (AMI)
411 Other acute and subsequent forms of Ischemic Heart
Disease
412 Old Myocardial Infarction
413 Angina Pectoris
414 Other forms of chronic ischemic heart disease




121 Acute Myocardial Infarction (AMI)
122 Subsequent Myocardial Infarction
123 Certain current complications following AMI
124 Other acute ischemic heart diseases
125 Chronic ischemic heart disease
Diseases Database (DiseaseDB)
Medical Object Oriented Software Enterprises
Ltd London UK
8695 - Ischemic or Ischaemic Heart disease, Myocardial




Med/1568 – Angina Pectoris
Medical Subject headings (MeSH)
Unites States National Library of Medicine
Bethesda, Maryland, USA
D017202 – Myocardial Ischemia
Table 3. Classification codes of Ischemic Heart Disease
3. Pathobiology of ischemic heart disease
Hypoxia refers to the physiological or pathological state in which oxygen supply is reduced
despite adequate perfusion of the tissue. Anoxia is the absence of oxygen from the tissue,
despite being adequately perfused. These are clearly distinguishable from ischemia where
oxygen supply is restricted as a direct result of suboptimal tissue perfusion. Ischemic tissue
also accumulates toxic metabolites due to the inadequate removal through the capillary and
venous blood systems.
The atherosclerotic process responsible for restriction of blood flow in the coronary arteries is
a multifactorial process and is initiated by damage to the endothelium. Cholesterol rich low
density lipoprotein (LDL) particles enter the intimal layer via the LDL receptor protein (Brown
and Goldstein 1979), a mosaic cell surface protein that recognizes apolipoprotein B100
embedded in the LDL particle. It also recognizes apolipoprotein E found in chylomicrons and
very low density lipoprotein remnants, or intermediate density lipoprotein. Macrophage cells
accumulate oxidized lipid independently of the LDL receptor by endocytosis. This results in
formation of juvenile raised fatty streaks within the endothelium. The macrophage release
their lipid content and cytokines into the intima. Cytokines stimulate intimal thickening by
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smooth muscle cell proliferation, which then secrete collagen, causing fibrosis (figure 3). The
lesion appears raised and yellow.
Figure 3. Medium powered H&E histological micrograph of an intimal lesion (x200). FC, foam cell infiltrate; IC, intimal
calcification; L, lumen; TI, tunica intima; TM, tunica media.
As the lesion develops, the medial layer of the vessel wall atrophies and the elastic lamina
becomes disrupted. Collagen forms a fibrous cap over the lesion that appears hard and white
(known as a fibrolipid plaque). The plaque contains macrophage laden with lipid (foam cells)
as well as extracellular or ‘free’ lipid within the lesion. The endothelium is now in a fragile
state. Ulceration of the cap occurs at weak points such as the shoulder region, near the
endothelial lining. Rupture to the cap can cause turbulent blood flow in the lumen. The exposed
lipid core causes aggregation of platelets and development of a thrombosis. This lesion grows
due to further platelet aggregation and is responsible for narrowing of the lumen of the artery
resulting in localized ischemia. Distal embolization of a piece of such thrombus may travel
downstream and can completely occlude smaller arteries.
The symptomatic part of the continuum is known as the acute coronary syndrome (ACS) which
is due to the rupture/erosion of the plaque. This produces, depending on the plaque size,
vascular anatomy and presence of collateral vessels, a mismatch between the supply and
demand for oxygen. A net reduction in supply compared to the demand results in ischemia.
Tissue hypoxia proceeds resulting in inadequate blood/oxygen perfusion. If blood flow is not
re-established, cardiac cell necrosis will occur. Post AMI survival results in remodelling
processes in the myocardium and the development of cardiac failure.
Ischemic Heart Disease8
4. Epidemiology of ischemic heart disease
According to the World Health Organisation, chronic diseases of which heart disease is the
single largest contributing category; are responsible for 63% of all global deaths (United
Nations High-Level Meeting on Noncommunicable Disease Prevention and Control 2012).
Non communicable diseases kill 9 million people under the age of 60 every year which has a
profound socio-economic impact.
The incidence of Ischemic heart disease (IHD) is higher than for any cancer or other non-CVD
condition. Cardiovascular diseases (CVD) are the leading cause of death in the Western World
and are dramatically increasing within developing countries. The Age-standardized estimate
of mortality by cardiovascular diseases and diabetes per 100,000 people is given in figure 4.
17.1 million people die as a direct result of CVD per year and 82% of these deaths occur in the
developing word
It is predicted that by 2030 23 million people will die from a CVD. Data from the USA suggests
that CVD was responsible for 34% of deaths in 2006 and over 151,000 Americans who died
were <65 years old. The incidence of CVD is declining in the Western World even though rates
of lifestyle associated risk factors such as obesity, smoking and type II diabetes mellitus are
increasing. The decline is in part due to advances in therapeutic and invasive intervention. In
creating better outcomes for those with acute cardiac conditions, patients develop heart failure
which requires longer term treatment and monitoring and may in fact be a greater health
burden than the acute events themselves.
Figure 4. Age-standardized estimate of mortality by cardiovascular diseases and diabetes per 100,000 people. Source:
Global Health Observatory Data Repository, World Health Organisation.
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There is no single causative risk factor for the development of IHD. A number of genetic and
environmental risk factors have been established as causative in the development of the
atherosclerotic lesion. Smoking and obesity cause 36% and 20% of IHD respectively. A large
European meta-analysis of 197,473 participants reported an small association between job
stress and the development of coronary artery disease (Kivimaki et al. 2012). There has been
extensive research linking a sedentary lifestyle and a lack of exercise with a risk of IHD. The
major risk factors for the development of IHD are given in table 4.
Constant risk factors Modifiable risk factors
Age Hypercholesterolaemia/dyslipidaemia
Gender Hypertension
Family history of IHD Obesity (particularly central abdominal obesity)
Personal history of early IHD Tobacco and passive tobacco Smoking
Diabetes Mellitus type I Excessive alcohol consumption
Elevated homocysteine Diabetes Mellitus type II
Elevated haemostatic factors Sedentary lifestyle
Baldness & hair greying Low antioxidant levels
Earlobe crease (Frank’s sign) Infection
Air pollution (CO, NO2, SO2)
Combined oral contraceptive pill
Table 4. Risk factors for the development of Ischaemic Heart Disease.
6. Signs and symptoms of ischemic heart disease
Ischemia may manifest in many forms. Most commonly, patients present with chest pain on
exertion, in cold weather or in emotional situations. This discomfort is known as angina
pectoris. Patients may present with acute chest pain at rest which typically radiates down the
left arm and up the left side of the neck. Patients may experience nausea, vomiting, sweating
and enhanced anxiety. Symptomatically, women present with less ‘textbook’ symptoms and
often describe their condition as weakness, indigestion and fatigue (Kosuge et al. 2006). Up to
60% of AMI are referred to as silent without any observation of chest pain or other symptoms
(Valensi et al. 2011).
Angina is diagnosed by evidence of deviation of the ST segment on the electrocardiogram,
reduced uptake of thallium-201 during myocardial perfusion imaging or regional or global
impairment of ventricular function. In patients with stable angina often have chest pain on
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exertion. Patients benefit from cardiac stress testing, echocardiography. If indicated patients
should receive coronary angiography to locate anatomically any stenosis with a view to
revascularisation by stenting during percutaneous coronary intervention or coronary artery
bypass grafting (CABG) surgery.
7. Diagnosis of ischemic heart disease
In the primary care setting, patients may be suspected of having ischemic heart disease based
on risk factor assessment and blood chemistry tests such as lipid profiling, inflammatory
markers and homocysteine concentration.
Primarily the diagnosis of IHD occurs in the acute setting when patients present with symp‐
tomatic chest pain. Patients often present with a myriad of symptoms which confuse the clinical
picture. Patients should receive immediate electrocardiography and pharmacological or
surgical intervention in those who demonstrate ST-segment elevation in the context of ST-
segment myocardial infarction (STEMI). In suspected non-ST segment elevation myocardial
infarction (NSTEMI) patients should undergo serial venepuncture for cardiac biomarkers,
namely the cardiac troponins which are indicative of myocyte necrosis. Patients may undergo
stress testing, whereby the stress response is induced by exercise or pharmacological agents
allowing comparison of the coronary circulation at rest and under stress. Patients are moni‐
tored continuously whilst exercising on a treadmill, on a ergometer bicycle or following
injection of agents such as adenosine, the adenosine A2A receptor Regadenoson or the beta-
agonist dobutamine. The agent of choice is dependent on drug interactions with medication
or concomitant disease states.
Cardiac ultrasound or echocardiography by two-dimensional, three-dimensional or Doppler
ultrasound create images of the myocardium at work. Transthoracic echocardiogram (TTE) is
the commonest form and the ultrasound transducer probe is placed non-invasively on the
thorax. Transoesophageal echogram (TOE) is an alternative method where the transducer tip
is passed into the oesophagus, allowing imaging directly behind the heart.
8. Treatment of ischemic heart disease
Stable IHD patients can be adequately treated in the primary care setting with emphasis on
both lifestyle and risk factor modifications to reduce the risk of a future adverse cardiac event.
Modification of lifestyle risk factors such as smoking cessation and weight loss control have a
direct impact on risk reduction. Further intervention such as treating hypertension, glycaemic
control in diabetics and therapeutic intervention in hyperlipidaemia result in risk reduction.
Furthermore, elective revascularisation of occluded coronary arteries may confer a reduction
in mortality risk compared to conservative therapy. A meta-analysis of 13,121 patients in
whom 6476 were randomised to revascularisation compared to medical treatment in the
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remainder demonstrated that bypass grafting and Percutaneous coronary intervention are
superior to medical therapy alone with respect to 1-10 year mortality (Jeremias et al. 2009).
Patients with symptomatic chest pain suggestive of an AMI and ST segment elevation should
receive immediate revascularisation. Fibrinolytic therapy should be administered within 30
minutes and door-to-balloon PCI should occur in no more than 90 minutes from the onset of
pain. For non ST segment elevation AMI patients, treatment with aspirin, glycoprotein IIb/IIIa
inhibitor such as clopidogrel, low molecular weight heparin, glyceryl trinitrate and opioid
therapy for persistent pain.
9. Conclusion
Ischemic heart disease is the major contributing cause of death in the Western World and the
incidence is increasing in developing countries. Successful advances in surgical and thera‐
peutic intervention are able to salvage myocardial tissue and increase prognosis if adminis‐
tered in the early phase following injury.
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Patients with congenital heart disease (CxHD) are surviving into adulthood, as well as living
longer and growing older [1], due the major achievements in their diagnosis, medical man‐
agement, surgical repair, and postoperative treatment in the last three to four decades. An
increasing numbers of patients with CxHD are encountered in our everyday practice. It is
therefore timely and appropriate to start addressing the somewhat-neglected issue of myo‐
cardial ischemia in this patient population [2].
CxHD is, by definition, cardiovascular disease present at birth. It refers to anatomic defects
and gross cardiac abnormalities due to an embryologic malformation in the structural
development of the heart and major blood vessels, which is actually of functional significance
[3]. Most CxHD occur due to gross structural developmental cardiovascular anomalies such
as septal defects, stenosis or atresia of valves, hypoplasia or absence of one ventricle, or
abnormal connections between great vessels and the heart. A few children are also born with
arrhythmias (mainly conduction defects), and hypertrophic or dilated cardiomyopathy,
although these are usually present later in childhood or adulthood. CxHD are the most
common of all congenital malformations, with a reported incidence of 6 to 8 cases per 1,000
live births, and in an even higher percentage of foetuses [4]. In some studies this incidence
reaches 12 to 14 per 1,000 live births [5].
There is a great number of recognized heart defects occurring alone and in combination,
ranging in severity from hemodynamically insignificant to extremely complex and life
threatening conditions (Table 1). Although there may be genetic or environmental situations
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that can affect the development of heart defects, in the majority of cases the cause is considered
multifactorial, with no specific identifiable trigger. Only approximately 15% of cases of CxHD
can be traced to a known cause [6]. Some types of CxHD can be related to chromosome or gene
defects, environmental factors or a multifactorial aetiology [7]. Only 2% of all cases of CxHD
can be attributed to known environmental factors. Risk factors, such as maternal insulin-
dependent diabetes mellitus and phenylketonuria, are well known as two of the leading causes
of CxHD. Other reported risk factors include maternal obesity, alcohol use in pregnancy,
rubella infection, febrile illness, use of drugs such as thalidomide and retinoic acid, and
exposure to organic solvents and lithium [8].
• Patent ductus arteriosus
• Atrial septal defect
• Ventricular septal defect
• Atrioventricular septal defect
• Aortopulmonary window
• Tetralogy of Fallot
• Pulmonary atresia or stenosis
• Aortic atresia or stenosis
• Mitral atresia or stenosis
• Tricuspid atresia or stenosis
• Left ventricular outflow obstruction
• Coarctation of the aorta
• Interrupted aortic arch
• Hypoplastic left heart syndrome
• d-Transposition of the great arteries
• l-Transposition of the great arteries (also known as
congenitally-corrected transposition of the great
arteries)
• Truncus arteriosus communis
• Double outlet right or left ventricle
• Ebstein’s disease
• Anomalies of the coronary arteries
• Vascular rings and pulmonary sling
• Total or partial anomalous pulmonary venous
connection
Table 1. Most common types of congenital heart defects.
Mortality occurs mainly in patients with severe forms of CxHD requiring prompt surgical
intervention [9]. Interestingly, the relative contribution of the causes of death in patients with
CxHD has changed over time. The CxHD causes 3% of all infant deaths and 46% of death from
congenital malformations, despite advances in detection and treatment. Arrhythmia followed
by congestive heart failure had been considered the main contributing cause of death.
However, the mortality figures collected over the past decade showed an increase in myocar‐
dial infarction as the cause of death [10]. Until the twentieth century, the majority of newborns
with CxHD died because treatment was not available. With the advances made in the field of
foetal and paediatric cardiology, survival and quality of life have improved, especially in the
past 10–20 years [11].
1.2. Myocardial ischemia
The advances in paediatric cardiac surgery were accompanied by refinements in extracorpor‐
eal perfusion technology that have led to significant improvements in the surgical results
during the past decades. Nevertheless, perioperative myocardial damage still remains the
most common cause of morbidity and death after a technically successful surgical correction.
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Despite the importance of this issue, there are a few publications about this. Studies show that
the younger the age of patients, the more vulnerable are their myocardium to injury caused
by ischemia during definitive repair of congenital heart disease. Therefore, perioperative care
for paediatric patients with congenital heart disease needs to take into consideration the
dependence of the myocardial damage on age and ischemic time [12]. Others researches have
shown that myocardial cell injury in infants submitted to open-heart surgery can be directly
associated with varying combinations of gross, microscopic, and histochemical myocardial
necrosis in up to 90% of patients who do not survive the perioperative period. The observed
alterations within the myocardium can potentially be attributed to the heart defect itself,
preoperative hemodynamic instability and its treatment, surgical techniques, cardiopulmo‐
nary bypass, myocardial protection strategies, and postoperative medical care.
Furthermore, patients with CxHD are at increased risk of developing myocardial ischemia or
premature coronary artery disease (CAD) as the result of: (a) congenital coronary artery
abnormalities (e.g., anomalous origin and course of coronary arteries, myocardial bridging,
coronary artery fistulas); (b) previous surgery (e.g., arterial switch operation for d-transposi‐
tion of the great arteries (d-TGA) and surgical coarctation repair); and (c) myocardial ischemia
not related directly to coronary artery anomalies but presenting after the atrial switch proce‐
dure for TGA (Mustard, Senning) and also in patients with congenitally corrected transposition
of the great arteries (ccTGA).
Clinical suspicion is a difficult task, especially in neonates and young infants, in whom the
clinical manifestations can be unspecific and transient. In older children and adolescents, chest
pain can be present, although myocardial ischemia is rarely the underlying cause [13].
The diagnostic and treatment of paediatric CxHD has undergone remarkable progress over
the last 60 years [14]. Moreover, in the past 10 years, significant advancements have been made
in foetal echocardiography; in postnatal echocardiography and angiography, leading to
greater accuracy in defining the cardiac defect; in interventional catheterization as a palliative
or curative measure; and in surgical techniques, which have led to an estimated million adults
living today with complex CxHD that required surgery in the neonatal period [15].
In the long term, as a consequence of successful cardiac surgeries in the past decades, there is
an increasing number of patients with CxHD reaching adulthood and becoming old. These
survivors with complex heart defects are now developing problems associated with aging. The
association of CxHD, heart surgeries, and chronic coronary artery disease is not well studied
yet [16]. It is possible that these patients are at an increased risk of myocardial ischemia, but
epidemiological studies are needed to answer to this question.
Therefore, perioperative myocardial injury is a major determinant of cardiac dysfunction after
operations for CxHD. It is very important detect and evaluate the degree of myocardial injury
as soon as possible after the operative procedure. Thus in an attempt to clarify possible
mechanisms involved in the development of ischemic heart disease in children with CxHD,
this study aims to describe the pathological alterations observed in different types of CxHD
in the heart of infants submitted to surgical correction of cardiac malformations, and to discuss
potential strategies to prevent them.
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In  normal  conditions,  an uninterrupted flow of  large  quantities  of  oxygenated blood to
the myocardium is critical to its normal function [17]. During the systole, this flow can be
abolished or even reversed towards the epicardial vessels. The blood must flow from low
to high intra-myocardial pressure, in order to meet the metabolic demands of each layer.
Such flow must be regulated in such way that areas of high demand can immediately in‐
crease their blood supply.
The myocardium extracts about 60 to 75% of oxygen from the blood that passes through it.
Because of this high level of extraction, coronary sinus blood has low oxygen tension, generally
around 25–35 mm Hg. This low level of oxygen tension requires that any increase in oxygen
demand be met by an increase in blood flow rather than an increase in extraction [17].
There are two main mechanisms by which myocardial ischemia can occur: (a) a reduction in
myocardial supply of oxygen, and (b) an increase in myocardial oxygen demand [18]. The first
situation can occur as a result of reduced coronary blood flow or reduced oxygen content
despite normal coronary flow. A reduced coronary blood flow can result from congenital
malformations of the coronary arteries, acquired coronary diseases, and also postoperative
states, especially after surgical reimplantation of the coronary arteries. Examples of reduced
oxygen content in coronary blood include cyanotic heart diseases, severe anaemia, and
hemoglobinopathies. The second mechanism can occur in the presence of hypertrophic
cardiomyopathy or vigorous exercises. The main diagnoses related to myocardial ischemia are
summarized in Table 2.
A number of conditions can lead to myocardial ischemia, including prenatal and birth
conditions, the anatomic defect, pre- and postoperative care, surgical technique, and myocar‐
dial protection during CPB. These conditions will be discussed in detail below.
2.1. Prenatal and birth conditions
Foetal hearts show a remarkable ability to develop under hypoxic conditions. The metabolic
flexibility of foetal hearts allows sustained development under low oxygen conditions. In fact,
hypoxia is critical for proper myocardial formation [19]. However, although “normal” hypoxia
(lower oxygen tension in the foetus as compared with the adult) is essential in heart formation,
further abnormal hypoxia in utero adversely affects cardiogenesis. Prenatal hypoxia alters
myocardial structure and causes a decline in cardiac performance. Not only are the effects of
hypoxia apparent during the perinatal period, but prolonged hypoxia in utero also causes
foetal programming of abnormality in the heart’s development. The altered expression
patterns of cardioprotective genes likely predispose the developing heart to increased
vulnerability to ischemia and reperfusion injury later in life [19].
In addition, myocardial dysfunction is a frequent sequel of perinatal asphyxia, resulting from
hypoxic-ischemic damage to the myocardium. It can lead to decreased perfusion, tachycardia,
hypotension, and need for inotropic support [20,21]. As a consequence, hemodynamic
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impairment can develop and the myocardium may suffer additional ischemic insults. Infec‐
tions, need for cardiopulmonary resuscitation, mechanical ventilation, preterm birth, among
other factors may also contribute to myocardial damage during this period.
2.2. The anatomic defect
Many CxHD are associated with anomalies such that the child is prone to myocardial ischemia
even after uncomplicated delivery and good hemodynamic conditions. They involve congen‐
ital anomalies of the coronary arteries and hypertrophic cardiomyopathy. Other diseases can
present early in life with congestive heart failure, circulatory shock, or severe hypoxemia. All
these factors can compromise coronary circulation and lead to myocardial ischemia.
2.2.1. Congenital anomalies of the coronary arteries
The entire blood flow to the myocardium comes from two main coronary arteries that arise
from the right and left aortic sinuses of Valsalva. In 69% of the population, the right coronary
Diagnosis related to the coronary arteries
• Anomalous coronary arteries
• Left main coronary artery from the pulmonary artery
• Left main coronary from the right coronary cusp
• Right coronary artery from the left coronary cusp
• Coronary artery fistula
• Coronary artery spasm
• Thromboembolic or embolic coronary artery disease
• Kawasaki disease
• Coronary artery dissection
• Ostial coronary artery disease status post surgical reimplantation
• d-Transposition of the great arteries (d-TGA) arterial switch
• Aortic root replacement
• Ross procedure
• Intramyocardial bridging
Diagnosis related to the myocardium (supply/demand mismatch)
• Hypertrophic cardiomyopathy
• Severe aortic stenosis
• Dilated cardiomyopathy
• Tachycardia in the face of limited coronary blood flow
Others
• Severe hypoxia or cyanosis
Table 2. Diagnosis related to myocardial ischemia.
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artery is dominant [18]. Although there are normal variations for the coronary anatomy, a
comprehensive discussion of this topic is beyond the scope of this chapter, which will focus
only on the clinically significant anomalies.
The most common anomaly, accounting for about one third of all major coronary arterial
anomalies, is origin of the left circumflex coronary artery from the right main coronary artery.
However, this anomaly is rarely of clinical significance. Less common, the origin of the left
coronary artery from the right sinus of Valsalva, is of greater significance, and was associated
with sudden death in children during or just after vigorous exercise when the vessel passes
between the two great arteries [18].
A single coronary artery may be observed in 5–20% of major coronary anomalies. About 40%
of these anomalies are associated with other cardiac malformations, including d-TGA,
tetralogy of Fallot, ccTGA, double-inlet left ventricle, double-outlet right ventricle, truncus
arteriosus, coronary-cameral fistulas, and bicuspid aortic valve [18]. Only a small number of
premature deaths have been reported with this anomaly.
When the coronary arteries (either right or left) have their origins in inappropriate sinus, the
mechanism of ischemia and death involves an increase in myocardial oxygen demand during
exercise that, in turn, causes increases in systolic blood pressure and aortic root distension. If
part of the anomalous artery runs within or adjacent to the aortic wall, it may be stretched,
compressed, or both, leading to insufficient coronary blood flow.
Other rare coronary anomalies include coronary atresia, stenosis or atresia of a coronary
ostium, all coronary arteries from pulmonary artery, left anterior descending coronary artery
from pulmonary artery, left circumflex coronary artery from the pulmonary artery or branches,
right coronary artery from pulmonary artery, myocardial bridges, etc.
2.2.2. Anomalous origin of left coronary artery from the pulmonary artery (ALCAPA)
In this anomaly the left coronary artery arises from the pulmonary artery. Therefore, after birth,
the left ventricle is perfused with desaturated blood in a regimen of low pressures. The left
ventricle becomes then hypoxic, and collaterals start to develop. The left ventricle vessels then
dilate to reduce their resistance and increase flow, but this is often not enough to prevent
ischemia with compromise of the left ventricular function. This leads to congestive heart failure
that can be worsened by mitral regurgitation. With time, the collaterals between right and left
coronary artery enlarge until the collateral flow tends to reverse in the left coronary and
ultimately into the pulmonary artery. The left-to-right shunt is usually not significant [18,22].
This anomaly is usually isolated but can be associated with patent ductus arteriosus, ventric‐
ular septal defect, tetralogy of Fallot, or coarctation of the aorta [18].
2.2.3. Tetralogy of fallot
In this disease, a hypertrophied right ventricle is always present, with a high oxygen demand
to overcome the outflow tract obstruction and provide pulmonary blood flow. In face of severe
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cyanosis, hemodynamic impairment, the oxygen supply may not balance the high require‐
ments of the right ventricle, leading to myocardial ischemia.
2.2.4. Pulmonary atresia with intact ventricular septum
In this disease, the absence of anterograde blood flow across the pulmonary valve associated
with the absence of a ventricular septal defect precludes the development of the right ventricle,
which becomes hypoplastic. A network of vascular channels, called sinusoids, then develops,
communicating the right ventricular cavity with one or both of the coronary arteries.
With  systemic  or  supra-systemic  systolic  pressure  within  the  right  ventricular  cavity,
blood flow in these fistulous connections may compete with the normal coronary blood
flow  originating  in  the  ascending  aorta.  Sometimes,  these  competing  blood  coronary
streams may cause tortuosity, severe intimal proliferation with obstruction, such that por‐
tions  of  the  myocardium  may  be  dependent  on  the  right  ventricle-originated  coronary
flow  (so-called  right  ventricle-dependent  coronary  circulation)  [23].  This  portion  of  the
myocardium would then be perfused with unsaturated blood. If  these sinusoids are not
diagnosed properly, a pulmonary valvotomy can be catastrophic, since the sudden fall in
right  ventricle  pressure  will  reflect  in  a  dramatic  fall  in  coronary  pressure,  leading  to
acute myocardial ischemia and, potentially, death.
2.2.5. Other heart defects
Children with a large patent ductus arteriosus with left-to-right shunt, those with severe aortic
regurgitation, and those with hypoplastic left heart syndrome, among others, are at great risk
for myocardial ischemia, especially in the presence of severe hypoxemia or hypotension. A
large patent ductus arteriosus with significant left-to-right shunt can decrease the diastolic
pressure in the aorta, significantly diminishing coronary blood flow. A severe aortic regurgi‐
tation can lead the same deleterious consequences in diastolic pressure. In patients with
hypoplastic left heart syndrome, the ascending aorta receives a retrograde poorly oxygenated
blood flow originated from a patent ductus arteriosus. Therefore, these patients are particu‐
larly sensitive to hypotension, severe hypoxemia, imbalances between pulmonary and
systemic blood flows, and a claudicating ductus arteriosus.
In patients with ccTGA, the right ventricle supports the systemic circulation and can become
dilated and hypertrophied with time. Once ventricular dilation and hypertrophy settle in, the
blood supply through a normal right coronary artery can become insufficient to meet the
increased metabolic demands of the systemic right ventricle [24,25], leading to further
ventricular dysfunction. The latter may also have a deleterious effect on left ventricular
perfusion, ultimately leading to left ventricular dysfunction [24]. Hypertrophy can also
develop in many other situations, especially aortic stenosis and chronic systemic hypertension.
2.3. Preoperative care and drugs
Preoperative care is of special interest in neonates and young infants because usually the
CxHD manifests as a critical illness. The neonatal myocardium is less compliant than that
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that can be worsened by mitral regurgitation. With time, the collaterals between right and left
coronary artery enlarge until the collateral flow tends to reverse in the left coronary and
ultimately into the pulmonary artery. The left-to-right shunt is usually not significant [18,22].
This anomaly is usually isolated but can be associated with patent ductus arteriosus, ventric‐
ular septal defect, tetralogy of Fallot, or coarctation of the aorta [18].
2.2.3. Tetralogy of fallot
In this disease, a hypertrophied right ventricle is always present, with a high oxygen demand
to overcome the outflow tract obstruction and provide pulmonary blood flow. In face of severe
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cyanosis, hemodynamic impairment, the oxygen supply may not balance the high require‐
ments of the right ventricle, leading to myocardial ischemia.
2.2.4. Pulmonary atresia with intact ventricular septum
In this disease, the absence of anterograde blood flow across the pulmonary valve associated
with the absence of a ventricular septal defect precludes the development of the right ventricle,
which becomes hypoplastic. A network of vascular channels, called sinusoids, then develops,
communicating the right ventricular cavity with one or both of the coronary arteries.
With  systemic  or  supra-systemic  systolic  pressure  within  the  right  ventricular  cavity,
blood flow in these fistulous connections may compete with the normal coronary blood
flow  originating  in  the  ascending  aorta.  Sometimes,  these  competing  blood  coronary
streams may cause tortuosity, severe intimal proliferation with obstruction, such that por‐
tions  of  the  myocardium  may  be  dependent  on  the  right  ventricle-originated  coronary
flow  (so-called  right  ventricle-dependent  coronary  circulation)  [23].  This  portion  of  the
myocardium would then be perfused with unsaturated blood. If  these sinusoids are not
diagnosed properly, a pulmonary valvotomy can be catastrophic, since the sudden fall in
right  ventricle  pressure  will  reflect  in  a  dramatic  fall  in  coronary  pressure,  leading  to
acute myocardial ischemia and, potentially, death.
2.2.5. Other heart defects
Children with a large patent ductus arteriosus with left-to-right shunt, those with severe aortic
regurgitation, and those with hypoplastic left heart syndrome, among others, are at great risk
for myocardial ischemia, especially in the presence of severe hypoxemia or hypotension. A
large patent ductus arteriosus with significant left-to-right shunt can decrease the diastolic
pressure in the aorta, significantly diminishing coronary blood flow. A severe aortic regurgi‐
tation can lead the same deleterious consequences in diastolic pressure. In patients with
hypoplastic left heart syndrome, the ascending aorta receives a retrograde poorly oxygenated
blood flow originated from a patent ductus arteriosus. Therefore, these patients are particu‐
larly sensitive to hypotension, severe hypoxemia, imbalances between pulmonary and
systemic blood flows, and a claudicating ductus arteriosus.
In patients with ccTGA, the right ventricle supports the systemic circulation and can become
dilated and hypertrophied with time. Once ventricular dilation and hypertrophy settle in, the
blood supply through a normal right coronary artery can become insufficient to meet the
increased metabolic demands of the systemic right ventricle [24,25], leading to further
ventricular dysfunction. The latter may also have a deleterious effect on left ventricular
perfusion, ultimately leading to left ventricular dysfunction [24]. Hypertrophy can also
develop in many other situations, especially aortic stenosis and chronic systemic hypertension.
2.3. Preoperative care and drugs
Preoperative care is of special interest in neonates and young infants because usually the
CxHD manifests as a critical illness. The neonatal myocardium is less compliant than that
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of the older child,  is  less  tolerant  to increases in afterload,  and is  less  responsive to in‐
creases in preload. In the other hand, despite being more labile,  this age group is more
resilient to metabolic or ischemic injuries,  which can play a relative protective role [17].
After  birth,  neonates  with  CxHD  can  deteriorate  their  hemodynamic  status  requiring
prompt interventions. The higher metabolic rate and oxygen consumption of the neonate
account  for  the  rapid appearance  of  hypoxemia  in  this  age  group.  In  addition,  undiag‐
nosed infants  and older  children may present  in  shock,  congestive  heart  failure,  severe
hypoxemia, severe arrhythmia with hemodynamic impairment, or a combination of them,
also requiring immediate intensive care. This highly specialized care requires careful eval‐
uation of the structure and function of the heart, the transitional neonatal circulation, and
the secondary effects of the defect on other organ systems. All efforts need to be put on
making a definitive, precise diagnosis,  so appropriate therapeutic measures can be start‐
ed [17].The treatment of the newborn or infant with severe hemodynamic compromise of‐
ten  involves  the  use  of  catecholamines  that,  despite  improving myocardial  contractility,
can further  increase  the  myocardial  metabolic  rate  and oxygen consumption.  Therefore,
the attending clinician shall be aware that these drugs need to be used only at the mini‐
mum effective dose to obtain the desired effect. Alternatively, when the renal function is
preserved,  milrinone  and  levosimendan  are  very  good  options,  since  they  can  increase
myocardial contractility without increasing metabolic rate and oxygen consumption.
Special attention shall be put also on coronary blood flow. Careful monitoring with continuous
electrocardiography, as well as serially measuring CK-MB and cardiac troponins, is mandatory
for the child with severe hemodynamic impairment, and prompt interventions need to be done
quickly in face of a suspected or confirmed coronary insufficiency.
In older patients, the CxHD usually present as congestive heart failure or arrhythmias, not
requiring critical care before surgery. There are, obviously, exceptions that shall be properly
managed.
2.4. Surgical technique
2.4.1. d-Transposition of the great arteries
In this malformation, a number of different patterns of coronary anatomy have been described.
Since the arterial switch operation includes the transfer of the coronary arteries along with the
aortic root, it is important that the surgeon knows exactly what the anatomy is. There are at
least nine anatomic variations in the way the two coronary arteries arise from the native aorta.
Some coronary patterns are more difficult to transfer than others. In 60% of cases, the coronary
arteries come from their appropriate sinuses and branch normally. However, the presence of
a ventricular septal defect or side-by-side great vessels should alert the cardiologist to an
increased likelihood of coronary anomalies, like left circumflex coronary artery arising from
the right coronary artery, or inversion of the coronary arteries origin [18,23].
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2.4.2. Tetralogy of Fallot
In this disease, the surgical repair includes patch-closure of the ventricular septal defect and
widening of the right ventricular outflow tract by infundibular muscle resection combined
with either a patch placement across the pulmonary valve annulus or use of a prosthetic
conduit from the right ventricle to the pulmonary artery. There are some aberrant coronary
patterns associated with tetralogy of Fallot. In some cases, there may be a large conus branch
or an accessory left anterior descendent artery running across the face of the right ventricular
outflow tract that may be inadvertently damaged during surgery, leading to myocardial
ischemia [23].
2.5. Cardiopulmonary bypass and myocardial protection
Recent advances in surgical techniques, myocardial preservation and postoperative care have
resulted in complete repair of many CxHD in the neonatal period or early infancy. On the other
hand, several investigators have reported that immature myocardium in the paediatric heart
is more vulnerable to surgically-induced injury than mature myocardium in the adult heart,
due to different structural and functional characteristics [26].
It is widely accepted that the immature heart has a greater tolerance to ischemia than the adult
or mature heart. However, most of this laboratory data has been obtained with normal hearts.
It is unclear what the ischemic tolerance is when there are pre-existing conditions such as
cyanosis, hypertrophy, or acidosis. Many of these conditions may be present in neonates and
infants who require surgical correction of their heart defect and may compromise myocardial
protection [26].
Newer surgical techniques are being developed to allow for total correction of many CxHD,
while limiting the time spent on continuous CPB or in deep hypothermia with circulatory
arrest [27]. Therefore, surgeries have been the choice of management in these patients.
However, there is a significant procedural- and anaesthesia-related morbidity and mortality
in patients with CxHD who undergo repeated surgical interventions [28,29].
Despite of the potentially detrimental side effects of CPB, this technique is still an essential
assisting method for open-heart surgery [30]. CPB is a primary circulatory support technique
to cardiac surgery in neonates and infants and remains one of the most important factors
associated with postoperative mortality and morbidity in open-heart surgery. With improve‐
ments in equipment and techniques, CPB has become safer and more reliable. However, it
causes profound alterations in physiological fluid homeostasis [31]. The age and size of the
patient, the underlying cardiac pathology, and the type of surgical techniques influence what
perfusion methods are chosen and the construction of the CPB circuit [32]. Despite significant
improvements, CPB remains a non-physiological procedure. The effects of hypothermia,
altered perfusion, hemodilution, acid-base management, embolization, and the systemic
inflammatory response have been challenging, particularly for neonates and infants. These
challenges are primarily related to the smaller circulatory volume, the immaturity of most
organ systems, and the increased capillary membrane permeability of neonates and infants
[32,33]. Moreover, cardiomyocytes can be affected by hypoxic conditions, and the ischemic
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of the older child,  is  less  tolerant  to increases in afterload,  and is  less  responsive to in‐
creases in preload. In the other hand, despite being more labile,  this age group is more
resilient to metabolic or ischemic injuries,  which can play a relative protective role [17].
After  birth,  neonates  with  CxHD  can  deteriorate  their  hemodynamic  status  requiring
prompt interventions. The higher metabolic rate and oxygen consumption of the neonate
account  for  the  rapid appearance  of  hypoxemia  in  this  age  group.  In  addition,  undiag‐
nosed infants  and older  children may present  in  shock,  congestive  heart  failure,  severe
hypoxemia, severe arrhythmia with hemodynamic impairment, or a combination of them,
also requiring immediate intensive care. This highly specialized care requires careful eval‐
uation of the structure and function of the heart, the transitional neonatal circulation, and
the secondary effects of the defect on other organ systems. All efforts need to be put on
making a definitive, precise diagnosis,  so appropriate therapeutic measures can be start‐
ed [17].The treatment of the newborn or infant with severe hemodynamic compromise of‐
ten  involves  the  use  of  catecholamines  that,  despite  improving myocardial  contractility,
can further  increase  the  myocardial  metabolic  rate  and oxygen consumption.  Therefore,
the attending clinician shall be aware that these drugs need to be used only at the mini‐
mum effective dose to obtain the desired effect. Alternatively, when the renal function is
preserved,  milrinone  and  levosimendan  are  very  good  options,  since  they  can  increase
myocardial contractility without increasing metabolic rate and oxygen consumption.
Special attention shall be put also on coronary blood flow. Careful monitoring with continuous
electrocardiography, as well as serially measuring CK-MB and cardiac troponins, is mandatory
for the child with severe hemodynamic impairment, and prompt interventions need to be done
quickly in face of a suspected or confirmed coronary insufficiency.
In older patients, the CxHD usually present as congestive heart failure or arrhythmias, not
requiring critical care before surgery. There are, obviously, exceptions that shall be properly
managed.
2.4. Surgical technique
2.4.1. d-Transposition of the great arteries
In this malformation, a number of different patterns of coronary anatomy have been described.
Since the arterial switch operation includes the transfer of the coronary arteries along with the
aortic root, it is important that the surgeon knows exactly what the anatomy is. There are at
least nine anatomic variations in the way the two coronary arteries arise from the native aorta.
Some coronary patterns are more difficult to transfer than others. In 60% of cases, the coronary
arteries come from their appropriate sinuses and branch normally. However, the presence of
a ventricular septal defect or side-by-side great vessels should alert the cardiologist to an
increased likelihood of coronary anomalies, like left circumflex coronary artery arising from
the right coronary artery, or inversion of the coronary arteries origin [18,23].
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2.4.2. Tetralogy of Fallot
In this disease, the surgical repair includes patch-closure of the ventricular septal defect and
widening of the right ventricular outflow tract by infundibular muscle resection combined
with either a patch placement across the pulmonary valve annulus or use of a prosthetic
conduit from the right ventricle to the pulmonary artery. There are some aberrant coronary
patterns associated with tetralogy of Fallot. In some cases, there may be a large conus branch
or an accessory left anterior descendent artery running across the face of the right ventricular
outflow tract that may be inadvertently damaged during surgery, leading to myocardial
ischemia [23].
2.5. Cardiopulmonary bypass and myocardial protection
Recent advances in surgical techniques, myocardial preservation and postoperative care have
resulted in complete repair of many CxHD in the neonatal period or early infancy. On the other
hand, several investigators have reported that immature myocardium in the paediatric heart
is more vulnerable to surgically-induced injury than mature myocardium in the adult heart,
due to different structural and functional characteristics [26].
It is widely accepted that the immature heart has a greater tolerance to ischemia than the adult
or mature heart. However, most of this laboratory data has been obtained with normal hearts.
It is unclear what the ischemic tolerance is when there are pre-existing conditions such as
cyanosis, hypertrophy, or acidosis. Many of these conditions may be present in neonates and
infants who require surgical correction of their heart defect and may compromise myocardial
protection [26].
Newer surgical techniques are being developed to allow for total correction of many CxHD,
while limiting the time spent on continuous CPB or in deep hypothermia with circulatory
arrest [27]. Therefore, surgeries have been the choice of management in these patients.
However, there is a significant procedural- and anaesthesia-related morbidity and mortality
in patients with CxHD who undergo repeated surgical interventions [28,29].
Despite of the potentially detrimental side effects of CPB, this technique is still an essential
assisting method for open-heart surgery [30]. CPB is a primary circulatory support technique
to cardiac surgery in neonates and infants and remains one of the most important factors
associated with postoperative mortality and morbidity in open-heart surgery. With improve‐
ments in equipment and techniques, CPB has become safer and more reliable. However, it
causes profound alterations in physiological fluid homeostasis [31]. The age and size of the
patient, the underlying cardiac pathology, and the type of surgical techniques influence what
perfusion methods are chosen and the construction of the CPB circuit [32]. Despite significant
improvements, CPB remains a non-physiological procedure. The effects of hypothermia,
altered perfusion, hemodilution, acid-base management, embolization, and the systemic
inflammatory response have been challenging, particularly for neonates and infants. These
challenges are primarily related to the smaller circulatory volume, the immaturity of most
organ systems, and the increased capillary membrane permeability of neonates and infants
[32,33]. Moreover, cardiomyocytes can be affected by hypoxic conditions, and the ischemic
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effects can induce rapid or gradual changes in the membrane systems that cause reversible or
irreversible injury [34]. Experimental studies of myocardial ischemia and reperfusion have
established that reperfusion also has negative consequences during circulatory interruption
[35,36]. Due to the necessary interruption in coronary circulation required by nearly all cardiac
surgeries, the potential for reperfusion damage is significant. If a reperfusion injury does occur,
the initial damage may contribute to the impaired cardiac performance that develops imme‐
diately after surgery that may then lead to myocardial fibrosis [37,38].
Myocardial preservation during surgically induced myocardial ischemia has been the subject
of hundreds of publications in recent years. The most used technique is hypothermic cardio‐
plegia. The consequences of incomplete myocardial protection during surgically induced
myocardial ischemia can have a dominant effect on the postoperative course, including low
cardiac output, elevated atrial filling pressures, and requirements for increased inotropic
support [39]. Cardioplegic solutions are used by most surgeons, and their basic components
are potassium (to achieve diastolic arrest) and cold temperature (to reduce the metabolic
demands of the heart during ischemia) [39]. There is a variety of different cardioplegic
solutions, and there is no consensus on which one is the best. In fact, there is wide variation
between institutions regarding cardioplegia and myocardial protection.
Aortic cross clamping during CPB allows the surgeon to intervene on the aortic root, the aortic
valve, and the left ventricle outflow tract. However, since during CPB myocardial perfusion
is retrograde, during cross clamping the heart is stopped and is not perfused [26,31,39].
Therefore, long cross clamping times are more likely to cause more ischemic injury to the heart.
2.6. Postoperative care and drugs
After surgery, the first 9–12 hours are crucial because during this time the patient will
experience a transient decrease in myocardial performance and cardiac output, with increasing
need of inotropic support as a consequence of CPB and ischemia-reperfusion injury in the heart
and lungs [40]. Besides, the child may deteriorate as a result of residual lesions, pulmonary
hypertension, and bleeding. All these factors may lead to poor organ perfusion and hypoten‐
sion, with consequent reduced coronary blood flow.
In some cases, when the surgical technique involves coronary reimplantation, like the arterial
switch for d-TGA, there is a considerable risk of myocardial ischemia. The implantation of the
coronary arteries on the neoaorta may be technically challenging, and the coronary insertion
may be stenotic or distorted, resulting in insufficient coronary flow. Other causes of insufficient
coronary blood flow include spasms of the coronary arteries, air embolism, and thrombosis.
Arrhythmias, especially on weaning from CPB, frequently indicate coronary insufficiency; the
coronary anastomoses should be promptly investigated before leaving the operating room, as
well as transesophageal assessment of left ventricle wall motion. Left ventricular dysfunction
may also indicate coronary insufficiency [17].
Many drugs used to improve myocardial contractility and cardiac output can substantially
increase myocardial oxygen requirements. In face of hypotension, low cardiac output, or
marginally sufficient coronary blood flow, these drugs may actually lead to or aggravate
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myocardial ischemia. These drugs include dopamine, dobutamine, epinephrine, and norepi‐
nephrine.
Arrhythmias, particularly tachyarrhythmias, can also significantly augment the oxygen
demand within the myocardium, while compromising the cardiac output, ultimately leading
to myocardial ischemia.
Severe blood loss can cause hypotension and a reduction on the arterial oxygen content,
substantially affecting oxygen transport to the myocardium.
3. Diagnostic evaluation
3.1. Acute ischemia
Chest pain is the hallmark of myocardial ischemia in adults and the elderly. In children and
adolescents, however, the great majority of chest pain episodes are of non-cardiac origin [23].
When myocardial ischemia is present in a critically ill patient admitted to an intensive care
unit, there may be no specific sign or symptom, and the diagnosis usually need to be made
based on ECG findings and biomarkers alone.
3.1.1. Electrocardiogram
The electrocardiogram (ECG) remains the most important diagnostic test in the evaluation for
myocardial ischemia. Many factors are involved in the interpretation if the ECG: age, auto‐
nomic tone, heart rate, race, gender, and body habitus. Interestingly, pseudo-abnormal ECGs
were found in up to 40% of Olympic athletes with structurally normal hearts [13]. It is
important to notice that the ECG should be obtained during the episode or shortly after the
event whenever possible; otherwise, the alterations in ECG may disappear. The main ECG
findings of myocardial ischemia are ST changes, namely elevation or depression of the ST
segment. Although repolarization changes, pericardial diseases, drugs, and electrolyte
abnormalities can also cause ST changes, a negative ECG is extremely predictive of non-
ischemic events [13].
3.1.2. Biomarkers
When myocardial ischemia occurs, some enzymes from the myocardium are released and can
be detected in peripheral blood approximately 2 hours later. The main biomarkers available
are cardiac troponins (both I and T) and creatine kinase MD isoenzyme (CK-MB). When
elevated, they can diagnose myocardial ischemia with good sensitivity and specificity [13].
3.1.3. Echocardiogram
Echocardiography is the predominant imaging modality used for the diagnosis and manage‐
ment of CxHD because of its widespread availability, ease of use, real-time imaging and cost
effectiveness. The role of echocardiography specifically for the detection of myocardial
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effects can induce rapid or gradual changes in the membrane systems that cause reversible or
irreversible injury [34]. Experimental studies of myocardial ischemia and reperfusion have
established that reperfusion also has negative consequences during circulatory interruption
[35,36]. Due to the necessary interruption in coronary circulation required by nearly all cardiac
surgeries, the potential for reperfusion damage is significant. If a reperfusion injury does occur,
the initial damage may contribute to the impaired cardiac performance that develops imme‐
diately after surgery that may then lead to myocardial fibrosis [37,38].
Myocardial preservation during surgically induced myocardial ischemia has been the subject
of hundreds of publications in recent years. The most used technique is hypothermic cardio‐
plegia. The consequences of incomplete myocardial protection during surgically induced
myocardial ischemia can have a dominant effect on the postoperative course, including low
cardiac output, elevated atrial filling pressures, and requirements for increased inotropic
support [39]. Cardioplegic solutions are used by most surgeons, and their basic components
are potassium (to achieve diastolic arrest) and cold temperature (to reduce the metabolic
demands of the heart during ischemia) [39]. There is a variety of different cardioplegic
solutions, and there is no consensus on which one is the best. In fact, there is wide variation
between institutions regarding cardioplegia and myocardial protection.
Aortic cross clamping during CPB allows the surgeon to intervene on the aortic root, the aortic
valve, and the left ventricle outflow tract. However, since during CPB myocardial perfusion
is retrograde, during cross clamping the heart is stopped and is not perfused [26,31,39].
Therefore, long cross clamping times are more likely to cause more ischemic injury to the heart.
2.6. Postoperative care and drugs
After surgery, the first 9–12 hours are crucial because during this time the patient will
experience a transient decrease in myocardial performance and cardiac output, with increasing
need of inotropic support as a consequence of CPB and ischemia-reperfusion injury in the heart
and lungs [40]. Besides, the child may deteriorate as a result of residual lesions, pulmonary
hypertension, and bleeding. All these factors may lead to poor organ perfusion and hypoten‐
sion, with consequent reduced coronary blood flow.
In some cases, when the surgical technique involves coronary reimplantation, like the arterial
switch for d-TGA, there is a considerable risk of myocardial ischemia. The implantation of the
coronary arteries on the neoaorta may be technically challenging, and the coronary insertion
may be stenotic or distorted, resulting in insufficient coronary flow. Other causes of insufficient
coronary blood flow include spasms of the coronary arteries, air embolism, and thrombosis.
Arrhythmias, especially on weaning from CPB, frequently indicate coronary insufficiency; the
coronary anastomoses should be promptly investigated before leaving the operating room, as
well as transesophageal assessment of left ventricle wall motion. Left ventricular dysfunction
may also indicate coronary insufficiency [17].
Many drugs used to improve myocardial contractility and cardiac output can substantially
increase myocardial oxygen requirements. In face of hypotension, low cardiac output, or
marginally sufficient coronary blood flow, these drugs may actually lead to or aggravate
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myocardial ischemia. These drugs include dopamine, dobutamine, epinephrine, and norepi‐
nephrine.
Arrhythmias, particularly tachyarrhythmias, can also significantly augment the oxygen
demand within the myocardium, while compromising the cardiac output, ultimately leading
to myocardial ischemia.
Severe blood loss can cause hypotension and a reduction on the arterial oxygen content,
substantially affecting oxygen transport to the myocardium.
3. Diagnostic evaluation
3.1. Acute ischemia
Chest pain is the hallmark of myocardial ischemia in adults and the elderly. In children and
adolescents, however, the great majority of chest pain episodes are of non-cardiac origin [23].
When myocardial ischemia is present in a critically ill patient admitted to an intensive care
unit, there may be no specific sign or symptom, and the diagnosis usually need to be made
based on ECG findings and biomarkers alone.
3.1.1. Electrocardiogram
The electrocardiogram (ECG) remains the most important diagnostic test in the evaluation for
myocardial ischemia. Many factors are involved in the interpretation if the ECG: age, auto‐
nomic tone, heart rate, race, gender, and body habitus. Interestingly, pseudo-abnormal ECGs
were found in up to 40% of Olympic athletes with structurally normal hearts [13]. It is
important to notice that the ECG should be obtained during the episode or shortly after the
event whenever possible; otherwise, the alterations in ECG may disappear. The main ECG
findings of myocardial ischemia are ST changes, namely elevation or depression of the ST
segment. Although repolarization changes, pericardial diseases, drugs, and electrolyte
abnormalities can also cause ST changes, a negative ECG is extremely predictive of non-
ischemic events [13].
3.1.2. Biomarkers
When myocardial ischemia occurs, some enzymes from the myocardium are released and can
be detected in peripheral blood approximately 2 hours later. The main biomarkers available
are cardiac troponins (both I and T) and creatine kinase MD isoenzyme (CK-MB). When
elevated, they can diagnose myocardial ischemia with good sensitivity and specificity [13].
3.1.3. Echocardiogram
Echocardiography is the predominant imaging modality used for the diagnosis and manage‐
ment of CxHD because of its widespread availability, ease of use, real-time imaging and cost
effectiveness. The role of echocardiography specifically for the detection of myocardial
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ischemia in the CxHD population is less well established. Furthermore, the indications and
clinical applications of other newer echo techniques such as tissue Doppler imaging, strain and
strain rate imaging, contrast and real-time three-dimensional (3D) echocardiography to detect
myocardial ischemia will need to be determined in these patients [2]. It can be helpful to detect
the following: hypertrophic cardiomyopathy, severe aortic stenosis, and dilated cardiomyop‐
athy, all of them potentially associated with coronary flow abnormalities and myocardial
ischemia. In some cases, it can show clues to the suspicion of ALCAPA and other coronary
abnormalities [13].
3.2. Chronic ischemia
The diagnosis of chronic ischemia in patients with CxHD may be challenging for the physician
because this population, often adults operated on early in life, may have pre-existing anatomic,
functional, or electrocardiographic abnormalities. They may also have pre-existing coronary
disease that, in association with other environmental, metabolic and genetic factors, may
increase the risk of coronary insufficiency. However, discussing the diagnosis of these
abnormalities is beyond the scope of this chapter.
4. Alterations observed within the myocardium
Myocardial infarction is defined by pathology as myocardial cell death due to prolonged
ischemia. Cell death is categorized pathologically by coagulation necrosis and/or contraction
band necrosis, which usually evolves through oncosis, but can result to a lesser degree from
apoptosis. Mallory, et al, 1939, and Lodge-Patch, 1951 described myocardial infarction as a
form of coagulation necrosis in which cells transform into eosinophilic hyaline masses [41,42].
Other types of necrosis are also quite common in myocardial infarction. The term contraction
band necrosis [43] have been used to describe degenerative changes of myocardial fibers
characterized by a hypercontraction or spasm of the fibers, with the formation of irregular
abnormal transverse bands due to compression of adjacent sarcomeres. These changes have
been observed in association with electric shock, deficiency of potassium, administration of
catecholamines, coronary arterial reperfusion, and death after cardiac surgery [44,45]. Al‐
though the primary event leading to the formation of “contraction bands” is unknown, most
often they probably develop in areas of reflow [46] or “twilight blood flow” after ischemia [47].
Colliquative myocytolysis, have been used to describe focal lesions, mainly in the subendo‐
cardium and in perivascular regions, which were characterized by progressive vacuolization
of fibers with lysis of contractile elements until only empty sarcolemmal tubes remain [48].
Schlesinger and Reiner, 1955 have proposed that focal myocytolysis is a result of metabolic
imbalances secondary to a large variety of disorders. In contraction band necrosis and
colliquative myocytolysis, healing is thought to occur by fibroblastic proliferation, without the
usual sequence of changes that occurs with coagulation necrosis. Careful analysis of histologic
sections by an experienced observer is necessary to distinguish these entities [49] (Fig. 1).
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Figure 1. Myocardial injuries observed in infants submitted to cardiac surgery with cardiopulmonary bypass. The his‐
topathology of myocardial injuries observed in infants with congenital cardiac heart disease submitted to surgery with
cardiopulmonary bypass (CPB). (A) Area of coagulation necrosis (CN) characterized by cells with a cytoplasm that ex‐
hibits an increased eosinophilia, loss of cross-striations, granularity, and nuclear karyolysis or pyknosis, H&E; 200x. (B)
Extensive area of fibrous tissue, Azan; 100x. (C) Contraction band necrosis (CBN), Azan; 400x. (D) Large calcified intra‐
mural band in the myocardium, H&E; 50x.
4.1. Cardiac surgery and myocardial injury
Myocardial injury in association with cardiac surgery can be caused by different mechanisms,
including direct trauma by sewing needles, focal trauma from surgical manipulation of the
heart, global ischemia from inadequate perfusion, myocardial cell protection or anoxia, and
other complications of the procedure [49]. Cardiac surgery with CPB is frequently associated
with postoperative organ dysfunction [50]. Paediatric patients are particularly prone to these
complications, and oxidative stress seems to contribute to CPB related postoperative compli‐
cations. Early systemic oxidative stress could also have been a consequence of ischemia-
reperfusion injury to the myocardium [51]. It is recognized that acute stress episodes can
induce heart injury that results in the release of cytosolic enzymes and catecholamines to the
blood [52,53]. Although catecholamines play an important role in normal cardiac function [54],
the use of CPB in cardiac surgery leads to a significant increase in circulating catecholamine
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ischemia in the CxHD population is less well established. Furthermore, the indications and
clinical applications of other newer echo techniques such as tissue Doppler imaging, strain and
strain rate imaging, contrast and real-time three-dimensional (3D) echocardiography to detect
myocardial ischemia will need to be determined in these patients [2]. It can be helpful to detect
the following: hypertrophic cardiomyopathy, severe aortic stenosis, and dilated cardiomyop‐
athy, all of them potentially associated with coronary flow abnormalities and myocardial
ischemia. In some cases, it can show clues to the suspicion of ALCAPA and other coronary
abnormalities [13].
3.2. Chronic ischemia
The diagnosis of chronic ischemia in patients with CxHD may be challenging for the physician
because this population, often adults operated on early in life, may have pre-existing anatomic,
functional, or electrocardiographic abnormalities. They may also have pre-existing coronary
disease that, in association with other environmental, metabolic and genetic factors, may
increase the risk of coronary insufficiency. However, discussing the diagnosis of these
abnormalities is beyond the scope of this chapter.
4. Alterations observed within the myocardium
Myocardial infarction is defined by pathology as myocardial cell death due to prolonged
ischemia. Cell death is categorized pathologically by coagulation necrosis and/or contraction
band necrosis, which usually evolves through oncosis, but can result to a lesser degree from
apoptosis. Mallory, et al, 1939, and Lodge-Patch, 1951 described myocardial infarction as a
form of coagulation necrosis in which cells transform into eosinophilic hyaline masses [41,42].
Other types of necrosis are also quite common in myocardial infarction. The term contraction
band necrosis [43] have been used to describe degenerative changes of myocardial fibers
characterized by a hypercontraction or spasm of the fibers, with the formation of irregular
abnormal transverse bands due to compression of adjacent sarcomeres. These changes have
been observed in association with electric shock, deficiency of potassium, administration of
catecholamines, coronary arterial reperfusion, and death after cardiac surgery [44,45]. Al‐
though the primary event leading to the formation of “contraction bands” is unknown, most
often they probably develop in areas of reflow [46] or “twilight blood flow” after ischemia [47].
Colliquative myocytolysis, have been used to describe focal lesions, mainly in the subendo‐
cardium and in perivascular regions, which were characterized by progressive vacuolization
of fibers with lysis of contractile elements until only empty sarcolemmal tubes remain [48].
Schlesinger and Reiner, 1955 have proposed that focal myocytolysis is a result of metabolic
imbalances secondary to a large variety of disorders. In contraction band necrosis and
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Figure 1. Myocardial injuries observed in infants submitted to cardiac surgery with cardiopulmonary bypass. The his‐
topathology of myocardial injuries observed in infants with congenital cardiac heart disease submitted to surgery with
cardiopulmonary bypass (CPB). (A) Area of coagulation necrosis (CN) characterized by cells with a cytoplasm that ex‐
hibits an increased eosinophilia, loss of cross-striations, granularity, and nuclear karyolysis or pyknosis, H&E; 200x. (B)
Extensive area of fibrous tissue, Azan; 100x. (C) Contraction band necrosis (CBN), Azan; 400x. (D) Large calcified intra‐
mural band in the myocardium, H&E; 50x.
4.1. Cardiac surgery and myocardial injury
Myocardial injury in association with cardiac surgery can be caused by different mechanisms,
including direct trauma by sewing needles, focal trauma from surgical manipulation of the
heart, global ischemia from inadequate perfusion, myocardial cell protection or anoxia, and
other complications of the procedure [49]. Cardiac surgery with CPB is frequently associated
with postoperative organ dysfunction [50]. Paediatric patients are particularly prone to these
complications, and oxidative stress seems to contribute to CPB related postoperative compli‐
cations. Early systemic oxidative stress could also have been a consequence of ischemia-
reperfusion injury to the myocardium [51]. It is recognized that acute stress episodes can
induce heart injury that results in the release of cytosolic enzymes and catecholamines to the
blood [52,53]. Although catecholamines play an important role in normal cardiac function [54],
the use of CPB in cardiac surgery leads to a significant increase in circulating catecholamine
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levels [55,56] and this excessive release is responsible for the development of various cardiac
dysfunctions, e.g. in cardiac remodelling following acute myocardial infarction [54], myocyte
death in heart failure [57,58], and myocardial infarction [59]. In a recent study, Oliveira, et al,
2011 described that multifocal areas of myocardial injury seem to be the cause of heart failure
for infants who do not survive beyond the perioperative period [60]. They were described in
patients submitted to surgery for CxHD with and without CPB, and in patients who died from
CxHD prior to surgical intervention. Most of the infants who had undergone surgery with CPB
showed important areas of contraction band necrosis and dystrophic calcification. Whereas
infants who had undergone surgery without CPB showed coagulation necrosis and healing,
suggesting ischemia as the main cause. Importantly, 4-hydroxinonenal (4-HNE), a marker of
lipid peroxidation, was strongly expressed, especially in irreversible myocardial lesions. This
finding suggests that 4-HNE may be the predominant oxidative stress mechanism that occurs
in these patients.
4.2. Adrenergic receptors and cardiopulmonary bypass
CPB and cardioplegic arrest remain the most popular techniques in clinical intervention during
open-heart surgery. However, both can directly or indirectly result in cardiac morbidity
following surgery [61]. Cardioplegic arrest renders the heart globally ischemic and, upon
reperfusion, triggers myocardial injury [62]. The use of CPB and cardioplegic arrest during
cardiac surgery also leads to desensitization of myocardial β-adrenergic receptors (β-ARs) and
impaired signalling through this pathway, which is critical in the regulation of cardiac function
[63,64]. Previous studies have demonstrated that cardiac β-AR signalling is impaired after CPB
with cardioplegic arrest in children with acyanotic heart disease who underwent cardiac
surgery [56]. Adrenergic receptors (ARs), first described by Ahlquist, 1948, belong to the
superfamily of membrane proteins that activate heterotrimeric guanine nucleotide (G) binding
proteins [65]. The heart expresses both β and α1 adrenergic receptors [66]. The effect of β-
adrenergic receptor activation is well established: the increase of both heart rate and force of
contraction. The effect of α1-receptor activation is more complex. It is usually described as a
biphasic or a triphasic effect: initial positive inotropy, followed by a transient negative and
finally a more sustained positive inotropy without effect on chronotropy [67]. In the heart,
agonist occupancy of β-ARs leads to the primary activation of the adenylyl cyclase (AC)
stimulatory G protein (Gs), which leads to increases in intracellular cAMP and protein kinase
A (PKA) activity [68]. Alterations in adrenergic signalling are important in a number of cardiac
diseases. Undoubtedly, the alterations that take place in the β-AR system during the progres‐
sion of heart failure (HF) are the most well characterized [68].
A primary mechanism of β-AR desensitization following prolonged stimulation is phosphor‐
ylation of agonist-occupied receptors by G protein-coupled receptor kinase-2 (GRK2), a
member of the family of serine-threonine kinases known as G protein-coupled receptor kinases
[69]. GRK2 has been shown to be important in the modulation of cardiac function in vivo [70,
71] and enhanced activity leads to uncoupling of β-ARs and impaired ventricular systolic and
diastolic function.
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Bulcao, et al, 2008 also found significant uncoupling of β-ARs from adenylyl cyclase under
basal conditions and following β-agonist stimulation in a patient population following CPB
and arrest [72].
In animal studies, inhibition of GRK2 has led to improved myocardial function after ischemic
injury [73]. Myocardial GRK2 activity is known to be elevated in patients with chronic heart
failure by approximately 2-3-fold compared to normal controls leading to impaired signalling
through β-ARs and blunted inotropic reserve [74]. This is thought to be an important mecha‐
nism in the pathogenesis of chronic heart failure resulting from an increase in circulating
catecholamines [75].During myocardial ischemia, there is a decrease in the supply of oxygen
and nutrients to the heart [62]. This, in turn, provokes a fall in energy production by the
mitochondria, which is quickly followed by abnormal accumulation and depletion of several
intracellular metabolites (e.g. a fall in adenosine triphosphate (ATP) and a rise in lactate). These
metabolic changes lead to a decrease in intracellular pH and an increase in the intracellular
concentrations of sodium and Ca2+, which further consumes ATP [76], moreover, a local
metabolic release of large amounts of noradrenaline occurs [77,78] together with an increased
density of β-adrenergic receptors [79-81]. Consecutively, the capacity of β-adrenergic agonists
to stimulate adenylate cyclase activity is enhanced during the first 15 minutes of ischemia [79].
With progressive ischemia, however, isoproterenol-stimulated activity of adenylate cyclase
decreases to below the control value, although the density of β-receptors remains elevated [80].
This dissociation of receptor number and functional activity has been found in different models
of cardiac ischemia [81], including the isolated perfused rat heart [79], and in human myocar‐
dium subjected to hypoxia during cardiopulmonary bypass surgery [56].
Similarly, heart failure in humans has also been characterized by specific alterations in the AR
signalling system [82]. The enhanced desensitization of myocardial ARs is likely due, at least
in part, to the elevated expression of GRK-2 present in human failing heart [74,83]. Mouse
models of severe heart failure have been used to demonstrate that inhibition of GRK-2 with a
peptide inhibitor can prevent agonist-stimulated desensitization of cardiac β-ARs. This is
sufficient to increase mean survival, reduce dilation, and improve cardiac function. This may
represent a novel strategy to improve myocardial function in the setting of compromised heart
function [70].
5. Strategies for prevention
Prevention of myocardial ischemia in the setting of CxHD is an enormous task. Given the
complex pathophysiology, it is very unlikely that a single intervention will show significant
reductions on the incidence of myocardial ischemia in patients with CxHD. We can, though,
comment on a few of issues that have been matter of investigation recently.
5.1. Before birth
The rate of CxHD that are diagnosed before birth is still low, especially in developing countries,
where foetal echocardiography is not widely available. Babies with a prenatal diagnostic of
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reperfusion, triggers myocardial injury [62]. The use of CPB and cardioplegic arrest during
cardiac surgery also leads to desensitization of myocardial β-adrenergic receptors (β-ARs) and
impaired signalling through this pathway, which is critical in the regulation of cardiac function
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agonist occupancy of β-ARs leads to the primary activation of the adenylyl cyclase (AC)
stimulatory G protein (Gs), which leads to increases in intracellular cAMP and protein kinase
A (PKA) activity [68]. Alterations in adrenergic signalling are important in a number of cardiac
diseases. Undoubtedly, the alterations that take place in the β-AR system during the progres‐
sion of heart failure (HF) are the most well characterized [68].
A primary mechanism of β-AR desensitization following prolonged stimulation is phosphor‐
ylation of agonist-occupied receptors by G protein-coupled receptor kinase-2 (GRK2), a
member of the family of serine-threonine kinases known as G protein-coupled receptor kinases
[69]. GRK2 has been shown to be important in the modulation of cardiac function in vivo [70,
71] and enhanced activity leads to uncoupling of β-ARs and impaired ventricular systolic and
diastolic function.
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failure by approximately 2-3-fold compared to normal controls leading to impaired signalling
through β-ARs and blunted inotropic reserve [74]. This is thought to be an important mecha‐
nism in the pathogenesis of chronic heart failure resulting from an increase in circulating
catecholamines [75].During myocardial ischemia, there is a decrease in the supply of oxygen
and nutrients to the heart [62]. This, in turn, provokes a fall in energy production by the
mitochondria, which is quickly followed by abnormal accumulation and depletion of several
intracellular metabolites (e.g. a fall in adenosine triphosphate (ATP) and a rise in lactate). These
metabolic changes lead to a decrease in intracellular pH and an increase in the intracellular
concentrations of sodium and Ca2+, which further consumes ATP [76], moreover, a local
metabolic release of large amounts of noradrenaline occurs [77,78] together with an increased
density of β-adrenergic receptors [79-81]. Consecutively, the capacity of β-adrenergic agonists
to stimulate adenylate cyclase activity is enhanced during the first 15 minutes of ischemia [79].
With progressive ischemia, however, isoproterenol-stimulated activity of adenylate cyclase
decreases to below the control value, although the density of β-receptors remains elevated [80].
This dissociation of receptor number and functional activity has been found in different models
of cardiac ischemia [81], including the isolated perfused rat heart [79], and in human myocar‐
dium subjected to hypoxia during cardiopulmonary bypass surgery [56].
Similarly, heart failure in humans has also been characterized by specific alterations in the AR
signalling system [82]. The enhanced desensitization of myocardial ARs is likely due, at least
in part, to the elevated expression of GRK-2 present in human failing heart [74,83]. Mouse
models of severe heart failure have been used to demonstrate that inhibition of GRK-2 with a
peptide inhibitor can prevent agonist-stimulated desensitization of cardiac β-ARs. This is
sufficient to increase mean survival, reduce dilation, and improve cardiac function. This may
represent a novel strategy to improve myocardial function in the setting of compromised heart
function [70].
5. Strategies for prevention
Prevention of myocardial ischemia in the setting of CxHD is an enormous task. Given the
complex pathophysiology, it is very unlikely that a single intervention will show significant
reductions on the incidence of myocardial ischemia in patients with CxHD. We can, though,
comment on a few of issues that have been matter of investigation recently.
5.1. Before birth
The rate of CxHD that are diagnosed before birth is still low, especially in developing countries,
where foetal echocardiography is not widely available. Babies with a prenatal diagnostic of
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CxHD may benefit from catheter-based interventions such as balloon valve dilations or device-
closure of abnormal communications. These interventions may lead to better intra-uterus
myocardial perfusion and development.
5.2. After birth
Babies with CxHD should ideally be delivered in a tertiary-care hospital with a dedicated
cardiac paediatric intensive care unit. However, this can only be accomplished by increasing
prenatal diagnostic of CxHD, which is known to be limited. Babies with a prenatal diagnostic
of CxHD that are delivered in an adequate setting are more likely to receive high quality care
and less likely to develop hemodynamic instability and myocardial ischemia.
In addition, a precise anatomic diagnosis is mandatory for an adequate preoperative manage‐
ment, and can help clinical decision making on drugs and dosing, oxygen supplementation,
and need for mechanical ventilation.
5.3. During surgery
Only a few episodes of myocardial ischemia occurring during surgical procedures can be
attributed to the procedure itself. When the procedures involve repositioning of the coronary
arteries, special attention should be put on the technique, but other factors may be equally
important. Minimizing the duration of CPB and aortic cross clamping can also help reducing
periods of myocardial ischemia. In particular, the type of cardioplegia and myocardial
protection may substantially affect the likelihood of ischemia both during and after surgery.
Some authors defend that blood cardioplegia may be superior to crystalloid cardioplegia
especially for longer (> 1 hour) myocardial ischemic time [26]. However, the superiority of one
type of cardioplegic solution over the others is still matter of debate.
5.4. Postoperatively
Immediately after surgery and within the first 24–48 hours, some strategies may significantly
reduce the risk of myocardial ischemia following heart surgery, such as: (a) use of coronary
vasodilators, like nitroglycerin, especially when the coronary arteries were surgically reposi‐
tioned; (b) avoiding hypotension; (c) avoiding hyperthermia; (d) minimizing the use of drugs
that increase myocardial oxygen demand; (e) keeping the haemoglobin content in blood of at
least 10 g/dL; and (f) avoiding tachycardia and aggressively treating tachyarrhythmias. In the
setting of hyperthermia, tachyarrhythmias, or low cardiac output syndrome, a mild hypo‐
thermia may result in lower oxygen requirements and lower heart rates with better diastolic
filling and improved cardiac output.
5.5. Long-term follow-up
Preventive measures for coronary disease in the long term in patients with CxHD are not
different from the general population. Dyslipidaemias, chronic arterial hypertension, diet,
exercise, are diabetes, among others, shall be managed accordingly. Screening for coronary
disease and myocardial ischemia should probably be more frequent and comprehensive in
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people with CxHD but, to date, there is no additional recommendation for these people in
order to prevent coronary disease in the adulthood.
6. Future research
Results of paediatric heart surgery have improved through evolution of surgical techniques,
CPB, and paediatric cardiac intensive care over the last several years. These efforts are the
result of the collaboration of all subspecialties involved in the care of paediatric patients with
CxHD. Despite these advances, the field of paediatric cardiac intensive care is still an exciting,
demanding, and evolving discipline, necessitating the ongoing commitment of various
disciplines to pursue a greater understanding of disease processes and how to best go about
treating them [84].
However, it is very important detect and evaluate the degree of myocardial injury as soon as
possible after the operative procedure, in an attempt to clarify possible mechanisms involved
in the development of ischemic heart disease in children with CxHD, aiming to discuss
potential strategies of the prevent this disease [85].
Future research should focus on molecular mechanisms of myocardial injury, including
ischemia-reperfusion injury and the systemic inflammatory response. Clinical trials compar‐
ing different myocardial protection strategies and anti-inflammatory drugs are strongly
needed. In addition, individualized care based on genetic profiles and the presence of
polymorphisms may also contribute to better outcomes.
7. Conclusions
In conclusion, myocardial ischemia following paediatric heart surgery for CxHD is an
important issue, probably under diagnosed by physicians, which can lead to catastrophic
consequences shortly after surgery or in the long term. The number of people with CxHD
reaching adulthood is increasing, and knowing the number of patients with CxHD who were
born, who are still alive, and who are reaching adulthood at any given time is required for the
adequate allocation of care. These patients are at an increased risk of chronic coronary artery
disease and myocardial ischemia. A better understanding of the underlying pathophysiology
and the development of screening tests and prophylactic and therapeutic interventions
deserve special attention from physicians and researchers.
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1. Introduction
The high rate of disability and mortality among patients with Diabetes Mellitus (DM) is mainly
caused by cardiovascular disorders. The pathogenic effect of a number of specific factors
(hyperglycemia, hyperinsulinemia, insulin resistance) accelerates the development and
progression of the diseases connected with atherosclerosis. They are the main causes of death
among population of industrialized countries. The incidence of cardiovascular disease is 3-4
times higher among patients with Type II DM in comparison with patients having normal
carbohydrate metabolism. However, atypical clinical course of coronary heart disease makes
diagnosis of coronary insufficiency among patients with DM rather difficult. It results in later
detection of disease, i.e. the disease is often detected on the stage of severe complications such
as sudden death or circulatory failure [1]. According to Thomas Killip [2], asymptomatic
myocardial ischemia occurs 2-4 times more often in diabetes, while Cohn P.F. and Fox K.M.
[3] say about 5-fold increased risk of cardiac mortality among patients with asymptomatic
myocardial ischemia. It should be noted that the presence of silent myocardial ischemia
increases the risk of complications such as acute myocardial infarction and unstable angina [4].
Although pathogenetic mechanisms of the appearance of silent and pain ischemia are consid‐
ered to be the same and they are caused by mismatch between myocardial oxygen demand
and coronary blood flow we still do not have a clear answer on the question about causes of
asymptomatic myocardial ischemia.
The absence of pain among patients with DM is connected with loss of sensitivity of opioid
receptors to adenosine which is one of the mediators of cardiac pain [3]. Other researchers
© 2013 Tatarchenko et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Co mons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Chapter 3
Significance of Arterial Endothelial Dysfunction and
Possibilities of Its Correction in Silent Myocardial
Ischemia and Diabetes Mellitus
I.P. Tatarchenko, N.V. Pozdnyakova, O.I. Morozova,
A.G. Mordovina, S.A. Sekerko and I.A. Petrushin
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53445
1. Introduction
The high rate of disability and mortality among patients with Diabetes Mellitus (DM) is mainly
caused by cardiovascular disorders. The pathogenic effect of a number of specific factors
(hyperglycemia, hyperinsulinemia, insulin resistance) accelerates the development and
progression of the diseases connected with atherosclerosis. They are the main causes of death
among population of industrialized countries. The incidence of cardiovascular disease is 3-4
times higher among patients with Type II DM in comparison with patients having normal
carbohydrate metabolism. However, atypical clinical course of coronary heart disease makes
diagnosis of coronary insufficiency among patients with DM rather difficult. It results in later
detection of disease, i.e. the disease is often detected on the stage of severe complications such
as sudden death or circulatory failure [1]. According to Thomas Killip [2], asymptomatic
myocardial ischemia occurs 2-4 times more often in diabetes, while Cohn P.F. and Fox K.M.
[3] say about 5-fold increased risk of cardiac mortality among patients with asymptomatic
myocardial ischemia. It should be noted that the presence of silent myocardial ischemia
increases the risk of complications such as acute myocardial infarction and unstable angina [4].
Although pathogenetic mechanisms of the appearance of silent and pain ischemia are consid‐
ered to be the same and they are caused by mismatch between myocardial oxygen demand
and coronary blood flow we still do not have a clear answer on the question about causes of
asymptomatic myocardial ischemia.
The absence of pain among patients with DM is connected with loss of sensitivity of opioid
receptors to adenosine which is one of the mediators of cardiac pain [3]. Other researchers
© 2013 Tatarchenko et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Co mons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
believe that the main cause of the development of silent myocardial ischemia is diabetic
autonomic neuropathy [5;6]. According to Kempler P. [7], 24-hour monitoring showed that
64.7% patients having DM with diabetic autonomic neuropathy suffered silent ischemia while
only 4.1% patients having DM without diabetic autonomic neuropathy suffered silent
ischemia.
Undoubtedly, diagnostic methods allowing the detection of disease before the development
of dangerous conditions are important in the absence of characteristic clinical symptoms
among patients with DM. Early diagnosis of coronary heart disease is particularly necessary.
The role of endothelial dysfunction in the formation of vascular complications attracts
attention of clinicians. The vascular endothelium certainly plays a key role in maintaining
normal vascular tone and structure, local homeostasis and processes of cell proliferation of the
vascular wall [8, 9]. The vascular endothelium is considered to be metabolically active tissue
formed by a corporation of specialized cells. It secretes both vasoconstrictors (angiotensin II,
endothelin, free radicals of incompletely oxidized fatty acids, prostaglandin F2 alpha, throm‐
boxane) and vasodilators (nitric oxide (NO), endothelial hyperpolarizing factor, prostacyclin),
their effects are balanced under physiological conditions. The dysfunction of endothelial cells
causes increased vascular permeability for macromolecules [10], changes in the level of
vasoactive substances and vascular expansion and vasospasm respectively [11; 12] and change
in the balance of coagulation and anticoagulation systems [13]. However, endothelial dys‐
function most often leads to changes in the vascular lumen. Endothelial cell dysfunction is
considered to be the change in the vascular response to the delivery acetylcholine into the
bloodstream and hyperemia which normally lead to vasodilatation due to release of NO.
In DM the ability of endothelial cells to synthesize NO is reduced [14; 15], the ability of
endothelial cells to release relaxing factors decreases while the formation of vasoconstric‐
tive factors persists or increases, i.e. the imbalance between the neurotransmitters provid‐
ing  the  best  rate  for  all  endothelium-dependent  processes  is  formed.  This  condition  is
defined as  endothelial  dysfunction.  The major  manifestations  of  endothelial  dysfunction
are violation of the endothelium relaxation of blood vessels and increased adhesiveness of
endothelial lining [16].
As Tooke J. noted, insulin may affect the endothelium of blood vessels in two ways causing
them to either expand or spasm [17]. Binding to its receptors on the surface of endothelial cells
insulin may act in two ways. The first way is an activation of NO secretion through the insulin
receptor substrate 1 and substrate 2 (IRS-1, IRS-2) and phosphatidylinositol-3-kinase (PI3-K).
This mechanism provides a vasodilator and antiatherogenic properties of insulin; it is involved
in insulin-dependent delivery of glucose into cells. The second way is implementation of the
mitogenic properties of insulin through a cascade of mediators (ras, raf, MEK) that increase
the activity of mitogen-activated protein kinase, which ends with cell proliferation and
migration of smooth muscle cells, activation of vasoconstrictor factor endothelin-1 and
increased blood pressure [18]. The first mechanism appeared not to function in conditions of
insulin resistance. It was the first way which was resistant to insulin; therefore, NO molecule
was not synthesized. At the same time, the second mechanism retains its high activity, so,
hyperinsulinemia has atherogenic effects.
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Endothelial  dysfunction of  the coronary arteries  manifests  in  reduced coronary flow re‐
serve,  inability of  vessels  to adequate expansion with an increase in myocardial  oxygen
demand.  It  has  a  significant  influence  on  the  occurrence  and  progression  of  ischemia.
Changes in vascular reactivity have an impact on atherogenesis processes, hyperglycemia
provokes  the  primary foci  of  atheromatous  lesions  of  the  vascular  wall  and creates  the
conditions for the formation of specific cellular component atheroma [19]. Violation of en‐
dothelial  function  is  believed  to  be  an  important  independent  risk  factor  for  coronary
heart disease [20], that is why the correction of endothelial dysfunction and control of tra‐
ditional risk factors for atherosclerosis should be considered as a strategic line of the ef‐
fective prevention of cardiovascular complications.
According to Schachinger V. and colleages [21], patients with risk of coronary atherosclerosis
traditionally suffer endothelial dysfunction of the coronary vessels, but it functions as a long-
term marker of the progression of atherosclerosis and cardiovascular events when coronary
heart disease is diagnosed. However, this assumption is not supported by all the researchers.
A significant difference in the prevalence of silent myocardial ischemia, depending on the
presence of DM is a matter of opinion too.
2. The subject and the methods of the research
Having conducted our research, we investigated the relationship between the severity of silent
myocardial ischemia and functional state of arteries endothelium, we studied the significance
of violations of vasomotor function with the loss of the ability to flow-dependent vasodilation
as a risk factor, which increases the probability of the episodes of silent myocardial ischemia
among patients with Type II DM.
To conduct the research we formed a group of patients with stable clinical course of coronary
heart disease during the previous month. All patients including people with Type II DM had
stable sinus rhythm. The research was conducted on condition that the patients took oral
antidiabetic drugs. The elimination criteria were Grade 3 hypertension (blood pressure was
above 180/110 mmHg); the presence of valvular heart disease and congestive heart failure 3-4
functional class; the presence of chronic liver and renal failure; chronic lung disease with
respiratory failure; a history of cerebral stroke.
We observed 128 patients (66 male and 62 female), average age was 59.3±4.7. Each patient
signed an agreement to take part in our research as a volunteer. The agreement was adopted
by the local ethics committee.
We included patients with coronary heart disease and Type II DM into group 1 (n=60).
Duration of diabetes was 6.4±1.5 years. The level of fasting plasma glucose was 7.7±1.5 mmol/
l. Group 2 (n=68) was formed by patients having coronary heart disease without violation of
carbohydrate metabolism (table 1).
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The complex survey included clinical and laboratory studies, 12-lead electrocardiography,
Holter ECG monitoring, stress testing (Bruce R. protocol), echocardiography, and ultrasound





Male/Female (n) 26 / 34 40 / 28
Age (years) 59.8 ± 4.3 58.7 ± 4.8
Smoking (Male/Female, n) 24 / 5 32 / 4



































hyper Dyslipidemia (n/%) 54 / 90 53 / 77.9
signs of CHF,% 42 / 60 37 / 54.4
Note: BMI - Body Mass Index; CHF - Chronic Heart Failure; CD - Cardiovascular Disease; hyper Dyslipidemia- total
cholesterol is more than 5.0 mmol/l and/or low-density lipoprotein cholesterol is more than 3 mmol/l when high density
lipoprotein cholesterol is less than 1 mmol/l; n - the absolute number of individuals with this figure; % - number of persons
with this figure from the total number of persons enrolled in the study.
Table 1. Clinical characteristics of patients
Vascular Doppler ultrasound was conducted before 10 a.m. when a patient was fasting. The
patient had a 10-minute rest before the test. During the test the patient was lying on his/her
back. Having scanned the common carotid artery, the brachial artery, common femoral artery
and tibial arteries we used a linear detector with the ability to visualize the image in the
frequency range 5-12 Hz.
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In B-mode we studied the following parameters: vascular permeability; vascular geometry
(the correspondence of vascular duct to the anatomical vessel trajectory); the diameter of the
vessel (intraluminal); the condition of the vascular wall (the integrity, the thickness of the
intima-media (Figure 1.), echogenicity, the degree of differentiation of the layers, the shape of
the surface); the state of the vessel lumen (presence, location, length, echogenicity of intralu‐
minal structures, the degree of obstruction); the state of the perivascular tissue (presence,
shape, extent, cause extravasal impact). In spectral Doppler mode, we analyzed quantitative
indicators of blood flow: peak systolic blood flow velocity (Vps, cm/s); the maximum end
diastolic blood flow velocity (Ved, cm/s); diastolic blood flow velocity (Vd, cm/s), evaluated in
arteries with high peripheral resistance; maximum blood flow velocity, averaged over time
(TAMX, cm/s); peripheral resistance index - RI.
Figure 1. Assessment of intima-media for ultrasound scanning in B-mode
To assess vasomotor function of vascular endothelium, we used a test with reactive hyperemia,
i.e. detection of endothelium-dependent vasodilation of the BA by the method of Celermaer
D.S. and Sorensen K.E. [22]. The sensor was located in the longitudinal section of a 3 - 4 cm
above the elbow. First, the diameter of the BA and the velocity of blood flow through it were
measured. Reactive hyperemia was produced by applying a sphygmomanometer cuff on the
upper third of the shoulder. During 3-4 minutes we maintained the cuff pressure in this patient
greater than systolic pressure by 40 mm Hg. After decompression, the next measurements
were carried out in 60 seconds. Endothelium dependent vasodilatation was calculated by the
following formula:
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lipoprotein cholesterol is less than 1 mmol/l; n - the absolute number of individuals with this figure; % - number of persons
with this figure from the total number of persons enrolled in the study.
Table 1. Clinical characteristics of patients
Vascular Doppler ultrasound was conducted before 10 a.m. when a patient was fasting. The
patient had a 10-minute rest before the test. During the test the patient was lying on his/her
back. Having scanned the common carotid artery, the brachial artery, common femoral artery
and tibial arteries we used a linear detector with the ability to visualize the image in the
frequency range 5-12 Hz.
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In B-mode we studied the following parameters: vascular permeability; vascular geometry
(the correspondence of vascular duct to the anatomical vessel trajectory); the diameter of the
vessel (intraluminal); the condition of the vascular wall (the integrity, the thickness of the
intima-media (Figure 1.), echogenicity, the degree of differentiation of the layers, the shape of
the surface); the state of the vessel lumen (presence, location, length, echogenicity of intralu‐
minal structures, the degree of obstruction); the state of the perivascular tissue (presence,
shape, extent, cause extravasal impact). In spectral Doppler mode, we analyzed quantitative
indicators of blood flow: peak systolic blood flow velocity (Vps, cm/s); the maximum end
diastolic blood flow velocity (Ved, cm/s); diastolic blood flow velocity (Vd, cm/s), evaluated in
arteries with high peripheral resistance; maximum blood flow velocity, averaged over time
(TAMX, cm/s); peripheral resistance index - RI.
Figure 1. Assessment of intima-media for ultrasound scanning in B-mode
To assess vasomotor function of vascular endothelium, we used a test with reactive hyperemia,
i.e. detection of endothelium-dependent vasodilation of the BA by the method of Celermaer
D.S. and Sorensen K.E. [22]. The sensor was located in the longitudinal section of a 3 - 4 cm
above the elbow. First, the diameter of the BA and the velocity of blood flow through it were
measured. Reactive hyperemia was produced by applying a sphygmomanometer cuff on the
upper third of the shoulder. During 3-4 minutes we maintained the cuff pressure in this patient
greater than systolic pressure by 40 mm Hg. After decompression, the next measurements
were carried out in 60 seconds. Endothelium dependent vasodilatation was calculated by the
following formula:
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Endothelium dependent vasodilatation= ((BA diameter after the test - initial diameter of the
BA)/initial diameter of the BA)×100%.
The degree of increase in BA diameter of more than 10% was regarded as a preserved endo‐
thelium dependent vasodilatation. In violation of endothelium vasomotor function of BA
diameter increase was less than 10%. We got more information on the status of endothelial
vasomotor function using the method of transcranial duplex scanning with the stress test,
which activates the metabolic mechanisms of influence on the endothelium, i.e. breath holding
test. We analyzed the nature of response to the functional stress test, taking into account the
index of reactivity:
1. positive - the index of reactivity was from 1.1 to 1.4;
2. negative - the index of reactivity was 0.9 to 1.1;
3. paradoxical - the index of reactivity was less than 0.9 [23].
ECG monitoring was conducted in the ordinary daily routine of a patient. The patient was to
keep a diary during ECG recording; he or she recorded the nature of his/her activities and his/
her state of health in detail. Besides a computer decoding, the analysis of the results of our
research included visual viewing of individual fragments of the ECG recording, which
increased the reliability of conclusions. We analyzed ischemic changes, taking into account
corrections of the original position in ST segment whether it was ST segment elevation or
depression (Figure 2.).
Figure 2. Variant of ischemic ST segment depression
When evaluating each episode, we noted the presence or absence of pain (according to a
patient’s diary or a marker on the monitor records; we calculated the total duration of daily
depression of ST segment (daily myocardial ischemia), a maximum depth of ST segment
depression (↓STmax), heart rate (HR) at the beginning of painful and painless episodes of ST
displacement.
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Statistical processing and analysis of the results obtained are presented in the system of
statistical analysis STATISTIKA (the package of applied programs STATISTIKA by company
StatSoft Inc., Version 6.0.).
3. The results of the research and the discussion
In countries that have achieved significant success in treatment and prevention of coronary
heart disease, patients with DM are the only group in which the death rate from this disease
has slightly decreased among men and increases among women [24]. In this connection, the
data of clinical analysis and comparative evaluation of ischemic episodes based on the results






The presence of SMI (n) 56 / 93.3%* 40 / 58.8%
Number of painful episode of myocardial ischemia 2.1 ± 0.3 2.1 ± 0.43
Number of silent myocardial ischemia 2.8 ± 0.4* 1.1 ± 0.3
DMI (min) 45.3 ± 3.2* 33.6 ± 2.4
PEMI (min) 14.7 ± 2.5 15.2 ± 1.7
Silent myocardial ischemia (min) 31.1 ± 2.1* 18.6 ± 2.2







Average heart rate(beats / min)
at the beginning of PEMI





VA during episodes of ischemia (n/%) 12 / 20* 8 / 11.8
The volume of work done (Watt) 400 ± 20* 580 ± 20
The threshold power of load (Watt) 66.5 ± 2.3* 83.3 ± 2.8
Time of occurrence
ST segment depression (min) 6.7 ± 0.3* 8.6 ± 0.4
Time of pain occurrence (min) 7.3 ± 0.4 8.5 ± 0.7
The number of leads with ST depression 6.3 ± 0.4* 4.4 ± 0.2
Note: DMI - Daily Myocardial Ischemia (duration of ischemic episodes per day); SMI - Silent Myocardial Ischemia; PEMI -
Painful Episode of Myocardial Ischemia; VA - Ventricular Arrhythmia; *- р < 0.05 – a significant difference.
Table 2. Comparative analysis of functional methods
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Endothelium dependent vasodilatation= ((BA diameter after the test - initial diameter of the
BA)/initial diameter of the BA)×100%.
The degree of increase in BA diameter of more than 10% was regarded as a preserved endo‐
thelium dependent vasodilatation. In violation of endothelium vasomotor function of BA
diameter increase was less than 10%. We got more information on the status of endothelial
vasomotor function using the method of transcranial duplex scanning with the stress test,
which activates the metabolic mechanisms of influence on the endothelium, i.e. breath holding
test. We analyzed the nature of response to the functional stress test, taking into account the
index of reactivity:
1. positive - the index of reactivity was from 1.1 to 1.4;
2. negative - the index of reactivity was 0.9 to 1.1;
3. paradoxical - the index of reactivity was less than 0.9 [23].
ECG monitoring was conducted in the ordinary daily routine of a patient. The patient was to
keep a diary during ECG recording; he or she recorded the nature of his/her activities and his/
her state of health in detail. Besides a computer decoding, the analysis of the results of our
research included visual viewing of individual fragments of the ECG recording, which
increased the reliability of conclusions. We analyzed ischemic changes, taking into account
corrections of the original position in ST segment whether it was ST segment elevation or
depression (Figure 2.).
Figure 2. Variant of ischemic ST segment depression
When evaluating each episode, we noted the presence or absence of pain (according to a
patient’s diary or a marker on the monitor records; we calculated the total duration of daily
depression of ST segment (daily myocardial ischemia), a maximum depth of ST segment
depression (↓STmax), heart rate (HR) at the beginning of painful and painless episodes of ST
displacement.
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Statistical processing and analysis of the results obtained are presented in the system of
statistical analysis STATISTIKA (the package of applied programs STATISTIKA by company
StatSoft Inc., Version 6.0.).
3. The results of the research and the discussion
In countries that have achieved significant success in treatment and prevention of coronary
heart disease, patients with DM are the only group in which the death rate from this disease
has slightly decreased among men and increases among women [24]. In this connection, the
data of clinical analysis and comparative evaluation of ischemic episodes based on the results






The presence of SMI (n) 56 / 93.3%* 40 / 58.8%
Number of painful episode of myocardial ischemia 2.1 ± 0.3 2.1 ± 0.43
Number of silent myocardial ischemia 2.8 ± 0.4* 1.1 ± 0.3
DMI (min) 45.3 ± 3.2* 33.6 ± 2.4
PEMI (min) 14.7 ± 2.5 15.2 ± 1.7
Silent myocardial ischemia (min) 31.1 ± 2.1* 18.6 ± 2.2







Average heart rate(beats / min)
at the beginning of PEMI





VA during episodes of ischemia (n/%) 12 / 20* 8 / 11.8
The volume of work done (Watt) 400 ± 20* 580 ± 20
The threshold power of load (Watt) 66.5 ± 2.3* 83.3 ± 2.8
Time of occurrence
ST segment depression (min) 6.7 ± 0.3* 8.6 ± 0.4
Time of pain occurrence (min) 7.3 ± 0.4 8.5 ± 0.7
The number of leads with ST depression 6.3 ± 0.4* 4.4 ± 0.2
Note: DMI - Daily Myocardial Ischemia (duration of ischemic episodes per day); SMI - Silent Myocardial Ischemia; PEMI -
Painful Episode of Myocardial Ischemia; VA - Ventricular Arrhythmia; *- р < 0.05 – a significant difference.
Table 2. Comparative analysis of functional methods
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In group 1 we observed periods of silent ischemia among 93.3% patients, painful episodes of
myocardial ischemia were detected in the form of compressive retrosternal pain, discomfort
in the chest and dyspnea among 66.7% patients. When analyzing daily trend of ST segment
and patients’ diary records, we registered a combination of painful episodes of myocardial
ischemia and silent myocardial ischemia in 60% cases. Only 6.7% patients with Type II DM
had painful episodes of myocardial ischemia while 33.3% patients had ischemic depression
episodes of ST segment without any subjective manifestations. That was a significant differ‐
ence in comparison with the corresponding figures in group 2, χ2=5.4 (p<0.05).
In group 2 episodes of silent myocardial ischemia were detected in 9 (13.2%) cases during a
day, the detection rate of painful episodes of myocardial ischemia was 59 (88.6%) cases, 28
(41.2%) patients having had only painful episodes of myocardial ischemia. According to diary
records, 51.7% patients with coronary heart disease had a combination of painful episodes of
myocardial ischemia and silent myocardial ischemia. A significant difference was obtained by
assessing the duration of all episodes of myocardial ischemia during the day in group 1 and
group 2, it was 45.3±3.2 min and 33.6±2.4 min< p<0.03 accordingly.
The average depth of ST segment depression did not differ significantly among patients of
both groups. However, maximum depth of ST depression in group 1 exceeded the same
indicator in group 2, it was 2.4±0.2 mm and 1.6±0.3 mm, p<0.05 accordingly. The value of heart
rate at the beginning of pain and painless episodes did not differ significantly according to
groups.
The amount of work done and threshold power were lower among patients of group 1 than
patients of group 2. 85% patients of group 1 had ischemic displacement of ST segment, it was
detected in more than 6-lead ECG during stress testing.
Measuring the ability to perceive pain which is associated with transient myocardial ischemia
has a prognostic value in stable angina. Angina/the equivalent of angina is a signal for patients
to regulate their daily physical activity.
We should note that later attack of pain with a delay relatively to the ischemic ST segment shift
was detected among 27(45%) patients of group 1 during stress test. In 31 (51.7%) cases the
emergence of pain coincided with the appearance of ischemic symptoms on the electrocar‐
diogram. However, in 2 cases the pain occurred before the appearance of ST depression.
Having analyzed the results, we obtained different data in group 2: the number of patients
with premature/simultaneous appearance of angina/its equivalent was 85.3% and it exceeded
the number of patients with late appearance of pain attack (14.7%), p<0.02. We assume that
data on the detection rate during stress testing of patients with the later occurrence of the
attack/equivalent of angina with respect to ischemic ST segment shift (45% and 14.7% - p<0.03
respectively), obtained in group 1 in comparison with group 2 may be explained by increased
sensitivity to pain among patients with insulin resistant diabetes. It is associated with a change
in neuronal component of pain inhibition system, which includes not only the conductors of
pain sensitivity, but peripheral receptors in the myocardium.
The data obtained are consistent with the results of daily monitoring of the ECG. The proba‐
bility of occurrence of asymptomatic episodes of ST depression is significantly higher among
Ischemic Heart Disease48
patients having coronary heart disease and DM than among patients with coronary heart
disease without violation of carbohydrate metabolism. Ratio silent myocardial ischemia/
painful episodes of myocardial ischemia was 1.29 in group 1, and it exceeded the same
indicator among patients of group 2 – 0.52 (χ2=3.84, р<0.05).
However, in our opinion, the pathogenesis of silent myocardial ischemia with violation of
carbohydrate metabolism is complex; it appears to be related not only to autonomous cardiac
neuropathy, but also to the development of angiopathy, microcirculation disturbance.
It should be noted that the presence and severity of endothelial dysfunction among patients
with documented lesions of coronary arteries is a proven marker of poor prognosis [25].
However, this large-scale destruction of the vascular bed does not occur for any other disease,
like DM; this is due to the influence of hyperglycemia on the primary target cell, vascular
endothelium. Studies carried out in a clinical setting, showed that in DM endothelial dysfunc‐
tion is associated with microangiopathy and atherosclerosis [26; 27].
When studying functional characteristics of vascular endothelium in the analyzed groups we
paid special attention to the results on detecting endothelium-dependent vasodilation of the
BA (Table 3).
Rate
Group 1 Group 2
initially after the test initially after the test
Diameter of the BA (mm) 3.8 ± 0.19 3.94 ± 0.11** 4.07 ± 0.18 4.57 ± 0.12*
Vps (m/s) 0.62 ± 0.04 0.84 ± 0.06 0.64 ± 0.05 0.92 ± 0.04*
Ved (m/s) 0.10 ± 0.05 0.13 ± 0.03 0.12 ± 0.06 0.16 ± 0.03*
ТАМX (m/s) 0.12 ± 0.03 0.29 ± 0.06** 0.13± 0.02 0.43 ± 0.04*
EDV BA (%) 3.7 ± 1.1** 12.3 ± 2.1%
Note: Vps - Peak systolic blood flow velocity; Ved - maximum end diastolic flow velocity; ТАМX - the time-averaged
maximum velocity of blood flow; EDV BA - endothelium dependent vasodilation of brachial artery; *- р< 0.05 - reliability
of differences between parameters obtained initially and after the test; ** - р< 0.05 - difference is reliable between
indicators of group 1 and group 2.
Table 3. Performance test with reactive hyperemia in groups of patients
The original diameter of the BA did not differ significantly in the analyzed groups; it was
3.8±0.19 mm and 4.07±0.18 mm, respectively. Evaluating the mechanism of endothelial
regulation of vascular tone among patients in group 1, in the presence of DM, we diagnosed
vasomotor endothelial dysfunction induced by shear stress in all cases. The diameter of the
BA increased after removal of the cuff by only 3.7±1.1% of the initial indicator in the group. At
the same time 53.3% (32) of patients had violation of endothelial vasomotor function as a lack
of vasodilating effect, i.e., less than 10% of the original value, 26.7% (16) of patients had
violation of endothelial vasomotor function as the lack of increase in BA diameter, and 20%
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In group 1 we observed periods of silent ischemia among 93.3% patients, painful episodes of
myocardial ischemia were detected in the form of compressive retrosternal pain, discomfort
in the chest and dyspnea among 66.7% patients. When analyzing daily trend of ST segment
and patients’ diary records, we registered a combination of painful episodes of myocardial
ischemia and silent myocardial ischemia in 60% cases. Only 6.7% patients with Type II DM
had painful episodes of myocardial ischemia while 33.3% patients had ischemic depression
episodes of ST segment without any subjective manifestations. That was a significant differ‐
ence in comparison with the corresponding figures in group 2, χ2=5.4 (p<0.05).
In group 2 episodes of silent myocardial ischemia were detected in 9 (13.2%) cases during a
day, the detection rate of painful episodes of myocardial ischemia was 59 (88.6%) cases, 28
(41.2%) patients having had only painful episodes of myocardial ischemia. According to diary
records, 51.7% patients with coronary heart disease had a combination of painful episodes of
myocardial ischemia and silent myocardial ischemia. A significant difference was obtained by
assessing the duration of all episodes of myocardial ischemia during the day in group 1 and
group 2, it was 45.3±3.2 min and 33.6±2.4 min< p<0.03 accordingly.
The average depth of ST segment depression did not differ significantly among patients of
both groups. However, maximum depth of ST depression in group 1 exceeded the same
indicator in group 2, it was 2.4±0.2 mm and 1.6±0.3 mm, p<0.05 accordingly. The value of heart
rate at the beginning of pain and painless episodes did not differ significantly according to
groups.
The amount of work done and threshold power were lower among patients of group 1 than
patients of group 2. 85% patients of group 1 had ischemic displacement of ST segment, it was
detected in more than 6-lead ECG during stress testing.
Measuring the ability to perceive pain which is associated with transient myocardial ischemia
has a prognostic value in stable angina. Angina/the equivalent of angina is a signal for patients
to regulate their daily physical activity.
We should note that later attack of pain with a delay relatively to the ischemic ST segment shift
was detected among 27(45%) patients of group 1 during stress test. In 31 (51.7%) cases the
emergence of pain coincided with the appearance of ischemic symptoms on the electrocar‐
diogram. However, in 2 cases the pain occurred before the appearance of ST depression.
Having analyzed the results, we obtained different data in group 2: the number of patients
with premature/simultaneous appearance of angina/its equivalent was 85.3% and it exceeded
the number of patients with late appearance of pain attack (14.7%), p<0.02. We assume that
data on the detection rate during stress testing of patients with the later occurrence of the
attack/equivalent of angina with respect to ischemic ST segment shift (45% and 14.7% - p<0.03
respectively), obtained in group 1 in comparison with group 2 may be explained by increased
sensitivity to pain among patients with insulin resistant diabetes. It is associated with a change
in neuronal component of pain inhibition system, which includes not only the conductors of
pain sensitivity, but peripheral receptors in the myocardium.
The data obtained are consistent with the results of daily monitoring of the ECG. The proba‐
bility of occurrence of asymptomatic episodes of ST depression is significantly higher among
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patients having coronary heart disease and DM than among patients with coronary heart
disease without violation of carbohydrate metabolism. Ratio silent myocardial ischemia/
painful episodes of myocardial ischemia was 1.29 in group 1, and it exceeded the same
indicator among patients of group 2 – 0.52 (χ2=3.84, р<0.05).
However, in our opinion, the pathogenesis of silent myocardial ischemia with violation of
carbohydrate metabolism is complex; it appears to be related not only to autonomous cardiac
neuropathy, but also to the development of angiopathy, microcirculation disturbance.
It should be noted that the presence and severity of endothelial dysfunction among patients
with documented lesions of coronary arteries is a proven marker of poor prognosis [25].
However, this large-scale destruction of the vascular bed does not occur for any other disease,
like DM; this is due to the influence of hyperglycemia on the primary target cell, vascular
endothelium. Studies carried out in a clinical setting, showed that in DM endothelial dysfunc‐
tion is associated with microangiopathy and atherosclerosis [26; 27].
When studying functional characteristics of vascular endothelium in the analyzed groups we
paid special attention to the results on detecting endothelium-dependent vasodilation of the
BA (Table 3).
Rate
Group 1 Group 2
initially after the test initially after the test
Diameter of the BA (mm) 3.8 ± 0.19 3.94 ± 0.11** 4.07 ± 0.18 4.57 ± 0.12*
Vps (m/s) 0.62 ± 0.04 0.84 ± 0.06 0.64 ± 0.05 0.92 ± 0.04*
Ved (m/s) 0.10 ± 0.05 0.13 ± 0.03 0.12 ± 0.06 0.16 ± 0.03*
ТАМX (m/s) 0.12 ± 0.03 0.29 ± 0.06** 0.13± 0.02 0.43 ± 0.04*
EDV BA (%) 3.7 ± 1.1** 12.3 ± 2.1%
Note: Vps - Peak systolic blood flow velocity; Ved - maximum end diastolic flow velocity; ТАМX - the time-averaged
maximum velocity of blood flow; EDV BA - endothelium dependent vasodilation of brachial artery; *- р< 0.05 - reliability
of differences between parameters obtained initially and after the test; ** - р< 0.05 - difference is reliable between
indicators of group 1 and group 2.
Table 3. Performance test with reactive hyperemia in groups of patients
The original diameter of the BA did not differ significantly in the analyzed groups; it was
3.8±0.19 mm and 4.07±0.18 mm, respectively. Evaluating the mechanism of endothelial
regulation of vascular tone among patients in group 1, in the presence of DM, we diagnosed
vasomotor endothelial dysfunction induced by shear stress in all cases. The diameter of the
BA increased after removal of the cuff by only 3.7±1.1% of the initial indicator in the group. At
the same time 53.3% (32) of patients had violation of endothelial vasomotor function as a lack
of vasodilating effect, i.e., less than 10% of the original value, 26.7% (16) of patients had
violation of endothelial vasomotor function as the lack of increase in BA diameter, and 20%
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(12) of patients had violation of endothelial vasomotor function in the form of pathological
vasoconstriction.
An interesting fact is that endothelial dysfunction induced by shear stress was detected in the
form of lack of increase in BA diameter and pathological vasoconstriction among patients with
Type II DM (33.3% of the total number of patients in group 1) having episodes of silent
myocardial ischemia without subjective symptoms, it was 15% и 18.3% of cases accordingly.
Correlation analysis showed a significant negative correlation between endothelial dysfunc‐
tion and the presence of silent myocardial ischemia (R= -0.68, p<0.01), duration of episodes of
silent myocardial ischemia (R= -0.53, p<0.01), lag time of pain in relation to coronary ST
depression (R= -0.61, p<0.01) in group 1.
We have received reliable dependence of endothelium dependent vasodilation from the
functional class (FC) of angina (R= -0.4215, p <0.04): endothelium dependent vasodilation was
2.4±0.3% in stable angina of FC III, that was significantly less than similar indicator among
patients with angina of FC I and FC II, it was 5.2± 0.2% and 4.05±0.15% (p <0.03), respectively.
In group 2 index of endothelium dependent vasodilation of BA was 12.3±2.1%. We did not
reveal any violations of the vasomotor function of vascular endothelium among 44.1% (30) of
patients of this group (endothelium dependent vasodilation was more than 10%). Endothelial
dysfunction was registered in 38 (40%) cases: in 29 (42.6%) cases patients suffered lack of
growth in BA diameter (endothelium dependent vasodilation was less than 10%), 7 (10.3%)
patients had no increase in BA diameter and only 2(3%) patients suffered pathological
vasoconstriction.
In Doppler test of linear velocity rates of blood flow of BA (peak systolic blood flow velocity
(Vps), maximum end diastolic flow velocity (Ved)), the time-averaged maximum velocity of
blood flow (ТАМX) did not differ significantly in the groups. However, the degree of increase
of the velocity indicators in comparison with reactive hyperemia test was significantly higher
in group 2, which also shows a decrease in vasodilating reserve in group 2.
Table 4 presents the results of the analysis of quantitative and qualitative assessment of intima-
media complex (IMC) of the arteries of the lower limb arteries, common carotid artery (CCA)
and the analysis of cerebrovascular reactivity in these tests with breath-holding.
The thickness of IMC of patients in group 1 was 1.24±0,06 mm in the CCA, in the common
femoral artery (CFA) it was 1.32±0.07 mm, the numerical values of these indices were higher
than similar indicators among patients of group 2, p<0.05. Doing a qualitative analysis of the
IMC state we revealed three different types of changes among patients with Type II DM: diffuse
uniform thickening of the IMC with the appearance of additional layers of high and low
echogenicity in the structure of the intima-media in the CFA, the superficial femoral artery
(SFA), the popliteal artery (PA), the posterior tibial artery (PTA), the anterior tibial artery
(ATA) (100% patients); in the CCA (95% patients); presence of multiple local zones of increased
echogenicity with visualization of atherosclerotic plaques in the structure of IMC (95% were
in the PTA and the ATA, 80% were in the PA, 71.7% were in the CFA and SFA; 66.7% patients
had it the CCA), increased echogenicity of IMC with the complete loss of its differentiation







Thickness of IMC of the CFA (mm) 1.32 ± 0.07 1.18 ± 0.09
The presence of atherosclerotic plaques in the arteries of
the lower limbs (n/%)
57 / 95 39 / 57.4*
Thickness of IMC of CCA (mm) 1.24 ± 0,06 1.12 ± 0.08
The presence of atherosclerotic plaques in CCA (n/%) 40 / 66.7 29 / 42.6
initial indices of blood flow in the MCA
Vps (cm/s) 75.3 ± 11.4** 79.2 ± 9.2
TAMX (cm/s) 37. 7 ± 8.5** 39.6 ± 7.63
RI 0.52 ± 0.06** 0.6 ± 0.05
indices of blood flow in the MCA after the test with breath-holding
Vps (cm/s) 76.2 ± 12.2** 96.2 ± 10.61*
TAMX (cm/s) 38.2 ± 4.9** 57.02 ± 11.2*
RI 0.51 ±0.10** 0.55 ± 0.09*
Note: CFA - common femoral artery; CCA - common carotid artery; MCA - middle cerebral artery; Vps - Peak systolic blood
flow velocity; ТАМX - the time-averaged maximum velocity of blood flow; RI - index of peripheral resistance; *- р< 0.05 -
reliability of differences between parameters obtained initially and after the test; ** - р< 0.05 - difference is reliable
between indicators of group 1 and group 2
Table 4. Analysis of the intima-media complex of the arteries in the two groups with the assessment of
cerebrovascular reactivity
Atherosclerotic vascular changes suffered by patients without DM differed from those of
patients with DM. In group 2 we recorded diffuse irregular thickening of the intima-media
complex with an increase of its echogenicity, sometimes with loss of differentiation of the layers
mainly in large arteries (55.9% cases were in the CCA, 70.6% were in the CFA and SFA, 54.4%
were in the PA, 45.6% were in the PTA and ATA), combined with abnormal thickening and
the presence of atherosclerotic plaques (42.6% cases were in the CCA, 57.4% were in the CFA
and SFA).
The analysis of cerebral reactivity in group 1 showed that the response on the metabolic
stimulation was negative among 52 (86.7%) patients; 6 (10%) patients had a paradoxical
reaction with reduced velocity parameters of the MCA.
Initial indices in group 2 did not differ significantly from the corresponding figures in group
1. However, having done breath holding test, we had a reliable increase by 16% in Vps and by
30% in TAMX (p<0.05). The reaction on the metabolic vasodilating test in the MCA was
negative only in 5 (7.35%) cases.
These data suggest that patients with coronary heart disease and violation of carbohydrate
metabolism in the peripheral blood vessels suffered the changes which had two-side and
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(12) of patients had violation of endothelial vasomotor function in the form of pathological
vasoconstriction.
An interesting fact is that endothelial dysfunction induced by shear stress was detected in the
form of lack of increase in BA diameter and pathological vasoconstriction among patients with
Type II DM (33.3% of the total number of patients in group 1) having episodes of silent
myocardial ischemia without subjective symptoms, it was 15% и 18.3% of cases accordingly.
Correlation analysis showed a significant negative correlation between endothelial dysfunc‐
tion and the presence of silent myocardial ischemia (R= -0.68, p<0.01), duration of episodes of
silent myocardial ischemia (R= -0.53, p<0.01), lag time of pain in relation to coronary ST
depression (R= -0.61, p<0.01) in group 1.
We have received reliable dependence of endothelium dependent vasodilation from the
functional class (FC) of angina (R= -0.4215, p <0.04): endothelium dependent vasodilation was
2.4±0.3% in stable angina of FC III, that was significantly less than similar indicator among
patients with angina of FC I and FC II, it was 5.2± 0.2% and 4.05±0.15% (p <0.03), respectively.
In group 2 index of endothelium dependent vasodilation of BA was 12.3±2.1%. We did not
reveal any violations of the vasomotor function of vascular endothelium among 44.1% (30) of
patients of this group (endothelium dependent vasodilation was more than 10%). Endothelial
dysfunction was registered in 38 (40%) cases: in 29 (42.6%) cases patients suffered lack of
growth in BA diameter (endothelium dependent vasodilation was less than 10%), 7 (10.3%)
patients had no increase in BA diameter and only 2(3%) patients suffered pathological
vasoconstriction.
In Doppler test of linear velocity rates of blood flow of BA (peak systolic blood flow velocity
(Vps), maximum end diastolic flow velocity (Ved)), the time-averaged maximum velocity of
blood flow (ТАМX) did not differ significantly in the groups. However, the degree of increase
of the velocity indicators in comparison with reactive hyperemia test was significantly higher
in group 2, which also shows a decrease in vasodilating reserve in group 2.
Table 4 presents the results of the analysis of quantitative and qualitative assessment of intima-
media complex (IMC) of the arteries of the lower limb arteries, common carotid artery (CCA)
and the analysis of cerebrovascular reactivity in these tests with breath-holding.
The thickness of IMC of patients in group 1 was 1.24±0,06 mm in the CCA, in the common
femoral artery (CFA) it was 1.32±0.07 mm, the numerical values of these indices were higher
than similar indicators among patients of group 2, p<0.05. Doing a qualitative analysis of the
IMC state we revealed three different types of changes among patients with Type II DM: diffuse
uniform thickening of the IMC with the appearance of additional layers of high and low
echogenicity in the structure of the intima-media in the CFA, the superficial femoral artery
(SFA), the popliteal artery (PA), the posterior tibial artery (PTA), the anterior tibial artery
(ATA) (100% patients); in the CCA (95% patients); presence of multiple local zones of increased
echogenicity with visualization of atherosclerotic plaques in the structure of IMC (95% were
in the PTA and the ATA, 80% were in the PA, 71.7% were in the CFA and SFA; 66.7% patients
had it the CCA), increased echogenicity of IMC with the complete loss of its differentiation







Thickness of IMC of the CFA (mm) 1.32 ± 0.07 1.18 ± 0.09
The presence of atherosclerotic plaques in the arteries of
the lower limbs (n/%)
57 / 95 39 / 57.4*
Thickness of IMC of CCA (mm) 1.24 ± 0,06 1.12 ± 0.08
The presence of atherosclerotic plaques in CCA (n/%) 40 / 66.7 29 / 42.6
initial indices of blood flow in the MCA
Vps (cm/s) 75.3 ± 11.4** 79.2 ± 9.2
TAMX (cm/s) 37. 7 ± 8.5** 39.6 ± 7.63
RI 0.52 ± 0.06** 0.6 ± 0.05
indices of blood flow in the MCA after the test with breath-holding
Vps (cm/s) 76.2 ± 12.2** 96.2 ± 10.61*
TAMX (cm/s) 38.2 ± 4.9** 57.02 ± 11.2*
RI 0.51 ±0.10** 0.55 ± 0.09*
Note: CFA - common femoral artery; CCA - common carotid artery; MCA - middle cerebral artery; Vps - Peak systolic blood
flow velocity; ТАМX - the time-averaged maximum velocity of blood flow; RI - index of peripheral resistance; *- р< 0.05 -
reliability of differences between parameters obtained initially and after the test; ** - р< 0.05 - difference is reliable
between indicators of group 1 and group 2
Table 4. Analysis of the intima-media complex of the arteries in the two groups with the assessment of
cerebrovascular reactivity
Atherosclerotic vascular changes suffered by patients without DM differed from those of
patients with DM. In group 2 we recorded diffuse irregular thickening of the intima-media
complex with an increase of its echogenicity, sometimes with loss of differentiation of the layers
mainly in large arteries (55.9% cases were in the CCA, 70.6% were in the CFA and SFA, 54.4%
were in the PA, 45.6% were in the PTA and ATA), combined with abnormal thickening and
the presence of atherosclerotic plaques (42.6% cases were in the CCA, 57.4% were in the CFA
and SFA).
The analysis of cerebral reactivity in group 1 showed that the response on the metabolic
stimulation was negative among 52 (86.7%) patients; 6 (10%) patients had a paradoxical
reaction with reduced velocity parameters of the MCA.
Initial indices in group 2 did not differ significantly from the corresponding figures in group
1. However, having done breath holding test, we had a reliable increase by 16% in Vps and by
30% in TAMX (p<0.05). The reaction on the metabolic vasodilating test in the MCA was
negative only in 5 (7.35%) cases.
These data suggest that patients with coronary heart disease and violation of carbohydrate
metabolism in the peripheral blood vessels suffered the changes which had two-side and
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diffuse nature with many sections of lesions, whereas patients without diabetes usually had
changes occurring on one side of the peripheral arteries and/or lesion of a single segment of
arterial tree. We calculated a negative correlation of thickness of IMC and endothelium
dependent vasodilatation (R= -0.8743, р<0.01).
Neurohumoral disorders should be taken into account in the process of remodeling of the heart
and blood vessels. Renin-angiotensin-aldosterone system (RAAS) is very important in the
pathophysiological processes that eventually lead to cardiovascular remodeling, increasing
the risk of cardiovascular complications [28]. Drug effect on the RAAS should be considered
the standard therapeutic procedure. In this connection, study and discussion of metabolic,
vascular and organ-protective effects of drugs, suppressing the activity of the RAAS are of
special importance. To exclude the development of left ventricular remodeling, impaired left
ventricular diastolic function and vasomotor endothelial dysfunction of the arteries from the
life of patients with Type II DM is not possible. However, when treating the patients, specific
efforts should be directed to slow the progression of these disorders.
We evaluated the effect of antagonist of telmisartan angiotensin II receptor on blood pressure
(BP), carbohydrate and lipid metabolism, the parameters of intracardiac hemodynamics and
left ventricular remodeling, endothelial vasomotor function of arteries. For 40 weeks Telmi‐
sartan - Mikardis (Boehringer Ingelheim Pharma) was prescribed to 60 patients with coronary
heart disease and Type II DM in addition to standard therapy (antiplatelet, statins, peripheral
vasodilators, and calcium antagonist in the pro re nata mode, oral hypoglycemic agents). The
average dose for the group was 80 mg per day during the first weeks, 40 mg/day were
prescribed to 24 patients during the next weeks and 36 patients took 80 mg/day).
The choice of telmisartan which is from the group of angiotensin receptor antagonists (ARA)
is dictated by the results of investigations, according to which there may be a substantial
difference in the influence of drugs on metabolic processes within the ARA drug group [29;
30]. This difference is explained by different ability of individual ARA to activate proliferator
activation receptors by peroxisome of γ type (PPAR-γ), i.e. nuclear factors discovered by their
ability to respond to xenobiotics by peroxisomal proliferation in the liver. According to Bakris
G. [29], attention to PPAR is paid due to their key role in the regulation of lipid and carbohy‐
drate metabolism in general and in the formation of insulin resistance and Type II DM in
particular. The synthesis of PPAR-γ activators gives additional possibilities in the treatment
of Type II DM and metabolic syndrome. However, the breadth of the spectrum of their effects
allows us to think about the potential of their use in primary and secondary prevention of
cardiovascular complications.
To assess the degree of compensation of carbohydrate metabolism, we measured the following
indicators: levels of fasting and postprandial (2 hours after eating) blood glucose (mmol/l) at
each visit, glycated hemoglobin (HbA1c, %), initially and after 40 weeks of observation.
85% of patients with Type II DM and stable angina who took telmisartan in addition to
standard therapy showed subjective improvement in physical condition. Having done the
analysis of anginal attacks in the group, we noted a significant reduction (from 21.7 ±  2.1 to
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14.3 ±  1.1 episodes) in angina attacks per week and a reduced need (from 12.8 ±  1.3 to 5.3 ±
1.1 tablets) for short-nitroglycerin per week by the 40th week of observation.
According to clinical measurements of blood pressure (BP) a significant reduction in office
systolic (SBP) blood pressure and diastolic blood pressure (DBP) was observed among patients
being treated with telmisartan during the test appearances, 95% of patients having target BP
level of SBP. Target BP level of DBP was in 96.7% cases, p <0.05.
According to the ambulatory blood pressure monitoring (ABPM), abnormal profile of blood
pressure trend was observed among 88.3% of patients, most of them (75%) forming the
category of "non-dippers" (patients with lack of normal physiological reduction in blood
pressure at night). However, we identified cases of distorted circadian rhythm with a pre‐
dominantly nocturnal hypertension (13.3%), i.e. the group of "night-pickers".
After 40 weeks of the therapy we received reduction in daily average SBP and DBP, time index
of hypertension for 24 hours, the variability in SBP and DBP (p<0.05) (Table 5).
We observed a normalization of circadian BP profile among 85% of patients that was 96.2% of
patients with abnormal circadian rhythm (non-dipper and night-picker). Therapy with
telmisartan allowed us to reduce indicators of the magnitude and rate of morning increase in
BP. Thus, the magnitude of morning increase in SBP decreased by 49% and the magnitude of
morning increase in DBP decreased by 51.4% while the rate of morning increase in SBP
decreased by 69% and the rate of morning increase in DBP decreased by 62.9% (p<0,03).
Rate Initial After 40 weeks
circadian blood pressure monitoring indicators
Daily average SBP (mmHg) 148.4 ± 11.3* 127.1 ± 3.3
Daily average DBP (mmHg) 89.3 ± 6.7* 77.2 ± 3.1
The daily variability of SBP (mmHg) 21.9 ± 2.8* 15.2 ± 1.7
The daily variability of DBP (mmHg) 16.4 ± 2.3* 9.9 ± 1.1
Time index of systolic hypertension in 24 hours (%) 80.4 ± 5.3* 32.3 ± 5.2
Time index of diastolic hypertension in 24 hours (%) 66.7 ± 3.4* 22.3 ± 2.5
The rate morning increase of SBP (mmHg/h) 29.7 ± 3.2 9.2 ± 1.4
The rate morning increase of DBP (mmHg/h) 17.8 ± 3.1 6.6 ± 1.0
circadian ECG monitoring indicators
DMI (min) 45.3 ± 3.2* 20.7± 1.4
PEMI (min) 14.7 ± 2.5 11.3 ± 1.3
SMI (min) 31.1 ± 2.1* 9.5 ± 1.5
Note: differences were significant between the numerical values of initial rates and rates after 40 weeks of therapy with
telmisartan.
Table 5. Dynamics of functional parameters during therapy with telmisartan
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dependent vasodilatation (R= -0.8743, р<0.01).
Neurohumoral disorders should be taken into account in the process of remodeling of the heart
and blood vessels. Renin-angiotensin-aldosterone system (RAAS) is very important in the
pathophysiological processes that eventually lead to cardiovascular remodeling, increasing
the risk of cardiovascular complications [28]. Drug effect on the RAAS should be considered
the standard therapeutic procedure. In this connection, study and discussion of metabolic,
vascular and organ-protective effects of drugs, suppressing the activity of the RAAS are of
special importance. To exclude the development of left ventricular remodeling, impaired left
ventricular diastolic function and vasomotor endothelial dysfunction of the arteries from the
life of patients with Type II DM is not possible. However, when treating the patients, specific
efforts should be directed to slow the progression of these disorders.
We evaluated the effect of antagonist of telmisartan angiotensin II receptor on blood pressure
(BP), carbohydrate and lipid metabolism, the parameters of intracardiac hemodynamics and
left ventricular remodeling, endothelial vasomotor function of arteries. For 40 weeks Telmi‐
sartan - Mikardis (Boehringer Ingelheim Pharma) was prescribed to 60 patients with coronary
heart disease and Type II DM in addition to standard therapy (antiplatelet, statins, peripheral
vasodilators, and calcium antagonist in the pro re nata mode, oral hypoglycemic agents). The
average dose for the group was 80 mg per day during the first weeks, 40 mg/day were
prescribed to 24 patients during the next weeks and 36 patients took 80 mg/day).
The choice of telmisartan which is from the group of angiotensin receptor antagonists (ARA)
is dictated by the results of investigations, according to which there may be a substantial
difference in the influence of drugs on metabolic processes within the ARA drug group [29;
30]. This difference is explained by different ability of individual ARA to activate proliferator
activation receptors by peroxisome of γ type (PPAR-γ), i.e. nuclear factors discovered by their
ability to respond to xenobiotics by peroxisomal proliferation in the liver. According to Bakris
G. [29], attention to PPAR is paid due to their key role in the regulation of lipid and carbohy‐
drate metabolism in general and in the formation of insulin resistance and Type II DM in
particular. The synthesis of PPAR-γ activators gives additional possibilities in the treatment
of Type II DM and metabolic syndrome. However, the breadth of the spectrum of their effects
allows us to think about the potential of their use in primary and secondary prevention of
cardiovascular complications.
To assess the degree of compensation of carbohydrate metabolism, we measured the following
indicators: levels of fasting and postprandial (2 hours after eating) blood glucose (mmol/l) at
each visit, glycated hemoglobin (HbA1c, %), initially and after 40 weeks of observation.
85% of patients with Type II DM and stable angina who took telmisartan in addition to
standard therapy showed subjective improvement in physical condition. Having done the
analysis of anginal attacks in the group, we noted a significant reduction (from 21.7 ±  2.1 to
Ischemic Heart Disease52
14.3 ±  1.1 episodes) in angina attacks per week and a reduced need (from 12.8 ±  1.3 to 5.3 ±
1.1 tablets) for short-nitroglycerin per week by the 40th week of observation.
According to clinical measurements of blood pressure (BP) a significant reduction in office
systolic (SBP) blood pressure and diastolic blood pressure (DBP) was observed among patients
being treated with telmisartan during the test appearances, 95% of patients having target BP
level of SBP. Target BP level of DBP was in 96.7% cases, p <0.05.
According to the ambulatory blood pressure monitoring (ABPM), abnormal profile of blood
pressure trend was observed among 88.3% of patients, most of them (75%) forming the
category of "non-dippers" (patients with lack of normal physiological reduction in blood
pressure at night). However, we identified cases of distorted circadian rhythm with a pre‐
dominantly nocturnal hypertension (13.3%), i.e. the group of "night-pickers".
After 40 weeks of the therapy we received reduction in daily average SBP and DBP, time index
of hypertension for 24 hours, the variability in SBP and DBP (p<0.05) (Table 5).
We observed a normalization of circadian BP profile among 85% of patients that was 96.2% of
patients with abnormal circadian rhythm (non-dipper and night-picker). Therapy with
telmisartan allowed us to reduce indicators of the magnitude and rate of morning increase in
BP. Thus, the magnitude of morning increase in SBP decreased by 49% and the magnitude of
morning increase in DBP decreased by 51.4% while the rate of morning increase in SBP
decreased by 69% and the rate of morning increase in DBP decreased by 62.9% (p<0,03).
Rate Initial After 40 weeks
circadian blood pressure monitoring indicators
Daily average SBP (mmHg) 148.4 ± 11.3* 127.1 ± 3.3
Daily average DBP (mmHg) 89.3 ± 6.7* 77.2 ± 3.1
The daily variability of SBP (mmHg) 21.9 ± 2.8* 15.2 ± 1.7
The daily variability of DBP (mmHg) 16.4 ± 2.3* 9.9 ± 1.1
Time index of systolic hypertension in 24 hours (%) 80.4 ± 5.3* 32.3 ± 5.2
Time index of diastolic hypertension in 24 hours (%) 66.7 ± 3.4* 22.3 ± 2.5
The rate morning increase of SBP (mmHg/h) 29.7 ± 3.2 9.2 ± 1.4
The rate morning increase of DBP (mmHg/h) 17.8 ± 3.1 6.6 ± 1.0
circadian ECG monitoring indicators
DMI (min) 45.3 ± 3.2* 20.7± 1.4
PEMI (min) 14.7 ± 2.5 11.3 ± 1.3
SMI (min) 31.1 ± 2.1* 9.5 ± 1.5
Note: differences were significant between the numerical values of initial rates and rates after 40 weeks of therapy with
telmisartan.
Table 5. Dynamics of functional parameters during therapy with telmisartan
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We indicated the positive dynamics of indicators characterizing the process of left ventricular
remodeling: a decrease in end-diastolic volume (EDV) and end-systolic volume (ESV) by 7.5%
and 8.4%, respectively, and an increase in ejection fraction by 6.6%, p<0.05. The fraction of
systolic shortening of the anterior-posterior size of the left ventricular increased by 8.2%.
Daily rates of myocardial ischemia have undergone significant changes: number of ischemic
episodes decreased from 4.8±0.34 to 2.3±0.3; maximum depth of ST segment depression
decreased from 2.5 ±  0.2 mm to 1.7 ±  0.1 mm; duration of ischemic episodes decreased from
45.3±3.2 min to 20.7 ±  1.4 min. We should emphasize that the positive dynamics was indicated
in most cases when we analyzed data on silent myocardial ischemia: duration of all episodes
of silent myocardial ischemia decreased during the day (p<0.05) and the number of episodes
of silent myocardial ischemia decreased from 2.8±0.4 to 1.2±0.2 per day too.
We explain the result obtained not only by improved circadian BP profile and adequate control,
but also by the presumable ability of the drug to effect myocardial blood flow making coronary
vasodilation and redistributing blood flow towards the subendocardial layers of myocardium,
which are particularly vulnerable to ischemia. We established the correlation of the duration
of painless ST segment depression and a daily index of SBP (R= -0.53, p<0.02), daily index of
DBP (R= -0.61, p<0.03).
These reactive hyperemia tests allowed us to indicate the improvement of vasomotor function
induced by shear stress, endothelium dependent vasodilatation increasing from 3.7±1.1% to
7.2±1.1%. We had positive dynamics of velocity indicators: peak systolic blood flow velocity
increased from 0.84±0.06 m/s to 0.94±0.04 m/s (р<0.05); maximum diastolic blood flow velocity
increased from 0.13±0.03 m/s to 0.18±0.03 m/s (р<0.05); time-averaged maximum flow velocity
increased from 0.29±0.06 to 0.46±0.04 (р<0.05).
Individual analysis  of  the endothelium dependent vasodilatation dynamics during treat‐
ment  with  telmisartan  showed  that  the  number  of  patients  with  impaired  endothelial
function decreased to 51.7%, while the number of persons with pathological vasoconstric‐
tion/vasodilation in the absence of performing the test with reactive hyperemia decreased
by 23.3% (Figure 3.).
Recovery of adequate dilatation response of vessels to reactive hyperemia test is a necessary
link in the chain of effective therapeutic intervention aimed at reducing of cardiovascular risk.
It is known that activation of the RAAS is an indispensable part of the pathogenesis of
endothelial dysfunction, so the use of these drugs in its correction seems most reasonable at
present. The mechanism of endothelial function improvement by drugs blocking the RAAS is
explained at present by the elimination of the adverse effects of ATII [31; 32] having a powerful
vasoconstriction influence by stimulating of AT1-receptor of vascular smooth muscle cells. It
is also considered as an inducer of oxidative stress with production of superoxide anion by
simulation of nicotinamide-adenine-dinucleotide-phosphate; the action of angiotensin II is
opposite to the action of nitric oxide, i.e. oxidase.
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Figure 3. Correction of endothelial vasomotor dysfunction of arteries during the course therapy with telmisartan.
We also associate the resulting effect of telmisartan to improve vasomotor endothelial function
with the complicated mechanism of regulation of the circadian blood pressure variability. In
this sense, control of blood pressure with ARA group drugs can be considered reasonable in
terms of impact on the pathophysiological mechanisms leading to the morning increase of BP,
and in terms of protection of patients at the beginning of drug action during the regular
morning drug intake. This fact may be proved by revealed correlation dependence of the
endothelium dependent vasodilatation dynamics from the time index of hypertension on DBP
for 24 hours (R= -0.64, p<0.003) and the daily index (R= 0.54, p<0.02).
Conducting therapy with telmisartan, we noted a significant decrease in glycated hemoglobin
level from 8.41±0.2% to 6.5±0.4%, a decrease of fasting plasma glucose from 8.72±0.35 mmol/l
to 6.67±0.4 mmol/l (p<0.02) and a decrease of postprandial blood glucose level from 9.2±1.68
to 8.5±1.38 mmol/l (p<0.05). The number of patients who achieved compensation of carbohy‐
drate metabolism in three indices of "glycemic triad" rose from 10% to 23.3%. We indicated the
correlation dependence of endothelium dependent vasodilation dynamics from glycated
hemoglobin (R= -0.56, p <0.05).
We evaluated the dynamics of lipid metabolism indices among patients with Type II DM
during therapy with telmisartan. After 40 weeks we noted an improvement of laboratory
parameters which showed a decrease in total cholesterol by 23%, low-density lipoprotein
cholesterol by 21%, triglycerides by 26% (p<0.05). We explain it by the increase in sensitivity
of tissues to insulin and decreased hyperinsulinemia, which largely determine the metabolism
of lipids in the body.
The data obtained allow us to state that telmisartan has a positive metabolic effect, which has
an additional metabolic effect along with mechanisms of local pancreatic RAAS blocking being
common for all the ARA drugs [33], i.e. agonistic effect on PPAR-ɣ-receptors, which control
the activity of cytokines - the regulators of intercellular interactions, leading to a positive
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We indicated the positive dynamics of indicators characterizing the process of left ventricular
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and 8.4%, respectively, and an increase in ejection fraction by 6.6%, p<0.05. The fraction of
systolic shortening of the anterior-posterior size of the left ventricular increased by 8.2%.
Daily rates of myocardial ischemia have undergone significant changes: number of ischemic
episodes decreased from 4.8±0.34 to 2.3±0.3; maximum depth of ST segment depression
decreased from 2.5 ±  0.2 mm to 1.7 ±  0.1 mm; duration of ischemic episodes decreased from
45.3±3.2 min to 20.7 ±  1.4 min. We should emphasize that the positive dynamics was indicated
in most cases when we analyzed data on silent myocardial ischemia: duration of all episodes
of silent myocardial ischemia decreased during the day (p<0.05) and the number of episodes
of silent myocardial ischemia decreased from 2.8±0.4 to 1.2±0.2 per day too.
We explain the result obtained not only by improved circadian BP profile and adequate control,
but also by the presumable ability of the drug to effect myocardial blood flow making coronary
vasodilation and redistributing blood flow towards the subendocardial layers of myocardium,
which are particularly vulnerable to ischemia. We established the correlation of the duration
of painless ST segment depression and a daily index of SBP (R= -0.53, p<0.02), daily index of
DBP (R= -0.61, p<0.03).
These reactive hyperemia tests allowed us to indicate the improvement of vasomotor function
induced by shear stress, endothelium dependent vasodilatation increasing from 3.7±1.1% to
7.2±1.1%. We had positive dynamics of velocity indicators: peak systolic blood flow velocity
increased from 0.84±0.06 m/s to 0.94±0.04 m/s (р<0.05); maximum diastolic blood flow velocity
increased from 0.13±0.03 m/s to 0.18±0.03 m/s (р<0.05); time-averaged maximum flow velocity
increased from 0.29±0.06 to 0.46±0.04 (р<0.05).
Individual analysis  of  the endothelium dependent vasodilatation dynamics during treat‐
ment  with  telmisartan  showed  that  the  number  of  patients  with  impaired  endothelial
function decreased to 51.7%, while the number of persons with pathological vasoconstric‐
tion/vasodilation in the absence of performing the test with reactive hyperemia decreased
by 23.3% (Figure 3.).
Recovery of adequate dilatation response of vessels to reactive hyperemia test is a necessary
link in the chain of effective therapeutic intervention aimed at reducing of cardiovascular risk.
It is known that activation of the RAAS is an indispensable part of the pathogenesis of
endothelial dysfunction, so the use of these drugs in its correction seems most reasonable at
present. The mechanism of endothelial function improvement by drugs blocking the RAAS is
explained at present by the elimination of the adverse effects of ATII [31; 32] having a powerful
vasoconstriction influence by stimulating of AT1-receptor of vascular smooth muscle cells. It
is also considered as an inducer of oxidative stress with production of superoxide anion by
simulation of nicotinamide-adenine-dinucleotide-phosphate; the action of angiotensin II is
opposite to the action of nitric oxide, i.e. oxidase.
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Figure 3. Correction of endothelial vasomotor dysfunction of arteries during the course therapy with telmisartan.
We also associate the resulting effect of telmisartan to improve vasomotor endothelial function
with the complicated mechanism of regulation of the circadian blood pressure variability. In
this sense, control of blood pressure with ARA group drugs can be considered reasonable in
terms of impact on the pathophysiological mechanisms leading to the morning increase of BP,
and in terms of protection of patients at the beginning of drug action during the regular
morning drug intake. This fact may be proved by revealed correlation dependence of the
endothelium dependent vasodilatation dynamics from the time index of hypertension on DBP
for 24 hours (R= -0.64, p<0.003) and the daily index (R= 0.54, p<0.02).
Conducting therapy with telmisartan, we noted a significant decrease in glycated hemoglobin
level from 8.41±0.2% to 6.5±0.4%, a decrease of fasting plasma glucose from 8.72±0.35 mmol/l
to 6.67±0.4 mmol/l (p<0.02) and a decrease of postprandial blood glucose level from 9.2±1.68
to 8.5±1.38 mmol/l (p<0.05). The number of patients who achieved compensation of carbohy‐
drate metabolism in three indices of "glycemic triad" rose from 10% to 23.3%. We indicated the
correlation dependence of endothelium dependent vasodilation dynamics from glycated
hemoglobin (R= -0.56, p <0.05).
We evaluated the dynamics of lipid metabolism indices among patients with Type II DM
during therapy with telmisartan. After 40 weeks we noted an improvement of laboratory
parameters which showed a decrease in total cholesterol by 23%, low-density lipoprotein
cholesterol by 21%, triglycerides by 26% (p<0.05). We explain it by the increase in sensitivity
of tissues to insulin and decreased hyperinsulinemia, which largely determine the metabolism
of lipids in the body.
The data obtained allow us to state that telmisartan has a positive metabolic effect, which has
an additional metabolic effect along with mechanisms of local pancreatic RAAS blocking being
common for all the ARA drugs [33], i.e. agonistic effect on PPAR-ɣ-receptors, which control
the activity of cytokines - the regulators of intercellular interactions, leading to a positive
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influence on carbohydrate and lipid metabolism and reduction of severity of insulin resistance
(IR) phenomenon.
4. The conclusion
So, patients with coronary heart disease and Type II DM had silent myocardial ischemia 2
times more often than patients with coronary heart disease who had no disorders of carbohy‐
drate metabolism. Patients with coronary heart disease and Type II DM had dominating daily
duration of episodes of myocardial ischemia and a maximum depth of ST segment depression.
Besides, they had reduced endothelium-dependent vasodilation reaction (endothelium-
dependent vasodilation =3.7±1.1%). Violation of the functional state of the vascular endothe‐
lium correlates with the registration frequency (R= -0.68, p<0.05) and duration of episodes of
silent myocardial ischemia (R= -0.53, p<0.01). Endothelial dysfunction of the coronary arteries
which is manifested by blood vessels inability to adequate increase in conditions of increased
myocardial oxygen demand has an influence on the genesis and progression of ischemia.
The results obtained during our research prove that metabolic factors play a significant role
in the development of endothelial dysfunction. To predict vascular complications it is neces‐
sary to assess vasomotor function of arteries endothelium among patients with Type II DM.
Prescribing receptor antagonists of angiotensin II, we take into account organ-protective effects
of drugs, manifested by the selective blockade of the tissue RAAS and indirect stimulation of
the AT2-receptors during their long-term intake.
It is considered to be a proved fact [34; 35] that the increased activity of tissue RAAS causes
long-term effects of angiotensin II (AII), which are manifested in structural and functional
changes in target organs and lead to the development of a number of pathological processes
such as hypertrophy, miofibroz, atherosclerotic lesion of vessels. The research [36] showed
that a human body had alternative ways with chymase, cathepsin G, serine proteases in
addition to ACE-dependent pathway of conversion of angiotensin I to angiotensin II. Accord‐
ing to Elmfeldt D. and colleagues [37], chymase dependent formation of AII prevails in
myocardial interstitium and adventitia and media of vessels, whereas ACE-dependent
formation prevails in blood plasma. This fact explains the risk of AII escape phenomenon
during the long-term intake of ACE (angiotensin-converting enzyme).
Additional metabolic effect of selective antagonist of AT1-receptor of telmisartan is agonistic
effect on PPAR-ɣ-receptors, which is manifested in a significantly improved glucose and lipid
profiles indices. This effect allows us to consider it as the drug of choice in the treatment of
patients suffering a combination of metabolic disorders, hypertension in clinical manifesta‐
tions of stable angina. Correlation analysis showed the dependence of HbA1c on the daily
duration of ST depression episodes (R=0.66, p<0.01) and the duration of asymptomatic ST
depression (R=0.75, p<0.02).
Modern methods in treatment of patients with coronary heart disease and DM allow using a
scheme of the multi-component therapy, in which much attention is given to the improvement
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of endothelial function. It leads to the concurrent positive therapeutic effects of telmisartan on
major links in the chain of cardiovascular complications in Type II DM improving glucose and
blood lipid profile indices, a more pronounced organ protective effect. In addition, it directly
prevents the development of ischemia and its main clinical manifestation.
Summary
The development of ischemic episodes in the absence of pain or angina equivalents (e.g.,
dyspnea, arrhythmias) is possible when a patient has coronary heart disease. Atypical clinical
course makes diagnosis of coronary insufficiency with disorders of carbohydrate metabolism
rather difficult. Having done the analysis of the daily trend of ST segment and the diary records
of patients with DM we have identified a silent myocardial ischemia in 93.3% cases, 60%
patients having a combination of painful and painless episodes of myocardial ischemia. 33.3%
from 93.3% cases of ischemic episodes of ST segment depression were not accompanied by
any subjective symptoms. Patients with coronary heart disease and DM have reduced
endothelium-dependent vasodilation reaction (endothelium-dependent vasodilation
=3.7±1.1%). Violation of the functional state of the vascular endothelium correlates with the
registration frequency (R= -0.68, p<0.05) and duration of episodes of silent myocardial ischemia
(R= -0.53, p<0.01).
Abbreviations
ABPM - ambulatory blood pressure monitoring
ARA - angiotensin receptor antagonists
ATII - angiotensin II
BP - blood pressure
CHD - Coronary Heart Disease
CHF - chronic heart failure
DM - Diabetes Mellitus
DB2 - Type 2 Diabetes Mellitus
ECG – electrocardiogram
ED - endothelial dysfunction
FC - Functional Class
IMC - Intima-Media Complex
IR - insulin resistance
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influence on carbohydrate and lipid metabolism and reduction of severity of insulin resistance
(IR) phenomenon.
4. The conclusion
So, patients with coronary heart disease and Type II DM had silent myocardial ischemia 2
times more often than patients with coronary heart disease who had no disorders of carbohy‐
drate metabolism. Patients with coronary heart disease and Type II DM had dominating daily
duration of episodes of myocardial ischemia and a maximum depth of ST segment depression.
Besides, they had reduced endothelium-dependent vasodilation reaction (endothelium-
dependent vasodilation =3.7±1.1%). Violation of the functional state of the vascular endothe‐
lium correlates with the registration frequency (R= -0.68, p<0.05) and duration of episodes of
silent myocardial ischemia (R= -0.53, p<0.01). Endothelial dysfunction of the coronary arteries
which is manifested by blood vessels inability to adequate increase in conditions of increased
myocardial oxygen demand has an influence on the genesis and progression of ischemia.
The results obtained during our research prove that metabolic factors play a significant role
in the development of endothelial dysfunction. To predict vascular complications it is neces‐
sary to assess vasomotor function of arteries endothelium among patients with Type II DM.
Prescribing receptor antagonists of angiotensin II, we take into account organ-protective effects
of drugs, manifested by the selective blockade of the tissue RAAS and indirect stimulation of
the AT2-receptors during their long-term intake.
It is considered to be a proved fact [34; 35] that the increased activity of tissue RAAS causes
long-term effects of angiotensin II (AII), which are manifested in structural and functional
changes in target organs and lead to the development of a number of pathological processes
such as hypertrophy, miofibroz, atherosclerotic lesion of vessels. The research [36] showed
that a human body had alternative ways with chymase, cathepsin G, serine proteases in
addition to ACE-dependent pathway of conversion of angiotensin I to angiotensin II. Accord‐
ing to Elmfeldt D. and colleagues [37], chymase dependent formation of AII prevails in
myocardial interstitium and adventitia and media of vessels, whereas ACE-dependent
formation prevails in blood plasma. This fact explains the risk of AII escape phenomenon
during the long-term intake of ACE (angiotensin-converting enzyme).
Additional metabolic effect of selective antagonist of AT1-receptor of telmisartan is agonistic
effect on PPAR-ɣ-receptors, which is manifested in a significantly improved glucose and lipid
profiles indices. This effect allows us to consider it as the drug of choice in the treatment of
patients suffering a combination of metabolic disorders, hypertension in clinical manifesta‐
tions of stable angina. Correlation analysis showed the dependence of HbA1c on the daily
duration of ST depression episodes (R=0.66, p<0.01) and the duration of asymptomatic ST
depression (R=0.75, p<0.02).
Modern methods in treatment of patients with coronary heart disease and DM allow using a
scheme of the multi-component therapy, in which much attention is given to the improvement
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of endothelial function. It leads to the concurrent positive therapeutic effects of telmisartan on
major links in the chain of cardiovascular complications in Type II DM improving glucose and
blood lipid profile indices, a more pronounced organ protective effect. In addition, it directly
prevents the development of ischemia and its main clinical manifestation.
Summary
The development of ischemic episodes in the absence of pain or angina equivalents (e.g.,
dyspnea, arrhythmias) is possible when a patient has coronary heart disease. Atypical clinical
course makes diagnosis of coronary insufficiency with disorders of carbohydrate metabolism
rather difficult. Having done the analysis of the daily trend of ST segment and the diary records
of patients with DM we have identified a silent myocardial ischemia in 93.3% cases, 60%
patients having a combination of painful and painless episodes of myocardial ischemia. 33.3%
from 93.3% cases of ischemic episodes of ST segment depression were not accompanied by
any subjective symptoms. Patients with coronary heart disease and DM have reduced
endothelium-dependent vasodilation reaction (endothelium-dependent vasodilation
=3.7±1.1%). Violation of the functional state of the vascular endothelium correlates with the
registration frequency (R= -0.68, p<0.05) and duration of episodes of silent myocardial ischemia
(R= -0.53, p<0.01).
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1. Introduction
Ischemic heart disease continues to be the leading cause of death in most countries and a major
health burden, with approximately 50% of deaths due to sudden cardiac death (SCD) [Zipes
& Wellens, 1998; Wong et al. 2001; Mazeika 2001]. The increasing prevalence of diabetes will
also impact on SCD incidence. Patients with either type 1 or type 2 diabetes have significantly
higher mortality and morbidity following acute myocardial infarction (AMI) than do the rest
of the population. Other conditions such as hypertension, hypertrophic cardiomyopathy,
aortic stenosis and aging may also increase the risk of SCD. Sex differences in prevalence and
clinical outcomes are recognised [Bairey et al. 2006; Wake et al. 2007], although many random‐
ized clinical trials do not have adequate numbers of women to allow sex-specific analyses
[Xhyheri & Bugiardini 2010; Melloni et al. 2010]. Ischemic heart disease is the primary cause
of death for women at all ages, with annual mortality rates for women 35-55 years greater than
breast cancer [Bell et al. 2000] and approximately 81% of deaths in low- and middle-income
countries [Mosca et al. 2011]. The incidence of SCD differs according to geographical region
depending on the prevalence of coronary or ischemic heart disease [Priori et al. 2001]. In the
United States, during 1989 to 1998, there was markedly less of a decline in SCD rates among
women than for men - women aged 35 to 44 years had a 21% increased SCD rate compared
with a 2.8% decline for men of the same age group [Zheng et al. 2001]. During the same period,
women were dying of a cardiac arrest before hospital arrival (52%) compared with 42% for
men [Shaw et al. 2006]. Compared to males women are generally older when presenting with
AMI [Canto et al. 2012] and with women’s longer life expectancy, the estimates are expected
to rise even further in future decades. Although risk factors for IHD and SCD are often assumed
to be similar in women and men, there are also differences. For instance, SCD will occur before
any other signs of coronary heart disease in women [de Vreede-Swagemakers et al. 1997;
Kannel et al. 1998; Albert et al. 2003] whereas ventricular dysrhythmias following AMI,
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1. Introduction
Ischemic heart disease continues to be the leading cause of death in most countries and a major
health burden, with approximately 50% of deaths due to sudden cardiac death (SCD) [Zipes
& Wellens, 1998; Wong et al. 2001; Mazeika 2001]. The increasing prevalence of diabetes will
also impact on SCD incidence. Patients with either type 1 or type 2 diabetes have significantly
higher mortality and morbidity following acute myocardial infarction (AMI) than do the rest
of the population. Other conditions such as hypertension, hypertrophic cardiomyopathy,
aortic stenosis and aging may also increase the risk of SCD. Sex differences in prevalence and
clinical outcomes are recognised [Bairey et al. 2006; Wake et al. 2007], although many random‐
ized clinical trials do not have adequate numbers of women to allow sex-specific analyses
[Xhyheri & Bugiardini 2010; Melloni et al. 2010]. Ischemic heart disease is the primary cause
of death for women at all ages, with annual mortality rates for women 35-55 years greater than
breast cancer [Bell et al. 2000] and approximately 81% of deaths in low- and middle-income
countries [Mosca et al. 2011]. The incidence of SCD differs according to geographical region
depending on the prevalence of coronary or ischemic heart disease [Priori et al. 2001]. In the
United States, during 1989 to 1998, there was markedly less of a decline in SCD rates among
women than for men - women aged 35 to 44 years had a 21% increased SCD rate compared
with a 2.8% decline for men of the same age group [Zheng et al. 2001]. During the same period,
women were dying of a cardiac arrest before hospital arrival (52%) compared with 42% for
men [Shaw et al. 2006]. Compared to males women are generally older when presenting with
AMI [Canto et al. 2012] and with women’s longer life expectancy, the estimates are expected
to rise even further in future decades. Although risk factors for IHD and SCD are often assumed
to be similar in women and men, there are also differences. For instance, SCD will occur before
any other signs of coronary heart disease in women [de Vreede-Swagemakers et al. 1997;
Kannel et al. 1998; Albert et al. 2003] whereas ventricular dysrhythmias following AMI,
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contribute to increased risk in men but not women [Dahlberg, 1990; Kim et al. 2001]. There
may are also be differences in mechanisms for SCD between older and premenopausal or
middle aged women. This chapter will review the sex differences in mechanism of SCD and
possible treatment strategies.
2. Ischemic heart disease and sudden cardiac death
Cardiovascular disease (CVD) is the primary cause of death globally with 17.3 million deaths
in 2008, representing approximately 50% of non-communicable disease deaths [World Health
Report (WHO), 2012]. Of these deaths, approximately 7.3 million (42%) were due to ischemic
heart disease (IHD). Figure 1 shows the proportion of IHD deaths according to income status
(data adapted from WHO Report 2012]. In middle- and high-income countries, IHD was the
primary cause of deaths, whereas it was fourth highest in low-income countries. In the United
States, coronary heart disease (CHD) resulted in 1 of every 6 deaths in 2008. According to the
recent American Heart Association report [Roger et al. 2012], there is a coronary event
approximately every 25 seconds, and approximately one death every minute. More women
(64%) than men (50%) die suddenly of coronary heart disease without any previous symptoms
of this disease, while people with previous AMI have sudden death rates 4 to 6 times that of
the general population [Roger et al. 2012].
Figure 1. Ischemic heart disease deaths according to income status
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The prevalence of SCD varies depending on the definition used between different studies.
Another confounder is that many sudden deaths are not witnessed, and without cardiac
monitoring at the time of death. Prevalence may vary from 13% when SCD is defined as death
suddenly or unexpectedly within an hour of onset of symptoms, to 18.5% of all deaths when
this period is extended to 24 hours after onset of symptoms [de Vreede-Swagemakers et al.
1997]. Most studies report that SCD results from a fatal cardiac arrhythmia, either degeneration
of ventricular tachycardia (VT) into ventricular fibrillation(VF), leading to disorganized
ventricular contraction or severe bradycardia or pulseless electrical activity [Lane et al. 2005].
Ventricular arrhythmias have been documented in 85% of patients with severe congestive
heart failure [Singh et al. 1997]. Dilated nonischemic and hypertrophic cardiomyopathies
contribute to the next largest number of SCDs, whereas other cardiac disorders, including
congenital heart defects and genetically determined ion channel anomalies, contribute 5–10%
of SCDs [Lane et al. 2005].
3. Risk factors for sudden cardiac death
To determine the risk factors for SCD many studies examine the same traditional factors
associated with IHD, which include systolic blood pressure, dyslipidemia, smoking, obesity,
heavy alcohol consumption, diabetes mellitus and age [Kannel et al. 1985; Jouven et al. 1999;
Khot et al. 2003; Sandhu et al. 2012], summarised in Table 1. Subjects with inherited arrhyth‐
mogenic disorders such as long-QT syndrome and Brugada syndrome are also at increased
risk for SCD. Similar risk factors for men and women were identified in the Framingham Study
which compared 2873 women with 2336 men aged 30 to 62 years [Schatzkln et al.1984; Kannel
et al. 1998]. Similar to IHD, the presence of hypertension and diabetes increased the risk of
SCD at all ages, whereas at all ages, sudden death risk ratios associated with diabetes were
greater in women than men. Interestingly, the risk factors of hematocrit and vital capacity,
predicted SCD in women but not men [Schatzkln et al. 1984]. Risk factors may also differ
between premenopausal and older women. For instance, coronary heart disease (CHD) death
in premenopausal women is due to plaque erosions with minimal coronary artery narrowing,
whereas older women have high cholesterol levels and plaque rupture, with severe coronary
artery narrowing [Canto et al. 2012].
As noted in Table 1, the risk factors for SCD are not consistently recorded and ventricular
ectopy is one risk factor which is omitted since some of the deaths may have occurred in the
absence of monitoring. Trials which have targeted only suppressing this ectopy to prevent
SCD have not been successful and possibly hazardous [Akiyama et al. 1991]. Parental history
of MI before age 60 years has also been identified as a risk factor for SCD, but only among
women younger than age 60 years. The traditional factors for IHD also elevate the risk of
SCD by 2- to 4-fold and include hypertension, diabetes and smoking [Albert et al. 2003].
Smoking was identified as a strong risk factor for SCD among young women (<60 years).
Since  it  is  a  modifiable  risk  factor,  Sandhu  and  colleagues  (2012)  recently  reported  a
prospective  study showing that  smoking cessation  significantly  reduced and eliminated
excess SCD risk [Sandhu et al. 2012].
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contribute to increased risk in men but not women [Dahlberg, 1990; Kim et al. 2001]. There
may are also be differences in mechanisms for SCD between older and premenopausal or
middle aged women. This chapter will review the sex differences in mechanism of SCD and
possible treatment strategies.
2. Ischemic heart disease and sudden cardiac death
Cardiovascular disease (CVD) is the primary cause of death globally with 17.3 million deaths
in 2008, representing approximately 50% of non-communicable disease deaths [World Health
Report (WHO), 2012]. Of these deaths, approximately 7.3 million (42%) were due to ischemic
heart disease (IHD). Figure 1 shows the proportion of IHD deaths according to income status
(data adapted from WHO Report 2012]. In middle- and high-income countries, IHD was the
primary cause of deaths, whereas it was fourth highest in low-income countries. In the United
States, coronary heart disease (CHD) resulted in 1 of every 6 deaths in 2008. According to the
recent American Heart Association report [Roger et al. 2012], there is a coronary event
approximately every 25 seconds, and approximately one death every minute. More women
(64%) than men (50%) die suddenly of coronary heart disease without any previous symptoms
of this disease, while people with previous AMI have sudden death rates 4 to 6 times that of
the general population [Roger et al. 2012].
Figure 1. Ischemic heart disease deaths according to income status
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The prevalence of SCD varies depending on the definition used between different studies.
Another confounder is that many sudden deaths are not witnessed, and without cardiac
monitoring at the time of death. Prevalence may vary from 13% when SCD is defined as death
suddenly or unexpectedly within an hour of onset of symptoms, to 18.5% of all deaths when
this period is extended to 24 hours after onset of symptoms [de Vreede-Swagemakers et al.
1997]. Most studies report that SCD results from a fatal cardiac arrhythmia, either degeneration
of ventricular tachycardia (VT) into ventricular fibrillation(VF), leading to disorganized
ventricular contraction or severe bradycardia or pulseless electrical activity [Lane et al. 2005].
Ventricular arrhythmias have been documented in 85% of patients with severe congestive
heart failure [Singh et al. 1997]. Dilated nonischemic and hypertrophic cardiomyopathies
contribute to the next largest number of SCDs, whereas other cardiac disorders, including
congenital heart defects and genetically determined ion channel anomalies, contribute 5–10%
of SCDs [Lane et al. 2005].
3. Risk factors for sudden cardiac death
To determine the risk factors for SCD many studies examine the same traditional factors
associated with IHD, which include systolic blood pressure, dyslipidemia, smoking, obesity,
heavy alcohol consumption, diabetes mellitus and age [Kannel et al. 1985; Jouven et al. 1999;
Khot et al. 2003; Sandhu et al. 2012], summarised in Table 1. Subjects with inherited arrhyth‐
mogenic disorders such as long-QT syndrome and Brugada syndrome are also at increased
risk for SCD. Similar risk factors for men and women were identified in the Framingham Study
which compared 2873 women with 2336 men aged 30 to 62 years [Schatzkln et al.1984; Kannel
et al. 1998]. Similar to IHD, the presence of hypertension and diabetes increased the risk of
SCD at all ages, whereas at all ages, sudden death risk ratios associated with diabetes were
greater in women than men. Interestingly, the risk factors of hematocrit and vital capacity,
predicted SCD in women but not men [Schatzkln et al. 1984]. Risk factors may also differ
between premenopausal and older women. For instance, coronary heart disease (CHD) death
in premenopausal women is due to plaque erosions with minimal coronary artery narrowing,
whereas older women have high cholesterol levels and plaque rupture, with severe coronary
artery narrowing [Canto et al. 2012].
As noted in Table 1, the risk factors for SCD are not consistently recorded and ventricular
ectopy is one risk factor which is omitted since some of the deaths may have occurred in the
absence of monitoring. Trials which have targeted only suppressing this ectopy to prevent
SCD have not been successful and possibly hazardous [Akiyama et al. 1991]. Parental history
of MI before age 60 years has also been identified as a risk factor for SCD, but only among
women younger than age 60 years. The traditional factors for IHD also elevate the risk of
SCD by 2- to 4-fold and include hypertension, diabetes and smoking [Albert et al. 2003].
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In considering risk factors for IHD and SCD, one cannot overlook how endogenous levels of
sex hormones may be contributing. Men and women show differences in ECG repolarization
with QT prolongation in women, while male hearts from many species are hypertrophied
relative to female hearts [Marsh et al. 1998]. In premenopausal women with normal ovulation,
estrogen and other endogenous hormones provide cardioprotection and lower incidence of
IHD compared to age-matched men. In contrast, during menopause, there is a fall in estrogen
levels to approximately one-tenth that of premenopausal levels [Paoletti et al. 1997] and
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estrogen. In the Women’s Ischemia Syndrome Evaluation (WISE) Study premenopausal
women that had a stress-induced disruption in ovulatory cycling with resulting low levels of
estrogen had a 7.4-fold increased risk of obstructive coronary artery disease [Shaw et al.
2006]. Although there is increased focus on the lack of estrogen, the role of androgens should
also be considered, given that they activate atherosclerotic-related genes in men but not women
and activate androgen receptors in cardiac myocytes of both men and women, to produce
hypertrophy [Marsh et al. 1999].
The risk factors for IHD common in postmenopausal women, include obesity, hypertension,
and dyslipidemia. Menopausal women also have a greater loss in physical functioning com‐
pared to men [Poehlman 2002], which aggravates weight gain, insulin resistance, and hyperten‐
sion [Shaw et al. 2006]. Loss of ovarian estrogen during menopause is also associated with
redistribution of abdominal fat, further increasing the risk of IHD [Lamon-Fava et al. 1996]. The
role of hormone replacement therapy (HRT) for postmenopausal women has been controver‐
sial. This is due to conflicting results from observational trials performed prior to 2002 which
showed a reduction in risk of cardiovascular disease, osteoporosis, and colon cancer whereas
large randomized clinical trials such as the Women’s Health Initiative showed no cardiovascu‐
lar benefit from hormone replacement therapy [Schierbeck et al. 2012]. The timing of initiating
hormone therapy has been suggested as a possible explanation for these conflicting results. The
observational studies started hormone therapy shortly after menopause, whereas the large
randomised studies, which showed no or negative cardiovascular effects, initiated hormone
therapy 5 to 20 years after menopause. The recent prospective, multicentre, HRT study, the
Danish Osteoporosis Prevention Study (DOPS) was initiated to evaluate HRT as primary
prevention for osteoporotic fractures [Schierbeck et al. 2012]. Healthy, recently postmenopaus‐
al women (within 7 months) aged 45-58 were recruited to the study and were randomly allocated
to receive HRT or no treatment (control). Treatment ceased after 11 years although partici‐
pants were followed for death, cardiovascular disease, and cancer for a further 5 years (total 16
years).Following 10 years randomised treatment, women receiving HRT early after meno‐
pause had significantly reduced risk of mortality, heart failure, or myocardial infarction, without
any increase in risk of cancer, venous thromboembolism, or stroke.
4. Mechanism of sudden cardiac death
Sustained VT and VF are responsible for at least two thirds of sudden cardiac deaths [Huikuri
et al. 2001] with sex-differences in arrhythmic SCD reported [Orencia et al. (1993); Kannel et al.
(1998); Zheng et al. (2001); Abildstrom et al. (2002); Adabag et al. (2008); Verheugt et al. (2008)].
Pre-existing coronary heart disease significantly contributes to SCD in men [Lane et al. 2005]
whereas women are 66% less likely to be diagnosed with coronary heart disease before SCD
[Albert et al. 1996; Chiuve et al. (2011)]. Several studies have investigated whether sex dispari‐
ties in the risk factors for SCD may contribute to these differences. Atherogenic risk factors were
found to be predictive in men but not women. Similarly, asymptomatic ventricular dysrhyth‐
mias are an independent risk for death in men but have not been shown to be a risk for women
[Dahlberg, 1990]. Patients with congestive heart failure due to cardiomyopathy or ischemic heart
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estrogen. In the Women’s Ischemia Syndrome Evaluation (WISE) Study premenopausal
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also be considered, given that they activate atherosclerotic-related genes in men but not women
and activate androgen receptors in cardiac myocytes of both men and women, to produce
hypertrophy [Marsh et al. 1999].
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and dyslipidemia. Menopausal women also have a greater loss in physical functioning com‐
pared to men [Poehlman 2002], which aggravates weight gain, insulin resistance, and hyperten‐
sion [Shaw et al. 2006]. Loss of ovarian estrogen during menopause is also associated with
redistribution of abdominal fat, further increasing the risk of IHD [Lamon-Fava et al. 1996]. The
role of hormone replacement therapy (HRT) for postmenopausal women has been controver‐
sial. This is due to conflicting results from observational trials performed prior to 2002 which
showed a reduction in risk of cardiovascular disease, osteoporosis, and colon cancer whereas
large randomized clinical trials such as the Women’s Health Initiative showed no cardiovascu‐
lar benefit from hormone replacement therapy [Schierbeck et al. 2012]. The timing of initiating
hormone therapy has been suggested as a possible explanation for these conflicting results. The
observational studies started hormone therapy shortly after menopause, whereas the large
randomised studies, which showed no or negative cardiovascular effects, initiated hormone
therapy 5 to 20 years after menopause. The recent prospective, multicentre, HRT study, the
Danish Osteoporosis Prevention Study (DOPS) was initiated to evaluate HRT as primary
prevention for osteoporotic fractures [Schierbeck et al. 2012]. Healthy, recently postmenopaus‐
al women (within 7 months) aged 45-58 were recruited to the study and were randomly allocated
to receive HRT or no treatment (control). Treatment ceased after 11 years although partici‐
pants were followed for death, cardiovascular disease, and cancer for a further 5 years (total 16
years).Following 10 years randomised treatment, women receiving HRT early after meno‐
pause had significantly reduced risk of mortality, heart failure, or myocardial infarction, without
any increase in risk of cancer, venous thromboembolism, or stroke.
4. Mechanism of sudden cardiac death
Sustained VT and VF are responsible for at least two thirds of sudden cardiac deaths [Huikuri
et al. 2001] with sex-differences in arrhythmic SCD reported [Orencia et al. (1993); Kannel et al.
(1998); Zheng et al. (2001); Abildstrom et al. (2002); Adabag et al. (2008); Verheugt et al. (2008)].
Pre-existing coronary heart disease significantly contributes to SCD in men [Lane et al. 2005]
whereas women are 66% less likely to be diagnosed with coronary heart disease before SCD
[Albert et al. 1996; Chiuve et al. (2011)]. Several studies have investigated whether sex dispari‐
ties in the risk factors for SCD may contribute to these differences. Atherogenic risk factors were
found to be predictive in men but not women. Similarly, asymptomatic ventricular dysrhyth‐
mias are an independent risk for death in men but have not been shown to be a risk for women
[Dahlberg, 1990]. Patients with congestive heart failure due to cardiomyopathy or ischemic heart
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disease have the highest rate of SCD, although the contributing factors remain poorly defined.
Recent studies have suggested that genetic or environmental factors may predispose to fatal
ventricular arrhythmia, particularly in women. However, mutations or rare variants in the
cardiac sodium channel SCN5A were found in <2% cases screened and further studies are
required [Albert et al. 2008]. Stress cardiomyopathy, also known as takotsubo cardiomyop‐
athy, transient apical ballooning or broken heart syndrome is found predominantly in postme‐
nopausal women [Nef et al. 2010]. Emotional or physical stress trigger symptom onset, which is
similar to those in AMI, including sudden onset of chest pain associated with ST-segment
elevation, and moderate increases in creatine kinase and troponin levels. Prognosis for stress
cardiomyopathy is favorable, although fatal complications may occur, including cardiogenic
shock, malignant arrhythmias and left ventricular free wall rupture.
Cardiac remodelling following either ischemia or AMI initially develops to compensate for
failing cardiac function with evidence of hypertrophy, cardiomyocyte apoptosis, inflammation
and fibrosis. Initially these changes are beneficial but ultimately transition to deteriorating
cardiac function and lead to heart failure [Abel et al. 2008]. Although left ventricular (LV)
dysfunction significantly increases the risk of SCD [Anand et al. 2006; Stecker et al. 2006], other
risk factors need to be considered since women are 50% less likely to exhibit severe LV
dysfunction, with structurally normal hearts identified at autopsy [Chugh et al. 2003].
Alternative mechanisms of SCD therefore need to be considered, given that women with
coronary heart disease have significantly lower risk for SCD.
The renin-angiotensin-aldosterone system (RAAS) plays a significant role in ischemic heart
disease and AMI and blockade of this system has emerged as an important therapeutic
intervention. Elevated plasma aldosterone levels are an independent risk factor for mortality
during AMI [Beygui et al. 2006; Palmer et al. 2008] and are predictive of cardiovascular events
in acute coronary syndrome in the presence or absence of AMI [Tomaschitz et al. 2010].
Aldosterone exerts its actions by interacting with its receptor, the mineralocorticoid receptor
(MR) or “aldosterone” receptor. Both aldosterone and the physiological glucocorticoids
(cortisol (humans)/corticosterone (rodents), which are at 100-fold higher circulating levels bind
to the MR. Selective activation of MR in target tissues is achieved by co-expression of the
enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HDS2). In contrast with vascular and
renal tissues, 11βHSD2 is not expressed in cardiomyocytes [Sheppard & Autelitano 2002], and
therefore endogenous glucocorticoids normally do not mimic aldosterone, but act as MR
antagonists [Gomez et al 1990; Sato & Funder, 1996; Young & Funder, 1996]. Redox regulation
has been shown to modulate glucocorticoid hormone action in vivo [Makino et al. 1999] and
expression of oestrogen receptors [Tamir et al. 2002]. For every molecule of cortisol converted
to cortisone, one molecule of the pyridine nucleotide NAD is reduced to NADH. Since NADH
has been shown to activate corepressors for other transcription factors in various systems
[Zhang et al. 2002; Fjeld et al. 2003], and changes in redox state may determine cardiomyocyte
MR activation by glucocorticoids [Mihailidou et al. 2009].
Elevated aldosterone levels promote electrical remodelling through activation of MR or
“aldosterone” receptors, thus potentially increasing the incidence of sudden cardiac death. In
experimental studies, aldosterone has a direct effect on cardiomyocyte calcium [Ouvrard-
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Pascaud et al. 2005] and sodium [Mihailidou et al. 2000] as well as producing hypokalemia
and hypomagnesemia [Mihailidou et al. 2002]. These electrolyte imbalances have been
translated clinically with the Framingham Heart Study showing that low serum concentrations
of potassium and magnesium were linked to increased risk of SCD. A decrease in potassium
of 0.48 mEq/litre or magnesium of 0.16 mEq/litre level was associated with a 27% (C.I. 6% -
51%) and a 20% (C.I. 3% - 41%) greater odds of complex or frequent ventricular premature
contractions [Tsuji et al. 1994].
Possible other targets include the gap junction connexins and identifying whether they are
regulated differently between males and females. Connexins allow rapid and coordinated
electrical excitation and facilitate intercellular exchange of small molecules. Experimental studies
have shown that normal gap junction expression and phosphorylation in the heart is essential
for organized myocellular electrical activity [Stauffer et al. 2011]. Interestingly female hearts have
higher levels of cardiac connexin 43 (Cx43) [Tribulova et al. 2005] and lower lethal arrhythmia
susceptibility [Knezl et al. 2008]. Further studies are required to confirm whether abnormali‐
ties in cardiac Cx43 expression and phosphorylation are the primary trigger of arrhythmogene‐
sis, since this occurs prior to other structural remodelling changes [Stauffer et al. 2011].
Recent studies have explored the role of microRNAs (miRNAs) in many biological and
pathological processes and the role of circulating miRNAs as sensitive biomarkers with
aberrant expression of miRNA directly reflecting disease state. Ai and colleagues (2010),
recently found upregulated cardiac miR-1 in an animal model of AMI, with similar increases
in plasma in patients with AMI. These increased miR-1 levels correlated with abnormal QRS
widening in AMI [Ai et al. 2010]. Over-expression of miR-1 has been shown to induce and
aggravate arrhythmogenesis. The mechanism proposed is by impairing cardiac conduction by
post-transcriptional repression of KCNJ2 that encodes the inward rectifier K+ channel subunit
Kir2.1 and GJA1 which encode connexin 43 gap junction channels [Yang et al. 2007].
5. Treatment strategies
Primary prevention of SCD continues to be a public health challenge since most deaths are
among people who were not identified as high risk prior to the event. Implantable cardiovert‐
er–defibrillator (ICD) therapy is the current recommended treatment strategy for high risk
patients with severe left ventricular dysfunction (Sudden Cardiac Death in Heart Failure Trial
(SCDHeFT), [Bardy et al. 2005]. Subgroup analysis in SCDHeFT as well as in another primary
prevention trial, the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation
(DEFINITE) [Kadish et al. 2004] suggested that women may receive less benefit from ICD
therapy than men. Interestingly in both these large trials, only 24%-30% of participants and
since women have a lower incidence of VF compared to men [Kim et al. 2001; Wigginton et al.
2002] and therefore may not have been adequately powered to determine the influence of
gender on outcome for ICD therapy.
ICDs treat (but do not prevent) the ventricular arrhythmias and therefore increased morbidity
remains. ICD therapy is rarely considered where LV function is preserved, except in specific
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2002] and therefore may not have been adequately powered to determine the influence of
gender on outcome for ICD therapy.
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conditions with increased SCD risk such as hypertrophic obstructive cardiomyopathy, long QT
and Brugada syndromes,  and idiopathic  VF [DiMarco 2003].  A community-based study
conducted by Stecker and colleagues (2006) showed that only 30% of patients that died from
SCD previously had sufficiently decreased LV systolic function to meet the criteria for ICD
implantation. Patients with normal LV systolic function were generally younger, predominant‐
ly female and less likely to have an established diagnosis of coronary heart disease. Since ICDs
treat the arhythmia but not prevent the underlying cause, there is a need to find new treat‐
ment strategies that target the cellular mechanisms involved. Standard antiarrhythmic medica‐
tion has not reduced (and in some cases, has increased), the incidence of SCD [Lane et al. 2005].
Suitable adjunct treatment in the primary and secondary prevention of SCD includes beta
blockers and non-anti-arrhythmic agents, i.e., those that do not directly target the electrophysio‐
logical action in cardiac muscle or specialized conduction system, such as angiotensin convert‐
ing  enzyme  inhibitors  (ACEI),  angiotensin  receptor–blockers,  lipid-lowering  agents,
aldosterone or MR antagonists, thrombolytic and antithrombotic agents [Lane et al. 2005].
It is worth considering the role of aldosterone or MR blockade for both primary prevention of
SCD for those at high-risk and as an adjunct therapy based on the important findings from the
large randomized clinical studies, the Randomized ALdactone Evaluation Study (RALES) [Pitt
et al. 1999] and the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and
Survival Study (EPHESUS) [Pitt et al. 2003], which showed a significant reduction in SCD. The
first of these trials, RALES, was a double blind study in patients who had severe heart failure
with left ventricular systolic dysfunction and were receiving standard therapy including ACE
inhibitor treatment, a loop diuretic, and digoxin. Patients were randomly assigned to receive
low dose MR antagonist, spironolactone or placebo added to their standard treatment. The
trial was discontinued early due to an interim analysis showing the addition of spironolactone
resulted in a 30% reduction in mortality and reducing SCD by 29%. In the next study, EPHESUS
[Pitt et al. 2003] was designed to determine whether selective MR blockade with eplerenone
could be tolerated by patients with acute myocardial infarction (AMI) complicated by heart
failure due to systolic left ventricular dysfunction. Addition of the selective MR antagonist,
eplerenone, substantially increased survival (15% reduction in mortality) and decreased
hospitalization, and had a 21% reduction in SCD.
6. Conclusion
Since women do not present with severe left ventricular dysfunction and diagnosed CHD
before SCD, they will not receive the current recommended treatment. Prospective studies are
required that have the same proportion of women to men with ischemic heart disease to
identify the sex-specific risk factors and pathophysiology of ischemic heart disease in women
which leads to an adverse cardiovascular outcome [Malenka et al. 2002]. Further investigations
are required to examine whether women will show the same benefit to adjunct treatment with
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor–blocking agents, lipid-
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conditions with increased SCD risk such as hypertrophic obstructive cardiomyopathy, long QT
and Brugada syndromes,  and idiopathic  VF [DiMarco 2003].  A community-based study
conducted by Stecker and colleagues (2006) showed that only 30% of patients that died from
SCD previously had sufficiently decreased LV systolic function to meet the criteria for ICD
implantation. Patients with normal LV systolic function were generally younger, predominant‐
ly female and less likely to have an established diagnosis of coronary heart disease. Since ICDs
treat the arhythmia but not prevent the underlying cause, there is a need to find new treat‐
ment strategies that target the cellular mechanisms involved. Standard antiarrhythmic medica‐
tion has not reduced (and in some cases, has increased), the incidence of SCD [Lane et al. 2005].
Suitable adjunct treatment in the primary and secondary prevention of SCD includes beta
blockers and non-anti-arrhythmic agents, i.e., those that do not directly target the electrophysio‐
logical action in cardiac muscle or specialized conduction system, such as angiotensin convert‐
ing  enzyme  inhibitors  (ACEI),  angiotensin  receptor–blockers,  lipid-lowering  agents,
aldosterone or MR antagonists, thrombolytic and antithrombotic agents [Lane et al. 2005].
It is worth considering the role of aldosterone or MR blockade for both primary prevention of
SCD for those at high-risk and as an adjunct therapy based on the important findings from the
large randomized clinical studies, the Randomized ALdactone Evaluation Study (RALES) [Pitt
et al. 1999] and the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and
Survival Study (EPHESUS) [Pitt et al. 2003], which showed a significant reduction in SCD. The
first of these trials, RALES, was a double blind study in patients who had severe heart failure
with left ventricular systolic dysfunction and were receiving standard therapy including ACE
inhibitor treatment, a loop diuretic, and digoxin. Patients were randomly assigned to receive
low dose MR antagonist, spironolactone or placebo added to their standard treatment. The
trial was discontinued early due to an interim analysis showing the addition of spironolactone
resulted in a 30% reduction in mortality and reducing SCD by 29%. In the next study, EPHESUS
[Pitt et al. 2003] was designed to determine whether selective MR blockade with eplerenone
could be tolerated by patients with acute myocardial infarction (AMI) complicated by heart
failure due to systolic left ventricular dysfunction. Addition of the selective MR antagonist,
eplerenone, substantially increased survival (15% reduction in mortality) and decreased
hospitalization, and had a 21% reduction in SCD.
6. Conclusion
Since women do not present with severe left ventricular dysfunction and diagnosed CHD
before SCD, they will not receive the current recommended treatment. Prospective studies are
required that have the same proportion of women to men with ischemic heart disease to
identify the sex-specific risk factors and pathophysiology of ischemic heart disease in women
which leads to an adverse cardiovascular outcome [Malenka et al. 2002]. Further investigations
are required to examine whether women will show the same benefit to adjunct treatment with
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor–blocking agents, lipid-
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1. Introduction
Acute Myocardial Infarction (AMI) is both a common and deadly type of cardiac event in
the United States. Although the age-adjusted hospitalization rate for AMI and its in-hospital
case fatality rates have both declined since the mid-1990s, there were still 634,000 inpatient
admissions in 2009 for which AMI was listed as the primary diagnosis [1, 2]. Moreover,
Americans suffered an estimated 610,000 first-time AMIs and 325,000 recurrent attacks, and
133,958 deaths in 2008 [2]. Because the declines in hospitalization and in-hospital mortality
rates have been associated with more aggressive therapeutic interventions [1], it is impor‐
tant to evaluate the cost-effectiveness of these interventions.
To evaluate specifically the cost-effectiveness of various interventions against AMI, direct cost
estimates of AMI are required [3-5]. Surprisingly, however, these cost estimates have not been
comprehensively examined in the U.S. Many studies have investigated the economic burden
of AMI, but all had some limitations [6-17]. Furthermore, in part because of limitations in avail‐
able studies, the costs of coronary heart disease (CHD) were used in one study to represent the
costs for AMI [6], albeit this is inappropriate. For example, a previous study of insured adults
aged 18-64 years found that only about 30% of CHD cases represented AMI [9]. Moreover, the
American Heart Association recently estimated that the total prevalence of CHD among per‐
sons aged ≥20 years was 7% but the AMI prevalence of AMI in this group was 3.1% [2]. In addi‐
tion, in 2005, hospitalization costs for AMI admissions among adults aged 18-64 years were
about $5000 more than those for CHD admissions of non-AMI [9]. Clearly, information on
costs that does not clearly distinguish between AMI and non-AMI admissions is of little use in
evaluating the cost-effectiveness of interventions to treat AMI [18].
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In the present study we estimated AMI-specific costs by exploring the hospitalization costs
of AMI while incorporating the impacts on costs of percutaneous coronary intervention
(PCI), coronary artery bypass graft (CABG) surgery, comorbidities, complications, ST-eleva‐
tion status, and length of stay (LOS) while controlling for age, sex, geographic regions, and
urban versus non-urban location. Because PCI, CABG surgery, and LOS are likely to be the
most influential factors on the costs and relevant factors for evaluating cost-effectiveness of
AMI interventions, we also conducted multivariate logistic regressions to identify the fac‐
tors predicting PCI, CABG surgery, and LOS.
2. Methods
2.1. Data source
The 2006-2008 MarketScan Commercial Claims and Encounter inpatient database was used for
this study; this database contains information on patients up to age 64 years from approxi‐
mately 40 privately insured employers, including state governments, with an average of near‐
ly 21 million covered lives per year. In 2006-2008 the database had more than 2.4 billion service
records representing commercially insured employees,  qualified retirees and dependents
from over 100 geographically diverse health insurance plans in all 50 U.S. states and the Dis‐
trict of Columbia. The advantages of using the MarketScan database for economic studies in‐
clude the large sample, detailed diagnosis codes for medical services, and hospitalization costs
that are based on payment to providers [19]. Many researchers have used the MarketScan data‐
base to investigate medical costs associated with cardiovascular disease [9, 20, 21]
Using the International Classification of Diseases, 9th revision (ICD-9) codes, we identified
hospitalizations with a primary diagnosis of AMI among patients aged 18-64 years who
were enrolled in non-capitated health insurance plans. We further separated the hospitaliza‐
tions into ST-elevated myocardial infarction (STEMI) and non-ST-elevated myocardial in‐
farction (NSTEMI) cases. Based on secondary diagnosis codes, we identified major
comorbidities, complications, and procedures for these hospitalizations (Table 1).
We excluded patients younger than 18 years because AMI is very uncommon in that group.
We did not include patients in capitated health insurance plans because their costs of hospital‐
ization would not reflect the medical services provided to them. We excluded hospitalizations
with a LOS greater than 30 days because we determined that these hospitalizations (n=131, fig‐
ure 1) would skew our results. To further limit the influence of extreme values on the cost esti‐
mates, we excluded all hospitalizations with a cost in the lowest or highest 1% of values (Figure
1). The costs in our study included all those for physician services, diagnostic tests, therapeu‐
tics, supplies, and room fees during the hospitalizations. These costs, as noted above, repre‐
sented total payment to providers rather than hospital charges. Accordingly, we did not need
to adjust charges into payments to reflect the true economic burden of hospitalizations, nor did
we use unit cost per bed day or an expert panel’s suggested cost as in many other studies [5, 11,
7, 22, 23]. We expressed the costs in 2008 dollars by adjusting the 2006 and 2007 value by the
consumer price index (CPI) provided by the Bureau of Labor Statistics [24].
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410.01, 410.11. 410.21. 410.31
410.71









Ventricular fibrillation 427.41, 427.42
Atrial tachycardia 427.0
Atrial fibrillation 427.31, 427.32
PCI 92980-92982, 92984, 92995, 92996, 00.66, 36.01-36.09
CABG surgery 33510-33519, 33521-33523, 33533-33536, 36.10-36.19
AMI: Acute myocardial infarction.
ICD-9: International classification of disease, 9th revision.
CPT-4: Current procedural terminology, 4th revision.
STEMI: ST-elevated myocardial infarction.
NSTEMI: Non-ST-elevated myocardial infarction.
PCI: Percutaneous coronary intervention.
CABG: Coronary artery bypass graft.
Table 1. Diagnostic codes for acute myocardial infarction (AMI) and selected comorbidities and procedures
2.2. Statistical analysis
After deriving the sample means of the costs for different population groups, AMI types, co‐
morbidities, complications, and procedures, we specified various versions of multivariate re‐
gression  models  to  examine  the  factors  influencing  the  costs  while  controlling  for
demographic variables and Charlson comorbidity index (CCI) [25]. We used CCI as a compre‐
hensive measure of disease severity. It measures the likelihood of death or serious disability in
the subsequent year by diagnosis codes of up to 18 different diseases. In addition to estimating
the various versions of regression for the whole study sample, we ran a regression on the costs
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gression  models  to  examine  the  factors  influencing  the  costs  while  controlling  for
demographic variables and Charlson comorbidity index (CCI) [25]. We used CCI as a compre‐
hensive measure of disease severity. It measures the likelihood of death or serious disability in
the subsequent year by diagnosis codes of up to 18 different diseases. In addition to estimating
the various versions of regression for the whole study sample, we ran a regression on the costs
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for STEMI and NSTEMI patients separately. Because PCI, CABG surgery and LOS were major
factors determining the costs, we used logistic regression to investigate the predictors of these
three factors. For the regression estimation, we used mixed-effects models with a repeated
measures approach to account for the fact that a single patient might have multiple admis‐
sions during the 3-year period. All tests of statistical significance were 2-tailed, and a p<0.001
was considered significant. All statistical analyses were performed using SAS version 9.1 [26].
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Ischemic Heart Disease80
N Mean costs (± SD)
Total sample 41,546 29,840.2 ± 22,900.6
Age group (year)
18-44 4671 27,537.1 ± 20,693.3
45-54 13,991 29,661.7 ± 22,073.7
55-64 22,884 30,419.4 ± 23,778.6
Sex
Female 10,874 27,102.7 ± 22,110.1
Male 30,672 30,810.7 ± 23,096.9
MSA
Yes 31,511 29,639.3 ± 22,661.9
No 10,035 30,471.0 ± 23,624.5
Region
Northeast 3296 27,623.5 ± 22,012.1
North Central 13,051 29,452.9 ± 21,927.1
South 20,992 29, 637.4 ± 23,020.8
West 4207 33,790.2 ± 25,373.3
AMI type
STEMI 18,979 32,030.3 ± 22,282.8
NSTEMI 22,567 27,998.3 ± 23,248.8
Hypertension
Yes 16,020 29,403.5 ± 21,868.0
No 25,526 30,114.3 ± 23,521.8
Congestive Heart Failure
Yes 4813 36,758.5 ± 29,163.4
No 36,733 28,933.7 ± 21,786.3
Cancer
Yes 551 29,024.5 ± 23,356.1
No 40,995 29,851.2 ± 22,894.5
Hyperlipidemia
Yes 14,075 29,375.3 ± 20,655.4
No 27,471 30,078.4 ± 23,966.5
Peripheral vascular disease
Yes 296 34,324.6 ± 26,393.2
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N Mean costs (± SD)
No 41,250 29,808.0 ± 22,870.8
Diabetes
Yes 7367 31,917.7 ± 24,735.0
No 34,179 29,392.4 ± 22,460.8
Obesity
Yes 2944 28,862.3 ± 21,845.5
No 38,602 29,914.8 ± 22,977.6
Stroke
Yes 1739 42,133.5 ± 30,090.3
No 39,807 29,303.2 ± 22,381.4
Kidney disease
Yes 1584 33,499.2 ± 27,595.5
No 39,962 29,695.2 ± 22,682.8
PCI
Yes 27,062 30,960.8 ± 19,564.6
No 14,484 27,746.5 ± 27,972.1
CABG
Yes 3879 63,105.9 ± 26,886.0
No 37,667 26,414.5 ± 19,450.5
Cardiogenic shock
Yes 1135 53,016.1 ± 32,754.6
No 40,411 29,189.3 ± 22,216.0
Ventricular tachycardia
Yes 2170 37,306.5 ± 27,619.9
No 39,376 29,428.7 ± 22,540.5
Atrial tachycardia
Yes 299 29,365.2 ± 25,149.5
No 41,247 29,843.6 ± 22,883.8
Ventricular fibrillation
Yes 1286 43,165.1 ± 29,468.8
No 40,260 29,414.6 ± 22,530.4
Atrial fibrillation
Yes 1975 38,109.7 ± 28,974.3
Ischemic Heart Disease82
N Mean costs (± SD)
No 39,571 29,427.5 ± 22,475.5
Charlson comorbidity index 41,456 1.55 ± 1.39
Length of stay (days) 41,456 4.66 ± 3.16
MSA: Metropolitan statistical area (resided in).
AMI: Acute myocardial infarction.
STEMI: ST-elevated myocardial infarction.
NSTEMI: Non-ST-elevated myocardial infarction.
PCI: Percutaneous coronary intervention.
CABG: Coronary artery bypass graft.
Table 2. Sample characteristics and mean costs (ages 18-64 years), 2006-2008 MarketScan inpatient database
3. Results
During 2006-2008, there were 41,546 hospitalizations with a primary diagnosis of AMI; their
mean cost was $29,840 (± 22,901) (Table 2). Mean cost increased with age, but just marginal‐
ly. Male patients cost more than female patients ($30,811 vs. $27,103, p<0.001), and the cost
of STEMI exceeded that of NSTEMI ($32,030 vs. 27,998, p<0.001). Major comorbidities that
increased the cost were stroke, heart failure, peripheral vascular disease, kidney disease, and
diabetes. All of the complications except atrial tachycardia increased the cost greatly. Hospi‐
talizations in which CABG surgery was performed cost a mean of $63,106, more than twice
as high as the mean of $26,415 for those without CABG surgery. PCI increased the cost mar‐
ginally.
The regression results indicated that age influenced the cost marginally after controlling for
procedures, comorbidities, complications, LOS, and ST-elevation status, as well as other
demographic variables (Model 6, Table 3). Hospitalizations of male patients had about
$3350-$4000 higher costs than those of their female counterparts in Model 1-4, but the differ‐
ences by sex dropped to $1437 when all the procedures and complications were considered
(Model 6). The cost in the West was $5608 to $6530 higher than in any other regions in the
fully adjusted model. The cost of hospitalization for STEMI was higher than that for NSTE‐
MI, but the difference decreased from about $3776 (model 2) to $1003 with adjustment for all
of the comorbidities, LOS, procedures, and complication (Model 6). CCI increased the cost
by $2362 (Model 3), but this increase largely disappeared after adding the LOS, procedures,
and complications (Model 6). Longer LOS increased the cost by about $2941 (p<0.001) per
day (Model 6). After controlling for all other factors, PCI increased the cost by about $12,546,
and CABG surgery increased the cost by about $28,406. These two procedures were the big‐
gest factors influencing the cost of AMI hospitalizations. Complications increased the cost
by $4669 in the fully adjusted model.
Costs of Hospitalizations with a Primary Diagnosis of Acute Myocardial Infarction Among Patients Aged...
http://dx.doi.org/10.5772/53499
83
N Mean costs (± SD)
No 41,250 29,808.0 ± 22,870.8
Diabetes
Yes 7367 31,917.7 ± 24,735.0
No 34,179 29,392.4 ± 22,460.8
Obesity
Yes 2944 28,862.3 ± 21,845.5
No 38,602 29,914.8 ± 22,977.6
Stroke
Yes 1739 42,133.5 ± 30,090.3
No 39,807 29,303.2 ± 22,381.4
Kidney disease
Yes 1584 33,499.2 ± 27,595.5
No 39,962 29,695.2 ± 22,682.8
PCI
Yes 27,062 30,960.8 ± 19,564.6
No 14,484 27,746.5 ± 27,972.1
CABG
Yes 3879 63,105.9 ± 26,886.0
No 37,667 26,414.5 ± 19,450.5
Cardiogenic shock
Yes 1135 53,016.1 ± 32,754.6
No 40,411 29,189.3 ± 22,216.0
Ventricular tachycardia
Yes 2170 37,306.5 ± 27,619.9
No 39,376 29,428.7 ± 22,540.5
Atrial tachycardia
Yes 299 29,365.2 ± 25,149.5
No 41,247 29,843.6 ± 22,883.8
Ventricular fibrillation
Yes 1286 43,165.1 ± 29,468.8
No 40,260 29,414.6 ± 22,530.4
Atrial fibrillation
Yes 1975 38,109.7 ± 28,974.3
Ischemic Heart Disease82
N Mean costs (± SD)
No 39,571 29,427.5 ± 22,475.5
Charlson comorbidity index 41,456 1.55 ± 1.39
Length of stay (days) 41,456 4.66 ± 3.16
MSA: Metropolitan statistical area (resided in).
AMI: Acute myocardial infarction.
STEMI: ST-elevated myocardial infarction.
NSTEMI: Non-ST-elevated myocardial infarction.
PCI: Percutaneous coronary intervention.
CABG: Coronary artery bypass graft.
Table 2. Sample characteristics and mean costs (ages 18-64 years), 2006-2008 MarketScan inpatient database
3. Results
During 2006-2008, there were 41,546 hospitalizations with a primary diagnosis of AMI; their
mean cost was $29,840 (± 22,901) (Table 2). Mean cost increased with age, but just marginal‐
ly. Male patients cost more than female patients ($30,811 vs. $27,103, p<0.001), and the cost
of STEMI exceeded that of NSTEMI ($32,030 vs. 27,998, p<0.001). Major comorbidities that
increased the cost were stroke, heart failure, peripheral vascular disease, kidney disease, and
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talizations in which CABG surgery was performed cost a mean of $63,106, more than twice
as high as the mean of $26,415 for those without CABG surgery. PCI increased the cost mar‐
ginally.
The regression results indicated that age influenced the cost marginally after controlling for
procedures, comorbidities, complications, LOS, and ST-elevation status, as well as other
demographic variables (Model 6, Table 3). Hospitalizations of male patients had about
$3350-$4000 higher costs than those of their female counterparts in Model 1-4, but the differ‐
ences by sex dropped to $1437 when all the procedures and complications were considered
(Model 6). The cost in the West was $5608 to $6530 higher than in any other regions in the
fully adjusted model. The cost of hospitalization for STEMI was higher than that for NSTE‐
MI, but the difference decreased from about $3776 (model 2) to $1003 with adjustment for all
of the comorbidities, LOS, procedures, and complication (Model 6). CCI increased the cost
by $2362 (Model 3), but this increase largely disappeared after adding the LOS, procedures,
and complications (Model 6). Longer LOS increased the cost by about $2941 (p<0.001) per
day (Model 6). After controlling for all other factors, PCI increased the cost by about $12,546,
and CABG surgery increased the cost by about $28,406. These two procedures were the big‐
gest factors influencing the cost of AMI hospitalizations. Complications increased the cost
by $4669 in the fully adjusted model.
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Independent variable Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 STEMI NSTEMI
Age





























































































































































































































































Model 1: Age, sex, MSA, and region;
Model 2: Model 1 + STEMI;
Model 3: Model 2 + comorbidities;
Model 4: Model 3 + length of stay;
Model 5: Model 4 + PCI, CABG surgery;
Model 6: Model 5 + complications;
MSA: Metropolitan statistical area (resided in).
STEMI: ST-elevated myocardial infarction.
NSTEMI: Non-ST-elevated myocardial infarction.
PCI: Percutaneous coronary intervention.
CABG: Coronary artery bypass graft.
Table 3. Coefficient estimates of hospitalization costs for patients with acute myocardial infarction
PCI and CABG surgery increased the cost for both the STEMI and NSTEMI groups, with
both procedures increasing the cost more for the NSTEMI group than for STEMI. LOS, in
contrast, increased the cost more for the STEMI than the NSTEMI group, while living in an
urban area (MSA in Table 3) decreased cost by $1496 for STEMI and $903 for NSTEMI.
Logistic regression indicated that patients aged 18-44 years were less likely than those aged
55-64 to undergo PCI or to have CABG surgery, and they were more likely to have a shorter
LOS (i.e., <5 days) (Table 4). Patients in urban area were more likely to have PCI, but less
likely to have CABG. Men were more likely to undergo PCI or to have CABG surgery than
were women, but their odd of a short LOS was greater. Versus patients who did not live in
urban areas, urban patients were more likely to have PCI, but they were less likely to under‐
go CABG surgery. Compared with patients in the West, patients in other regions were more
likely to have a long LOS (i.e., ≥5 days), but they were usually less likely to have PCI and
CABG surgery, with PCI in the North Central region the exception. STEMI patients were
more likely than NSTEMI patients to undergo PCI and CABG surgery, and they were more
likely to have a long LOS. Patients with comorbidities or complications were more likely to
have a long LOS, but they were less likely to have PCI or CABG surgery. Patients undergo‐
ing PCI were more likely to have a short LOS, while patients undergoing CABG surgery
were far more likely to have a long LOS.
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Independent variable PCI (yes vs. no) CABG (yes vs. no) Length of stay (<5 vs. ≥5)
Age 18-44 vs. 55-64 years 0.877 (0.814, 0.944) 0.718 (0.616, 0.836) 0.706 (0.651, 0.765)
Age 45-54 vs. 55-64 years 1.170 (1.112, 1.232) 1.010 (0.921, 1.107) 0.807 (0.767, 0.851)
Male 1.813 (1.724, 1.907) 2.776 (2.502, 3.081) 0.760 (0.721, 0.801)
MSA 1.249 (1.184, 1.317) 0.905 (0.824, 0.995) 1.044 (0.988, 1.104)
Region
Northeast vs. West 0.792 (0.711, 0.884) 0.488 (0.391, 0.608) 1.560 (1.392, 1.747)
North Central vs. West 1.153 (1.059, 1.256) 0.969 (0.830, 1.132) 1.267 (1.158, 1.387)
South vs. West 0.884 (0.815, 0.959) 0.934 (0.806, 1.081) 1.486 (1.364, 1.620)
STEMI vs. NSTEMI 4.514 (4.293, 4.746) 1.337 (1.219, 1.467) 1.333 (1.267, 1.402)
Charlson comorbidity index 0.890 (0.876, 0.905) 0.887 (0.862, 0.913) 1.432 (1.408, 1.457)
Length of stay (days) 0.981 (0.973, 0.990) 1.405 (1.388, 1.422) ---
PCI --- 0.060 (0.053, 0.067) 0.819 (0.776, 0.866)
CABG 0.062 (0.056, 0.069) --- 47.992 (41.288, 55.785)
Complications 0.894 (0.834, 0.959) 0.863 (0.771, 0.966) 2.621 (2.460, 2.793)
PCI: Percutaneous coronary intervention.
CABG: Coronary artery bypass graft.
MSA: Metropolitan statistical area (resided in).
STEMI: ST-elevated myocardial infarction.
NSTEMI: Non-ST-elevated myocardial infarction.
Table 4. Coefficient estimates of logistic regression of PCI, CABG, and length of stay
4. Discussion
The large number of hospitalizations in our economic study of inpatients who had suffered
an AMI enabled us to explore a variety of factors that influenced their costs. The results sug‐
gest that CABG and PCI are the biggest drivers of hospital costs for AMI patients, adding,
respectively, $12,546 and $28,406 to the cost of a stay. The cost effects of PCI and CABG in
our study were comparable to the $15,089 and $28,974 additional costs, respectively, found
in a Medicare population [7]. Another study reported similar costs for PCI and CABG [17].
In an earlier study using MarketScan data from 2003 to 2006, Zhao and Winget found that
the total hospitalization costs of PCI and CABG surgery patient costs were, respectively,
Ischemic Heart Disease86
$31,379 and $63,909 [10]. Unfortunately, Zhao and Winget did not explore the effects of PCI
and CABG on the costs of stay, as we did in our study. Such information is needed to evalu‐
ate the cost-effectiveness of AMI interventions [4].
Two other significant drivers of cost in our study were complications and LOS. Having one
or more complications increased the cost by over $4600, and LOS increased the cost by over
$2900 per day. LOS was highly correlated with CABG surgery and with complications, as
indicated in our logistic models (Table 4). Thus, interventions aiming to prevent or better
manage the complications of AMI patients might be cost-effective in reducing the hospitali‐
zation costs of this group.
Hospitalizations with STEMI had, on average, higher costs than NSTEMI hospitalizations,
but after including PCI and CABG surgery as well as complications, comorbidities, and LOS
in the regression model, the magnitude of the effect became much smaller. This may be be‐
cause of differences in treatment approaches and in complications between the two kinds of
hospitalizations. For example, over 80% of STEMI hospitalizations had a PCI while only
about 51% in the NSTEMI group did. However, the NSTEMI group had a higher rate of
CABG surgery than did STEMI (12% vs. 8%) (not shown in tables). On the other hand, com‐
pared with NSTEMI cases, the STEMI group had a higher rate of cardiogenic shock, ventric‐
ular tachycardia, and ventricular fibrillation, but it had a lower rate of heart failure, atrial
tachycardia, and atrial fibrillation. All of these factors would affect the cost differences be‐
tween STEMI and NSTEMI hospitalizations. The fact that STEMI cost more than NSTEMI
was consistent with the literature; in Mexico, for example, STEMI cost nearly $2800 more
than NSTEMI [11].
The predictors of PCI, CABG surgery, and LOS that we set forward in this study provide
important information for secondary cost-effectiveness analyses of AMI interventions. We
found that male patients were more likely than females to have PCI and CABG surgery, but
their odds of a shorter LOS (<5 days) were greater. STEMI status greatly increased the prob‐
ability of having PCI (coefficient estimate of 4.514) and significantly increased the probabili‐
ty of CABG surgery (coefficient estimate of 1.337), and it was associated with greater odds of
a longer LOS (≥5 days). Patients with comorbidities and complications were relatively less
likely to undergo PCI and CABG surgery, but they were more likely to have a longer LOS.
All of these results could be used as inputs in cost-effectiveness evaluations of AMI inter‐
ventions.
The numerous strengths of this study notwithstanding, several limitations should be consid‐
ered when interpreting our results. First, all of our patients were covered by non-capitated
private insurance plans. Although the costs of these patients accurately reflect the true eco‐
nomic burden imposed by their hospitalizations, the special population may have limited
the generalizability of our results to the broader U.S. population. Second, all of our patients
were 18-64 years old. The elderly population (aged >64 years) has much higher incidence
and prevalence of AMI and its related comorbidities and complications [1, 2]; as a conse‐
quence, the total costs of AMI should be higher in this population than among those 18-64.
Although many studies have focused on the cost of AMI among the elderly [4, 5, 8], new
estimation methods are needed along with high-quality data to develop better cost estimates
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ventions.
The numerous strengths of this study notwithstanding, several limitations should be consid‐
ered when interpreting our results. First, all of our patients were covered by non-capitated
private insurance plans. Although the costs of these patients accurately reflect the true eco‐
nomic burden imposed by their hospitalizations, the special population may have limited
the generalizability of our results to the broader U.S. population. Second, all of our patients
were 18-64 years old. The elderly population (aged >64 years) has much higher incidence
and prevalence of AMI and its related comorbidities and complications [1, 2]; as a conse‐
quence, the total costs of AMI should be higher in this population than among those 18-64.
Although many studies have focused on the cost of AMI among the elderly [4, 5, 8], new
estimation methods are needed along with high-quality data to develop better cost estimates
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for this population. Unfortunately, our data would not be appropriate for an analysis of
costs among the elderly population for AMI hospitalization. A third limitation is that we es‐
timated the costs of hospitalizations only. With survival rates increasing because of advan‐
ces in technology [1], AMI patients are living longer. Correspondingly, the lifetime costs of
outpatient care and medications for afflicted patients should be increasing. Additionally,
productivity losses from the morbidity and premature mortality associated with AMI are al‐
so high [10] and should be considered in any comprehensive economic evaluations.
Given all of these factors, the hospitalization costs presented in our report should be treated
as a conservative estimate of the economic burden associated with AMI. Moreover, we
should note the limitation that we analyzed the costs of hospitalizations with AMI as a pri‐
mary diagnosis. Although this decision let us cover the majority of AMI cases, there may be
substantial additional hospitalizations in which AMI is a secondary diagnosis [9]. These hos‐
pitalizations should certainly be included in any complete analysis of the costs of hospitali‐
zations of AMI patients. Because examining the costs of AMI as a secondary diagnosis
would require a different analytical framework from the one we used, it would have been
beyond the scope of our analysis.
5. Conclusion
Using a large set of claims data, we estimated the hospitalization costs of patients with a pri‐
mary diagnosis of AMI and identified the main cost drivers of this important problem. Be‐
cause most previous studies did not provide any information on the predictors of the costs
of AMI hospitalizations [27], we hope that the present study has to some degree filled this
gap in the literature. The high costs of AMI could be an economic justification for policy
makers to support efforts to prevent AMI. In addition, the detailed information presented
herein about the impact of various factors on the costs, procedures, and LOS associated with
hospitalizations having a primary diagnosis of AMI can be used to evaluate and support
health economic research such as studies on the cost-effectiveness of interventions to control
this problem.
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1. Introduction
Ischemia (from the Greek ισχαιμία, ischaimía; isch- root denoting a restriction or thinning or
to make or grow thin, haema blood) is the restriction of blood supply and thus the inadequate
delivery of oxygen and removal of carbon dioxide from cellular tissue. This imbalance may
lead to dysfunctional or permanent damage to the affected tissue and organ.
Cardiac ischemia occurs when there is a supply versus demand mismatch in coronary blood
flow. In patients who present with unstable angina, ischemia occurs due to partial or total
occlusion of a coronary artery due to plaque rupture. In stable angina however, there is
progressive vascular occlusion resulting ultimately in a luminal stenosis of greater than 70%,
impeding blood flow to the distal tissue. If the ischemia is reversible, no permanent myocardial
damage occurs.If however the ischemic episode is prolonged; there will be cellular necrosis
which will lead to acute myocardial infarction (AMI).The immediate clinical challenge is to be
able to identify acutely impaired myocardial perfusion before the necrotic process starts.
Currently, the only strategy for this is to detect ST-segment changes on the electrocardiogram
(ECG), however the ECG is non-diagnostic in many cases. The sensitivity of the admission
ECG for the diagnosis of AMI is typically around 50%. Reperfusion, be it pharmacological or
surgical, is the essential life-saving intervention with the aim of salvaging myocardial tissue
localised at the affected site. Many patients however who present with chest pain to the
emergency department (ED) do not have a final diagnosis of AMI. There is therefore a need
for a strategy which could detect cardiac ischemia before necrosis occurs and result in prompt
revascularisation. Blood borne biomarkers for ischemia may be of diagnostic and prognostic
value.
To date, a number of candidate biomarkers of ischemia are being researched. However, one,
Ischemia modified albumin (IMA®), has been developed into a commercially available cardiac
biomarker assay and licensed for routine clinical application both by CE marking in Europe
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and Food and Drug Administration (FDA) approval in the United States. This chapter will
explore the rational for the necessity of cardiac ischemia biomarker testing and detail the
development of the IMA assay with emphasis on its clinical and prognostic utility.
1.1. The cardiovascular disease epidemic
Cardiovascular disease (CVD) accounts for the majority of global deaths. CVD was responsible
for 29% of all global deaths in 2004. According to the World Heart Federation, CVD is
responsible for 17.1 million deaths globally each year. Surprisingly, 82% of these deaths occur
in the developing world. Such numbers are often difficult to comprehend. CVD is responsible
for one in every five deaths disease kills one person every 34 seconds in the USA alone. 35
people under the age of 65 die prematurely in the United Kingdom every day due to CVD. It
is predicted that by 2030 23 million people will die annually from a cardiovascular related
disease. Data from the USA suggests that CVD was responsible for 34% of all deaths in 2006
and over 151,000 Americans who died were under 65 years of age.
1.2. Acute chest pain
Patients with chest pain constitute the largest single category of patients admitted to hospitals
in the UK [1]. In the USA, registry data recorded 11.2 million chest pain presentations to the
ED in 2008 alone. The presentations are also diagnostically challenging. The majority of
admissions have either stable ischemic heart disease (IHD) or no ischemic heart disease [2].
Such admission episodes are often short and clinically inappropriate. Conversely, it has been
estimated that between 2 and 7% of patients with AMI are inappropriately discharged from
the ED [3, 4] and suffer disproportionate morbidity and mortality. Attempts to improve
diagnosis have included risk scoring systems [5], computerised decision support [6, 7] and
automated ECG interpretation [8]. Although clinical assessment remains integral to the
assessment of patients with chest pain, cardiac biomarker measurement has become an
essential component in the diagnostic armamentarium.
2. Pathophysiology of cardiac ischemia
The mechanisms involved in the development of cardiovascular disease are multifactorial and
include abnormalities in cholesterol and lipid metabolism, inflammation and oxidative stress
processes within the vascular wall, cellular disruption to the endothelium and intra-lumenal
platelet activation/aggregation. The ischemia cascade from initiation of local ischemia to the
development of symptomatic chest pain is depicted in figure 1.The pathological processes
responsible for the development of atherosclerotic lesions and endothelial dysfunction are
advanced far earlier than when patients typically become symptomatic and present with chest
pain. The disease process does not occur in distinct episodes but rather is a continuum from
asymptomatic vascular dysfunction thorough to angina in those with myocardial ischemia,
which, without intervention can progress to non-ST segment elevation myocardial infarction
(NSTEMI) or cumulate into ST segment elevation myocardial infarction (STEMI). Patients
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presenting at any stage in the process may be diagnosed with acute coronary syndrome (ACS).
The earlier in the disease continuum the presentation is; the greater the opportunity for
successful myocardial tissue preservation. As there is no definitive biomarker for ischemia,
current treatment focuses on the need for urgent therapeutic revascularisation in patients with




























Figure 1. Development of Ischemia in the ischemia cascade.
The pathological process unless disrupted by therapeutic intervention results in the death of
cardiac myocytes. Predisposing this terminal event, a vulnerable atherosclerotic plaque
becomes disrupted exposing the thrombogenic lipid core and sub endothelium to the luminal
milieu. Exposure results in platelet activation and aggregation and along with the coagulation
cascade, an intracoronary thrombus forms. The thrombus may not obstruct the lumen and the
patient is asymptomatic, however if the lumen is totally occluded, AMI will ensue. A partially
occluded lumen and reduced oxygen supply both contribute to the development of ischemic
myocardium.
3. Clinical detection of cardiac ischemia
The clinical presentation of cardiac ischemia is difficult to definitively diagnose. Currently
there is no gold standard test to detect ischemia however a number of reliable tests exist.
Biomarkers of Cardiac Ischemia
http://dx.doi.org/10.5772/55250
93
and Food and Drug Administration (FDA) approval in the United States. This chapter will
explore the rational for the necessity of cardiac ischemia biomarker testing and detail the
development of the IMA assay with emphasis on its clinical and prognostic utility.
1.1. The cardiovascular disease epidemic
Cardiovascular disease (CVD) accounts for the majority of global deaths. CVD was responsible
for 29% of all global deaths in 2004. According to the World Heart Federation, CVD is
responsible for 17.1 million deaths globally each year. Surprisingly, 82% of these deaths occur
in the developing world. Such numbers are often difficult to comprehend. CVD is responsible
for one in every five deaths disease kills one person every 34 seconds in the USA alone. 35
people under the age of 65 die prematurely in the United Kingdom every day due to CVD. It
is predicted that by 2030 23 million people will die annually from a cardiovascular related
disease. Data from the USA suggests that CVD was responsible for 34% of all deaths in 2006
and over 151,000 Americans who died were under 65 years of age.
1.2. Acute chest pain
Patients with chest pain constitute the largest single category of patients admitted to hospitals
in the UK [1]. In the USA, registry data recorded 11.2 million chest pain presentations to the
ED in 2008 alone. The presentations are also diagnostically challenging. The majority of
admissions have either stable ischemic heart disease (IHD) or no ischemic heart disease [2].
Such admission episodes are often short and clinically inappropriate. Conversely, it has been
estimated that between 2 and 7% of patients with AMI are inappropriately discharged from
the ED [3, 4] and suffer disproportionate morbidity and mortality. Attempts to improve
diagnosis have included risk scoring systems [5], computerised decision support [6, 7] and
automated ECG interpretation [8]. Although clinical assessment remains integral to the
assessment of patients with chest pain, cardiac biomarker measurement has become an
essential component in the diagnostic armamentarium.
2. Pathophysiology of cardiac ischemia
The mechanisms involved in the development of cardiovascular disease are multifactorial and
include abnormalities in cholesterol and lipid metabolism, inflammation and oxidative stress
processes within the vascular wall, cellular disruption to the endothelium and intra-lumenal
platelet activation/aggregation. The ischemia cascade from initiation of local ischemia to the
development of symptomatic chest pain is depicted in figure 1.The pathological processes
responsible for the development of atherosclerotic lesions and endothelial dysfunction are
advanced far earlier than when patients typically become symptomatic and present with chest
pain. The disease process does not occur in distinct episodes but rather is a continuum from
asymptomatic vascular dysfunction thorough to angina in those with myocardial ischemia,
which, without intervention can progress to non-ST segment elevation myocardial infarction
(NSTEMI) or cumulate into ST segment elevation myocardial infarction (STEMI). Patients
Ischemic Heart Disease92
presenting at any stage in the process may be diagnosed with acute coronary syndrome (ACS).
The earlier in the disease continuum the presentation is; the greater the opportunity for
successful myocardial tissue preservation. As there is no definitive biomarker for ischemia,
current treatment focuses on the need for urgent therapeutic revascularisation in patients with




























Figure 1. Development of Ischemia in the ischemia cascade.
The pathological process unless disrupted by therapeutic intervention results in the death of
cardiac myocytes. Predisposing this terminal event, a vulnerable atherosclerotic plaque
becomes disrupted exposing the thrombogenic lipid core and sub endothelium to the luminal
milieu. Exposure results in platelet activation and aggregation and along with the coagulation
cascade, an intracoronary thrombus forms. The thrombus may not obstruct the lumen and the
patient is asymptomatic, however if the lumen is totally occluded, AMI will ensue. A partially
occluded lumen and reduced oxygen supply both contribute to the development of ischemic
myocardium.
3. Clinical detection of cardiac ischemia
The clinical presentation of cardiac ischemia is difficult to definitively diagnose. Currently
there is no gold standard test to detect ischemia however a number of reliable tests exist.
Biomarkers of Cardiac Ischemia
http://dx.doi.org/10.5772/55250
93
Historically patients were admitted for monitoring or discharged on the basis of clinical
interpretation by the ED physician. It is accepted that this is no longer acceptable clinical
practice.
The typical presentation is exertional or stress induced central chest pain. These episodes
usually last from a few minutes to hours and can resolve upon rest. Common descriptions by
the patient include tightness, crushing stabbing or burning pain. Patients may also have nausea
and vomiting, dyspnoea, palpitations. Typical symptoms increase the likelihood of an AMI
however atypical presentations cannot be used to exclude AMI. Women, the elderly and those
with diabetes mellitus often present with atypical chest pain.
The clinical history and physical examination will assess the presence of risk factors for AMI,
however alone; the initial clinical examination is insensitive and unspecific for diagnosis. It
may however give insight to differential or alternative diagnoses in those patients who, upon
further investigation do not have an AMI. The 12 lead ECG is additive to the physical exami‐
nation. The majority of ECG traces performed at admission are non-diagnostic with approxi‐
mately 5% of suspected AMI patients having a diagnostic trace indicative of AMI. Although
the ECG is relatively insensitive, the presence of ST segment elevation however is 100%
diagnostic for AMI and serves as the criterion for immediate induction of fibrinolytic therapy
or emergency interventional revascularization.
3.1. Cardiac imaging
Recently cardiac imaging has played an important role in the detection of ischemia. Perfusion
abnormalities can be detected by single-photon emission computer tomography (SPECT)
myocardial perfusion imaging (MPI) and mechanical dysfunction can be detected by echo‐
cardiography or gated MPI. Gated SPECT MPI can identify regional and global dysfunction
of the left ventricle as ischemia impairs myocellular contractility. SPECT requires uptake of an
isotope by active membrane transport mechanisms and caution should be advised in those
patients with impaired renal clearance. Both echocardiography and SPECT are sensitive and
specific and have a high negative predictive value for the diagnosis and prognosis of patients
with suspected ACS. These diagnostic modalities however are grossly expensive, time
consuming, technically more challenging and are not as widely available as compared to the
simple ECG or a blood borne biomarker. The use cardiac imaging in the ED on a 24 hour, 7
day a week basis is therefore compromised.
3.2. Cardiac biomarkers of ischemia
There have been progressive developments within basic and clinical research to identify
candidate biomarkers of ischemia and to develop simple to use assays. Any such assay needs
to have similar analytical (limit of detection, precision, reference intervals) and clinical
performance (sensitivity, specificity, risk stratification and predictive value) compared to that
of markers of necrosis, such as high sensitivity cardiac troponin assays. A number of candidate
biomarkers have been identified. However very few make it from a research grade assay to a
fully licenced automated assay for clinical use. The most promising biomarkers to date are
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reviewed below. Of these, Ischemia Modified Albumin has been the most successful biomarker
and greater attention is given to this marker.
4. Malondialdehyde low density lipoprotein
Malondialdehyde low density lipoprotein (MDA-LDL) is a sensitive biomarker for ACS
patients with unstable angina and AMI. MDA is a candidate compound which causes oxidative
modification of LDL. MDA (propanedial, C3H4O2) is a reactive aldehyde produced by degra‐
dation of polyunsaturated lipids or released during prostanoid metabolism. This reactive
oxygen species causes oxidative modification to LDL. MDA-LDL reacts with the charged
amino group of B-100 protein lysyl residues. Plasma concentrations of MDA-LDL identify
patients with coronary artery disease. Modified LDL may also instigate an immune response
leading to autoantibody and LDL immune complex production. MDA-LDL not only serves as
an oxidative stress marker but as a marker of plaque destabilisation.
5. Myeloperoxidase
Myeloperoxidase (MPO, EC 1.11.2.2, 1.11.2.2) is a 150 KDa protein dimer consisting of two 15
KDa light chains and two variable weight glycosylated heavy chains bound by a heme group
responsible for the green colour when secreted in pus and mucus. There are three known
isoforms which differ in the size of the heavy chain [9]. It is encoded by the MPO gene located
on chromosome 17 [10]. MPO is most abundant in neutrophil granulocytes. It is a lysosomal
enzyme stored in azurophilic granules of polymorphonucleocytes and macrophages. MPO
catalyses the conversion of chloride and hydrogen peroxide into hypochlorite (hypochlorous
acid). Furthermore, MPO oxidises tyrosine to the tyrosyl radical using hydrogen peroxide as
an oxidising agent. Both hypochlorite and the tyrosyl radical are cytotoxic and are produce to
kill pathogens in response to infection. Elevation in MPO is therefore not indicative of cardiac
ischemia, as increases occur in infection, inflammation and infiltrative disease processes, thus
reducing the specificity for cardiac ischemia.
MPO may contribute to the pathophysiology of ACS, as the hypochlorite end product is an
oxidizing agent of low density lipoprotein (LDL) and may play a key role in the degradation
of collagen and contributing to the destabilisation of the plaque. Patients with ACS who have
elevated MPO are at risk of short and long-term adverse outcomes. In a case-control study
from the USA, Zhang and colleagues demonstrate that MPO concentrations are significantly
greater in patients (n=158) with coronary artery disease compared to controls (n=175) who do
not demonstrate angiographically significant coronary disease [11]. Plasma MPO concentra‐
tions identify patients at risk of major adverse cardiac events in the absence of necrosis. In 604
sequential chest pain admissions, MPO predicted adverse cardiac events (AMI, need for
revascularisation or death)at 30 days (odds ratio 2.2, 95%CI 1.1-4.6) and 6 months (odds ratio
4.1, 95%CI 2.0-8.4) [12].
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tions identify patients at risk of major adverse cardiac events in the absence of necrosis. In 604
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6. Whole blood choline
Choline (2-hydroxy-N,N,N-trimethylethanaminium, C5H11NO) is a water soluble essential
nutrient. It is a product of phosphodiesteric cleavage of membrane phospholipids such as
phosphatidylcholine and sphingomyelin; catalysed by phospholipase D (EC 3.1.4.4). Choline
is the precursor to actylcholine production.
Physiologically choline provides cell structural integrity, is the precursor for acetylcholine
production and a source of methyl groups that participate in the S-adenosylmethionine
synthesis pathway.
Whole blood (WBCHO) and plasma choline concentrations increase after stimulation of
phospholipase D and the activation of coronary plaque cell surface receptors or ischemia.
Phospholipase D activation in coronary plaques causes stimulation of macrophage by oxidised
LDL, secretion of matrix metalloproteinase enzymes and activation of platelets. WBCHO can
be measured by high performance liquid chromatography coupled to mass spectrometry
(HPLC-MS). In a study of over 300 patients with suspected ACS, WBCHO measured at
admission was a significant predictor of cardiac death, cardiac arrest, arrhythmia, heart failure
or the need for percutaneous coronary intervention (PCI) at 30 day follow up [13]. The
predictive power was enhanced by the addition of either cTnT or cTnI and served not as a
marker of myocardial cell necrosis but identified patients at high risk with unstable angina.
WBCHO is therefore a better predictive tool than plasma choline for early risk stratification in
patients who are cardiac troponin negative on admission. The current detection methodology
using HPLC-MS is not suitable for urgent clinical use.
7. Free fatty acids
Fatty acids are carboxylic acid molecules with a long aliphatic tail known as a chain, which are
either saturated or unsaturated. Most naturally occurring fatty acids have an even number of
carbon atoms (4 to 28) in the tail region. Fatty acids are produced from the breakdown of
triglyceride or phospholipid. The majority fatty acids circulate bound to albumin with a very
small percentage appearing as the unbound free fatty acid (FFAu) form [14]. The circulating
level of FFA is limited to the availability of the albumin binding sites.
The mechanism of FFAu release is not fully understood however increased catecholamines
following cardiac ischemia may activate FFAu release following lipolysis in adipocytes. FFAu
are 14-fold higher post-PCI, compared to pre procedural concentrations and were higher in
those with associated ischemic ST segment changes [15]. A recombinant fatty acid binding
protein bound to a fluorescent tag (ADIFAB) [16;17] has been developed and a second
generation assay using a fluorescent molecular probe (ADIFAB2] and a portable reader makes
this a potential early marker for the point of care setting. Whilst this marker shows promise in
the early phase of ischemia induced ACS, further trials are required to evaluate the diagnosis
and prognostic value of FFAu in the chest pain population.
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8. Ischemia modified albumin
The NH2-terminal of human serum albumin (HSA, 66.5 kDa, 585 amino acids) is known to be a
binding site for transition metal ions such as cobalt, copper and nickel [18]. Using one and two
dimensional 1H-NMR studies, Sadler and colleagues demonstrated binding of Ni++, Cu++, Co++,
Cd++ and Al+++ to bovine and human serum albumin. Strong binding was associated with three
N-terminal amino acid residues (Asp-Thr-His in bovine albumin and Asp-Ala-His in human
albumin). A Lysine residue designated Lys4 is also involved in the binding site. The authors
demonstrated for the fist time selective reduction in the intensities of resonances to the εCH2
resonance of Lys4 on the addition of Co++ to HSA. There are in fact, four metal-binding sites with
different specificities in HSA. In addition to the NH2-terminal, three other sites occur at (i) reduced
cysteine at residue Cys34, (ii) site A, including histidine at His67 as a ligand and (iii) the non-
localized site B. Cu++ and Ni++ preferentially bind the NH2-terminus site. Cd++ bind sites A and B,
Zn++ binds site A and Au+ and Pt++ bind at residue Cys34.
A reduction in oxygen supply causes localized acidosis and the generation of free radicals.
Copper and zinc ions, normally bound to proteins in the plasma are released from protein
binding sites to circulate in the free form [19-21]. The N-terminus of albumin binds transition
metals. The N-terminus however, is susceptible to biochemical alteration [22]. The altered form
is referred to as ischemia modified albumin (IMA). Following a period of ischemia, a reduction
in the ability of albumin to bind cobalt is apparent. This is the basis of the albumin cobalt-
binding test (ACB® test) for IMA. IMA has been extensively studied in the basic science and
clinical research settings and is an FDA cleared CE marked clinical assay for the detection of
cardiac ischemia.
It is currently not known if there are any significant changes in total human serum albumin
between ischemic and non ischemic patients in the general chest pain population. Many
divalent metals bind HSA in the circulation but in concentrations far lower than that required
to impact albumin directly. The N-terminal portion of HSA is susceptible to biochemical
degradation and is less stable than the albumin of other species [22] including bovine, dog,
goat, horse, pig rabbit, rat and sheep but not chicken. Using electrospray-mass spectrometry
and N-terminal sequencing, Chan and colleagues have demonstrated degradation corre‐
sponding to the first two resides (Asp-Ala) which is dependent both on temperature and the
N-terminal alpha-amino group.
IMA however is a form of HSA where the N-terminal amino acids are unable to bind transition
metal ions. Myocardial ischemia is known to generate free radicals [21;23], induce localised
acidosis [20] and the release of free iron and copper ions bound to enzymes and proteins.
[19;24]. Direct evidence of Cu/Fe mobilization in the coronary flow following prolonged (25-60
minute) ischemia but not short (15-21 minute) ischemia has been demonstrated [24]. Both
copper and iron concentrations in the first coronary flow fraction were 50-fold and 15-fold
higher respectively following prolonged ischemia, compared to pre-ischemic concentrations.
This suggests that both copper and iron play a causative role in ischemic cardiac injury by their
ability to catalyse the production of free radicals and could be the target of therapeutic
intervention to salvage tissue damage [19]. It was therefore postulated that following a period
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in the ability of albumin to bind cobalt is apparent. This is the basis of the albumin cobalt-
binding test (ACB® test) for IMA. IMA has been extensively studied in the basic science and
clinical research settings and is an FDA cleared CE marked clinical assay for the detection of
cardiac ischemia.
It is currently not known if there are any significant changes in total human serum albumin
between ischemic and non ischemic patients in the general chest pain population. Many
divalent metals bind HSA in the circulation but in concentrations far lower than that required
to impact albumin directly. The N-terminal portion of HSA is susceptible to biochemical
degradation and is less stable than the albumin of other species [22] including bovine, dog,
goat, horse, pig rabbit, rat and sheep but not chicken. Using electrospray-mass spectrometry
and N-terminal sequencing, Chan and colleagues have demonstrated degradation corre‐
sponding to the first two resides (Asp-Ala) which is dependent both on temperature and the
N-terminal alpha-amino group.
IMA however is a form of HSA where the N-terminal amino acids are unable to bind transition
metal ions. Myocardial ischemia is known to generate free radicals [21;23], induce localised
acidosis [20] and the release of free iron and copper ions bound to enzymes and proteins.
[19;24]. Direct evidence of Cu/Fe mobilization in the coronary flow following prolonged (25-60
minute) ischemia but not short (15-21 minute) ischemia has been demonstrated [24]. Both
copper and iron concentrations in the first coronary flow fraction were 50-fold and 15-fold
higher respectively following prolonged ischemia, compared to pre-ischemic concentrations.
This suggests that both copper and iron play a causative role in ischemic cardiac injury by their
ability to catalyse the production of free radicals and could be the target of therapeutic
intervention to salvage tissue damage [19]. It was therefore postulated that following a period
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of cardiac ischemia, these processes would result in a change in the ability of the N-terminus
of HSA to bind transition metal ions. The release of these ions likely initiates one potential
pathway for IMA generation, rather than be considered an interference that may negatively
affect IMA. In support of this suggestion, decreased albumin cobalt binding was reported in
99 acute chest pain patients with myocardial ischemia [25] compared to 44 chest pain patients
with no evidence of myocardial ischemia. Albumin cobalt binding was also assessed in 41
patients undergoing elective coronary artery angioplasty. Samples were tested using the
Albumin Cobalt Binding (ACB) assay before, immediately after, 6 and 24 hours post procedure
and compared to results from 13 patients undergoing cardiac catheterization without balloon
angioplasty, thus serving as the control group. ACB concentrations were significantly elevated
immediately post procedure, compared to the control population and ACB concentrations
returned to baseline after six hours [26]; suggesting that HSA undergoes a significant reduction
in the capacity to bind exogenous Co++ immediately after coronary artery occlusion induced
during elective angioplasty. Modification of the Asp-Ala-His-Lys site by N-terminal acetyla‐
tion or deletion of one or more residues abolishes this cobalt binding [27].
The postulated mechanism (figure 2) of IMA generation is that localised ischemia results in
acidosis. The localised acidotic environment stimulates the release of Cu++ ions from weak
binding sites on circulating proteins such as caeruloplasmin. Caeruloplasmin (EC 1.16.3.1,
151kDa) is a ferroxidase enzyme encoded by the CP gene located on Chromosome 3. The
enzyme is synthesised in the liver and carries approximately 70% of the total copper in human
plasma (a further 15% carried by HSA and the remainder by macroglobulins). Each enzyme
molecule contains 6 atoms of copper within its structure.
In the presence of a reducing agent such as ascorbic acid, free copper II  is converted to
copper I which can react with oxygen to form copper II and generate superoxide free radicals
(O2 •–). Superoxide dismutase (EC 1.15.1.1) converts the superoxide free radical to hydro‐
gen peroxide which is then degraded by catalase. The copper II ions released are immediate‐
ly scavenged by human serum albumin but they are tightly bound to the N-terminus. Copper
bound albumin is then damaged by hydroxyl free radicals (OH •), causing removal of the
three N terminal amino acids and release of the copper II ion to repeat the process in a
chain reaction [28].Marx and Chevion demonstrated by SDS/polyacrylaminde gel electropho‐
resis the site specific alteration of HSA in the presence of 50 μM Cu++ and increasing portions
of 0.2 m Mascorbate; where after the addition of 5 portions, bands at 3, 18, 22, 47 and 50
kDa were observed. The authors also demonstrated that degradation does not occur in the
absence of Cu++ or in the addition of 1 m Methylenediaminetetraacetic acid (EDTA) or citrate
chelating agents [28].
This postulated mechanism, although theoretically attractive has not been borne out in
practice. In a study of patients with increased IMA, the N-terminal portion of albumin was
sequenced in 8 cases [29] by cleavage of the 11 amino acid resides at the NH2 terminus, by
rapid liquid-phase Edman degradation. The N-terminal amino acid sequence showed normal
residues for 6 of 7 patient samples with elevated IMA and one non-ischemic sample (table 1).
The remaining patient sample with high IMA demonstrated two missing amino acids at the
N-terminus. Clinically this patient did not have an ischemic cardiac event.
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Subject NH2-terminal HSA Sequence
Control (wild type) DAHKSEVAHRF
Non-ischemic patient, high serum IMA ----HKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Ischemic patient, high serum IMA DAHKSEVAHRF
Table 1. Amino (NH2) terminal sequence analysis of human serum albumin (HAS) from 6 ischemic patients, a control
(wild type) and one non ischemic patient with a high serum IMA concentration. (Source: Adapted from Bhagavan et
al, ClinChem 2003;49:581-585)
The in vivo half-life of HSA is 19-20 days. HSA with a truncated NH2-terminus would pre‐
sumably have similar in vivo half life properties and yet IMA returns to baseline rapidly after
an ischaemic cardiac event. This indicates that the alteration to albumin to create IMA is
transient and reversible, rather than a finite chemical alteration. Recent physicochemical
Figure 2. Mechanism of Ischemia Modified Albumin generation. [1]Tissue hypoxia from anaerobic metabolism re‐
duces ATP and causes a [2]lower localized pH inducing acidosis. [3]Cu++ ions are released from plasma proteins such as
caeruloplasmin. In the presence of ascorbic acid, [4]Cu++ is converted to Cu+. Cu+ reacts with O2 to form [5]O2 •–. Super‐
oxide dismutase dismutates the O2 •– to [6]H2O2, which in presence of Cu++ or Fe+, undergoes the Fenton reaction
forming [7]OH •hydroxyl radicals. Free Cu++ is scavenged by [8]HSA, where it binds tightly to the N-terminus. OH • radi‐
cals alter the amino acid N-terminus of [9]HSA rendering it incapable of binding Cu++. These two altered forms are
known as IMA.
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gen peroxide which is then degraded by catalase. The copper II ions released are immediate‐
ly scavenged by human serum albumin but they are tightly bound to the N-terminus. Copper
bound albumin is then damaged by hydroxyl free radicals (OH •), causing removal of the
three N terminal amino acids and release of the copper II ion to repeat the process in a
chain reaction [28].Marx and Chevion demonstrated by SDS/polyacrylaminde gel electropho‐
resis the site specific alteration of HSA in the presence of 50 μM Cu++ and increasing portions
of 0.2 m Mascorbate; where after the addition of 5 portions, bands at 3, 18, 22, 47 and 50
kDa were observed. The authors also demonstrated that degradation does not occur in the
absence of Cu++ or in the addition of 1 m Methylenediaminetetraacetic acid (EDTA) or citrate
chelating agents [28].
This postulated mechanism, although theoretically attractive has not been borne out in
practice. In a study of patients with increased IMA, the N-terminal portion of albumin was
sequenced in 8 cases [29] by cleavage of the 11 amino acid resides at the NH2 terminus, by
rapid liquid-phase Edman degradation. The N-terminal amino acid sequence showed normal
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The remaining patient sample with high IMA demonstrated two missing amino acids at the
N-terminus. Clinically this patient did not have an ischemic cardiac event.
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al, ClinChem 2003;49:581-585)
The in vivo half-life of HSA is 19-20 days. HSA with a truncated NH2-terminus would pre‐
sumably have similar in vivo half life properties and yet IMA returns to baseline rapidly after
an ischaemic cardiac event. This indicates that the alteration to albumin to create IMA is
transient and reversible, rather than a finite chemical alteration. Recent physicochemical
Figure 2. Mechanism of Ischemia Modified Albumin generation. [1]Tissue hypoxia from anaerobic metabolism re‐
duces ATP and causes a [2]lower localized pH inducing acidosis. [3]Cu++ ions are released from plasma proteins such as
caeruloplasmin. In the presence of ascorbic acid, [4]Cu++ is converted to Cu+. Cu+ reacts with O2 to form [5]O2 •–. Super‐
oxide dismutase dismutates the O2 •– to [6]H2O2, which in presence of Cu++ or Fe+, undergoes the Fenton reaction
forming [7]OH •hydroxyl radicals. Free Cu++ is scavenged by [8]HSA, where it binds tightly to the N-terminus. OH • radi‐
cals alter the amino acid N-terminus of [9]HSA rendering it incapable of binding Cu++. These two altered forms are
known as IMA.
Biomarkers of Cardiac Ischemia
http://dx.doi.org/10.5772/55250
99
studies using electronic absorption EPR and NMR spectroscopy of Co-binding to HSA under
anaerobic conditions to prevent Co++ oxidation have suggested a different explanation. Using
competition experiments with cadmium (Cd++) which binds sites A and B and Cu++ which binds
the NH2-terminus, three binding sites for Co++ were identified on HSA. Sites A and B showed
greater avidity for Co++ binding than the NH2-terminal binding site [30]. Fatty acid binding to
albumin occurs at one of the additional cobalt binding sites with a negative allosteric interac‐
tion. It is hypothesised, that in myocardial ischemia the release of fatty acids results in binding
of fatty acids to albumin. This would then reduce the ability of albumin to take up cobalt hence
account for the presence of IMA [30]. If this also produced a conformational change in the
albumin affecting the N terminal site, this would also reduce cobalt binding.
8.1. Kinetic release of ischemia modified albumin
Studies in patients receiving angioplasty where ischemia is induced in a controlled manner,
have defined the kinetics of IMA production. There is a rapid rise in IMA values after balloon
inflation with a subsequent fall at 6 hours and return to normal by 24 hours [31;32]. The rise
in IMA occurs earlier than the rise in cardiac troponin and natriuretic peptides (figure 3) and
occurs early after the onset of plaque rupture.










Figure 3. Kinetic release of Ischemia modified albumin (IMA, dotted line) and other cardiac markers, cardiac tropo‐
nin (cTn, solid line) and natriuretic peptide (NTproBNP, dashed line) [bottom panel], in relation to extent and timing of
tissue damage [top panel]
The magnitude of IMA elevation has been found to correlate with the number and frequency
of transluminal balloon inflations during the PCI procedure [33]. 34 patients received standard
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routine care for elective single vessel PCI for the management of stable angina pectoris. 44%
of patients received 1-4 balloon inflations whilst, 56% received >5 inflations. IMA concentra‐
tions were higher in those with more balloon inflations, higher pressure load of the balloon
and the longer the duration of the inflation. IMA is thus not only a marker of the occurrence
of ischemia but is also an indicator of the severity of the ischemic episode.
IMA concentrations are lower in patients who demonstrate angiographic evidence of collateral
vessels present in the coronary circulation, according to Rentrop’s classification [34]. IMA
levels post-PCI are higher than baseline, however post-PCI values are lower compared to post-
PCI values in those patients without a collateral circulation; irrespective of the extent of
coronary artery disease or those who underwent a large number of balloon inflations for longer
duration [35]. The lower IMA concentrations in patients with a collateral circulation likely
represent a cardioprotective effect against PCI-induced ischemia. IMA elevation is also
correlated to the need for subsequent revascularization [36]. Elevated IMA greater than 130
KU/L was associated with a higher frequency of target lesion revascularization at 4-years
follow-up in 60 patients who underwent a successful elective single vessel PCI for stable angina
pectoris at baseline. The accepted gold standard blood marker for myocardial ischemia is
myocardial lactate extraction. Simultaneous IMA and lactate was measured in 10 patients
undergoing PCI for chronic stable angina. Post-PCI IMA concentrations paralleled that of
transmyocardial lactate [32].
Elevation in serum IMA has been recorded following coronary vasospasm [37]. Twenty six
patients with variant angina underwent intracoronary ergonovine spasm provocation testing.
Arterial IMA concentrations were measured pre and post procedure and compared to 18
patients undergoing elective PCI and 10 patients with normal coronary angiography. IMA was
significantly elevated following drug induced coronary vasospasm compared to baseline and
elevated values detected coronary vasospasm with an area under the curve (AUC) of the
receiver operating characteristic (ROC) curve of 0.98 (95%CI 0.92-1.00). Other studies involving
invasive cardiac procedures have shown rises in IMA where ischemia might occur, occurring
concurrently with ECG changes in cardioversion[38], but show a variable picture when there
is non-ischemic myocardial damage as in cardiac ablation [39;40].
8.2. Measurement of ischemia modified albumin
The original biochemical test for IMA was known as the albumin cobalt binding (ACB®) assay.
This was developed by Ischemia Technologies Inc, Colorado, USA). The assay measures the
cobalt binding capacity of albumin in a sample of serum. A known amount of cobalt is added
to the patient serum sample. Dithiothreitol (DTT) is added which binds any remaining
unbound cobalt and the colorimetric change is measured spectrophotometrically. In serum
from non-ischaemic patients, cobalt binds to the N-terminus of HSA, leaving little free cobalt
to react with DTT and form a coloured product. Conversely, in serum of patients with ischemia,
cobalt does not bind to the N-terminus of modified HSA, leaving more free cobalt to react with
DTT and form a darker colour. As normal albumin will bind cobalt, the amount of free cobalt,
hence the absorbance will be proportional to the amount of IMA present (figure 4).
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cobalt binding capacity of albumin in a sample of serum. A known amount of cobalt is added
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unbound cobalt and the colorimetric change is measured spectrophotometrically. In serum
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cobalt does not bind to the N-terminus of modified HSA, leaving more free cobalt to react with
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Biomarkers of Cardiac Ischemia
http://dx.doi.org/10.5772/55250
101
Non ischemic Sample Ischemic Sample
IMA Cu++
Ischemia modified AlbuminUnbound Cobalt
HSA with 
Co++ at the 
N-terminus
Figure 4. Measurement of Ischemia Modified Albumin by the Albumin Cobalt Binding (ACB) assay. A known
amount of CoCl2 is added to a serum sample. DTT is added which binds unbound Co++ causing a colorimetric change
read spectrophotometrically.
The first generation assay was semi-automated and required a sample pre-treatment step
where 500μL of serum sample was added to an Eppendorf tube containing 0.45g CaCl2. The
sample was inverted twice and centrifuged at 1200g for 10 minutes. 300μL of supernatant was
removed for assay of IMA. For the assay, powdered DTT was provided which required
reconstitution in the ratio 15mg DTT: 10 mL diluent. The reconstituted reagent and power
required storage at 2-8oC and the working solution had a shelf life of 3-5 days. The second
generation of the assay used 7.5mg DTT to 10mL diluent. The third generation assay which
became commercially available did not contain the sample pre treatment step and the assay
kit contained a concentrated liquid form of DTT which was reconstituted in buffer with a fixed
volume 200 μL pipette.
The assay can be performed manually with a spectrophotometer, however it was also initially
automated on the Cobas MIRA Plus (Roche Diagnostics) automated spectrophotometer [41].
The assay has since been adapted for other automated clinical chemistry platforms includ‐
ing the LX-20 (Beckman Coulter, Brea, CO, USA) [42], Hitachi 911 (Hitachi, Japan) [43] Hitachi
7600 (Hitachi, Japan) [44] and the Konelab 20 (Thermo Scientific, United Kingdom) [45]. To
date a commercialised point of care device for IMA remains to be developed however a pre-
commercial  portable  spectrophotometer  and IMA assay  has  been  developed by  (Micro‐
wells Biotechnology Co. Ltd, Shanghai, China). In the Microwells assay, the DTT has been
replaced with a  stable  azo dye chromogen.  An automated method to measure ischemia
induced alterations of the binding capacity of HSA for nickel [27] has been described [46].
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The nickel binding assay correlated well to the ACB assay (r=0.5387, p<0.001) however the
AUC of the ROC curve was higher for the nickel binding assay (0.7582) compared to the
ACB assay  (0.7289)  suggesting  nickel  binding  has  a  superior  ability  to  discriminate  be‐
tween ACS and non-ACS compared to the ACB assay. There are rumours of an ELISA assay
for  IMA.  This  assay  is  not  validated  for  clinical  diagnostic  or  therapeutic  use  and  an
independent performance validation and comparison to the ACB assay does not appear in
the current literature. The development of an ELISA however is probably not valid given
the  rapid  alteration  and  return  to  baseline  of  IMA  following  ischemia,  suggesting  the
alteration is  transient and not a permanent change to a specific  epitope which could be
detected by an antibody.
The in vitro stability of the IMA has been shown to be two hours at either 4oC or 20°C, but
values increase significantly after four hours irrespective of the storage temperature [33].It is
likely that the changes are due to in vitro pH changes altering the metal binding capacity of
human serum albumin. Samples frozen at -20°C are stable although values have been reported
to be slightly higher once thawed, compared to freshly analysed samples [47]. The assay
incubation temperature can also affect cobalt binding to HSA and thus influence the IMA
concentration [48].
A study of 109 subjects (55 men and 54 women; age range, 20 to 85 years) to determine the
95th percentile reference range for IMA has been performed [49]. The concentrations ranged
from 25.7 to 84.5 KU/L with an upper 95th percentile of 80.2 KU/L. This study used the first
generation of the assay utilising the pre-handling sample preparation step. Further studies of
healthy subjects have reported higher IMA ranges. Abadie and colleagues demonstrated a
mean IMA value of 89 KU/L from 69 subjects with a mean age of 49 years [50] whilst Maguire
and colleagues demonstrated a 97.5th percentile of 110 KU/L [42] from a population of 81
healthy volunteers (28 men and 53 women aged 22-86 years). Values ranged from 82.0 to 110
KU/L and values were similar between males and females (99.1 vs 100.7 KU/L, p=0.12). The
biological variation of IMA has been studied [51].In a population of 17 apparently healthy
individuals (7 male, 10 female, aged 26-61 years), the within subject coefficient of variation
was 2.89% and the between subject coefficient of variation was 6.76%, calculated from weekly
blood draws performed at the same time by the same phlebotomist for 5 consecutive weeks.
Again there was no specific gender difference in IMA concentrations however the authors
reported statistically different IMA concentrations between Caucasian and Black populations,
with higher IMA concentrations in Black males and females compared to Caucasian counter‐
parts.
Total serum albumin concentrations might be expected to affect the performance of IMA
measurement. There is a relationship between IMA values and serum albumin concentration,
although this is much less marked across the reference interval for albumin [52]. The use of an
albumin adjusted correction has been proposed [53] although a reference interval study found
albumin correction to have little impact compared to other analytical factors [42]. It has been
reported that the changes in IMA observed in patients with chest pain was attributable only
to changes in the serum albumin concentration [54].
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Figure 4. Measurement of Ischemia Modified Albumin by the Albumin Cobalt Binding (ACB) assay. A known
amount of CoCl2 is added to a serum sample. DTT is added which binds unbound Co++ causing a colorimetric change
read spectrophotometrically.
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where 500μL of serum sample was added to an Eppendorf tube containing 0.45g CaCl2. The
sample was inverted twice and centrifuged at 1200g for 10 minutes. 300μL of supernatant was
removed for assay of IMA. For the assay, powdered DTT was provided which required
reconstitution in the ratio 15mg DTT: 10 mL diluent. The reconstituted reagent and power
required storage at 2-8oC and the working solution had a shelf life of 3-5 days. The second
generation of the assay used 7.5mg DTT to 10mL diluent. The third generation assay which
became commercially available did not contain the sample pre treatment step and the assay
kit contained a concentrated liquid form of DTT which was reconstituted in buffer with a fixed
volume 200 μL pipette.
The assay can be performed manually with a spectrophotometer, however it was also initially
automated on the Cobas MIRA Plus (Roche Diagnostics) automated spectrophotometer [41].
The assay has since been adapted for other automated clinical chemistry platforms includ‐
ing the LX-20 (Beckman Coulter, Brea, CO, USA) [42], Hitachi 911 (Hitachi, Japan) [43] Hitachi
7600 (Hitachi, Japan) [44] and the Konelab 20 (Thermo Scientific, United Kingdom) [45]. To
date a commercialised point of care device for IMA remains to be developed however a pre-
commercial  portable  spectrophotometer  and IMA assay  has  been  developed by  (Micro‐
wells Biotechnology Co. Ltd, Shanghai, China). In the Microwells assay, the DTT has been
replaced with a  stable  azo dye chromogen.  An automated method to measure ischemia
induced alterations of the binding capacity of HSA for nickel [27] has been described [46].
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parts.
Total serum albumin concentrations might be expected to affect the performance of IMA
measurement. There is a relationship between IMA values and serum albumin concentration,
although this is much less marked across the reference interval for albumin [52]. The use of an
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8.3. Clinical utility of ischemia modified albumin in chest pain patients
Clinical  validation of  any test  for  ischemia is  difficult  as  there  is  currently  no accepted
diagnostic gold standard, although blood lactate has been used previously.In addition, there
is no predicate test which can be used against which to perform an initial validation. The
initial studies using IMA were based on the ability of an early measurement to predict the
final diagnosis of AMI as defined by the elevation of cardiac troponin at 6-12 hours post
chest pain. Two studies utilised the first generation pre-release ACB test and a third study
manufactured an in-house method. The first study examined acute coronary syndrome (ACS)
patients  and  utilised  serial  sampling  on  admission  and  two  subsequent  samples  [55].
Diagnostic sensitivity of the admission sample for a final diagnosis of AMI was 23.9% for
cardiac troponin I (cTnI) alone, 39.1% for IMA alone and 55.9% for the two combined. The
second study examined enrolled 256 ACS patients [49]. AUC of the ROC curve for the ACB
test  was 0.78 with a sensitivity and specificity of  83% and 69% respectively at  the opti‐
mised decision threshold for AMI. The third study enrolled 75 patients with ischemia and
92 non-ischemic patients [29]. IMA had poor predictive power in discriminating between
AMI  and  non-AMI  in  patients  with  underlying  ischemic  heart  disease  (AUC  of  0.66).
However, the test gave good discrimination between patients with or without ischemia. The
AUC for the ROC curve for diagnosis of ischemia was 0.95 with sensitivity of 94% and
specificity of 88%. In these initial studies there were significant problems with sample stability
and the assay involved in addition of calcium chloride and centrifugation as part of the
routine method. This made the method unsuitable from routine analysis and the assay was
reformulated.
The majority of patients who present to hospital with chest pain and suspected ACS are
eventually ruled out for acute myocardial infarction and active unstable coronary disease.
The ideal role of an ischemia marker would therefore be as rule out test.The most logical
place to use such a test is therefore in the ED.A study of ED presentations examined 208
patients the diagnostic sensitivity of IMA measurement alone was 82% at 46% specificity in
samples taken within the first 3 hours. The combination of ECG, cardiac troponin T (cTnT)
and IMA showed 95% sensitivity for diagnosis of ACS at presentation [56]. One year follow
up performed on this population demonstrated a survival disadvantage in patients with
IMA greater than the median concentration of the study group [57]. A subsequent study of
538 patients admitted to a chest pain evaluation unit found admission measurement of IMA
plus cTnT had 100% sensitivity for prediction of a final diagnosis of AMI [1].  The pres‐
ence of an elevated IMA and an elevated cTnT on admission predicted 21% risk of major
adverse cardiac events (MACE) compared to patients where both were not elevated, even
in  patients  where  the  final  diagnosis  excluded  AMI  by  troponin  based  criteria.  IMA
measurement appears to work best as part of a panel of other tests or a test sequence [50].
Admission measurement of IMA has been found to be superior to biomarkers of necrosis
and to show 97% sensitivity when combined with them. Not all investigators have consid‐
ered the diagnostic performance of IMA either alone or in combination with cardiac troponin,
or  other  biomarkers  of  necrosis,  to  be  adequate.  A  prospective  ED study enrolling  277
patients and using a positive IMA or troponin as the index test and an 8 hour troponin as
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the definitive test found only a 97.6% sensitivity with 97% negative predictive value. The
investigators did not consider this to be adequate when compared with troponin but did
not  provide  any  follow-up  data  [58].  A  second  large  study  prospectively  enrolling  189
patients  presenting  to  the  ED with  chest  pain  and found an elevated IMA was  a  poor
predictor of cardiac events within the next 72 hours [59]. Conversely, another study found
elevated IMA predicted long-term cardiac events [60]. The most consistent finding across
all studies of IMA is of a high negative predictive value. This has been highlighted in a
meta-analysis specifically examining the role of IMA as a rule out test [61]. The summar‐
ised data of over 1800 patients demonstrated a triple negative prediction test (non-diagnos‐
tic ECG, negative cTn and negative IMA) with a sensitivity and negative predictive value
for ACS of 94.4% and 97.1% respectively.
The prognostic value of IMA in the ACS setting has been investigated [57;60;62;63]. Using a
ROC derived cut off of 477 KU/L, Aparci and colleagues found significantly higher mortality
at one year in those who had serum IMA >477 KU/L, compared to those with IMA <477 KU/L
[60]. Furthermore, using cox regression modelling, IMA was related to mortality, independ‐
ently of the presence of hypertension, diabetes or advanced age. In a larger cohort of 245
consecutive attendances to the ED, in which there were 31 composite endpoint (cardiac death,
AMI or recurrent angina) at 30-days from presentation and 16 deaths at one year; the short
and long term ability of IMA to predict outcome was assessed. Short term survival was
significantly compromised in those with IMA > 93.3 KU/L compared to those with lower IMA
concentrations at both 30 days and 1 year [57]. Using the cohort of the French Nationwide
OPERA study IMA, cTn, CRP and BNP were measured within 24hours from admission in 471
patients hospitalized with AMI. Using a primary end point of death, resuscitated cardiac arrest,
recurrent AMI or ischemia, heart failure or stroke, 75 in-hospital events and 144 events at 1
year were recorded. Using quartile analysis, 40% of patients reached the end point with IMA
concentrations in the highest quartile (>104 KU/L), compared to only 20% of patients in the
lowest quartile of 83 KU/L [63]. In those STEMI patients who are treated with primary PCI,
IMA is a powerful predictor of 30-day mortality however it does not add to the validated
Thrombolysis In Myocardial Infarction (TIMI) risk score [64].
8.4. Clinical utility of ischemia modified albumin in non–chest pain patients
Any marker associated with pathological processes upstream of cardiac necrosis will invari‐
ably suffer from a lack of specificity; unlike the cardiac troponins for cardiac necrosis. The
further upstream in the ischemic continuum the more likely is the lack of cardiac specificity of
the biomarker. Elevations in circulating IMA concentrations are not specific for myocardial
ischemia. Mechanistically, IMA can be generated during any ischemic process within the body.
A comprehensive review of IMA elevations in non-cardiac conditions is beyond the scope of
this chapter but an in-depth summary is given in table 2.Those conditions that have been
studied most are explained in more detail below.
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eventually ruled out for acute myocardial infarction and active unstable coronary disease.
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up performed on this population demonstrated a survival disadvantage in patients with
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plus cTnT had 100% sensitivity for prediction of a final diagnosis of AMI [1].  The pres‐
ence of an elevated IMA and an elevated cTnT on admission predicted 21% risk of major
adverse cardiac events (MACE) compared to patients where both were not elevated, even
in  patients  where  the  final  diagnosis  excluded  AMI  by  troponin  based  criteria.  IMA
measurement appears to work best as part of a panel of other tests or a test sequence [50].
Admission measurement of IMA has been found to be superior to biomarkers of necrosis
and to show 97% sensitivity when combined with them. Not all investigators have consid‐
ered the diagnostic performance of IMA either alone or in combination with cardiac troponin,
or  other  biomarkers  of  necrosis,  to  be  adequate.  A  prospective  ED study enrolling  277
patients and using a positive IMA or troponin as the index test and an 8 hour troponin as
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the definitive test found only a 97.6% sensitivity with 97% negative predictive value. The
investigators did not consider this to be adequate when compared with troponin but did
not  provide  any  follow-up  data  [58].  A  second  large  study  prospectively  enrolling  189
patients  presenting  to  the  ED with  chest  pain  and found an elevated IMA was  a  poor
predictor of cardiac events within the next 72 hours [59]. Conversely, another study found
elevated IMA predicted long-term cardiac events [60]. The most consistent finding across
all studies of IMA is of a high negative predictive value. This has been highlighted in a
meta-analysis specifically examining the role of IMA as a rule out test [61]. The summar‐
ised data of over 1800 patients demonstrated a triple negative prediction test (non-diagnos‐
tic ECG, negative cTn and negative IMA) with a sensitivity and negative predictive value
for ACS of 94.4% and 97.1% respectively.
The prognostic value of IMA in the ACS setting has been investigated [57;60;62;63]. Using a
ROC derived cut off of 477 KU/L, Aparci and colleagues found significantly higher mortality
at one year in those who had serum IMA >477 KU/L, compared to those with IMA <477 KU/L
[60]. Furthermore, using cox regression modelling, IMA was related to mortality, independ‐
ently of the presence of hypertension, diabetes or advanced age. In a larger cohort of 245
consecutive attendances to the ED, in which there were 31 composite endpoint (cardiac death,
AMI or recurrent angina) at 30-days from presentation and 16 deaths at one year; the short
and long term ability of IMA to predict outcome was assessed. Short term survival was
significantly compromised in those with IMA > 93.3 KU/L compared to those with lower IMA
concentrations at both 30 days and 1 year [57]. Using the cohort of the French Nationwide
OPERA study IMA, cTn, CRP and BNP were measured within 24hours from admission in 471
patients hospitalized with AMI. Using a primary end point of death, resuscitated cardiac arrest,
recurrent AMI or ischemia, heart failure or stroke, 75 in-hospital events and 144 events at 1
year were recorded. Using quartile analysis, 40% of patients reached the end point with IMA
concentrations in the highest quartile (>104 KU/L), compared to only 20% of patients in the
lowest quartile of 83 KU/L [63]. In those STEMI patients who are treated with primary PCI,
IMA is a powerful predictor of 30-day mortality however it does not add to the validated
Thrombolysis In Myocardial Infarction (TIMI) risk score [64].
8.4. Clinical utility of ischemia modified albumin in non–chest pain patients
Any marker associated with pathological processes upstream of cardiac necrosis will invari‐
ably suffer from a lack of specificity; unlike the cardiac troponins for cardiac necrosis. The
further upstream in the ischemic continuum the more likely is the lack of cardiac specificity of
the biomarker. Elevations in circulating IMA concentrations are not specific for myocardial
ischemia. Mechanistically, IMA can be generated during any ischemic process within the body.
A comprehensive review of IMA elevations in non-cardiac conditions is beyond the scope of
this chapter but an in-depth summary is given in table 2.Those conditions that have been
studied most are explained in more detail below.
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Table 2. Increased serum IMA concentrations in conditions other than acute coronary syndrome.
8.4.1. Skeletal muscle ischemia
Studies of subjects with skeletal muscle ischemia have produced contradictory results. In
healthy subjects undergoing arduous physical exertion, IMA has been reported to fall imme‐
diately post exercise and then subsequently rise [65-67] or return to normal [68]. Subjects
undergoing a forearm ischemia test when the forearm muscles are exercised for 1 minute with
the external compression of the arm blood supply showed a fall in IMA, maximal at 3 minutes
from the test, returning to baseline by 30 minutes [69]. A similar rise in serum lactate occurred.
Conversely during standardized exercise in a plantar flexion pedal combined with inflation
of a femoral blood pressure cuff (at 0, 60, 90, 120 and 150 mmHg) to induce calf muscle ischemia
an increase in IMA was observed after release of the cuff and returned to baseline within 30
minutes [70]. Peri-operative skeletal muscle ischemia induced by femoral blood pressure cuff
being inflated to 300 mmHg in 23 patients undergoing arthroscopic knee surgery. Increased
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IMA and myoglobin and decreased albumin were observed following release of the cuff [71].
In patients with peripheral vascular disease (PVD) undergoing a treadmill walk test, a decrease
in serum IMA immediately post-test has been documented [72;73]. In 40 consecutive patients
undergoing exercise electrocardiography, a significant decrease in IMA at peak exercise then
a subsequent rise in IMA has been observed, however there was no difference in IMA
concentrations between those patients with positive and negative stress test results [74].
Revascularisation for PVD is accompanied by a post procedural rise in IMA [72;73;75]. In
skeletal muscle ischemia, an initial fall with subsequent rise appears to be a consistent finding
without adequate explanation. Smooth muscle ischemia does not appear to be associated with
a rise in IMA [76]. The effect of skeletal muscle on ischemia will limit the application of IMA
measurement after cardiac stress testing for detection of myocardial ischemia and may explain
the inconsistent findings[54;74;77;78].
8.4.2. Ischemic stroke
Patients with acute ischemic stroke demonstrate abnormalities in a number of biomarkers of
nitrosative and oxidative stress. In 41 patients with ischemic stroke, Senes and colleagues
demonstrate that nitrate, IMA and thiobarbituric acid-reactive substances (TBARS) concen‐
trations are significantly increased compared to 37 age and gender matched controls [79]. In a
larger cohort of 118 patients presenting within 3 hours of neurological deficit, IMA was
elevated in those with cerebral infarction and intracranial haemorrhage (ICH) but normal
reference values were observed in those with transient ischemic attacks (TIA) lasting less than
1 hour or those with epileptic seizures [80]. Within 24 hours of injury IMA increased during
cerebral infarction but not in intracranial haemorrhage and may offer diagnostic utility in the
differential diagnosis of neurological deficit. IMA also correlated with National Institutes of
Health Stroke Scale (NIHSS) Score in both cerebral infarction and ICH. Conversely, Herisson
and colleagues did not demonstrate a causal relationship between IMA or heart type fatty acid
binding protein and NIHSS score or stroke volume [81]. Ahn and colleagues have utilised an
albumin-adjusted IMA index for the early detection of ischemic stroke [82]. In 52 patients, 28
(54%) with Ischemic stroke, 24 (46%) non-stroke, the AUC of ROC curve analysis was 0.928 for
IMA but 0.99 for albumin-adjusted IMA index. The sensitivity and specificity of the IMA index
was superior to IMA concentration alone.
8.4.3. Pulmonary embolus
Pulmonary  embolus  (PE)  is  an  acute  medical  emergency estimated to  occur  in  3.5/1000
hospitalized patients.  Patients  experience  sudden onset  dyspnoea,  tachypnoea,  pleuritic-
type chest pain, cyanosis and haemoptysis. PE has an associated mortality of 26%. Diagno‐
sis is primarily based on typical clinical presentation using the Wells and Geneva clinical
probability scores. D-dimer measurement and pulmonary angiography are often clinically
useful. The ECG can demonstrate acute corpulmonale in large PE’s but lacks specificity. IMA
has been measured in a number of studies of PE patients. Turedi and colleagues [83] have
demonstrated that IMA was significantly elevated in 30 PE patients compared to 30 healthy
controls and adequately discriminated between the presence and absence of PE. The positive
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Table 2. Increased serum IMA concentrations in conditions other than acute coronary syndrome.
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Studies of subjects with skeletal muscle ischemia have produced contradictory results. In
healthy subjects undergoing arduous physical exertion, IMA has been reported to fall imme‐
diately post exercise and then subsequently rise [65-67] or return to normal [68]. Subjects
undergoing a forearm ischemia test when the forearm muscles are exercised for 1 minute with
the external compression of the arm blood supply showed a fall in IMA, maximal at 3 minutes
from the test, returning to baseline by 30 minutes [69]. A similar rise in serum lactate occurred.
Conversely during standardized exercise in a plantar flexion pedal combined with inflation
of a femoral blood pressure cuff (at 0, 60, 90, 120 and 150 mmHg) to induce calf muscle ischemia
an increase in IMA was observed after release of the cuff and returned to baseline within 30
minutes [70]. Peri-operative skeletal muscle ischemia induced by femoral blood pressure cuff
being inflated to 300 mmHg in 23 patients undergoing arthroscopic knee surgery. Increased
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IMA and myoglobin and decreased albumin were observed following release of the cuff [71].
In patients with peripheral vascular disease (PVD) undergoing a treadmill walk test, a decrease
in serum IMA immediately post-test has been documented [72;73]. In 40 consecutive patients
undergoing exercise electrocardiography, a significant decrease in IMA at peak exercise then
a subsequent rise in IMA has been observed, however there was no difference in IMA
concentrations between those patients with positive and negative stress test results [74].
Revascularisation for PVD is accompanied by a post procedural rise in IMA [72;73;75]. In
skeletal muscle ischemia, an initial fall with subsequent rise appears to be a consistent finding
without adequate explanation. Smooth muscle ischemia does not appear to be associated with
a rise in IMA [76]. The effect of skeletal muscle on ischemia will limit the application of IMA
measurement after cardiac stress testing for detection of myocardial ischemia and may explain
the inconsistent findings[54;74;77;78].
8.4.2. Ischemic stroke
Patients with acute ischemic stroke demonstrate abnormalities in a number of biomarkers of
nitrosative and oxidative stress. In 41 patients with ischemic stroke, Senes and colleagues
demonstrate that nitrate, IMA and thiobarbituric acid-reactive substances (TBARS) concen‐
trations are significantly increased compared to 37 age and gender matched controls [79]. In a
larger cohort of 118 patients presenting within 3 hours of neurological deficit, IMA was
elevated in those with cerebral infarction and intracranial haemorrhage (ICH) but normal
reference values were observed in those with transient ischemic attacks (TIA) lasting less than
1 hour or those with epileptic seizures [80]. Within 24 hours of injury IMA increased during
cerebral infarction but not in intracranial haemorrhage and may offer diagnostic utility in the
differential diagnosis of neurological deficit. IMA also correlated with National Institutes of
Health Stroke Scale (NIHSS) Score in both cerebral infarction and ICH. Conversely, Herisson
and colleagues did not demonstrate a causal relationship between IMA or heart type fatty acid
binding protein and NIHSS score or stroke volume [81]. Ahn and colleagues have utilised an
albumin-adjusted IMA index for the early detection of ischemic stroke [82]. In 52 patients, 28
(54%) with Ischemic stroke, 24 (46%) non-stroke, the AUC of ROC curve analysis was 0.928 for
IMA but 0.99 for albumin-adjusted IMA index. The sensitivity and specificity of the IMA index
was superior to IMA concentration alone.
8.4.3. Pulmonary embolus
Pulmonary  embolus  (PE)  is  an  acute  medical  emergency estimated to  occur  in  3.5/1000
hospitalized patients.  Patients  experience  sudden onset  dyspnoea,  tachypnoea,  pleuritic-
type chest pain, cyanosis and haemoptysis. PE has an associated mortality of 26%. Diagno‐
sis is primarily based on typical clinical presentation using the Wells and Geneva clinical
probability scores. D-dimer measurement and pulmonary angiography are often clinically
useful. The ECG can demonstrate acute corpulmonale in large PE’s but lacks specificity. IMA
has been measured in a number of studies of PE patients. Turedi and colleagues [83] have
demonstrated that IMA was significantly elevated in 30 PE patients compared to 30 healthy
controls and adequately discriminated between the presence and absence of PE. The positive
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predictive value of IMA for PE is higher than that for D-dimer (79.4% compared to 69.4%)
and in combination with the Wells and Geneva criteria,  IMA offers an alternative to D-
dimer testing [84].
8.4.4. Chronic kidney disease
Patients with chronic kidney disease (CKD) have a reduced life span compared to those
without renal disease. Mortality rates are highest in those receiving haemodialysis as renal
replacement therapy (RRT). Cardiovascular mortality accounts for the majority of renal deaths.
Between 2001 and 2006, 24% of deaths in UK RRT patients were due to ischemic heart disease
[85]. This rate is consistent with data from other countries. Cardiovascular morbidity is also
increased. 55% of patients receiving haemodialysis RRT also have concomitant congestive
cardiac failure. [86]. IMA levels have been determined in patients with CKD [87-89] and in
patients receiving haemodialysis (HD) [90-94].
In  2006,  Sharma  and  colleagues  demonstrated  that  patients  with  elevated  IMA  have  a
significantly  large  left  ventricle,  decreased  systolic  function  and  greater  estimated  left
ventricular  filling pressure [88].  Further,  in  multivariate  analysis,  a  positive dobutamine
stress echocardiogram (DSE) combined with elevated IMA and cTnT and E/Ea ratio were
independent prognostic factors for death. IMA values increase significantly in those patients
with a positive DSE compared to those with no ischemic response [87]. In a modestly small
study of 17 anaemic CKD patients and 19 controls, Cichota and colleagues demonstrated
that IMA increased in patients compared to the control group. IMA correlated to lactate,
haemoglobin and creatinine [89].
Pre and post-HD IMA concentrations are significantly correlated [90], however in this study
IMA concentrations were not significantly different between those CKD patients with or
without  ischemic  heart  disease,  diabetes  mellitus  or  peripheral  vascular  disease.  Fast
intravenous iron administration during HD is associated with oxidative stress and inflamma‐
tion.  In a study of  20 HD patients receiving slow intravenous iron administration,  IMA
concentrations were significantly increased across three HD sessions independently of slow
i.v. iron administration [91].Following adjustment of albumin by two methods, post dialysis
IMA levels remain significantly increased following HD [92].  Paroxonase-1 (PON-1) is  a
calcium dependent esterase (arylesterase, aromatic esterase 1, serum aryldialkylpohospha‐
tase  1,  EC 3.1.8.1)  is  a  major  anti-atherosclerotic  component  of  HDL cholesterol.  PON-1
concentrations are lower in CKD patients with and without haemodialysis RRT compared
to controls suggesting chronic oxidative stress and accelerated atherosclerosis are a feature
of  CKD.  In  a  pilot  study  of  CKD  patients  receiving  HD,  PON-1  concentrations  were
significantly and inversely correlated to IMA suggesting an oxidative stress and ischemic
process occurs during HD [93]. Recently Albarello and colleagues have evaluated the effect
of IMA and protein carbonyl groups as markers of protein oxidation in 23 CKD patients
receiving HD. The authors confirm previous reports of higher IMA post-HD than pre-HD
and observed a significant correlation between IMA and protein carbonyl groups, attribut‐
ed to oxidative stress associated with HD [94].
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8.4.5. Hyperlipidaemia and obesity
IMA measurement may be of benefit in hypercholesterolaemic patients. IMA is correlated to
cholesterol, low density lipoprotein (LDL) and antibodies to oxidised LDL (ox-LDL) [24]. In a
study of 37 subjects with hypercholesterolaemia compared to 37 controls, Duarte and collea‐
gues [95] confirm these findings observing IMA correlations to cholesterol, LDL ox-LDL
antibodies and to high sensitivity C-reactive protein, suggesting that hypercholesterolaemia
is associated with inflammatory and oxidative stress processes, contributing to the advance‐
ment of atherosclerosis. IMA is related to the presence of metabolic syndrome independently
of age, gender, presence of diabetes or hypercholesterolaemia[96]. Furthermore, the use of 10
mg/day ezetimibe immunotherapy for a duration of 12 weeks in 31 hypercholesterolaemic
patients reduced both LDL cholesterol and IMA [97]. The reduction of IMA was independent
of the reduction in LDL suggesting that ezetimibe may reduce the burden of oxidative stress
in hypercholesterolaemia.
IMA concentrations are higher in obese subjects, with a positive correlation between IMA and
body mass index (BMI).In a large study of 148 volunteers in Brazil; subjects were classified as
normal, overweight or obese, defined as BMI of 18.5-24.9, 25.0-29.9 and >30 kg/m2 respectively.
IMA concentrations increased exponentially between the three groups, the highest being in
those subjects with BMI >30 kg/m2. Similar findings have been demonstrated in obese post‐
menopausal women where IMA and IMA: Albumin ratio are higher in those subjects with BMI
26-32 kg/m2 compared to those with BMI 21-25 kg/m2. The obese concentrations were similar
to those with documented coronary artery disease but normal BMI. In the obese women IMA
was positively correlated to BMI, hs-CRP, insulin concentrations and homeostasis assessment
model score [98].
8.4.6. Diabetes mellitus
Patients with type 2 diabetes mellitus who demonstrate poor glycaemic control have higher
IMA concentrations than those with good glycaemic control. IMA was significantly higher in
76 diabetic patients compared to 25 control subjects and IMA concentrations are correlated to
HbA1c [99], glucose and hs-CRP [100]. Conversely, Dahiya and colleagues suggest no
significant changes in IMA occur in 60 newly diagnosed type 2 diabetics, compared to 30
control subjects [101]. Diabetic patients who undertake chronic exercise for three months
demonstrate lower post exercise IMA concentrations suggesting that exercise alleviates some
of the oxidative stress associated with diabetes mellitus [102].
8.4.7. Bowel ischemia
Bowel (mesenteric) ischemia occurs infrequently however if not recognised early, carries a
devastatingly high mortality. The presentation is often characterised by generalised abdominal
pain, fever, diarrhoea or constipation, tachycardia, hematochezia (blood per rectum), nausea
and vomiting. Diagnosis is difficult due to non specific signs and symptoms, plain x-ray or
laboratory tests (increased white blood cell count and serum lactic acid). Mesenteric angiog‐
raphy is considered to be the gold standard test which can differentiate between embolic,
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predictive value of IMA for PE is higher than that for D-dimer (79.4% compared to 69.4%)
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ventricular  filling pressure [88].  Further,  in  multivariate  analysis,  a  positive dobutamine
stress echocardiogram (DSE) combined with elevated IMA and cTnT and E/Ea ratio were
independent prognostic factors for death. IMA values increase significantly in those patients
with a positive DSE compared to those with no ischemic response [87]. In a modestly small
study of 17 anaemic CKD patients and 19 controls, Cichota and colleagues demonstrated
that IMA increased in patients compared to the control group. IMA correlated to lactate,
haemoglobin and creatinine [89].
Pre and post-HD IMA concentrations are significantly correlated [90], however in this study
IMA concentrations were not significantly different between those CKD patients with or
without  ischemic  heart  disease,  diabetes  mellitus  or  peripheral  vascular  disease.  Fast
intravenous iron administration during HD is associated with oxidative stress and inflamma‐
tion.  In a study of  20 HD patients receiving slow intravenous iron administration,  IMA
concentrations were significantly increased across three HD sessions independently of slow
i.v. iron administration [91].Following adjustment of albumin by two methods, post dialysis
IMA levels remain significantly increased following HD [92].  Paroxonase-1 (PON-1) is  a
calcium dependent esterase (arylesterase, aromatic esterase 1, serum aryldialkylpohospha‐
tase  1,  EC 3.1.8.1)  is  a  major  anti-atherosclerotic  component  of  HDL cholesterol.  PON-1
concentrations are lower in CKD patients with and without haemodialysis RRT compared
to controls suggesting chronic oxidative stress and accelerated atherosclerosis are a feature
of  CKD.  In  a  pilot  study  of  CKD  patients  receiving  HD,  PON-1  concentrations  were
significantly and inversely correlated to IMA suggesting an oxidative stress and ischemic
process occurs during HD [93]. Recently Albarello and colleagues have evaluated the effect
of IMA and protein carbonyl groups as markers of protein oxidation in 23 CKD patients
receiving HD. The authors confirm previous reports of higher IMA post-HD than pre-HD
and observed a significant correlation between IMA and protein carbonyl groups, attribut‐
ed to oxidative stress associated with HD [94].
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demonstrate lower post exercise IMA concentrations suggesting that exercise alleviates some
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8.4.7. Bowel ischemia
Bowel (mesenteric) ischemia occurs infrequently however if not recognised early, carries a
devastatingly high mortality. The presentation is often characterised by generalised abdominal
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thrombotic or nonocclusive ischemia. In a preliminary study of 26 patients presenting with
symptoms of internal ischemia, Polk and colleagues [103] identified 12 with a positive clinical
diagnosis. Positive patients had higher IMA concentrations than those without intestinal
ischemia. IMA detected bowel ischemia with a sensitivity of 100% and a specificity of 86%. In
a case-controlled study from Turkey, Gunduz and colleagues [104] demonstrated that pre-
operative IMA concentrations were significantly higher in patients with thromboembolic
occlusion of the superior mesenteric artery (SMA) compared to an age-matched control group
of healthy volunteers. A number of animal studies of mesenteric ischemia have provided
conflicting results. In a Wistar rat model [105] a time dependent response in IMA in mesenteric
ischemia has been demonstrated. 36 mature female rats underwent either simple laparotomy
in the control groups or laparotomy followed by clamping of the SMA in the subject group.
IMA concentrations were highest 6 hours from ischemic onset, however IMA at 30 minutes
and 2 hours were also significantly higher in the clamped group compared to the control group.
Elevations of IMA tracked changes in both lactate and malondialdehyde. A similar time
dependent change in IMA was demonstrated in New Zealand rabbits undergoing ligation of
the SMA compared to either a control group or those undergoing a sham procedure [106]with
elevation of IMA at 2 and 6 hours significantly higher than baseline and higher than IMA
concentrations in the control rabbits. IMA concentrations mimicked elevations in serum IL-6
with elevated IL-6 in the ischemia group at 1, 3 and 6 hours, but no elevations in the sham
operated or control group. In a further study of mesenteric ischemia in a Wistar rat model,
Uygun and colleagues [107] demonstrated similar IMA concentrations in control, sham, 2-hour
and 6-hour post-SMA ischemia refuting the previous animal studies. It seems likely that IMA
may offer additional diagnostic value in the early presentation of mesenteric ischemia. Further
prospective studies are required to assess both the diagnostic and prognostic ability of IMA
in conjunction with mesenteric angiography to detect bowel ischemia.
8.4.8. Obstetric and gynaecological use of IMA
The care of women and their unborn child during pregnancy is greatly challenging for
obstetricians. The adult can interact and provide a history of signs and symptoms whereas the
unborn child can only be examined indirectly by means of imaging, foetal heart monitors and
a limited number of direct interventions. Women achieving spontaneous preterm (<37 weeks)
labour account for 10% of all births and are attributable to 75% of neonatal deaths. The foetus
relies entirely on the maternal placenta for O2/CO2 exchange. This delicate dependence,
between the placenta and the foetus is crucial to normal healthy growth. Any malfunction or
disruption to the adequate supply of oxygen can cause hypoxia and potentially fatal acidosis.
A limited degree of acidosis is well tolerated by the foetus; however chronic acidosis or hypoxia
may lead to a significant mortality and morbidity with potential log-term sequelae. Currently
the mechanism of foetal hypoxia and acidosis is unclear, and physiological consequence of
foetal acidosis is believed to target the cell energy availability and /or cell poisoning.
During pregnancy plasma proteins change markedly due to increased plasma volume,
increased renal blood flow and altered protein synthesis in response to hormonal changes.
Plasma volume expansion of up to 45% [1300mL) compared to the non-pregnant state causes
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an overall net decrease in plasma protein concentration by 10-12 g/L which is reached around
week 28 of gestation. The predominant cause of lowered albumin is dilutional, oestrogen is
known to affect albumin. The alteration to plasma albumin concentrations throughout the
pregnancy period is shown in table 3. The lower concentration of albumin also results in an
apparent decrease in substances normally bound to this protein.
Time point Mean albumin concentration (g/L)
Reference interval
(g/L)
Non pregnant control 41 36-46
12 weeks 38 33-43
18 weeks 35 30-39
24 weeks 33 29-37
28 weeks 32 28-37
32 weeks 32 38-36
36 weeks 32 38-36
Full term 32 26-38
1 day post partum 29 23-38
6 weeks post partum 42 37-47
Table 3. Alteration to plasma HSA concentrations during the gestational period.
The HSA reference interval in the full term healthy neonate between term and day 4 is 28-44
g/L. Albumin concentrations increase a little from birth to puberty where the adolescent
reference interval (day 4 to 14 years) is 38-54 g/L.
Current experimental studies suggest that foetal development occurs in a hypoxic intrauterine
environment and the presence of reperfusion and oxidative stress is believed to be crucial for
trophoblast development [108]. Trophoblast invasion of the maternal spiral arteries allows the
increase of uterine blood supply necessary to maintain the pregnant state. Serum IMA during
normal pregnancy is elevated compared to non-pregnant controls [109-112]. Prefumo and
colleagues [109] demonstrate supra-physiological IMA concentrations in early normal
pregnancy (11-13 weeks of gestation) suggesting that trophoblast development occurs in a
hypoxic uterus. In a large population of 117 pregnant women compared to non-pregnant
healthy women, Guven and colleagues demonstrated a cross-sectional elevation in IMA in
pregnant women. IMA increased significantly through each trimester. Further, there the
authors demonstrated a significant negative correlation between IMA and HSA, suggesting
that elevated IMA in pregnancy represents a physiologic state of oxidative stress.
Increased intrauterine hypoxia predisposes to defective endovascular trophoblast invasion of
the maternal spiral arteries which may possibly lead to the development of pre-eclampsia; a
hypertensive state (>140/90 mmHg) associated with significant proteinuria (≥300mg/dL). Pre-
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thrombotic or nonocclusive ischemia. In a preliminary study of 26 patients presenting with
symptoms of internal ischemia, Polk and colleagues [103] identified 12 with a positive clinical
diagnosis. Positive patients had higher IMA concentrations than those without intestinal
ischemia. IMA detected bowel ischemia with a sensitivity of 100% and a specificity of 86%. In
a case-controlled study from Turkey, Gunduz and colleagues [104] demonstrated that pre-
operative IMA concentrations were significantly higher in patients with thromboembolic
occlusion of the superior mesenteric artery (SMA) compared to an age-matched control group
of healthy volunteers. A number of animal studies of mesenteric ischemia have provided
conflicting results. In a Wistar rat model [105] a time dependent response in IMA in mesenteric
ischemia has been demonstrated. 36 mature female rats underwent either simple laparotomy
in the control groups or laparotomy followed by clamping of the SMA in the subject group.
IMA concentrations were highest 6 hours from ischemic onset, however IMA at 30 minutes
and 2 hours were also significantly higher in the clamped group compared to the control group.
Elevations of IMA tracked changes in both lactate and malondialdehyde. A similar time
dependent change in IMA was demonstrated in New Zealand rabbits undergoing ligation of
the SMA compared to either a control group or those undergoing a sham procedure [106]with
elevation of IMA at 2 and 6 hours significantly higher than baseline and higher than IMA
concentrations in the control rabbits. IMA concentrations mimicked elevations in serum IL-6
with elevated IL-6 in the ischemia group at 1, 3 and 6 hours, but no elevations in the sham
operated or control group. In a further study of mesenteric ischemia in a Wistar rat model,
Uygun and colleagues [107] demonstrated similar IMA concentrations in control, sham, 2-hour
and 6-hour post-SMA ischemia refuting the previous animal studies. It seems likely that IMA
may offer additional diagnostic value in the early presentation of mesenteric ischemia. Further
prospective studies are required to assess both the diagnostic and prognostic ability of IMA
in conjunction with mesenteric angiography to detect bowel ischemia.
8.4.8. Obstetric and gynaecological use of IMA
The care of women and their unborn child during pregnancy is greatly challenging for
obstetricians. The adult can interact and provide a history of signs and symptoms whereas the
unborn child can only be examined indirectly by means of imaging, foetal heart monitors and
a limited number of direct interventions. Women achieving spontaneous preterm (<37 weeks)
labour account for 10% of all births and are attributable to 75% of neonatal deaths. The foetus
relies entirely on the maternal placenta for O2/CO2 exchange. This delicate dependence,
between the placenta and the foetus is crucial to normal healthy growth. Any malfunction or
disruption to the adequate supply of oxygen can cause hypoxia and potentially fatal acidosis.
A limited degree of acidosis is well tolerated by the foetus; however chronic acidosis or hypoxia
may lead to a significant mortality and morbidity with potential log-term sequelae. Currently
the mechanism of foetal hypoxia and acidosis is unclear, and physiological consequence of
foetal acidosis is believed to target the cell energy availability and /or cell poisoning.
During pregnancy plasma proteins change markedly due to increased plasma volume,
increased renal blood flow and altered protein synthesis in response to hormonal changes.
Plasma volume expansion of up to 45% [1300mL) compared to the non-pregnant state causes
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an overall net decrease in plasma protein concentration by 10-12 g/L which is reached around
week 28 of gestation. The predominant cause of lowered albumin is dilutional, oestrogen is
known to affect albumin. The alteration to plasma albumin concentrations throughout the
pregnancy period is shown in table 3. The lower concentration of albumin also results in an
apparent decrease in substances normally bound to this protein.
Time point Mean albumin concentration (g/L)
Reference interval
(g/L)
Non pregnant control 41 36-46
12 weeks 38 33-43
18 weeks 35 30-39
24 weeks 33 29-37
28 weeks 32 28-37
32 weeks 32 38-36
36 weeks 32 38-36
Full term 32 26-38
1 day post partum 29 23-38
6 weeks post partum 42 37-47
Table 3. Alteration to plasma HSA concentrations during the gestational period.
The HSA reference interval in the full term healthy neonate between term and day 4 is 28-44
g/L. Albumin concentrations increase a little from birth to puberty where the adolescent
reference interval (day 4 to 14 years) is 38-54 g/L.
Current experimental studies suggest that foetal development occurs in a hypoxic intrauterine
environment and the presence of reperfusion and oxidative stress is believed to be crucial for
trophoblast development [108]. Trophoblast invasion of the maternal spiral arteries allows the
increase of uterine blood supply necessary to maintain the pregnant state. Serum IMA during
normal pregnancy is elevated compared to non-pregnant controls [109-112]. Prefumo and
colleagues [109] demonstrate supra-physiological IMA concentrations in early normal
pregnancy (11-13 weeks of gestation) suggesting that trophoblast development occurs in a
hypoxic uterus. In a large population of 117 pregnant women compared to non-pregnant
healthy women, Guven and colleagues demonstrated a cross-sectional elevation in IMA in
pregnant women. IMA increased significantly through each trimester. Further, there the
authors demonstrated a significant negative correlation between IMA and HSA, suggesting
that elevated IMA in pregnancy represents a physiologic state of oxidative stress.
Increased intrauterine hypoxia predisposes to defective endovascular trophoblast invasion of
the maternal spiral arteries which may possibly lead to the development of pre-eclampsia; a
hypertensive state (>140/90 mmHg) associated with significant proteinuria (≥300mg/dL). Pre-
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eclampsia affects 6-8% of pregnancies worldwide. Papageorghiou and colleagues have
demonstrated that first trimester serum IMA are significantly higher in women who develop
pre-eclampsia compared to those with a normal pregnancy [113]. Both IMA and normalised
IMA (IMA: Albumin ratio) were higher in 20 pre-eclamptic women compared to 22 normal
pregnancies [112]. These data suggest IMA could be a biological marker of pre-eclampsia
however larger studies are required to fully characterise the supra-normal IMA and normal‐
ised IMA reference interval in normal pregnancy.
Maternal IMA and normalised IMA concentrations are also increased in women with recurrent
pregnancy loss (two or more unexplained miscarriages in the first trimester) compared to
healthy pregnancy [114], suggesting that an increase of intrauterine oxidative stress and
hypoxia contribute to placental deficiency and subsequently recurrent early miscarriage.
The use of umbilical cord blood for IMA has also been examined. Neonatal cord blood IMA
concentrations are higher than IMA concentrations in healthy adults [115] but is not attribut‐
able to changes in HSA concentration. Elevated fetal IMA may reflect transient localised
ischemia from external forces exerted on the foetus during labour. In a case-control study of
26 newborns, 12 delivered at normal term and 14 with complicated labour or delivered pre-
term; cord blood IMA concentrations were significantly higher (50%) than those with un‐
eventful deliveries, suggesting IMA is a marker of fetal distress. Doubly-clamped cord blood
IMA concentrations are similar in intrauterine growth restriction, compared to those delivered
with appropriate for gestational age full-term pregnancies [116]. The similar IMA concentra‐
tions may be due to the ‘brain sparing effect’ accompanied by oligohydraminos (deficiency in
amniotic fluid), which is characterised by rerouting the blood supply and the nutrient to vital
organs such as the heart, brain and adrenal glands. IMA concentrations in cord blood are higher
following caesarean section compared to vaginal delivery and in multigravida compared to
primigravida [116] and may be attributable to higher oxidative stress on both accounts.
Cigarette smoking during the gestational period alters the oxidant/antioxidant balance in
favour of oxidative stress. In response, IMA and MDA concentrations in pregnant smokers are
significantly higher and vitamins A and E, SOD and total antioxidant capacityare significantly
lower, compared to non-smoking pregnant women [117].
9. Cardiac troponin: Ischemia or necrosis?
The release of cTn was previously thought to occur only in the presence of cell necrosis. The
recent development of high sensitivity cTn (hs-cTn) assays has lead to a) the ability to define
a true 99th percentile and near-Gaussian distribution in the healthy population and b) earlier
diagnosis of AMI with increased sensitivity but at the cost of specificity [118]. A number of
clinical and physiological situations have arisen which suggests cTn is released during
ischemia in the absence of overt necrosis [119]. These include patients who present with
superventricular tachycardia [120] without electrocardiographic changes; in patients with
pulmonary embolism [121] where cTn release may indicate a reversible release and under
physiological strain following endurance exercise [122]. In all cases the kinetic release is
Ischemic Heart Disease112
shortlived with post even values returning to baseline normally within a 24 hour window.
Although the mechanisms have not been elucidated postulates include, physiological cardio‐
myocyte turnover, cellular release of proteolytic degradation products, alteration in plasma
membrane permeability and the formation of membranous secretion vesicles containing
intracellular derived cTn.
10. Conclusions
Although there are a number of candidate biomarkers for the detection of cardiac ischemia in
the research and development world; biomarkers upstream of cardiac cell necrosis lack
specificity. They are therefore, at best additive to the diagnostic and prognostic utility of cTn
in the early investigation of patients presenting with ischemic type symptoms. The clinical
utility of novel biomarkers of ischemia lies in their negative predictive value rather than their
ability to adequately rule-in ACS. Given the development of sensitive cTn methods, further
work is needed to characterise the release mechanisms of cTn from cardiomyocytes.
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1. Introduction
Uric acid is a weak acid distributed throughout the extracellular fluid compartments
(Emmerson, 1996). The normal blood uric acid level in humans is approximately 4 mg/dl (0.24
mmol/l) (Ganong, 2005). Uric acid is the end product of purine degradation. Purines are
degraded ultimately to uric acid through the action of the enzyme xanthine oxidase that
converts xanthine to urate (Mc Lean, 2003). In most mammals, the liver enzyme uricase (urate
oxidase) is responsible for further metabolism of uric acid to allantoin, which is more soluble
waste product. However, humans lack the enzyme uricase, resulting in higher blood uric acid
levels (Hediger et al., 2005). They might provide humans a survival advantage over the other
primates because of the function of uric acid as antioxidant (Mc Lean, 2003). ). For an individ‐
ual, urate concentration is determined by the balance between the rate of purine metaboloism,
both endogenous and exogenous, and the efficiency of renal clearance. Alteration in this
balance may account for hyperuricemia. In the majority (90%) of patients with primary gout,
hyperuricemia results from relative renal undersecretion, whereas in 10% of patients, there is
overproduction of endogenous uric acid (Fam, 2002).
Elevated serum uric acid, besides its documented link to gouty arthritis, has been reported to
be closely-associated with the metabolic syndrome and, as well, to be a correlate of the
development and progression of cardiovascular diseases (Baker et al., 2005), though the role
of uric acid in this respect is still unclear. Several possible pathological mechanisms linking
hyperuricemia to cardiovascular disease were suggested; including the deleterious effects of
elevated uric acid on endothelial dysfunction, oxidative metabolism, as well as platelet
adhesiveness, hemorheology and aggregation (Hoieggen et al., 2003). However, no enough or
definite experimental data exist concerning the association of hyperuricemia with the different
cellular elements of blood. The aim of this work was to investigate the effects of elevated serum
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uric acid levels on the physiology of the different cellular blood elements in rats and their link
to cardiovascular ailment.
2. Methods
This study was performed on 58 albino rats, of both sexes, weighing 180- 250g. Rats included
in the present study were divided into 2 main groups: hyperuricemic group (group I) and
normouricemic control group (group II). Hyperuricemia was achieved by using the uricase
inhibitor oxonic acid (oxonic acid, potassium salt, supplied by Acros Organics, Geel, Belgium),
with concomitant supplementation of diet with 3% uric acid. Oxonic acid was administered
orally for 5 days, 2 and 4 weeks by gavage in a dose of 750 mg/kg body weight (Khosla et al.,
2005), dissolved in 0.25% methylcellulose. Concomitant supplementation of diet with uric acid
was done to obtain better and maintained hyperuricemic response (Mazzali et al., 2001). The
control groups were received the solvent orally for 5 days, 2 and 4 weeks. Studied rats were
allocated into the following groups and subgroups: Group I: Hyperuricemic rats, that received
the oxonic/uric acid regimen. Rats in this group were further subdivided into 3 subgroups
according to the duration of hyperuricemia: Group Ia: Five-days hyperuricemic rats (n=10),
receiving the oxonic/uric acid regimen for 5 consecutive days. Group Ib: Two-weeks hyper‐
uricemic rats (n=11), receiving the regimen 6 days/week for 2 weeks. Group Ic: Four-weeks
hyperuricemic rats (n=10), receiving the regimen 6 days /week for 4 weeks. Group II: Nor‐
mouricemic control rats, that received methylcellulose, the solvent for oxonic acid, orally by
gavage. Rats in this group were further subdivided into 3 subgroups, matching the hyperur‐
icemic subgroups:
Group IIa: Five-days control rats (n=8), receiving the solvent for five consecutive days. Group
IIb: Two-weeks control rats (n=8), receiving the solvent 6 days/week for 2 weeks. Group IIc:
Four-weeks control rats (n=11), receiving the solvent 6 days/week for 4 weeks.
Experimental procedure: At the end of the experimental period, overnight fasted rats were
weighed and anaesthetized with intraperitoneal injection of sodium thiopental (40 mg/kg body
weight). One ml of blood was drawn into a tube containing EDTA for assessment of complete
blood picture. Three ml of blood was collected in a chilled plastic tube containing sodium
citrate 3.8%, gently mixed for assessment of platelet aggregation. Another blood samples were
collected in chilled plastic tubes containing sodium citrate 3.8gm/100 ml (9 volumes of blood
to 1 volume of sodium citrate) and gently shaken. These blood samples were used for study
of platelet aggregation. The citrated blood was centrifuged at 1500 r.p.m. for 5 min. The
supernatant platelet rich plasma (PRP) was pipetted into clean plastic tubes. The remaining
blood sample was centrifuged at 10,000 r.p.m. for 10 min. to prepare platelet poor plasma
(PPP). Standard PRP: the number of platelets in PRP was counted using coulter T-660 counter.
The platelet number was adjusted to a standardized number of 3 x 105 platelet per μl by dilution
with autologus platelet poor plasma.
Aggregation study: platelet aggregation was performed using Chrono-Log automatic aggreg‐
ometer (model 540-VC, Chrono-Log Corp, Harvertown, USA) coupled with computer and
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printer. ADP as an aggregating agent was used at a final concentration of 10 uM. The maximum
aggregation was recorded after 3 min. Platelet aggregation was tested by the turbidimetric
technique, according to the method of Mustard et al. (1964). Platelet aggregation was induced
in stirred platelet-rich plasma (PRP) by addition of the aggregating agent ADP (Park com).
The platelet count in PRP was adjusted to a standardized number of 3x105 platelet/μl by
dilution with autologus platelet poor plasma to obtain standard PRP. Platelet aggregation was
performed by the use of a chrono-Log automatic aggregometer (model 540, chrono-Log
Corporation, Harvertown, USA), coupled with computer and printer.
Enzymatic determination of plasma uric acid was carried out according to the method of
Barhan and Trinder (1972). Nitrate concentration in plasma was estimated according to the
method described by Bories and Bories (1995). C-reactive protein (CRP) was determined
qualitatively by the use of latex slide test, described by Singer et al. (1957).
3. Results
Administration of oxonic/uric acid regimen for 5 days, 2 and 4 weeks resulted in a highly
significant hyperuricemic response, being less marked in the 4-weeks treated group. This
observation could be explained by increased urinary uric acid excretion in the later group.
Hediger et al. (2005) demonstrated increased mRNA transcription of the urate transporters
(URAT1) in association with hyperuricemia. No significant changes were found as regard
erythrocyte parameters, platelet count or mean platelet volume between hyperuricemic and
control groups.
As regards the leucocyte changes accompanying hyperuricemia, the neutrophil% was
significantly increased and lymphocyte % was significantly decreased compared to control
values despite the non-significant changes in the total leucocytic count. Neutrophils were
speculated to liberate a potent activation signal after interaction with monosodium urate
crystals, and that this activation can further stimulate surrounding neutrophils and contribute
to amplification of the inflammatory response, with the redox pathways being implicated in
these reactions (Desaulniers et al., 2006). Further, C-reactive protein, the systemic inflamma‐
tory marker, was markedly increased in the 2- and 4-weeks hyperuricemic rats compared to
controls. Uric acid was reported to induce expression of CRP in vascular endothelial and
smooth muscle cells, which was proposed to provide a pathogenic link to explain the associ‐
ation of the systemic inflammatory response and elevated uric acid in patients with cardio‐
vascular disease and diabetes.(Kang et al., 2005; Saito et al., 2003). The increased neutrophil %,
and the significant positive correlation observed between uric acid level and neutrophil %,
together with the increased CRP, encountered in the present study, support the previous
findings of Ruggiero et al.(2006) pointing to significant and independent association of uric
acid level with neutrophil count and CRP level. On the other hand, the lymphocyte % was
significantly reduced in all the hyperuricemic groups. The encountered lymphocytopenia
could be attributed to the increased free radical burden in hyperuricemia, leading to increased
lymphocyte apoptosis. Uric acid has been demonstrated to act in some instances as prooxidant,
generating free radicals (Patterson et al., 2003).
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Figure  1.  changes  in  plasma uric  acid  in  the  different  hyperuricemic  groups   and their  matching control
groups 
With regard to platelet changes associated with hyperuricemia, enhanced ADP-induced pla‐
telet aggregation was encountered in all the hyperuricemic groups compared to controls, the
effect being more marked in the 5-days and 2-weeks groups, showing higher uric acid lev‐
els. Moreover, a significant positive correlation between plasma uric acid and platelet aggre‐
gation was demonstrated in all the tested groups of rats. The observed enhancement of
platelet aggregation is in accordance with previous reports (Alderman and Aiyer, 2004).
The enhanced platelet aggregation demonstrated in the present study could be explained by
many mechanisms. Urate crystals were reported to stimulate arachidonic acid metabolism in
platelets.(Serhan et al., 1984) Moreover, neutrophilia demonstrated in the present study might
contribute to platelet hyperaggregability, as neutrophils were reported to be potent inducers
of platelet Ca2+ flux, aggregation and secretion. (Faint, 1992). Furthermore, the observed
lymphocytopenia could play a role in the increased platelet activity. In 1987, Wu et al. proposed
lymphocytes to possess PGI2 synthase activity which is capable of converting platelet-derived
PGH2 into PGI2 that is sufficient to inhibit platelet function. Therefore, the encountered
decrease in lymphocytes could provide an additional explanation for the enhanced platelet
aggregability.
The observed decrease in plasma nitrate level in the 4-weeks hyperuricemic rats, together with
the significant negative correlation between plasma levels of uric acid and nitrate demonstrat‐
ed in this group, reflect possible lowering of nitric oxide (NO) bioavailability with prolongation
of hyperuricemia. Reduced NO production in association with hyperuricemia has been
reported by several investigators.(Waring and Esmail, 2005) The reduced NO, together with
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the inflammatory response, could imply increased risk of cardiovascular pathology in
hyperuricemic subjects by promoting development of endothelial dysfunction.
In conclusion, the neutrophil and platelet activation, known predisposing factors to throm‐
bosis, together with increased CRP production and reduced NO production, might share in
causing the hyperuricemia-associated endothelial dysfunction and atherosclerotic plaque
formation. Therefore, it could be recommended that physicians should be aware of the role of
elevated uric acid in inducing cardiovascular insult, and that individuals suffering from
hyperuricemia should be advised to have a strict follow-up for their platelet function, which
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Figure 2. changes in plasma nitrate in the normouricemic  and the different hyperuricemic groups 
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Table 1. Results of the changes in leucocyte parameters in the different studied groups P: Significance of difference
from matched control rats calculated by Student’s ″t″test for unpaired data. NS: Not significant.
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Figure 3. Tracing of ADP-induced platelet aggregation in the different studied groups; 5 days normouricemic rats (A),
hyperuricemic rats for 5 days (B), normouricemic rats for 2 weeks (C), hyperuricemic rats for 2 weeks (D), normourice‐











Figure 4. Graphs showing correlations of plasma uric acid versus neutrophil %, lymphocyte%, and platelet aggrega‐
tion in all the studied groups of rats.
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1. Introduction
Magnesium is the 4th most abundant intracellular cation in the body. Normal adult plasma
concentration ranges from 1.7 to 2.5 mg/dL. Most of the body’s reserves are found in the skeletal
bone mass.
Hypomagnesaemia is a common electrolyte abnormality seen in around 12% hospitalized
patients and has an incidence as high as 60 to 65 % in Intensive Care Unit patients.
Clinical signs and symptoms are only possible in severe magnesium deficiency. Surprisingly,
magnesium depletion can present despite a near normal serum magnesium level.
Common nutritional sources include green leafy vegetables, legumes, nuts, animal proteins,
seafood and sea greens like kelp.
Absorption takes place in the upper small intestine, where nearly 30 to 50% of consumed
magnesium is taken up depending upon the endogenous magnesium status.
Magnesium is excreted by the kidneys.
In circulation 33% is albumin bound (non-filterable), 12% complexed with anions & 55% is in
the free ionized form (filterable fraction)
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2. Magnesium at cellular level
Magnesium serves as a cofactor for over 300 enzymes involved in Deoxyribonucleic Acid
(DNA) and Ribonucleic Acid (RNA) synthesis, protein synthesis, energy metabolism and
maintenance of electrical potential of nervous tissue and cell membranes.
Of particular importance is the role of this element in regulating potassium fluxes through
Sodium (Na) Pottasium (K) ATPase pump and involvement in metabolism of Calcium.
(Magnesium is a natural calcium channel blocker)
Na K Pump – the sodium potassium pump is activated by magnesium. With magnesium
deficiency there is impaired pump activity, whereby insufficient potassium can be pumped
into the cell, although the supply may be great enough.
The energy substrate for the transport activity of the sodium/potassium pump is represented
by Adenosine Triphosphate (ATP) in form of its magnesium complex. This ATP-Mg++ complex
is split by the ATPase delivering the transport energy and therefore it is said that the ATPase
is directing the sodium/potassium pump.
Furthermore with Magnesium deficiency there is not enough energy substrate. Hence the cell
membrane shows increased permeability and the potassium gradient cannot be maintained.
Potassium leaves the cell, in compensation sodium and hydrogen influx takes place passively. Magne‐
sium leaves the cell, if not enough ATP is present for forming the ATP-Mg complex and calcium influx
will follow.
Calcium (Ca) Pump and Na/Ca exchange - There are two possibilities for elimination of
calcium out of the cell, but unfortunately both are impaired by magnesium deficiency:
They are the calcium pump and the sodium/calcium exchange.
Calcium pump- After muscle contraction calcium ions will be transported back again from
the cytosol to the stores of the sarcoplasmatic reticulum by the calcium pump. The concentra‐
tion gradient at this action needs a high expense of energy: one ATP for two calcium ions. The
calcium transport-ATPase is magnesium dependent.
Sodium calcium exchange-. During the action potential calcium influx takes place along the
slow calcium channels into the cell and induces the contraction process. The calcium influx
will be compensated again by an exchange of three sodium ions into the cell. The energy for
the exchange originates from the high extracellular sodium concentration, but these three
sodium-ions must be removed again out of the cell by the sodium/potassium pump which
requires one ATP. If the performance of the sodium/potassium pump is impaired, cellular
sodium will increase and inhibit sodium/calcium exchange. This can be due to ATP deficiency,
myocardial ischemia/ reperfusion injury, potassium/ magnesium deficiency.
Increased sodium within the cell results in hypertension and the increased calcium within the cell
increases the vascular tone in the smooth muscle of the artery to aggravate the hypertension.
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3. Causes of hypomagnesaemia
Pathologic effects of primary nutritional deficiency of magnesium is rare unless a relatively
low magnesium intake is accompanied with prolonged diarrhea or excessive urinary magne‐
sium losses.
Gastrointestinal Causes-
• Acute/ Chronic Diarrhea
• Malabsorption syndromes
• Steatorrhea
• Small bowel bypass
• Inborn errors of metabolism – autosomal recessive disorder, chromosome 9, selective defect
in magnesium absorption due to a mutation in gene that encodes for a member of receptor
channel family.
• Acute pancreatitis – Saponification of magnesium and potassium ions.
Renal Causes-
• Loop and thiazide diuretics – cause mild hypomagnesaemia, because volume contraction
increase proximal sodium, water and magnesium reabsorption
• Alcoholics- Alcohol induced tubular dysfunction which is reversible within 4 weeks.
• Hypercalcemia- increased filtered calcium load competes with magnesium in transport
across the ascending limb of loop of Henle.
• Nephrotoxins- Aminoglycosides, amphotericin B, cisplatin, cyclosporine
• Loop of Henle & Distal tubule dysfunction – Barters Syndrome and Gitelmans syndrome.
Figure 1. ATP-Mg++ : Energy Supply for pumps and exchange
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4. Effects of hypomagnesaemia on tissues
• Hypokalemia- Hypokalemia induced due to deficiency of magnesium is refractory to
potassium supplementation until magnesium deficiency is corrected.
• Hypocalcaemia- due to diminished secretion of Parathyroid hormone and resistance to the
effect of parathyroid hormone at the receptor level. Parathyroid hormone (PTH) induced
release of calcium from bone is impaired when plasma Mg < 0.8 mg/ dL.
• Vitamin D Deficiency- Low plasma level of Calcitriol is noted in Hypomagnesaemia which
further contributes to Hypocalcaemia.
5. Clinical manifestations of hypomagnesaemia
• Cardiac Effects - Arrhythmias, Heart Disease
• Metabolic Effects - Hypokalemia, Hypocalcemia, Diabetes, Osteoporosis
• Neurological Effects– Headache, paresthesias, tremors, muscular spasms, tetany, convul‐
sions, migraine, irritability, anxiety, weakness, mood swings, depression.
• ECG Changes-
Initial stage- widening of QRS Complex peaking of T waves
Later stage- prolongation of PR interval, progressive widening of QRS complex and diminu‐
tion of T wave.
6. Diagnosis of magnesium deficiency
The serum magnesium level correlates poorly with total body stores. As a result, there have
been several intracellular assays of magnesium from lymphocytes, red blood cells, and muscle
biopsies. These assays include nuclear magnetic resonance (NMR) spectroscopy and ion-
specific electrode measures. But since these tests are very expensive, therefore they are not
clinically applicable at present. For these reasons, despite its limitations serum magnesium
levels are commonly and easily carried out to evaluate the magnesium status. If the serum
magnesium level is low, intracellular magnesium is also low but it is important to understand
that many patients may have normal serum magnesium levels but may still be intracellularly
depleted. [1]
7. Discussion
Low serum magnesium is an independent predictor of CHD in both gender. Although relation
exist more in women and less in men. A cross-sectional cohort study has shown inverse
Ischemic Heart Disease136
association between serum magnesium and carotid intima-media thickness(12.). Low serum
magnesium causes endothelial damage that accelerates the atherosclerotic process leading to
ACS. Evidence links significant low serum magnesium to CHD in patient with Acute Myo‐
cardial Infarction (AMI) versus control [13] [14]. This cohort of 15,792 middle aged subjects
were assessed over a four to seven year period as part of the Atherosclerosis Risk in Com‐
munities (ARIC) study [2]. The relative risk of CHD across quartiles of serum magnesium was
1.0 (in the lowest quartile), 0.92, 0.48 and 0.44. Both men and women who developed CHD had
lower mean baseline serum magnesium concentration than the disease-free controls.
Another study of 50 patients with coronary heart disease found that oral magnesium supple‐
ment therapy improved endothelial function and exercise tolerance compared to placebo.
Autopsy has shown that magnesium concentrations in cardiac muscle of individuals who died
of heart disease is lower than those of accident victims [15] [16] One study, found a 20%
reduction in magnesium in the non-infarcted and a 50% reduction in the infarcted myocardi‐
um. Also infarcted myocardium had a depressed magnesium/calcium ratio [16]. A prospective
National Health and Nutritional Examination Survey (NHANES) I follow up study showed
the important role of modifiable dietary and behavioral characteristics in the causation and
prevention of coronary heart disease hospitalization and mortality. This study was done over
a 10 years follow up of 8251 subjects. The study emphasized the role of modifiable dietary
factors including magnesium as well as behavioral characteristics in the causation and
prevention of CHD [17].
Another epidemiologic study showed an inverse association between dietary magnesium
and incident CHD. These associations were present after adjustment for multiple confound‐
ing factors,  including race,  smoking, alcohol intake,  life style & exercise,  waist/hip ratio,
fibrinogen  &  lipids  level,  diuretics  use  and  HRT  [17].  Diabetes  and  hypertension  may
merely be confounders but low magnesium concentration may contribute to the pathogen‐
esis of diabetes or hypertension [18] [19]. High intake of foods rich in magnesium includ‐
ing  green  vegetables,  nuts  and  whole  grains  may  provide  protection  against  CHD  by
increasing magnesium levels [20]
The following effects of magnesium might play an important role in protecting the myocar‐
dium in patients of Unstable Angina:
• Reducing the ischemic myocardial death by reducing the intracellular calcium overload by
limiting the reperfusion injury.
• Dilating the coronary arteries. [21]
• Reducing the after load. [22]
• Inhibiting the platelet function by its effect on prostacyclin secretion.
• Attenuating the catecholamine release by reducing the sympathetic activity. [23]
Other effects of magnesium beneficial in myocardial infarction and life threatening ventricular
arrhythmias include the above and following:
• Direct antiarrhythmic effect.
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• Reducing free radical formation.
• Enhanced collateral flow.
Magnesium has been shown to inhibit calcium influx in the cell, it reduces the mitochondrial
calcium overload, conserves the intracellular ATP as Mg2+-ATP, and raising extracellular
magnesium has been shown to be protective in ischemia. Magnesium inhibits the spasm of the
coronary arteries [21], increases the coronary blood flow, and decreases the coronary vascular
resistance in patients of Variant Angina. This can be a direct effect of magnesium on coronary
vasculature or it can be an indirect effect by reducing the catecholamine release.
High catecholamine levels play an important role in the pathogenesis and prognosis of
unstable angina and are closely related to the extension of an infarct [24]. Magnesium tends to
inhibit the release of catecholamines from the adrenal medulla and reduces the sensitivity of
a- adrenergic receptors to catecholamines, thereby reducing the arrythmogenic and the pressor
effects of the catecholamines [25]. Deficiency of magnesium therefore enhances the sympa‐
thetic activity and increases the catecholamine induced myocardial damage.
A double blind randomized placebo controlled study was conducted to assess the 24 hour
infusion of magnesium in patients of unstable angina [26]. In this study the patients who
presented with unstable angina and had electrocardiographic changes were randomized to
receive 24hour intravenous infusion of magnesium or placebo within 12hr of admission. The
chosen primary endpoints in this study included ECG changes as assessed by 48h Holter
monitoring, resting 12 lead ECGs, CK-MB release and urinary catecholamine levels.
In this study patients were followed for 1month. Thirty-one patients received magnesium
sulphate and 31 placebo. Baseline characteristics and extent of coronary disease were similar
in both groups. On 48 h Holter monitoring, 14 patients(50%) were found to have transient ST
segment shifts in the magnesium group versus 12 patients (46%) in the placebo group.
However, there were fewer ischemic episodes in the magnesium group (51 versus 101, P<0001)
and there was a trend towards an increase in the total duration of ischemia in the placebo group
compared to the magnesium group in the second 24 h. It was found that regression of T wave
changes on the 24 h ECG and reduction in the ST segment changes in the 12 lead ECG, occurred
more frequently in patients who received magnesium compared to those treated with placebo
(11 patients versus 0 patients respectively, P<0005).
Creatine kinase-MB release was significantly less at 6 and 24 h in patients who received
magnesium compared to those treated with placebo. Catecholamine excretion was lower in
patients treated with magnesium than in those treated with placebo in the first 12 h sample,
P<005). On continuous ECG monitoring, a similar proportion of patients in each treatment
group had evidence of myocardial ischemia in the first 24 h of recording. However, the number
of episodes was significantly less in the magnesium group and the number of patients with
transient myocardial ischemia in this group fell from 11 patients (39%) to five (18%) in the
second 24 h of recording with no change in the placebo group (10 patients [39%] in both the
first and second 24 h).
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This study concluded that magnesium infusion reduces the ischemic ECG changes, cardiac
markers, and urinary catecholamine excretion in the acute phase of unstable angina. Therefore
magnesium is useful in these patients.
Among the other studies which have suggested that magnesium may reduce mortality and
serious arrhythmias post acute myocardial infarction is the Second Leicester intravenous
magnesium intervention trial (LIMIT-2) study [27], which was a double-blind randomized trial
of 2316 patients with suspected acute MI who received either intravenous magnesium sulfate
or placebo along with other currently accepted therapies for MI, including thrombolysis.
Thirty-five percent of the patients received a fibrinolytic agent, usually streptokinase, and 66
percent received aspirin. The presence of an acute MI was confirmed in 65 percent of cases.
An important design feature of this trial was that magnesium was administered prior to a
fibrinolytic agent. A treatment effect was observed in all subgroups, including those receiving
thrombolysis and it showed a 24% reduction in mortality, 25% reduction in the incidence of
left ventricular failure and 21% reduction in the mortality from ischemic heart disease.
In another small trial which revealed a positive association of magnesium to coronary heart
disease, 194 patients with an acute MI who were not considered candidates for fibrinolytic
therapy were randomized to receive either intravenous magnesium sulfate or placebo. In this
study the benefits of magnesium compared to placebo showed a reduction in the in-hospital
mortality especially in the elderly and a lower incidence of both arrhythmias and left ventric‐
ular dysfunction.
However, this was not supported by the results of International Study of Infarct Survival
(ISIS-4) study [28] which showed that a 24-h infusion of magnesium has no beneficial effect in
those receiving thrombolysis for acute myocardial infarction. In this study, patients were
randomized after the thrombolytic agent had been administered, a mean of 8 h after the onset
of pain, compared to a median of 3 h in the Leicester intravenous magnesium intervention trial
(LIMIT-2) trial, in which iv magnesium was given prior to thrombolysis. Animal studies have
shown that the effect of magnesium is greatest if given before spontaneous or induced
reperfusion, as this reduces the reperfusion induced myocardial injury, and this may account,
in part, for the lack of benefit seen in International Study of Infarct Survival (ISIS-4).
8. Conclusion
Data  suggest  that  hypomagnesemia  may precede  CHD.  The  U.S.  National  Academy of
Sciences has estimated that a nation-wide initiative to add calcium and magnesium to soft
water might reduce the annual cardiovascular death rate by 150,000 in the United States.
[7].  It  is  recommended  to  design  further  observational  and  interventional  studies  to
substantiate the link.
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• Reducing free radical formation.
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1. Introduction
Ischemic heart disease is a clinical syndrome resulting from myocardial ischemia and is
characterized by an imbalance between the supply and demand of myocardial blood flow
and myocardial oxygen metabolism. It is currently one of the major diseases that endanger
human health. Early and effective reconstruction of ischemic myocardial blood perfusion is
the fundamental measure taken to prevent the development of ischemic myocardial injury,
reduce myocardial infarct size, and improve the clinical prognosis. However, several studies
have discovered that in some cases, reperfusion of ischemic cells could cause further injury
in the form of ischemia/reperfusion injury. The clinical manifestations of myocardial ische‐
mia-reperfusion injury include arrhythmia, myocardial stunning, and no-reflow. Although
lethal reperfusion injury in clinical practice is more difficult to identify, it is the most serious
consequence of ischemia/reperfusion injury and is also the main reason preventing the is‐
chemic myocardium recovery from effective reperfusion therapy. Therefore, studies on the
modes of myocardial cell death after ischemia/reperfusion are of great significance. Previous
studies suggested that myocardial cell death following myocardial ischemia/reperfusion in‐
jury were mainly necrosis and apoptosis. Apoptosis receives more attention due to its death
program. However, in recent years, a number of studies have suggested that, another proce‐
dural manner of death---autophagy, type II programmed cell death, also plays a critical role
in ischemia/reperfusion injury. The study of this death pathway may provide a new effec‐
tive way to block myocardial ischemia/reperfusion injury. Therefore, in this chapter, the
roles and possible mechanisms of autophagy in myocardial ischemia/reperfusion injury will
be reviewed.
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2. Definition, formation and classification of autophagy
In 1962, Ashford and Porter discovered the ‘self-eating’ phenomenon in liver cells using an
electron microscope [1]. After that, this process was named autophagy by Duve, a Belgian
cellular biologist and chemist [2].
Autophagy is the transportation and degradation of damaged, denatured or aged proteins.
It is a common cellular physiological process which can maintain cell homeostasis. Autopha‐
gy is an evolutionary conserved pathway of self-digestion that occurs in various eukaryotic
organisms from yeast to mammals [3]. It is also a cellular defense mechanism in many
pathological processes. The autophagy process time is relatively short (T1/2 for 8 mins), it
illustrates that autophagy is an effective response to environmental changes for cells, and it
plays a pivotal role in metabolism: (1) Since autophagy is an adaptive response to exoge‐
nous stimuli (including nutritional deficiencies, the cell density load, hypoxia, oxidative
stress, infection, etc.), and its products of degradation, such as amino acids, nucleotides, and
free fatty acids, can participate in the material and energy cycle; (2) As a housekeeper mech‐
anism for cells to maintain a steady state, autophagy can adjust the renovation of long-lived
proteins, peroxisomes, mitochondria and endoplasmic reticulum; (3) Autophagy is involved
in tissue-specific integration; (4) Autophagy can act as a defense mechanism to remove the
damaged cytoplasm and metabolites, and the reconstruction on the subcellular level can
protect the affected cells. Meanwhile, as a cell death procedure, autophagy can induce cell
initiative death [4].
Although autophagy and autophagy-related processes are dynamic, they can be broken
down into several discrete steps. There are four steps in autophagy: induction, formation of
autophagosomes, formation of autolysosomes and degradation of the content. Autophagy
serves as a response to stress such as nutrient limitation, and this is one of its primary roles
in unicellular organisms such as yeast. Then, portions of cytoplasm are first isolated (seques‐
tered) within a double membrane enclosed vacuole called an autophagosome. In studies on
yeast, the isolation membrane has been shown to develop from a small vesicle that later
transforms into a cup-like structure surrounding the material to be degraded [5]. The forma‐
tion of an autophagosome (sequestration) is complete when the edges of the ‘cup’ merge. It
has been found that the proteins forming the isolation membrane in yeast are unique, differ‐
ent from those in other cellular compartments, which suggests a de novo formation of this
membrane [6]. It is still discussed whether the isolation membrane also forms de novo in
higher organisms, including mammals, or if it originates from another organelle, such as en‐
doplasmic reticulum, lysosome or Golgi complex. The sequestration membrane that later
gives rise to the autophagosome has been termed phagophore or pre-autophagosome [7]. In
yeast and mammalian cells, autophagy occurs at a basal level. The general diameter of auto‐
phagosomes is 300-900 nm, and the average level is 500 nm. Since the beginning of the for‐
mation of the autophagosomes, cytoplasm and nucleoplasm become darker, but the nucleus
structure has no noticeable changes. Mitochondria and endoplasmic reticulum swell, Gorky
body expands, and then the membrane-specialized structures such as microvilli disappear,
membrane foamed and retracted. At the later stages of autophagy, the volume and number
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of autophagosomes filled with myelin or liquid increase, and then some gray ingredients
and a small number of condensated nuclear materials will exist. These features can be used
as morphological indicators during inspection.
Depending on the different ways cellular material is transported to lysosomes, there are
three types of autophagy: microautophagy, macroautophagy, chaperone-mediated autopha‐
gy (CMA). Macroautophagy is commonly referred to as autophagy, and the cytoplasm is
wrapped by the dropped bilayers from the non-ribosomal region of endoplasmic reticulum,
the Golgi apparatus and other bilayers. In microautophagy, it also goes through the same
process of wrapping, but the substrate is engulfed by inward invagination of the lysosomal
membrane. In the process of CMA, intracytoplasmic proteins are bound to the molecular
chaperone, then transported to the lysosome cavity, and digested by the lysosomal enzyme.
CMA sequester proteins that expose a KFERQ-like pentapeptide which are mediated by
heat shock cognate 70 (HSC70) and its co-chaperones. Lysosomal-associated membrane pro‐
tein 2 (LAMP-2A) acts as a receptor on the lysosome and mediates the degradation of un‐
folded proteins. Macroautophagy is the major regulated cellular pathway for degrading
long-lived proteins and the only known pathway for degrading cytoplasmic organelles (Fig‐
ure 1). Therefore, this chapter focuses on macroautophagy.
3. Signaling regulation of autophagy
Autophagy is highly conservative during the evolution process. Homologous gene partici‐
pation in autophagy not only be found in yeasts and Drosophila melanogaster but also in
vertebrates and humans. In order to unify the standard, Klionsky, in 2003, named these ho‐
mologous genes as autophagy-related genes (Atg) to stand for autophagy genes and the cor‐
responding proteins [8]. So far, scientists have already found more than 30 Atgs and most of
their homologous analogues. In addition, the Atg protein can be divided into five groups:
Atg1 protein kinase complex, Atg9, the class III phosphatidylinositol 3-kinase (PI3K)-Be‐
clin1complex, Atg12 conjugation system and Atg8 conjugation system. Atg1 protein kinase
complex is essential for the induction of autophagy. There are two mammalian homologs of
Atg1 that appear to function in autophagy, the Unc-51-like kinase 1 (ULK1) and -2 (ULK2),
which is the mammalian homologues of serine/threonine protein kinase Atg1, existing in the
form of ULK1-mammalian Atg13 (mAtg13) -focal adhesion kinase family interacting protein
of 200 kDa (FIP200) -Atg10 complex [9]. Under nutritional deficiency conditions, ULK1 is ac‐
tivated and then phosphorylates mAtg13, FIP200 and itself to initiate autophagy. Regarding
the substrates of the Atg1 kinase during autophagy, it is suggested that mAtg13 and FIP200
are phosphorylated by ULKs, and ULKs also undergo autophosphorylation, which is con‐
ducive to a conformational change and autophagy induction. Mammalian target of rapam‐
mycin (mTOR) can phosphorylate and inactivate ULKs and Atg13 under nutrient-rich
conditions. Upon mTOR inhibition by starvation or rapamycin, ULK1 and ULK2 are activat‐
ed and phosphorylate Atg13 and FIP200, which are essential for autophagy activity. Recent
studies have suggested that Atg13 may be phosphorylated by TOR or Atg1/ULKs on differ‐
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2. Definition, formation and classification of autophagy
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of autophagosomes filled with myelin or liquid increase, and then some gray ingredients
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Atg1 that appear to function in autophagy, the Unc-51-like kinase 1 (ULK1) and -2 (ULK2),
which is the mammalian homologues of serine/threonine protein kinase Atg1, existing in the
form of ULK1-mammalian Atg13 (mAtg13) -focal adhesion kinase family interacting protein
of 200 kDa (FIP200) -Atg10 complex [9]. Under nutritional deficiency conditions, ULK1 is ac‐
tivated and then phosphorylates mAtg13, FIP200 and itself to initiate autophagy. Regarding
the substrates of the Atg1 kinase during autophagy, it is suggested that mAtg13 and FIP200
are phosphorylated by ULKs, and ULKs also undergo autophosphorylation, which is con‐
ducive to a conformational change and autophagy induction. Mammalian target of rapam‐
mycin (mTOR) can phosphorylate and inactivate ULKs and Atg13 under nutrient-rich
conditions. Upon mTOR inhibition by starvation or rapamycin, ULK1 and ULK2 are activat‐
ed and phosphorylate Atg13 and FIP200, which are essential for autophagy activity. Recent
studies have suggested that Atg13 may be phosphorylated by TOR or Atg1/ULKs on differ‐
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ent residues [10]. It is likely that phosphorylation of Atg13 is dependent to a greater extent
on TOR in yeast, but on Atg1 in Drosophila.
Figure 1. Different Types of Autophagy (Cite from < Mizushima N, Komatsu M. Cell 2011;147(4) 728-741>).
The conjugation of Atg12 and Atg8 is essential for the formation of autophagosomes. Atg12
was the first ubiquitin-like Atg protein to be identified, which can be activated by Atg7 and
Atg10. Then it is conjugated to Atg5 and promotes the formation of the autophagy precursor
[11]. The amino-acid sequence of Atg12 ends with a glycine residue and there is no protease
involved in Atg12 conjugation. Analogous to ubiquitination, there is an E1-like enzyme,
Atg7, and Atg12 is activated by forming a thioester bond between the C-terminal Gly 186 of
Atg12 and the Cys 507 of Atg7. After activation, Atg12 is transferred to Atg10, which is an
E2 enzyme, and is eventually conjugated to the target protein Atg5 at Lys 149 through an
isopeptide bond. There is no typical E3 enzyme involved in Atg12-Atg5 conjugation. Atg5
interacts further with a small coiled-coil protein, Atg16, and Atg12-Atg5-Atg16 forms a mul‐
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timeric complex through the homo-oligomerization of Atg16. The ubiquitin-like (Ubl) pro‐
tein Atg8 is attached to phosphatidylethanolamine (PE). The C-terminal Arg 117 residue of
Atg8 is initially proteolytically removed by a cysteine protease, Atg4, to expose Gly 116.
This exposed glycine forms a thioester bond with Cys 507 of Atg7, which is also the site that
participates in the Atg12-Atg5 conjugation. This feature differentiates Atg7 from most other
E1 enzymes, which activate single Ubl proteins. Activated Atg8 is then transferred to the E2-
like enzyme Atg3, also through a thioester bond. In the final step of Atg8 lipidation, Gly 116
of Atg8 is conjugated to PE through an amide bond; Atg8-PE exists in a tightly membrane-
associated form. Microtubule-associated protein l light chain 3 (LC3) is the mammalian ho‐
mologues of Atg8. LC3 is activated by Atg7, transferred to Atg3, and conjugated to
phosphatidylethanolamine (PE) on the surface of autophagic vacuoles membranes to pro‐
mote the forming of autophagosomes [12].
Recently, the PI3K-Becline 1 complex and Atg9 have been shown to be the essential compo‐
nents involved in autophagy signaling and the membrane transportation of autophagic va‐
cuoles. This autophagy-specific class III-PI3K-Becline 1 complex appears to be essential to
recruit the Atg12-Atg5 conjugation to the pre-autophagosomal structure. Atg12-Atg5 conju‐
gation is then required for the elongation of the isolation membrane and for the proper lo‐
calization of conjugated LC3/Atg8 [13]. Atg9 is required for autophagy in both yeast and
mammalian cells and has been speculated to be involved in delivery of membrane lipids to
form autophagosomes. In mammalian cells, mAtg9 traffics between the trans-Golgi net‐
work, endosomes and newly formed autophagosomes [14].
Cells regulate autophagy through a set of precise signaling pathways including integrating
nutriment, growth factors, hormones, stress and intracellular energy information. A key reg‐
ulator point of autophagy in mammals is kinase mTOR. The kinase TOR is a major evolutio‐
narily conserved sensor in the autophagy signaling pathway in eukaryotes, but it also
regulates many other aspects of cell function, including transcription, translation, and cell
size and cytoskeletal organization. In mammals, mTOR can be included in two different
complexes, mTORC1 and mTORC2. Although these two TOR complexes share common
components, they display distinct cellular functions and phosphorylate different down‐
stream substrates. The activity of mTORC1 is regulated via the integration of many signals,
including growth factors, insulin, nutrients, energy availability, and cell stressors such as
hypoxia, osmotic stress, reactive oxygen species (ROS) and viral infection. mTORC1 is the
only known target of the drug rapamycin and is required for signaling to ribosomal S6 kin‐
ases (S6K) and eIF4E-binding proteins (4EBP1 and 4EBP2). mTORC1 has recently been
shown to consist of four proteins: mTOR, mLST8 (also known as GbL), proline-rich PKB/Akt
substrate 40-kDa (PRAS40), and raptor (regulatory associated protein of mTOR); and it
plays a major role in controlling translation and cell growth in response to nutrients. The
adaptor protein is common to both mTOR complexes. Raptor binds mTOR, S6K and
4EBP1/2 and facilitates mTOR phosphorylation of these molecules; but whether raptor en‐
hances or represses mTOR kinase activity remains unclear [15]. Unlike mTORC1, mTORC2
has some functions that cannot be inhibited by rapamycin, including the control of actin cy‐
toskeleton dynamics. The mTORC2 complex consists of mTOR, mLST8, mammalian stress-
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mammalian cells and has been speculated to be involved in delivery of membrane lipids to
form autophagosomes. In mammalian cells, mAtg9 traffics between the trans-Golgi net‐
work, endosomes and newly formed autophagosomes [14].
Cells regulate autophagy through a set of precise signaling pathways including integrating
nutriment, growth factors, hormones, stress and intracellular energy information. A key reg‐
ulator point of autophagy in mammals is kinase mTOR. The kinase TOR is a major evolutio‐
narily conserved sensor in the autophagy signaling pathway in eukaryotes, but it also
regulates many other aspects of cell function, including transcription, translation, and cell
size and cytoskeletal organization. In mammals, mTOR can be included in two different
complexes, mTORC1 and mTORC2. Although these two TOR complexes share common
components, they display distinct cellular functions and phosphorylate different down‐
stream substrates. The activity of mTORC1 is regulated via the integration of many signals,
including growth factors, insulin, nutrients, energy availability, and cell stressors such as
hypoxia, osmotic stress, reactive oxygen species (ROS) and viral infection. mTORC1 is the
only known target of the drug rapamycin and is required for signaling to ribosomal S6 kin‐
ases (S6K) and eIF4E-binding proteins (4EBP1 and 4EBP2). mTORC1 has recently been
shown to consist of four proteins: mTOR, mLST8 (also known as GbL), proline-rich PKB/Akt
substrate 40-kDa (PRAS40), and raptor (regulatory associated protein of mTOR); and it
plays a major role in controlling translation and cell growth in response to nutrients. The
adaptor protein is common to both mTOR complexes. Raptor binds mTOR, S6K and
4EBP1/2 and facilitates mTOR phosphorylation of these molecules; but whether raptor en‐
hances or represses mTOR kinase activity remains unclear [15]. Unlike mTORC1, mTORC2
has some functions that cannot be inhibited by rapamycin, including the control of actin cy‐
toskeleton dynamics. The mTORC2 complex consists of mTOR, mLST8, mammalian stress-
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activated protein kinase-interacting protein 1 (mSin1), and rapamycin-insensitive
companion of mTOR (rictor). Recent studies indicate that when eutrophy, mTOR activates
the PI3K-I/ protein kinase B (PKB) signaling pathway, it leads multiple serine sites to phos‐
phorylation and then reduces the affinity of Atg13 and Atg1. Since Atg1-Atg13 compounds
decreased, Atg9 cannot be transferred to the autophagosome formation sites and autophagy
was inhibited.
AMP-activated protein kinase (AMPK) was initially identified as a serine/threonine kinase
that negatively regulates several key enzymes of the lipid anabolism. Meanwhile, AMPK is
regarded as the major energy-sensing kinase that activates a whole variety of catabolic proc‐
esses in multicellular organisms such as glucose uptake and metabolism, while simultane‐
ously inhibiting several anabolic pathways, such as lipid, protein, and carbohydrate
biosynthesis. Activated AMPK can inhibit mTOR by interfering with the activity of GTPase
Rheb and with protein synthesis, degrade the phosphorylation of ULK1 and promote disin‐
tegration of ULK1 from the mTOR compounds. In starved cells, when the AMP/ATP ratio
increases; the binding of AMP to AMPK promotes its activation by the AMPK kinase LKB.
Moreover, Ca2+/calmodulin-dependent kinase kinase beta (CaMKK-beta) has been identified
as being an AMPK kinase. The activity of AMPK is required for autophagy to be induced in
response to starvation in mammalian cells and in yeast in a TORC1-dependent manner.
Moreover, autophagy induction is also dependent on the inhibition of mTORC1 by AMPK
in non-starved cells in response to an increase in free cytosolic Ca2+. In this setting, the acti‐
vation of AMPK and stimulation of autophagy are dependent on CaMKK-beta. The induc‐
tion of autophagy through AMPK activation probably also occurs in other settings, such as
hypoxia. AMPK is probably a general regulator of autophagy upstream of mTOR [16]. An‐
other potential candidate of autophagy regulation down-stream of AMPK is elongation fac‐
tor-2 kinase (eEF-2 kinase), which controls the rate of peptide elongation [17]. Activation of
eEF-2 kinase increases autophagy and slows protein translation. The activity of eEF-2 kinase
is regulated by mTOR, S6K, and AMPK. During periods of ATP depletion, AMPK is activat‐
ed and eEF-2 kinase is phosphorylated, leading to a balance between the inhibition of pep‐
tide elongation and the induction of autophagy. However, how eEF-2 kinase impinges on
the molecular machinery of autophagy remains to be elucidated.
There also is an indirectly-TOR-dependent signaling pathway, named class I PI3K/Akt path‐
way, which when responding to insulin-like and other growth factor signals, the signaling
molecules link receptor tyrosine kinases to activate TOR kinase and thereby repress autoph‐
agy. In addition, autophagy can mediate inactive proteins to degrade to amino acids and
then provide metabolic substrates for cardiac development and ischemic hypoxia forming a
cardiac protection method. Autophagy is among the important mechanisms of hypoxic
adaptation and is perhaps one of the last resorts for the salvage of ATP in hypoxic cells and
organs.
p53 is a responsive stress protein which also plays a crucial role in the regulation of autoph‐
agy through the transcription-dependent/independent pathways. In the transcription-inde‐
pendent pathway, p53 can activate AMPK and down-regulate mTOR; in the transcription-
dependent pathway, through the up-regulation of PTEN (inhibitor of mTOR), the tuberous
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sclerosis-1 (TSC1) gene or cell death gene damage-regulated autophagy modulator 1
(DRAM1), mTOR is down-regulated, and autophagy is induced (Figure 2). In addition, c-jun
N signal kinases (JNK), GTPases, Erk1/2, ceramide are also involved in regulating autopha‐
gy. The cytoplasmic form of p53 has been shown to have an inhibitory effect on autophagy,
suggesting that activation of autophagy by p53 depends on its transactivating effect on
genes such as DRAM1 [18].
Figure 2. Signaling Pathway of Autophagy (Cite from http://www.cellsignal.com/).
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4. The role of autophagy in the maintenance of normal myocardium
In the basal state, autophagy showed low expression in the heart to maintain normal myo‐
cardial function. And most of its function is to perform homeostatic functions by eliminating
long-live organelles and proteins. Autophagy can be upregulated rapidly when myocardi‐
um cells need to generate intracellular nutrients and energy, for example during starvation
or trophic factor withdrawal. Nutritional status, hormonal factors, and other cues like tem‐
perature, oxygen concentrations, and cell density are important in the control of autophagy.
The molecular mechanism of autophagy is still poorly understood. There are more than 30
genes that have been confirmed to be related to autophagy, and half of them are highly con‐
servative in most metazoa [19]. Knockout Atg5 gene (a decisive gene in autophagy) in early
stage adult rat hearts has showed no obvious abnormality, however, after increased after‐
load for one week, left ventricular can cause myocardial ubiquitination and mitochondrial
aggregation, resulting in myocardial hypertrophy and decrease in myocardial contractility,
which indicates that autophagy may play an important role in maintenance of homeostasis,
size of myocardium, general construction and function of myocardial cells. Paradoxically,
partially reduced autophagic activity caused by heterozygous deletion of Beclin 1 improves
cardiac function upon pressure overload. Consistent with this phenomenon, partial suppres‐
sion of autophagy with histone deacetylase (HDAC) inhibitors can ameliorate pressure
overload-induced cardiac hypertrophy in mice [20]. These data suggest that partial, but not
complete, suppression of autophagy may be beneficial.
In short, autophagy adapts to the myocardial energy demand by maintaining energy metab‐
olism, so as to protect the myocardial function.
5. The protective effect of autophagy in myocardial ischemia/hypoxia
In recent years, a large number of studies suggested that autophagy played a protective role
to rescue cardiomyocytes in ischemia/hypoxia. In [21], researchers discovered that 40 mins
of hypoxia induced significant autophagosome and autolysosome formation, according to a
rabbit hypoxic heart model. At the same time, ultrastructural analysis revealed autophago‐
somes in close proximity to swollen and fragmented mitochondria. And in rodents, 30 mins
after ischemia induced dramatic up-regulation of autophagosome formation [22]. Previous
report also demonstrated that the level of autophagy was rapidly increased within 30 mins
after coronary ligation in mice, especially in the risk area (salvaged cardiomyocytes border‐
ing the infarcted area) [23]. Recent work has revealed that inactivation of hypoxia-inducible
factor 1α (HIF-1α) in fibroblasts blunts hypoxia-induced autophagy [24]. These results
strongly suggested that autophagy was activated by myocardial ischemia/hypoxia. Further‐
more, these investigators reported that suppression of autophagy using 3-methyladenine or
bafilomycin A1 enhanced myocyte death triggered by glucose deprivation. During postin‐
farction cardiac remodeling, lysosomes and autophagosomes became more numerous in the
cardiomyocytes, thus ensuring that autophagy could provide enough energy to cardiomyo‐
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cytes. The protective effects of autophagy may be that cells were likely to be provided ener‐
gy, free amino acids and fatty acids through decomposition of their own material.
Additionally, autophagy may maintain cardiomyocyte survival after ischemia/hypoxia by
inhibiting apoptosis [25]. Autophagy is a recycling process of cytoplasmic components, such
as long-lived proteins and organelles. The prosurvival role of autophagy has been observed
in yeast, plants, flies, and mammals. Inhibition of autophagy results in accumulation of cyto‐
plasmic components and promotion of apoptosis. Treatment with pharmacological autopha‐
gy inhibitors and knockdown of Atg genes (Atg5, Atg10, Atg12, and Beclin 1) can increase
apoptosis and cell death in nutrient-deprived cells. In reference [26], autophagy delayed
apoptotic cell death in breast cancer cells following DNA damage. These results suggested
that the effect of inhibiting apoptosis may be related to autophagosomes wrapping damaged
mitochondria, because it will not only prevent the release of cytochrome C, but also inhibit
the formation of apoptotic bodies.
Numerous studies show that mTOR is a key factor in regulating autophagy in ischemia/
hypoxia. In mammalian cells, phosphorylation of mTOR inhibits cell autophagy. Converse‐
ly, dephosphorylation of mTOR enhances autophagy. The activity of mTOR is adjusted by
many factors. AMPK is the important factor which would inhibit the activity of mTOR to
enhance autophagy in ischemia. AMPK serves as a general integrator of metabolic responses
to changes in energy availability and is activated in response to elevations of the AMP/ATP
ratio. Data in reference [27] suggested that autophagy has been reported to be up-regulated
in response to reduced cellular content of ATP. In cultured cardiac myocytes, glucose depri‐
vation caused significant reduction in the levels of ATP, which coincided with up-regulation
of autophagy. Moreover, myocardial ischemia causes a decrease in ATP levels and an in‐
crease in the AMP/ATP ratio, resulting in activation of the AMPK [28]. Under conditions of
stress (including hypoxia and ischemia), a signaling cascade is initiated involving phosphor‐
ylation of AMPK and subsequent inhibition of mTOR. Inhibition of mTOR, in concert with
other protein partners, provides the critical step in initiating autophagosome formation.
6. The expression and regulation of autophagy during myocardial
ischemia/reperfusion
Autophagy is induced during myocardial ischemia. Although it was speculated that activa‐
tion of autophagy may be reverted when ischemia is relieved, in fact, autophagy may be fur‐
ther enhanced by reperfusion [22, 29]. A variety of factors that can regulate the autophagy
during myocardial ischemia/reperfusion, such as ROS generated by mitochondrial respira‐
tion, endoplasmic reticulum stress, calcium, vitamin D compounds, ATP, thapsigargin, cal‐
cium protease, and so on. Different signal transduction pathways are involved in the
occurrence of autophagy at different stages of myocardial ischemia/reperfusion.
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aggregation, resulting in myocardial hypertrophy and decrease in myocardial contractility,
which indicates that autophagy may play an important role in maintenance of homeostasis,
size of myocardium, general construction and function of myocardial cells. Paradoxically,
partially reduced autophagic activity caused by heterozygous deletion of Beclin 1 improves
cardiac function upon pressure overload. Consistent with this phenomenon, partial suppres‐
sion of autophagy with histone deacetylase (HDAC) inhibitors can ameliorate pressure
overload-induced cardiac hypertrophy in mice [20]. These data suggest that partial, but not
complete, suppression of autophagy may be beneficial.
In short, autophagy adapts to the myocardial energy demand by maintaining energy metab‐
olism, so as to protect the myocardial function.
5. The protective effect of autophagy in myocardial ischemia/hypoxia
In recent years, a large number of studies suggested that autophagy played a protective role
to rescue cardiomyocytes in ischemia/hypoxia. In [21], researchers discovered that 40 mins
of hypoxia induced significant autophagosome and autolysosome formation, according to a
rabbit hypoxic heart model. At the same time, ultrastructural analysis revealed autophago‐
somes in close proximity to swollen and fragmented mitochondria. And in rodents, 30 mins
after ischemia induced dramatic up-regulation of autophagosome formation [22]. Previous
report also demonstrated that the level of autophagy was rapidly increased within 30 mins
after coronary ligation in mice, especially in the risk area (salvaged cardiomyocytes border‐
ing the infarcted area) [23]. Recent work has revealed that inactivation of hypoxia-inducible
factor 1α (HIF-1α) in fibroblasts blunts hypoxia-induced autophagy [24]. These results
strongly suggested that autophagy was activated by myocardial ischemia/hypoxia. Further‐
more, these investigators reported that suppression of autophagy using 3-methyladenine or
bafilomycin A1 enhanced myocyte death triggered by glucose deprivation. During postin‐
farction cardiac remodeling, lysosomes and autophagosomes became more numerous in the
cardiomyocytes, thus ensuring that autophagy could provide enough energy to cardiomyo‐
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cytes. The protective effects of autophagy may be that cells were likely to be provided ener‐
gy, free amino acids and fatty acids through decomposition of their own material.
Additionally, autophagy may maintain cardiomyocyte survival after ischemia/hypoxia by
inhibiting apoptosis [25]. Autophagy is a recycling process of cytoplasmic components, such
as long-lived proteins and organelles. The prosurvival role of autophagy has been observed
in yeast, plants, flies, and mammals. Inhibition of autophagy results in accumulation of cyto‐
plasmic components and promotion of apoptosis. Treatment with pharmacological autopha‐
gy inhibitors and knockdown of Atg genes (Atg5, Atg10, Atg12, and Beclin 1) can increase
apoptosis and cell death in nutrient-deprived cells. In reference [26], autophagy delayed
apoptotic cell death in breast cancer cells following DNA damage. These results suggested
that the effect of inhibiting apoptosis may be related to autophagosomes wrapping damaged
mitochondria, because it will not only prevent the release of cytochrome C, but also inhibit
the formation of apoptotic bodies.
Numerous studies show that mTOR is a key factor in regulating autophagy in ischemia/
hypoxia. In mammalian cells, phosphorylation of mTOR inhibits cell autophagy. Converse‐
ly, dephosphorylation of mTOR enhances autophagy. The activity of mTOR is adjusted by
many factors. AMPK is the important factor which would inhibit the activity of mTOR to
enhance autophagy in ischemia. AMPK serves as a general integrator of metabolic responses
to changes in energy availability and is activated in response to elevations of the AMP/ATP
ratio. Data in reference [27] suggested that autophagy has been reported to be up-regulated
in response to reduced cellular content of ATP. In cultured cardiac myocytes, glucose depri‐
vation caused significant reduction in the levels of ATP, which coincided with up-regulation
of autophagy. Moreover, myocardial ischemia causes a decrease in ATP levels and an in‐
crease in the AMP/ATP ratio, resulting in activation of the AMPK [28]. Under conditions of
stress (including hypoxia and ischemia), a signaling cascade is initiated involving phosphor‐
ylation of AMPK and subsequent inhibition of mTOR. Inhibition of mTOR, in concert with
other protein partners, provides the critical step in initiating autophagosome formation.
6. The expression and regulation of autophagy during myocardial
ischemia/reperfusion
Autophagy is induced during myocardial ischemia. Although it was speculated that activa‐
tion of autophagy may be reverted when ischemia is relieved, in fact, autophagy may be fur‐
ther enhanced by reperfusion [22, 29]. A variety of factors that can regulate the autophagy
during myocardial ischemia/reperfusion, such as ROS generated by mitochondrial respira‐
tion, endoplasmic reticulum stress, calcium, vitamin D compounds, ATP, thapsigargin, cal‐
cium protease, and so on. Different signal transduction pathways are involved in the
occurrence of autophagy at different stages of myocardial ischemia/reperfusion.
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6.1. The role of Beclin 1 in the occurrence of autophagy during myocardial ischemia/
reperfusion
Induction of autophagy in the ischemic phase was accompanied by activation of AMPK and
mTOR. In contrast, autophagy during reperfusion was accompanied by upregulation of Be‐
clin 1 rather than by activation of AMPK. Induction of autophagy and cardiac injury during
the reperfusion phase was significantly attenuated in Beclin 1+/- mice. Collectively, in the is‐
chemic heart, autophagy is stimulated through an AMPK-dependent mechanism, whereas
ischemia/reperfusion stimulates autophagy through a Beclin 1-dependent but not an AMPK-
independent pathway [22]. Using cultured cardiomyocytes, previous studies have demon‐
strated that the inhibition of autophagy by urocortin during the reperfusion phase is
mediated in part by inhibition of Beclin 1 expression, an effect which is mediated by activa‐
tion of the PI3K/Akt pathway [30]. Recent experimental data also show that the clearance of
autophagosomes is impaired in myocardial reperfusion injury which is mediated in part by
ROS-induced decline in LAMP-2A and upregulation of Beclin 1, contributing to increased
cardiomyocyte death [31, 32]. Thus, ROS and ROS-mediated upregulation of Beclin 1 in the
myocardial reperfusion phase may play an important role in the occurrence of autophagy.
Therefore, it is now widely recognized that the autophagy was induced through the AMPK-
eEF2K/mTOR pathway during the ischemic phase of ischemic/reperfusion injury, but was
triggered through the Class III PI3K/Beclin 1 pathway during the reperfusion phase.
6.2. The role of Bcl-2 family members in the occurrence of autophagy during myocardial
ischemia/reperfusion
It is well known that the Bcl-2 family proteins play essential roles in regulating apoptosis in
the cardiovascular system, and several studies have revealed that the Bcl-2 family members
(Bnip3, Bcl-2, Bcl-XL, Bax, etc.) also play important roles in the induction of autophagy dur‐
ing myocardial ischemia/reperfusion injury.
6.2.1. Bnip3
Bnip3 (Bcl-2/adenovirus E1B-19 KD interacting protein 3) with a single Bcl-2 homology 3
(BH3) domain is a pro-apoptotic Bcl-2 family protein which is most sensitive to hypoxia
and plays an important role in myocardial ischemia/reperfusion injury. It was found that
the  overexpression  of  Bnip3  significantly  increased  autophagy,  whereas,  overexpression
of the dominant-negative Bnip3 significantly reduced autophagy induced by myocardial
ischemia/reperfusion  in  HL-1  cardiac  myocytes  [33].  These  results  suggest  that  Bnip3
plays a fundamental role in the induction of autophagy during myocardial ischemia and
reperfusion.  However,  more  studies  are  still  needed  to  clarify  the  role  of  Bnip3  in  re‐
sponse  to  ischemia/reperfusion,  and  the  most  reasonable  explanation  is  that  the  mito‐
chondrial  dysfunction caused by Bnip3 can enhance  the  level  of  autophagy in  order  to
remove damaged organelles.
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6.2.2. Bcl-2/Bcl-XL and Bax
Bcl-2 family members are key modulators of apoptosis that have recently been shown to al‐
so regulate autophagy. Transgenic mice overexpressing the anti-apoptotic human Bcl-2
cDNA in the heart is effective at reducing myocardial reperfusion injury and improving
heart function [34, 35]. However, blockage of the activity of the proapoptotic molecule Bax
in a knockout mouse model attenuates ischemia/reperfusion injury [36]. Recent reports dem‐
onstrated that Beclin 1 possessed a BH3 domain. The BH3 domain of Beclin 1 is bound to
and inhibited by Bcl-2 or Bcl-XL [37, 38]. A BH3 mutant of Beclin1 which has reduced affini‐
ty for Bcl-XL/Bcl-2 was a more potent inducer of autophagy than wild type Beclin 1. Overex‐
pression of Bcl-2 in the heart reduced starvation-induced autophagy. Thus, Bcl-2 not only
functions as an antiapoptotic protein, but also as an antiautophagy protein via its inhibitory
interaction with Beclin 1. These antiapoptosis and antiautophagy functions of Bcl-2 may pro‐
tect the myocardium against ischemia/reperfusion injury [39]. Meanwhile, some studies
found that Bnip3 enhanced autophagy, possibly due to competitive disruption of Bcl-2 bind‐
ing to Beclin 1 [24] or interacting with Rheb to inhibit mTOR [40]. Of course, more studies
are needed to clarify these relationships.
6.3. The role of angiotensin II (Ang II) receptor signaling in the induction of autophagy
during myocardial ischemia/reperfusion
Recent report demonstrated that overexpression of Ang II type 1 (AT1) receptor caused a
significant increase in autophagy after treatment with Ang II in cultured neonatal rat cardio‐
myocytes. However, overexpression of the Ang II type 2 (AT2) receptor can inhibit autopha‐
gy in an Ang II-independent manner. Neonatal cardiomyocytes cultured from hypertrophic
heart rats (HHRs) were more susceptible to AT1 receptor-stimulated autophagy than cardio‐
myocytes from normal heart rats (NHRs). Moreover, there was a greater up-regulation of
autophagic markers in adult HHR hearts than in NHR hearts following ischemia/reperfu‐
sion in vitro [41]. Additionally, AT1 receptor blockaded with olmesartan plays a protective
role in myocardial ischemia-reperfusion injury [42]. Therefore, it is inferred that Ang II/AT1
receptor signaling might also be involved in the stimulation of autophagy during myocar‐
dial ischemia/reperfusion.
Thus, in addition to the Beclin 1, many Bcl-2 family members and angiotensin II/AT1 recep‐
tor signaling may also be involved in the stimulation of autophagy, but additional studies
are needed to clarify the role of these pathways in the occurrence of autophagy during ische‐
mia/reperfusion injury of the heart.
7. The role of autophagy in myocardial ischemia/reperfusion
The autophagy is induced during the ischemia/reperfusion process; however, the role of au‐
tophagy during myocardial ischemia/reperfusion is still inconclusive.
It is well-documented that autophagy occurs at basal levels but can be further induced by
stresses, such as nutrient depletion. Autolysosomal degradation of membrane lipids and
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ischemia/reperfusion  in  HL-1  cardiac  myocytes  [33].  These  results  suggest  that  Bnip3
plays a fundamental role in the induction of autophagy during myocardial ischemia and
reperfusion.  However,  more  studies  are  still  needed  to  clarify  the  role  of  Bnip3  in  re‐
sponse  to  ischemia/reperfusion,  and  the  most  reasonable  explanation  is  that  the  mito‐
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pression of Bcl-2 in the heart reduced starvation-induced autophagy. Thus, Bcl-2 not only
functions as an antiapoptotic protein, but also as an antiautophagy protein via its inhibitory
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tect the myocardium against ischemia/reperfusion injury [39]. Meanwhile, some studies
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ing to Beclin 1 [24] or interacting with Rheb to inhibit mTOR [40]. Of course, more studies
are needed to clarify these relationships.
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significant increase in autophagy after treatment with Ang II in cultured neonatal rat cardio‐
myocytes. However, overexpression of the Ang II type 2 (AT2) receptor can inhibit autopha‐
gy in an Ang II-independent manner. Neonatal cardiomyocytes cultured from hypertrophic
heart rats (HHRs) were more susceptible to AT1 receptor-stimulated autophagy than cardio‐
myocytes from normal heart rats (NHRs). Moreover, there was a greater up-regulation of
autophagic markers in adult HHR hearts than in NHR hearts following ischemia/reperfu‐
sion in vitro [41]. Additionally, AT1 receptor blockaded with olmesartan plays a protective
role in myocardial ischemia-reperfusion injury [42]. Therefore, it is inferred that Ang II/AT1
receptor signaling might also be involved in the stimulation of autophagy during myocar‐
dial ischemia/reperfusion.
Thus, in addition to the Beclin 1, many Bcl-2 family members and angiotensin II/AT1 recep‐
tor signaling may also be involved in the stimulation of autophagy, but additional studies
are needed to clarify the role of these pathways in the occurrence of autophagy during ische‐
mia/reperfusion injury of the heart.
7. The role of autophagy in myocardial ischemia/reperfusion
The autophagy is induced during the ischemia/reperfusion process; however, the role of au‐
tophagy during myocardial ischemia/reperfusion is still inconclusive.
It is well-documented that autophagy occurs at basal levels but can be further induced by
stresses, such as nutrient depletion. Autolysosomal degradation of membrane lipids and
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proteins generate free fatty acids and amino acids, which can be reused to maintain mito‐
chondrial ATP production and protein synthesis and promote cell survival. When the myo‐
cardium was suppressed with ischemia, the blood supply was decreased and the energy
was insufficient, which means that there was an inadequate supply of nutrients. In these
conditions, AMPK acts as a sensor for energy deprivation and activation of AMPK mediates
metabolic adaptation during ischemia.
Many studies have shown that the autophagy induced by lack of blood supply plays a pro‐
tective effect during periods of ischemia. For example, see [43], autophagy is significantly
up-regulated during chronic ischemia in the pig heart. In this model, the level of autophagy
was inversely correlated with that of apoptosis in the ischemic area. The ischemic area was
recovered when the coronary flow was restored, suggesting that autophagy may protect
myocardium from apoptosis during hibernation. Inhibition of endogenous AMPK sup‐
pressed autophagy during prolonged ischemia, which was accompanied by enlargement of
the myocardial infarction. Although one may speculate that activation of autophagy may be
reverted as soon as ischemia is relieved, the level of autophagy in fact further increases dur‐
ing reperfusion. However, a higher level of autophagy is not due to the lack of energy dur‐
ing blood flow restoration after reperfusion. Mechanisms mediating autophagy during
reperfusion appear different from those involved in autophagy during ischemia. Energy cri‐
sis, a major stimulus for autophagy, in the heart is at least partially resolved at the time of
reperfusion [32]. Instead, ROS appears to be a major promoter of autophagy during reperfu‐
sion. ROS induces mitochondrial damage, as evidenced by mitochondrial permeability tran‐
sition pore (mPTP) opening and mitochondrial fragmentation, which in turn promotes
autophagy and/or mitophagy, a specialized form of autophagy which removes mitochon‐
dria [44]. ROS oxidizes and inhibits the cysteine protease activity of Atg4, which results in
LC3 lipidation and autophagy.
Whether autophagy induced during reperfusion is beneficial or detrimental remains con‐
troversial. Previous data [32] have shown that, although autophagic flux is inhibited dur‐
ing ischemia/reperfusion, enhancing autophagic flux during ischemia/reperfusion protects
against  ischemia/reperfusion  injury  in  cardiomyocytes  in  vitro.  The  number  of  Bax  (+)
cardiac  cells  induced by reperfusion was significantly  increased when Beclin-1  or  Atg-5
were knocked out,  but was reduced when there was an overexpression of Beclin-1 [45].
In an in vivo model  of  myocardial  ischemia/reperfusion in pigs,  autophagy was signifi‐
cantly activated when the coronary perfusion is restored, which was accompanied by re‐
duction  of  apoptosis  in  myocardial  cells  and  almost  complete  recovery  of  cardiac
function [46].  Other experiments have also demonstrated that autophagy activation dur‐
ing  myocardial  ischemia/reperfusion  can  remove  the  damaged  mitochondria  caused  by
Bnip3.  These results  indicate  that  autophagy may promote cell  survival  during myocar‐
dial ischemia/reperfusion injury.
In contrast,  study in reference [30] showed that inhibiting autophagy by treatment with
3-methyladenine or by Beclin1 knock down increases the survival  of  cardiomyocytes af‐
ter ischemia/reperfusion in vitro. As results in [22],  the myocardial infarct size increased
by  40%  in  rats  subjected  to  reperfusion,  while  the  infarct  size  was  down-regulated  to
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20% after  the  autophagy gene  Beclin1  knockout.  Inhibition  of  cathepsin,  which  can  de‐
grade  autophagosomes,  can  significantly  reduce  myocardial  cell  damage  and  apoptosis
during the reperfusion phase.  Therefore,  the roles  of  autophagy are not  very clear  dur‐
ing myocardial reperfusion. Further studies are needed to investigate the real roles of au‐
tophagy  in  myocardial  ischemia/reperfusion  injury.  However,  it  is  still  speculated  that
the excessive degradation of important proteins and organelles by autophagy will  cause
cell death.
8. The role of autophagy in aging hearts subjected to ischemia/
reperfusion
Aging is characterized by a progressive accumulation of damaged cells and organs. Autoph‐
agy degraded damaged organelles and macromolecule materials in stress, which prolonged
life span [47]. Autophagy, including the autophagosome formation, the maturation, and the
efficiency of autophagosome-lysosome fusion, as well as the proteolysis activity of lyso‐
somes, declines with age [48]. All of these factors induce an abundance of the lipofuscin pol‐
ymer accumulated in lysosomes. The lipofuscin polymer could not be degraded by
lysosomes. The lysosome with an abundance of lipofuscin polymer lost its bio-function.
Therefore, some damaged organelles and macromolecule materials could not be cleaned up,
which accounted for the aging process. Several studies supported enhancing autophagy as
the most efficient anti-aging intervention [49, 50].
In the heart, autophagy maintains a low basal level to perform biological functions, such as
degrading dysfunctional organelles, maintaining cardiac morphology and function [51, 52].
However, autophagy in cardiomyocytes were up-regulated in response to environmental
stress conditions, such as ATP depletion (e.g. during starvation), oxidative damage, and mi‐
tochondrial permeability transition pore opening (e.g. myocardial ischemia/reperfusion in‐
jury) [53, 54]. Activation of autophagy during ischemia is essential for cell survival and
maintenance of cardiac function. However, autophagy was activated in the heart subjected
to ischemia/reperfusion. Recent reviews show autophagy during reperfusion could be either
protective or detrimental [41]. Serious induction of autophagy accompanied by robust up-
regulation of Beclin-1 could cause autophagic cell death, thereby proving to be detrimental.
If ischemia is mild, activation of autophagy during reperfusion may be modest and thus
may not be harmful.
Until now, there is little information related to autophagy in myocardial ischemia/reperfu‐
sion injury in aging. Our primary data showed that ischemia/reperfusion injury was more
serious in aging hearts compared with young hearts. Beclin-1 was increased in aging hearts
subjected to ischemia/reperfusion, which indicated activated autophagy. However, further
research is needed to know the exact role of autophagy in myocardial ischemia/reperfusion
injury, especially in aging. Moreover, recent studies suggest that autophagy is one of the im‐
portant mechanisms in myocardial ischemia/reperfusion preconditioning. Decreased au‐
tophagy may contribute to the weakened protective role of preconditioning in aging hearts
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pressed autophagy during prolonged ischemia, which was accompanied by enlargement of
the myocardial infarction. Although one may speculate that activation of autophagy may be
reverted as soon as ischemia is relieved, the level of autophagy in fact further increases dur‐
ing reperfusion. However, a higher level of autophagy is not due to the lack of energy dur‐
ing blood flow restoration after reperfusion. Mechanisms mediating autophagy during
reperfusion appear different from those involved in autophagy during ischemia. Energy cri‐
sis, a major stimulus for autophagy, in the heart is at least partially resolved at the time of
reperfusion [32]. Instead, ROS appears to be a major promoter of autophagy during reperfu‐
sion. ROS induces mitochondrial damage, as evidenced by mitochondrial permeability tran‐
sition pore (mPTP) opening and mitochondrial fragmentation, which in turn promotes
autophagy and/or mitophagy, a specialized form of autophagy which removes mitochon‐
dria [44]. ROS oxidizes and inhibits the cysteine protease activity of Atg4, which results in
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against  ischemia/reperfusion  injury  in  cardiomyocytes  in  vitro.  The  number  of  Bax  (+)
cardiac  cells  induced by reperfusion was significantly  increased when Beclin-1  or  Atg-5
were knocked out,  but was reduced when there was an overexpression of Beclin-1 [45].
In an in vivo model  of  myocardial  ischemia/reperfusion in pigs,  autophagy was signifi‐
cantly activated when the coronary perfusion is restored, which was accompanied by re‐
duction  of  apoptosis  in  myocardial  cells  and  almost  complete  recovery  of  cardiac
function [46].  Other experiments have also demonstrated that autophagy activation dur‐
ing  myocardial  ischemia/reperfusion  can  remove  the  damaged  mitochondria  caused  by
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ter ischemia/reperfusion in vitro. As results in [22],  the myocardial infarct size increased
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which accounted for the aging process. Several studies supported enhancing autophagy as
the most efficient anti-aging intervention [49, 50].
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However, autophagy in cardiomyocytes were up-regulated in response to environmental
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jury) [53, 54]. Activation of autophagy during ischemia is essential for cell survival and
maintenance of cardiac function. However, autophagy was activated in the heart subjected
to ischemia/reperfusion. Recent reviews show autophagy during reperfusion could be either
protective or detrimental [41]. Serious induction of autophagy accompanied by robust up-
regulation of Beclin-1 could cause autophagic cell death, thereby proving to be detrimental.
If ischemia is mild, activation of autophagy during reperfusion may be modest and thus
may not be harmful.
Until now, there is little information related to autophagy in myocardial ischemia/reperfu‐
sion injury in aging. Our primary data showed that ischemia/reperfusion injury was more
serious in aging hearts compared with young hearts. Beclin-1 was increased in aging hearts
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injury, especially in aging. Moreover, recent studies suggest that autophagy is one of the im‐
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subjected to ischemia/reperfusion. Therefore, excessive autophagy results in autophagic cell
death and loss of cardiomyocytes, responsible for the worsening of aging myocardial ische‐
mia/reperfusion injury. The molecular transduction pathways need to be investigated fur‐
ther. It could help to develop therapies that up-regulate the repair qualities of the
autophagic process and down-regulate the cell death aspects, which would be of great value
in the treatment of aging myocardial ischemia/reperfusion injury.
9. The investigative methods of autophagy
9.1. Electron microscopy
Electron microscopy is the most reliable method for testing autophagy at present and can be
used to quantify the autophagic activity of cells. In electron microscopy, the autophagosome
is composed of double membrane structures that wrap abnormal cytoplasmic material.
Then, the autolysosome is composed of the monolayer membrane structure which wraps cy‐
toplasm ingredients at different degradation stages. Because of the difficulty of distinguish‐
ing between autophagosomes and autolysosomes, both of them are often called ‘autophagic
vacuoles’. The proportion of autophagic vacuoles is calcultaed accounting for the total area
or volume of cytoplasm through electron microscopy, which can be used to quantify cell au‐
tophagic activity.
9.2. Specific markers
Atg8 includes three kinds of homology in humans: GABARAP, GATE-16 and LC3. The C-
terminal proteolysis of LC3 is processed by Atg4, based on the residues Phe80 and Leu82 of
LC3 that may be recognized by Atg4, and immediately follows synthesis to yield a soluble
form, LC3-I. LC3-I is converted to a membrane bound form, LC3-II, through a ubiquitin-like
reaction involving Atg7, a ubiquitin-acivating enzyme (E1)-like enzyme, and Atg3, a ubiqui‐
tin-conjugating enzyme (E1)-like enzyme (E2). LC3-II combines to phosphatidyl ethanola‐
mine (PE) on the membrane surface of autophagic vacuoles. In addition, LC3-II is easily
located within the cell after the formation of the fusion protein with the green fluorescent
protein (GFP). Therefore, GFP-LC3 II is usually used as the marker protein of the autopha‐
gosome membrane in mammalian cells.
Beclin 1 is involved in the formation of autophagosomes, which are the mammalian yeast
homologues of Apg6/Vps30. Some researches show that autophagy is significantly attenuat‐
ed in Beclin 1+/- mice, but apoptosis is normal. These results indicate that Beclin 1 is a signif‐
icant positive control gene in autophagy. Therefore, by testing the expression level of
Beclin1, combined with other biochemistry indexes, the autophagic activity of cells can be
monitored and judged dynamically.
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9.3. Monodansylcadaverine (MDC) dyeing
MDC is a kind of fluorescent dye, which is used as a tracer of the autophagic vacuoles. MDC
can specifically bind to the ubiquitin-proteasome sample protein binding systems (Atg8). In
addition, MDC can be absorbed by cells and selectively gathered in autophagic vesicles,
showing punctuate structure under fluorescence microscope. Therefore, the quantitative de‐
tection of autophagy uses this method. However, most of the MDC is not marked in GFP-
LC3. However, MDC is not a reliable marker of autophagosomes. Therefore, other
experimental evidences that represent the autophagic activity of cells are needed.
9.4. Specific agonists and inhibitors
Rapamycin is a novel macrolide immunosuppressant, and induces cell autophagy by inhib‐
iting the mTOR pathway. In scientific studies, Rapamycin is the specific agonist of autopha‐
gy. The main inhibitors of the phosphor-lipin acid radical inositol 3 kinase include 3-MA,
which can specifically block the fusion of autophagic vacuoles and lysosomes. Rapamycin is
widely used as an inhibitor of autophagy, and Wortmannin, LY29400297 and Bafilomycin
A1 are included.
10. Perspectives
Autophagy is intimately involved not only in the physiology of the heart, but also in devel‐
opment of the ischemic heart. The regulation of autophagy may be a new approach for the
treatment of ischemic heart disease. However, to translate the knowledge of autophagy into
treatment of ischemic heart disease, it is necessary to know more precisely about the forma‐
tion, function, mechanism, and regulation of autophagy. When autophagy is protective and
when it is detrimental for the ischemic heart needs further clarification. Another problem is
how to regulate autophagy without affecting other life activities, since even the evolutionar‐
ily conserved autophagy genes also have autophagy-dependent functions. There is continu‐
ing research on this topic. In addition, the signaling mechanisms positively or negatively
regulating autophagy in the heart have not been completely elucidated. Judging from the di‐
versity of autophagy regulators, it is believed that more unknown signal transduction path‐
ways will also be proven to be involved in the activation of autophagy. In short, only
clarifying the activation mechanism, function, time course, and its relationship with cell
death, etc. autophagy can truly benefit patients with ischemic heart disease.
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or volume of cytoplasm through electron microscopy, which can be used to quantify cell au‐
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gosome membrane in mammalian cells.
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1. Introduction
1.1. Treatment for ischemic heart diseases: State-of-the-art
Cardiovascular diseases, especially ischemic heart disease, are the leading cause of mortality
in the United States [1]. In the past decades, pharmacological therapy, such as β-blocker,
Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker(ARB) have
been shown to ameliorate cardiac dysfunction and limit heart remodeling following myocar‐
dial infarction [2]. Moreover, the development of coronary artery bypass graft (CABG) can
recanalize occlusive coronary and salvage the remaining surviving myocardium [3]. More
recently, with the development of percutaneous coronary intervention (PCI), retrograde
approach through collaterals has been introduced for percutaneous recanalization of chronic
total occlusion (CTO) of the coronary arteries, a new option for the patient with CTO beyond
CABG [4]. Unfortunately, even with great advances of these modern technologies, myocardial
infarctions will eventually develop into decompensated chronic heart failure. Heart trans‐
plantation is currently the last resort for the patient with end-stage heart failure. However, this
therapeutic option is limited by donor organ shortage and eventual organ rejection [5].
Therefore, new therapies are required to prevent the progression of pathological remodeling
and cell death, as well as to induce tissue recovery in the ischemic heart. Regenerative
cardiovascular medicine becomes a holy grail with the goal to replace and repair the damaged
myocardium and reverse heart dysfunction. In the past two decades, a variety of stem cells
have been investigated by scientists to achieve this goal [6]. Recently developed reprogram‐
ming technology, induced pluripotent stem cells (iPSC) has become an alternative source for
embryonic stem cells (ESC) without the ethical drawbacks [7], showing their powerful
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potential to differentiate into desired cell type [8]. A new discipline termed stem cell engi‐
neering has recently emerged aiming to reconstruct the damaged heart by integrating
progenitor/stem cell biology and bioengineering technology [9]. In this chapter, the recent the
recent advances and challenges of progenitor/stem cell engineering for the therapy of ischemic
heart disease will be discussed from a translational perspective.
2. Proper cell sources
Appropriate cell sources for stem cell engineering must meet the following requirements: 1)
The cell must be electromechanically coupled with the host heart tissue. 2) They must survive
in the hostile environment created by ischemic stress [10]. In this regard, several cell types have
been tried. Skeletal myoblast was the pioneering attempt but it was found to be limited to
contract synchronously with the host myocardium [11]. Bone marrow derived stem cells or
hematopoietic stem cells are easily obtained in clinical setting but their potential of cardiogenic
differentiation is still being debated [10]. The recent discovery of multipotent cardiac progen‐
itors have been proven to give rise to cardiomyocytes, endothelial, and smooth muscle cells,
forming the basic “components” for heart reconstruction [12]. The attempt to discover
endogenous cardiac progenitors showed some of those express c-Kit [13, 14] or Sca-1 [14]
markers. Transplantation of c-Kit+ cell resulted in neovascularization and cardiomyogenesis
in the infarcted heart [13]. Moreover, the cardiosphere obtained from human heart tissue
contained a mixed population of c-Kit+ and Sca-1+ cells and could regenerate infarcted heart
[15]. These encouraging results led to the initiation of several phase 1 clinical trials: ALCADIA
((AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy,
NCT00981006), SCIPIO (Cardiac Stem Cell Infusion in Patients with Ischemic Cardiomyop‐
athy) (NCT00474461), and CADUCEUS (NCT00893360). Preliminary data from the SCIPIO
and CADUCEUS (CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar
dysfunction) trials have been recently published in the Lancet [16, 17]. Both studies were aimed
to evaluate the feasibility and safety of intracoronary injection of autologous heart-derived
cells in a patient post myocardial infarction. The SCIPIO study [16] used c-kit+ cells that were
cultured from atrial tissue, whereas the CADUCEUS study [17] is using cardiospheres cultured
from biopsy-obtained right ventricular tissue. There is no report related to severe side effect
associated with cardiac cell injection in these two studies, although more adverse events were
observed in CADUCEUS study (treatment group). Both studies reported reduction in infarct
size following cell injection, but only the SCIPIO trial reported an improvement in left
ventricular ejection fraction (LVEF). There are still some limitations in these results, as
indicated by the limited sample size (16 in SCIPIO and 17 in CADUCEUS) and the absence of
a placebo group. Therefore, phase 2 study must be initiated in the future to further confirm its
safety and efficacy.
Furthermore, stimulation of the adult progenitor pool with epicardial origin after an acute
myocardial infarction (AMI) has been reported with some progress [18-20].  The success‐
ful  production  of  iPSC  by  transducing  pluripotent-regulated  transcriptional  factors  has
made it a powerful weapon for ex vivo  expansion of cardiomyocytes [21]. And the direct
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differentiation of pluripotent stem cells can be enhanced by administration of BMP4 and
activin A [22, 23]. How to remove undifferentiated stem cells from differentiated cardio‐
myocytes  has  been a  major  challenge in  translational  cardiovascular  medicine.  Potential
solutions to this problem might be can be overcome by i) purification of isl-1+ ventricular
precursors  followed  by  committed  differentiation  [24]  or  ii)  transgenic  enrichment  via
negative  selection  of  iPSC using  a  suicide  gene  (thymidine  kinase)/positive  selection  of
cardiomyocytes  expressing a  bicistronic  reporter  GFP expression under  control  of  alpha
myosin heavy chain promoter [25]. Taken together, these cells provide a valuable source
for  generation  of  a  cell  sheet/patch  for  tissue  engineering  purpose.  Therefore,  there  are
two techniques commonly used for cardiac repair. The first is transplantation of stem cells
with  cardiogenic  potential  into  injured heart  or  pre-induction  of  stem cells  into  cardio‐
myocytes followed by implantation. The second is stimulation of the endogenous cardiac
progenitor pool to propagate cardiovascular offspring. More recently,  the laboratories of
Deepak Srivastava and Eric  Olson reported a  new method,  termed by “in  vivo reprog‐
ramming  of  cardiomyocytes”,  making  in  vivo  transformation  of  scar  tissue  into  beating
heart muscle possible. By transducing with retroviruses encoding GMT (GATA4, MEF2C,
TBX5) [26] or GMTH (GMT+Hand2) [27] in vivo following left anterior descending artery
(LAD) ligation, cardiac fibroblasts,  the natural “partner” of cardiomyocytes, become acti‐
vated, migrate to the injured site, and proliferate, thus rendering these cells susceptible to
retroviral infection and subsequent epigenetic reprogramming event. Both groups report‐
ed a significant conversion of transduced fibroblasts, identified by genetic lineage tracing
of  non-cardiomyocyte  in  the  heart,  to  an  ‘‘induced  cardiomyocyte-like  (iCM)’’  or  ‘‘in‐
duced  cardiac-like  myocyte  (iCLM)’’  state  iCMs/iCLMs.  Although  without  presence  of
rhythm disorder  in  mice,  it  is  necessary  to  test  the  approach in  pigs,  whose  hearts  are
similar to those of human in terms of size and physiology, to further evaluate its efficacy
and safety before clinical trial.
3. Engineering approach
Direct injection of cell suspension into infarcted area or peri-infarcted area is still the main
progenitor/stem cell treatment used for cardiac repair. Nevertheless, the poor survival of stem
cells in the harsh environment (hypoxia, inflammatory cytokines, etc.) limits the reparative
function of progenitor/stem cells in ischemic heart [28].
Combining progenitor/stem cell biology and bioengineering, tissue engineering holds great
promise to generate viable three dimensional heart tissue with vasculature prior to engraftment
to the heart, as an integral part of the host. This tissue graft should display contractile and elec‐
tromechanical coupled properties, contributing to the improvement of heart function. The re‐
cent evidence from large animals indicated that human ES-derived cardiomyocytes electrically
coupled and suppressed arrhythmias in injured hearts. This provided support for the contin‐
ued development of human stem cell derived tissue graft for cardiac repair [29]. The conven‐
tional approach involved seeding cell on scaffolds and culture in vitro prior to implantation.
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Eschenhagen and Zimmermann constructed an engineering heart tissue (EHT) by seeding
neonatal rat cardiomyocytes and a mix of collagen I, extracellular matrix proteins (Matrigel)
into a lattices or circular molds. Upon spontaneous remodeling of the liquid reconstitution
mixture and cyclic mechanical, EHT spontaneously and synchronously contracted after one
to two weeks of cultivation, which highlights the great importance of physical stimulation on
the maintenance of the physical and mechanical function of EHT [30]. This pioneering work
for the first time showed EHT could ameliorate cardiac function post MI.
3.1. Scaffold free tissue construct
The use of cell sheets provides a simple scaffold-free approach by seeding cardiac cells on poly
(N-isopropylacrylamide)-grafted polystyrene dishes and then lowering the temperature to
20ºC, thus inducing the detachment of intact cell monolayers without enzymatic digestion.
Using this method, a 1-mm-thick cell patch can be created by serial stacking of multiple
monolayer sheets [31]. A recent study by Murry group using ESC-derived cardiomyocytes
reported another scaffold free approach, demonstrating cell aggregation is sufficient to
generate functional EHT also showing endothelial cell and fibroblast are required for the
survival and integration of EHT and in host myocardium [32]. Further studies are needed to
optimize the proportion of cardiomyocyte, endothelial cells, and fibroblast for maximal
performance of EHT.
3.2. Construction of myocardial tissue/heart using decellularized native tissue
In order to create decellularized scaffolds, Taylor and her team perfused rat hearts with
detergents to remove the cells and leave a complex architecture of acellular extracellular
matrix  (ECM) behind.  [33].  This  native  scaffold  was  reseeded with  cardiomyocytes  and
endothelial cells taken from rats. They then placed these constructs in bioreactors that si‐
mulated blood pressure, electrical stimulation, and other aspects of cardiac physiology to
assure  integration of  the  scaffold and seeded cells.  Although approximately  only 2% of
normal contractile activity was acquired from this approach, this is a successful proof-of-
concept trial and might be the ultimate biomimetic method for constructing an intact hu‐
man heart.
3.3. Porous scaffolds
By using electrical stimulation, Vunjak-Novakovic et al., established a method to assemble
individual cardiomyocytes into a functional cell patch [34]. The hydrogel-encapsulated
neonatal rat heart cells were cultivated on porous collagen scaffolds. Currently, this method‐
ology has been applied in other cell types (e.g. hESC) [35] and with other scaffold material (e.g.
synthetic elastomers) [36]. 3 days before electrical stimulation, the cells were cultured in petri
dishes to allow sufficient expression of gap junction protein (e.g. Cx43) and other molecules
involved in contraction. Then the cells were subjected to electrical stimulation to induce
synchronous contraction and alteration of structural organization, resulting in the formation
of mature myocardium with elongated, viable cells aligned in parallel.
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3.4. Biological and synthetic polymers
Collagen is the first biological polymer used for fabrication of three dimensional tissues. It was
reported that neonatal rat cardiomyocytes spontaneously contracted when cultivated in
gelatin coated scaffold. Although the implanted cardiomyocytes survived in infarcted heart,
LVEF is not significantly improved after long term observation. Furthermore, Zimmermann’s
group engineered contractile 3-D heart tissue, in which cardiomyocytes encapsulated with
ring--shaped hydrogels (collagen and Matrigel) showing reduction of ventricle dilatation,
significant ventricular wall thickening and improvement of the fractional shortening (FS) [30].
The improvement of cardiac function, myofibril organization indicated that mechanical
stimulation is important for maturation of myocardial structure. Leor et al. also reported that
3-D alginate scaffolds seeded with fetal rat cardiomyocytes attenuated left ventricular
dilatation and deterioration of the heart function after myocardial infarction [37].
4. Progenitor/stem cell niche engineering
As we discussed above, the laboratories of Deepak Srivastava and Eric Olson were successful
in reprogramming cardiac fibroblasts in vivo into cardiomyocytes with a significant efficiency.
In 2010, Deepak’s team attempted to reprogram cardiac fibroblast into cardiomyocytes with
the same combination of transcription factors in vitro but experienced low efficiency [38], while
recently Sean M. Wu’s team reported in some cases, the reprogramming is still inefficiency
[39]. The great difference with respect to reprogramming efficiency in vitro and in vivo using
the same transcription factor cocktail suggested that the local microenvironment (niche) is a
critical checkpoint for cell reprogramming and regeneration. In vivo, the stem cell niche is a
complex and dynamic unit, and how these components interact to modulate progenitor/stem
cell fate is on the horizon to be understood. Alteration of the properties of progenitor/stem cell
niches may provide new therapeutic strategies for progenitor/stem cell engineering by
interrupting cardiac remodeling or accelerating the reparative process. Here we discuss two
key expects of progenitor/stem cell niche, namely mechanical cue and chemical cues and their
implication for progenitor/stem cell engineering.
4.1. Matrix rigidity
Progenitor/stem cell engineering involves coordination of selective proliferation of precursor/
stem cells and differentiation into target somatic cells (cardiomyocytes, smooth muscle cell,
and endothelial cells). Mechanical cues influence proliferation, differentiation, migration, and
spatial morphological organization. These cues include the rigidity of the surrounding matrix
or cell adhesion substratum. Thus, better understanding of the role of matrix rigidity is critical
for optimization of the regimes of mechanical conditioning of cultured tissue constructs. Based
on a pioneering study which discovered mechanosensitive transcriptional mechanism in 2009
[40], Kshitiz et al showed that resident cardiac progenitor cells continually monitored cell
substratum rigidity and demonstrated enhanced proliferation, endothelial differentiation, and
morphogenesis when the cell substratum rigidity closely matched that of myocardium [41].
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neonatal rat heart cells were cultivated on porous collagen scaffolds. Currently, this method‐
ology has been applied in other cell types (e.g. hESC) [35] and with other scaffold material (e.g.
synthetic elastomers) [36]. 3 days before electrical stimulation, the cells were cultured in petri
dishes to allow sufficient expression of gap junction protein (e.g. Cx43) and other molecules
involved in contraction. Then the cells were subjected to electrical stimulation to induce
synchronous contraction and alteration of structural organization, resulting in the formation
of mature myocardium with elongated, viable cells aligned in parallel.
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3.4. Biological and synthetic polymers
Collagen is the first biological polymer used for fabrication of three dimensional tissues. It was
reported that neonatal rat cardiomyocytes spontaneously contracted when cultivated in
gelatin coated scaffold. Although the implanted cardiomyocytes survived in infarcted heart,
LVEF is not significantly improved after long term observation. Furthermore, Zimmermann’s
group engineered contractile 3-D heart tissue, in which cardiomyocytes encapsulated with
ring--shaped hydrogels (collagen and Matrigel) showing reduction of ventricle dilatation,
significant ventricular wall thickening and improvement of the fractional shortening (FS) [30].
The improvement of cardiac function, myofibril organization indicated that mechanical
stimulation is important for maturation of myocardial structure. Leor et al. also reported that
3-D alginate scaffolds seeded with fetal rat cardiomyocytes attenuated left ventricular
dilatation and deterioration of the heart function after myocardial infarction [37].
4. Progenitor/stem cell niche engineering
As we discussed above, the laboratories of Deepak Srivastava and Eric Olson were successful
in reprogramming cardiac fibroblasts in vivo into cardiomyocytes with a significant efficiency.
In 2010, Deepak’s team attempted to reprogram cardiac fibroblast into cardiomyocytes with
the same combination of transcription factors in vitro but experienced low efficiency [38], while
recently Sean M. Wu’s team reported in some cases, the reprogramming is still inefficiency
[39]. The great difference with respect to reprogramming efficiency in vitro and in vivo using
the same transcription factor cocktail suggested that the local microenvironment (niche) is a
critical checkpoint for cell reprogramming and regeneration. In vivo, the stem cell niche is a
complex and dynamic unit, and how these components interact to modulate progenitor/stem
cell fate is on the horizon to be understood. Alteration of the properties of progenitor/stem cell
niches may provide new therapeutic strategies for progenitor/stem cell engineering by
interrupting cardiac remodeling or accelerating the reparative process. Here we discuss two
key expects of progenitor/stem cell niche, namely mechanical cue and chemical cues and their
implication for progenitor/stem cell engineering.
4.1. Matrix rigidity
Progenitor/stem cell engineering involves coordination of selective proliferation of precursor/
stem cells and differentiation into target somatic cells (cardiomyocytes, smooth muscle cell,
and endothelial cells). Mechanical cues influence proliferation, differentiation, migration, and
spatial morphological organization. These cues include the rigidity of the surrounding matrix
or cell adhesion substratum. Thus, better understanding of the role of matrix rigidity is critical
for optimization of the regimes of mechanical conditioning of cultured tissue constructs. Based
on a pioneering study which discovered mechanosensitive transcriptional mechanism in 2009
[40], Kshitiz et al showed that resident cardiac progenitor cells continually monitored cell
substratum rigidity and demonstrated enhanced proliferation, endothelial differentiation, and
morphogenesis when the cell substratum rigidity closely matched that of myocardium [41].
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This process is mediated by p190RhoGAP, a guanosine triphosphatase–activating protein for
RhoA, acting through RhoA-dependent and -independent mechanisms. Downregulation of
p190RhoGAP triggered a series of developmental events by coupling cell-cell and cell-
substratum interactions to genetic circuits controlling differentiation. Hence, preconditioning
of endothelial progenitors could change p190RhoGAP abundance and thus promote angio‐
genesis in engrafted heart. More generally, the results suggest the importance of the feedback
between the rigidity of a developing or regenerating tissue and the control of cell growth and
differentiation, which may be critical for adaptive development and maintenance of structur‐
ally complex tissues and organs.
Figure 1. Fabrication of “Super Cell Patch”. Progenitor/cells were treated with exosome containing microRNAs
(miRs), growth factors (GFs) and cytokines etc. Then the progenitor/stem cells were administered with optimized ECM
to provide the suitable matrix rigidity for engraftment. Subsequently, confluent cells forming sheets were released
from the dish surface by decreasing temperature from 37ºC to 20ºC. Then, several cell sheets were stratified and




Recent studies have suggested four potential mechanisms for how exogenous-culture-
expanded MSC may contribute to cardiovascular repair: transdifferentiation, cell fusion with
a native cell, stimulation of endogenous cardiac progenitor/stem cells via direct cell-cell
communication or paracrine mechanism [42]. Transdifferentiation of MSC into cardiomyo‐
cytes is not inefficient in current regimes [10]. Cell fusion is a rare event[43]. As aforemen‐
tioned, the observed salutary effects of progenitor/stem cell on cardiac repair probably resulted
from paracrine mechanism. And the cardiogenic differentiation of CSC stimulated by MSC
processed a limited capacity [44]. By antibody array and Liquid Chromatography with
Tandem Mass Spectrometry Detection (LC-MS/MS), compelling evidences have shown MSC
could secrete a wide spectrum of trophic proteins that could induce proliferation and differ‐
entiation of CPC and angiogenesis [45]. Interestingly, in 2007, the paper published on Nature
Cell Biology revealed mRNAs and microRNAs in the exosome (the major microvesicle for
intercellular communication) can be delivered from one cell to another, and can be functional
in this new location [46]. This hallmark study elicited amazing expansion of studies on
exosomes in the last 3 years, making it a very exciting field now. A recent study has targeted
exosomes to the brain to treat Alzheimer's disease by engineering exosomes with dendrite cells
marker [47]. This study highlighted the possibility that cardiac-specific exosomes can be
engineered to treat ischemic heart diseases without any risk of immunorejection or carcino‐
genesis by viral infection. Thus, compared to the delivery of single growth factors or cytokines,
the direct administration of exosomes derived from preconditioned progenitors/stem cells into
ischemic heart or using cell sheet/patch modified with preconditioned exosomes might be a
new trend to improve cardiac repair in a more efficient way (Fig. 1).
5. Conclusions
Progenitor/stem cell engineering has presented as an exciting and promising avenue for the
treatment of ischemic heart diseases. Regeneration of damaged heart by progenitor/stem cell
engineering is becoming a fact rather than fiction. The translation of experimental discovery
in progenitor/stem cell engineering into clinical application should be accelerated and large
scale clinical trials should be initiated in the patients with ischemic heart diseases. Therefore,
the collaboration of progenitor/stem cell biologists, bioengineers, and physicians is possibly
the future modality in personalized regenerative medicine.
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1. Introduction
In nuclear cardiology, myocardial perfusion imaging has been widely and thoroughly inves‐
tigated and used in various heart diseases, especially in ischemic heart diseases. However,
beyond perfusion imaging, myocardial fatty acid metabolic imaging may yield valuable in‐
sight into the pathologic process of various heart diseases including ischemic heart diseases,
cardiomyopathy, and diabetic heart etc [1, 2].
To run the contractile machinery and ion pumps to maintain rhythmic beating and integrity
of the myocardium, the healthy heart derives its energy from a variety of oxidizable sub‐
strates such as fatty acids, glucose, lactate, amino acids etc. Approximately two-thirds or
more of the total energy produced by myocardium is derived from fatty acid oxidation and
the most of the remaining energy is covered by the glucose metabolism. Both fatty acid and
glucose are catabolized to acetyl-COA through beta-oxidation and glycolysis and the metab‐
olite is oxidized in the tricarboxylic acid (TCA) cycle (Fig 1). To respond the constantly
changing environmental conditions and energy demands, the heart maintains the balance
between its energetic supply and demands by shifting fluxes through existing various meta‐
bolic pathways. Short-term modulation of substrate switching is based on an effective inter‐
play between various substrates, with metabolism of one substrate automatically
suppressing the pathway of another substrate via rapid enzymatic changes. In the postpran‐
dial and under resting conditions, long-chain fatty acids are the predominant energy sub‐
strate for adult heart. On the other hand, during exercise or stress, predominant energy
source shifts to carbohydrate [3] because the efficiency of glucose as substrate exceeds the
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1. Introduction
In nuclear cardiology, myocardial perfusion imaging has been widely and thoroughly inves‐
tigated and used in various heart diseases, especially in ischemic heart diseases. However,
beyond perfusion imaging, myocardial fatty acid metabolic imaging may yield valuable in‐
sight into the pathologic process of various heart diseases including ischemic heart diseases,
cardiomyopathy, and diabetic heart etc [1, 2].
To run the contractile machinery and ion pumps to maintain rhythmic beating and integrity
of the myocardium, the healthy heart derives its energy from a variety of oxidizable sub‐
strates such as fatty acids, glucose, lactate, amino acids etc. Approximately two-thirds or
more of the total energy produced by myocardium is derived from fatty acid oxidation and
the most of the remaining energy is covered by the glucose metabolism. Both fatty acid and
glucose are catabolized to acetyl-COA through beta-oxidation and glycolysis and the metab‐
olite is oxidized in the tricarboxylic acid (TCA) cycle (Fig 1). To respond the constantly
changing environmental conditions and energy demands, the heart maintains the balance
between its energetic supply and demands by shifting fluxes through existing various meta‐
bolic pathways. Short-term modulation of substrate switching is based on an effective inter‐
play between various substrates, with metabolism of one substrate automatically
suppressing the pathway of another substrate via rapid enzymatic changes. In the postpran‐
dial and under resting conditions, long-chain fatty acids are the predominant energy sub‐
strate for adult heart. On the other hand, during exercise or stress, predominant energy
source shifts to carbohydrate [3] because the efficiency of glucose as substrate exceeds the
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efficiency of fatty acids as substrate by as much as 40% [4]. In ischemia, oxidative metabo‐
lism of free fatty acid is decreased because β-oxidation of fatty acid in mitochondria requires
a large amount of oxygen, and glucose becomes the preferred substrate for anaerobic glycol‐
ysis that requires less oxygen consumption [5,6]. This metabolic switch from predominat fat‐
ty acid use to predominant glucose use seems crucial in preserving myocardial viability.
(Fig 2) Therefore, different imaging tracers that permit direct assessment of myocardial me‐
tabolism are desired to evaluate the pathophysiological changes in various heart disease.
Current available tracers for metabolic imaging are several fatty acid tracers, 18F-FDG for the
evaluation of glucose metabolism, and 11C-acetate for the assessment of oxygen consump‐
tion. Of these tracers, only 123I-labeled fatty acid tracers are currently available for SPECT
imaging. In this chapter, basic characteristics and clinical value of 123I-labeld fatty acid
agents, especially β-methyl-p-123I-iodophenyl-pentadecanoic acid (BMIPP) follows.
Figure 1. Schematic presentation of substrates metabolism in myocardium. ADP = adenosine diphosphate, AMP = ad‐
enosine monophosphate, ATP = adenosine triphosphate, BMIPP = β-methyl-iodophenyl-pentadecanoic acid, CoA =
coenzyme A, FFA = free fatty acid, PDH = pyruvate dehydrogenase, TCA = tricarboxylic acid, TG = triglyceride
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Figure 2. Relation between myocardial perfusion and fatty acid and glucose metabolism.
When myocardial  perfusion decreases,  fatty  acid metabolism can not  be maintained be‐
cause β-oxidation of  fatty acid in mitochondria requires a  large amount of  oxygen,  and
glucose becomes the preferred substrate for anaerobic glycolysis that requires less oxygen
consumption.  Therefore,  the  decrease  in  tracer  uptake  for  fatty  acid  substrate  analogue
such as  BMIPP becomes  more  prominent  than the  decrease  of  perfusion tracer.  On the
contrary,  anaerobic glucose metabolism relatively increases,  presenting increased or pre‐
served FDG uptake in the area with reduced perfusion. When myocardial perfusion de‐
creases  further,  glucose  anaerobic  metabolism  also  declines  finally  and  myocardial
viability will be lost eventually.
2. Myocardial fatty acid metabolism
Although the primary sources of energy are lactate and glucose for fetal heart, fatty acids
comprise 60% to 80% of the energy source in adult heart to run the contractile machinery
and ion pumps to maintain rhythmic beating and integrity of the myocardium [7].
Due to hydrophobic nature of  fatty acids,  they are delivered to the heart  by binding to
plasma  albumin  or  lipoproteins.  After  dissociating  from  albumin  or  lipoprotein,  fatty
acids can pass through the sarcolemmal membrane by diffusion or a facilitated transport
mechanism. The fatty  acid translocase CD36 was suggested that  it  accounts  for  the key
Role of Fatty Acid Imaging with 123I- β-methyl-p-123I-Iodophenyl-Pentadecanoic Acid (123I-BMIPP)...
http://dx.doi.org/10.5772/53548
177
efficiency of fatty acids as substrate by as much as 40% [4]. In ischemia, oxidative metabo‐
lism of free fatty acid is decreased because β-oxidation of fatty acid in mitochondria requires
a large amount of oxygen, and glucose becomes the preferred substrate for anaerobic glycol‐
ysis that requires less oxygen consumption [5,6]. This metabolic switch from predominat fat‐
ty acid use to predominant glucose use seems crucial in preserving myocardial viability.
(Fig 2) Therefore, different imaging tracers that permit direct assessment of myocardial me‐
tabolism are desired to evaluate the pathophysiological changes in various heart disease.
Current available tracers for metabolic imaging are several fatty acid tracers, 18F-FDG for the
evaluation of glucose metabolism, and 11C-acetate for the assessment of oxygen consump‐
tion. Of these tracers, only 123I-labeled fatty acid tracers are currently available for SPECT
imaging. In this chapter, basic characteristics and clinical value of 123I-labeld fatty acid
agents, especially β-methyl-p-123I-iodophenyl-pentadecanoic acid (BMIPP) follows.
Figure 1. Schematic presentation of substrates metabolism in myocardium. ADP = adenosine diphosphate, AMP = ad‐
enosine monophosphate, ATP = adenosine triphosphate, BMIPP = β-methyl-iodophenyl-pentadecanoic acid, CoA =
coenzyme A, FFA = free fatty acid, PDH = pyruvate dehydrogenase, TCA = tricarboxylic acid, TG = triglyceride
Ischemic Heart Disease176
Figure 2. Relation between myocardial perfusion and fatty acid and glucose metabolism.
When myocardial  perfusion decreases,  fatty  acid metabolism can not  be maintained be‐
cause β-oxidation of  fatty acid in mitochondria requires a  large amount of  oxygen,  and
glucose becomes the preferred substrate for anaerobic glycolysis that requires less oxygen
consumption.  Therefore,  the  decrease  in  tracer  uptake  for  fatty  acid  substrate  analogue
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served FDG uptake in the area with reduced perfusion. When myocardial perfusion de‐
creases  further,  glucose  anaerobic  metabolism  also  declines  finally  and  myocardial
viability will be lost eventually.
2. Myocardial fatty acid metabolism
Although the primary sources of energy are lactate and glucose for fetal heart, fatty acids
comprise 60% to 80% of the energy source in adult heart to run the contractile machinery
and ion pumps to maintain rhythmic beating and integrity of the myocardium [7].
Due to hydrophobic nature of  fatty acids,  they are delivered to the heart  by binding to
plasma  albumin  or  lipoproteins.  After  dissociating  from  albumin  or  lipoprotein,  fatty
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uptake mechanism of  long-chain fatty  acid through the  analysis  of  minority  of  patients
with  absent  uptake  of  123I-BMIPP  (15-(p-iodophenyl)-3(R,  S)-methylpentadecanoic  acid)
even without significant cardiac abnormality [8,9] The patients with deficient myocardial
uptake of BMIPP has been proved to correspond to the patients with type I  CD36 defi‐
ciency (neither platelets nor monocytes expresse CD36) [10-12] and biopsy specimen from
the patients  with absent  myocardial  BMIPP uptake and type I  CD36 deficiency demon‐
strated no expression of CD36 on the myocardial capillary endothelial cells [13]. These pa‐
tients without BMIPP cardiac uptake showed compensatory increased FDG uptake [14,15]
and  several  gene  abnormalities  related  to  CD36  deficiency  have  been  reported  [16,17].
Based on these clinical data and other animal experiments, it has been proved that CD36
plays a crucial role in fatty acid transport into the cells [18].
Once the fatty acid is taken up by the myocyte, it undergoes adenosine triphosphate (ATP)
dependent conversion to acyl-CoAs and are consequently trapped inside the cell. Then the
acyl-CoAs are taken up by mithochondria via an acyl carnitine carrier system and is rapidly
catabolized by β-oxidation into 2-carbon fragments, acetyl-CoAs, which enter the TCA cycle
for further oxidation to become water and carbon dioxide. (Fig 1) The half-life of β-oxidation
is fast and in the order of minutes, but is dependent on the adequate oxygen availability.
The remainder of the total fatty acid entering the myocyte is incorporated into the lipid pool,
mainly in the form of triglycerides and phospholipids, or into myocardial structural lipids
and presents in the myocardium for a long time. Turnover in the lipid pool is much slower
with the half-life of the order of hours.
3. Tracers for fatty acid imaging for SPECT (Fig 3)
In mid 1970’s, several iodinated long chain fatty acids were developed by introducing ra‐
dioiodine to the terminal position of fatty acids without altering extraction efficiency com‐
pared  with  the  natural  compound  [19-21].  These  straight  chain  fatty  acids,  123I-
hexadecanoic  acid  (IHXA)  and  123I  -heptadecanoic  acid  (IHDA)  were  proved  to  be  an
indicator of myocardial perfusion in canine model and human [20,21]. After rapid initial
myocardial  extraction these traces showed biexponential  clearance similar to that of 11C-
palmitate with rapid and slow components, those were thought to represent β-oxidation
of fatty acids and fatty acids storage in lipid pool, respectively. However, a canine study
suggested that washout rate of radioactivity from the heart reflected the back diffusion of
deiodinated free iodine not by β-oxidation [20]. A clinical study with IHDA demonstrated
high image quality early after injection but it deteriorated rapidly because of rapid reduc‐
tion of myocardial counts and increase in background counts by deiodinated radioiodine
[23].  Accordingly, these characteristics of the tracers make IHDA and IHXA unattractive
for clinical use, especially for SPECT study.
To overcome the problem of these alkyl fatty acids, the phenyl fatty acid was developed by
attaching iodide to the para position of phenyl ring (IPPA) [24]. Because this agent demon‐
strates high myocardial uptake without essential release of free radioiodide into circulation,
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the image quality is excellent. Animal experiment demonstrated that the IPPA accumulated
rapidly to myocardium followed by a two-component tracer clearance similar to 14C-palmi‐
tate, permitting estimation of metabolic rate [25]. The uptake of IPPA during exercise is re‐
lated to myocardial perfusion and its catabolism follows the usual metabolic pathway for β-
oxidation [26]. Through β-oxidation IPPA is metabolized to iodobenzoic acid and its
metabolite iodohippurate, and these are rapidly excreted from the kidneys with the iodine
still attached, resulting in high image quality with low background by preventing the build‐
up of free radioiodide [27]. Coronary occlusion and reperfusion blunted the uptake of IPPA
and prolonged the clearance, but permanent coronary occlusion decreased the uptake signif‐
icantly and accelerated the clearance, indicating that the IPPA can be used to localize the
area of myocardial ischemia and infarction [28]. However, still relatively fast rate of metabo‐
lism and clearance of IPPA precludes the clinical SPECT imaging, even in a rotating multi-
detector SPECT system. For initial IPPA uptake imaging, acquisition time should be
shortened to prevent progressive undersampling due to rapid count decrease from the myo‐
cardium, resulting in the deterioration of image quality, and dynamic SPECT study may be
necessary for kinetic analysis of β-oxidation. For this purpose, dynamic SPECT with cadmi‐
um zinc-telluride (CZT) multi-detector might be the choice of data acquisition and analysis
because of its high sensitivity [29].
Figure 3. Iodinated fatty acids analogues for SPECT. BMIPP = β-methyl-iodophenyl pentadecanoic acid, DMIPP = di‐
methyl-iodophenyl pentadecanoic acid, IHDA = 123I-heptadecanoic acid, IHXA =123I-hexadecanoic acid, IPPA = iodo‐
phenyl pentadecanoic acid,
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uptake mechanism of  long-chain fatty  acid through the  analysis  of  minority  of  patients
with  absent  uptake  of  123I-BMIPP  (15-(p-iodophenyl)-3(R,  S)-methylpentadecanoic  acid)
even without significant cardiac abnormality [8,9] The patients with deficient myocardial
uptake of BMIPP has been proved to correspond to the patients with type I  CD36 defi‐
ciency (neither platelets nor monocytes expresse CD36) [10-12] and biopsy specimen from
the patients  with absent  myocardial  BMIPP uptake and type I  CD36 deficiency demon‐
strated no expression of CD36 on the myocardial capillary endothelial cells [13]. These pa‐
tients without BMIPP cardiac uptake showed compensatory increased FDG uptake [14,15]
and  several  gene  abnormalities  related  to  CD36  deficiency  have  been  reported  [16,17].
Based on these clinical data and other animal experiments, it has been proved that CD36
plays a crucial role in fatty acid transport into the cells [18].
Once the fatty acid is taken up by the myocyte, it undergoes adenosine triphosphate (ATP)
dependent conversion to acyl-CoAs and are consequently trapped inside the cell. Then the
acyl-CoAs are taken up by mithochondria via an acyl carnitine carrier system and is rapidly
catabolized by β-oxidation into 2-carbon fragments, acetyl-CoAs, which enter the TCA cycle
for further oxidation to become water and carbon dioxide. (Fig 1) The half-life of β-oxidation
is fast and in the order of minutes, but is dependent on the adequate oxygen availability.
The remainder of the total fatty acid entering the myocyte is incorporated into the lipid pool,
mainly in the form of triglycerides and phospholipids, or into myocardial structural lipids
and presents in the myocardium for a long time. Turnover in the lipid pool is much slower
with the half-life of the order of hours.
3. Tracers for fatty acid imaging for SPECT (Fig 3)
In mid 1970’s, several iodinated long chain fatty acids were developed by introducing ra‐
dioiodine to the terminal position of fatty acids without altering extraction efficiency com‐
pared  with  the  natural  compound  [19-21].  These  straight  chain  fatty  acids,  123I-
hexadecanoic  acid  (IHXA)  and  123I  -heptadecanoic  acid  (IHDA)  were  proved  to  be  an
indicator of myocardial perfusion in canine model and human [20,21]. After rapid initial
myocardial  extraction these traces showed biexponential  clearance similar to that of 11C-
palmitate with rapid and slow components, those were thought to represent β-oxidation
of fatty acids and fatty acids storage in lipid pool, respectively. However, a canine study
suggested that washout rate of radioactivity from the heart reflected the back diffusion of
deiodinated free iodine not by β-oxidation [20]. A clinical study with IHDA demonstrated
high image quality early after injection but it deteriorated rapidly because of rapid reduc‐
tion of myocardial counts and increase in background counts by deiodinated radioiodine
[23].  Accordingly, these characteristics of the tracers make IHDA and IHXA unattractive
for clinical use, especially for SPECT study.
To overcome the problem of these alkyl fatty acids, the phenyl fatty acid was developed by
attaching iodide to the para position of phenyl ring (IPPA) [24]. Because this agent demon‐
strates high myocardial uptake without essential release of free radioiodide into circulation,
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Accordingly, a new fatty acid tracer with more prolonged cardiac retention has been devel‐
oped to improve quantitative image quality. For this purpose methyl branching was intro‐
duced at β-carbon position to slow myocardial clearance by inhibiting β-oxidation. Tow
forms of iodine labeled modified fatty acids, 15-(p-iodophenyl)3-R, S-methylpentadecanoic
acid (BMIPP) and 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid (DMIPP), has been de‐
veloped [30,31]. In fasted rats, myocardial half-time of BMIPP and DMIPP are far longer, at
30-45 min and 6-7 hr, respectively, than that of IPPA (5-10 min) [31]. In human, DMIPP
showed higher liver uptake than that of BMIPP (heart/liver ratio was 0.39 ± 0.05 and 1.00 ±
0.12, respectively: p<0.001), suggesting that BMIPP is more favorable cardiac SPECT agent
[32]. Especially in Japan and some European countries, BMIPP has since been widely stud‐
ied to investigate the clinical significance and basic properties. In Japan, 123I-BMIPP has been
used in daily clinical practice for nearly 2 decades since 1993.
4. Myocardial kinetic of 123I-BMIPP (Fig 4)
After intravenous injection of 123I-BMIPP, the tracer is delivered to myocardium depending
on the regional flow and transported into myocardial cells via fatty acid translocase/CD36
involvement [10,11,13,16-18]. Once BMIPP is taken up by the myocyte, it will either back-
diffuse to the plasma, accumulate in the lipid pool or undergo limited alpha and beta oxida‐
tion. Most of the BMIPP in the cytoplasm undergoes ATP dependent conversion to BMIPP-
CoA and incorporated into triglyceride pool [31,33]. Canine study demonstrated that high
first pass extraction (74%) within 30 sec of intracoronary BMIPP infusion, followed by a
small fraction of washout (8.7% of infused BMIPP) for the next 30 min [34]. The washed out
radioactiviy consist of backdiffused BMIPP (24% of all washed out radioactivity), α oxida‐
tion metabolite (27%), intermediate metabolites (33%), and full metabolite (16%), suggesting
only small amount of BMIPP-CoA transported into mitochondria is metabolized by α oxida‐
tion (because first β oxidation is blocked by β-methyl branching), followed by β oxidation.
The high uptake and low washout of the tracer indicates that BMIPP can be substantially
considered as a metabolically trapped tracer like FDG.
Thirty minutes coronary occlusion and reperfusion was found to increase early back dif‐
fusion of nonmetabolized BMIPP from 25.1% to 34.7%, and in mild ischemia with 10 mi‐
nutes occlusion,  back diffusion of  BMIPP was closely correlated with lactate production
(marker of ischemic severity) [35]. Pharmacological intervention with etomoxir, one of the
carnitine  palmotoyltransferase  I  inhibitor  that  inhibits  the  transport  of  long chain lipids
into the mitochondria, enhanced early washout of radioactivity until 8 minutes after injec‐
tion due to increased back diffusion of BMIPP [36]. Dynamic SPECT in patients with coro‐
nary  artery  disease  demonstrated  that  the  BMIPP  washout  was  observed  early  after
BMIPP injection (2-6 min after injection) in the segments with stress induced thallium de‐
fects but not in the segments with normal thallium uptake and fixed thallium defects [37].
In patients with acute coronary syndrome, early dynamic BMIPP SPECT showed similar
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BMIPP and thallium uptake, whereas conventional BMIPP images at 30 min demonstrat‐
ed the discordant BMIPP uptake less than thallium [38]. These findings suggest that, in is‐
chemic myocardium, initial myocardial distribution of BMIPP may represent blood flow,
followed by back diffusion of free BMIPP which is not incorporated into triglyceride pool
after conversion to BMIPP-CoA, resulting in discordant BMIPP uptake less than thallium
on static images obtained 20-30 min after BMIPP injection.
In the first step of the common pathway of fatty acid metabolism, BMIPP also underwent
ATP dependent conversion to BMIPP-CoA. Once BMIPP-CoA is synthesized, it is hardly
back-diffused out of the cell and is retained within it [39,40]. Therefore, BMIPP myocardial
retention may relate to the ATP level of the cells. Both in mouse myocardium treated with
an electron transport uncoupler, dinitrophenol, which reduced intracellular ATP level with‐
out affecting acyl-CoA synthetase activity or CoA level, and in acutely damaged canine my‐
ocardium by coronary occlusion and reperfusion, BMIPP uptake was found to correlate
with the tissue ATP levels [41,42]. Therefore, myocardial BMIPP uptake most likely reflects
activation of BMIPP by CoA and indirectly reflects cellular ATP production resulting from
fatty acid metabolism.
During acute phase of ischemia, reduced availability of oxygen suppresses β-oxidation and
increases the proportion of fatty acid in the triglyceride pool. At this moment BMIPP may
enter into this enlarged triglyceride pool. Accordingly, BMIPP uptake may possibly be in‐
creased in acute ischemia. Canine experiments with occlusion and reperfusion model
showed higher BMIPP uptake than thallium (reverse mismatch) which is an opposite find‐
ing observed in clinical studies [43,44]. However, BMIPP uptake may change as a function
of time after ischemia. A rat study with 20 min coronary occlusion and reperfusion demon‐
strated higher BMIPP uptake than thallium at 1 day after reperfusion but showed similar to
or lower than thallium uptake at 5 day after reperfusion [45]. Another rat study with 20 min
coronary occlusion and reperfusion revealed that increased BMIPP uptake in area at risk at
20 min and 1 day after reperfusion, followed by reduction of uptake at 3 to 7 days, though,
recovered to normal level at 30 days after reperfusion [46]. By contrast, thallium uptake did
not change throughout the 30 days observation period. As a result, higher BMIPP uptake
than thallium in acute phase was inverted in subacute phase (discordant or mismatch
BMIPP uptake less than thallium) and recovered to the similar uptake to that of thallium.
After a transient ischemic insult, recovery of myocardial perfusion, metabolism and function
may be temporally different. Although, delayed recovery of function after transient ische‐
mia is well documented in the experimental and clinical setting as stunned myocardium, de‐
layed recovery of regional metabolism or metabolic stunning which provide imprint prior
ischemic event has been recognized recently. This delayed recovery of metabolism after
quick recovery of perfusion provides a concept of ischemic memory imaging [47-50]. Thus
BMIPP imaging during or after an episode of myocardial ischemia might provide crucial in‐
sights into pathophysiology of coronary artery disease over perfusion imaging.
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0.12, respectively: p<0.001), suggesting that BMIPP is more favorable cardiac SPECT agent
[32]. Especially in Japan and some European countries, BMIPP has since been widely stud‐
ied to investigate the clinical significance and basic properties. In Japan, 123I-BMIPP has been
used in daily clinical practice for nearly 2 decades since 1993.
4. Myocardial kinetic of 123I-BMIPP (Fig 4)
After intravenous injection of 123I-BMIPP, the tracer is delivered to myocardium depending
on the regional flow and transported into myocardial cells via fatty acid translocase/CD36
involvement [10,11,13,16-18]. Once BMIPP is taken up by the myocyte, it will either back-
diffuse to the plasma, accumulate in the lipid pool or undergo limited alpha and beta oxida‐
tion. Most of the BMIPP in the cytoplasm undergoes ATP dependent conversion to BMIPP-
CoA and incorporated into triglyceride pool [31,33]. Canine study demonstrated that high
first pass extraction (74%) within 30 sec of intracoronary BMIPP infusion, followed by a
small fraction of washout (8.7% of infused BMIPP) for the next 30 min [34]. The washed out
radioactiviy consist of backdiffused BMIPP (24% of all washed out radioactivity), α oxida‐
tion metabolite (27%), intermediate metabolites (33%), and full metabolite (16%), suggesting
only small amount of BMIPP-CoA transported into mitochondria is metabolized by α oxida‐
tion (because first β oxidation is blocked by β-methyl branching), followed by β oxidation.
The high uptake and low washout of the tracer indicates that BMIPP can be substantially
considered as a metabolically trapped tracer like FDG.
Thirty minutes coronary occlusion and reperfusion was found to increase early back dif‐
fusion of nonmetabolized BMIPP from 25.1% to 34.7%, and in mild ischemia with 10 mi‐
nutes occlusion,  back diffusion of  BMIPP was closely correlated with lactate production
(marker of ischemic severity) [35]. Pharmacological intervention with etomoxir, one of the
carnitine  palmotoyltransferase  I  inhibitor  that  inhibits  the  transport  of  long chain lipids
into the mitochondria, enhanced early washout of radioactivity until 8 minutes after injec‐
tion due to increased back diffusion of BMIPP [36]. Dynamic SPECT in patients with coro‐
nary  artery  disease  demonstrated  that  the  BMIPP  washout  was  observed  early  after
BMIPP injection (2-6 min after injection) in the segments with stress induced thallium de‐
fects but not in the segments with normal thallium uptake and fixed thallium defects [37].
In patients with acute coronary syndrome, early dynamic BMIPP SPECT showed similar
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BMIPP and thallium uptake, whereas conventional BMIPP images at 30 min demonstrat‐
ed the discordant BMIPP uptake less than thallium [38]. These findings suggest that, in is‐
chemic myocardium, initial myocardial distribution of BMIPP may represent blood flow,
followed by back diffusion of free BMIPP which is not incorporated into triglyceride pool
after conversion to BMIPP-CoA, resulting in discordant BMIPP uptake less than thallium
on static images obtained 20-30 min after BMIPP injection.
In the first step of the common pathway of fatty acid metabolism, BMIPP also underwent
ATP dependent conversion to BMIPP-CoA. Once BMIPP-CoA is synthesized, it is hardly
back-diffused out of the cell and is retained within it [39,40]. Therefore, BMIPP myocardial
retention may relate to the ATP level of the cells. Both in mouse myocardium treated with
an electron transport uncoupler, dinitrophenol, which reduced intracellular ATP level with‐
out affecting acyl-CoA synthetase activity or CoA level, and in acutely damaged canine my‐
ocardium by coronary occlusion and reperfusion, BMIPP uptake was found to correlate
with the tissue ATP levels [41,42]. Therefore, myocardial BMIPP uptake most likely reflects
activation of BMIPP by CoA and indirectly reflects cellular ATP production resulting from
fatty acid metabolism.
During acute phase of ischemia, reduced availability of oxygen suppresses β-oxidation and
increases the proportion of fatty acid in the triglyceride pool. At this moment BMIPP may
enter into this enlarged triglyceride pool. Accordingly, BMIPP uptake may possibly be in‐
creased in acute ischemia. Canine experiments with occlusion and reperfusion model
showed higher BMIPP uptake than thallium (reverse mismatch) which is an opposite find‐
ing observed in clinical studies [43,44]. However, BMIPP uptake may change as a function
of time after ischemia. A rat study with 20 min coronary occlusion and reperfusion demon‐
strated higher BMIPP uptake than thallium at 1 day after reperfusion but showed similar to
or lower than thallium uptake at 5 day after reperfusion [45]. Another rat study with 20 min
coronary occlusion and reperfusion revealed that increased BMIPP uptake in area at risk at
20 min and 1 day after reperfusion, followed by reduction of uptake at 3 to 7 days, though,
recovered to normal level at 30 days after reperfusion [46]. By contrast, thallium uptake did
not change throughout the 30 days observation period. As a result, higher BMIPP uptake
than thallium in acute phase was inverted in subacute phase (discordant or mismatch
BMIPP uptake less than thallium) and recovered to the similar uptake to that of thallium.
After a transient ischemic insult, recovery of myocardial perfusion, metabolism and function
may be temporally different. Although, delayed recovery of function after transient ische‐
mia is well documented in the experimental and clinical setting as stunned myocardium, de‐
layed recovery of regional metabolism or metabolic stunning which provide imprint prior
ischemic event has been recognized recently. This delayed recovery of metabolism after
quick recovery of perfusion provides a concept of ischemic memory imaging [47-50]. Thus
BMIPP imaging during or after an episode of myocardial ischemia might provide crucial in‐
sights into pathophysiology of coronary artery disease over perfusion imaging.
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Figure 4. Schematic presentation of 123I-BMIPP metabolism in myocardium. Abbreviations: see Figure 1.
5. 123I-BMIPP imaging in ischemic heart diseases
5.1. Acute myocardial infarction
Discrepant  BMIPP uptake less  than thallium has  been reported initially  in  17  out  of  28
patients  with acute  myocardial  infarction.  Such discordant  BMIPP uptake was observed
more often in areas of acute than chronic phase of myocardial infarction (59% at <4 week
versus  31% at  >4  week after  onset),  and more  often  in  areas  supplied  with  revascular‐
ized than non-revascularized arteries (74% versus 28%, respectively). In addition, region‐
al  wall  motion  was  more  severely  impaired  in  such  perfusion-metabolic  mismatching
area [51]. In patients with acute myocardial infarction, BMIPP and 99mTc-MIBI SPECT at 4
to 10 days after thrombolysis demonstrated that the segments with more reduced BMIPP
uptake  than  MIBI  uptake  (mismatching)  showed either  normal  wall  motion  or  demon‐
strated inotropic reserve during dobutamine stimulation [52]. In addition, several studies
had demonstrated that  areas  of  discordant  BMIPP uptake less  than perfusion tracers  in
acute  or  subacute  stages  of  myocardial  infarction  showed improvement  of  wall  motion
abnormality  on  the  subsequent  follow-up  periods  [47,53-59].  These  findings  suggested
that  mismatch  or  discordant  BMIPP  uptake  less  than  perfusion  is  indicative  of  jeopar‐
dized but viable myocardium and may correspond to stunned myocardium where func‐
tional  abnormality  is  prolonged  in  association  with  sustained  metabolic  abnormalities
(metabolically  stunned  myocardium)  after  perfusion  recovery  by  successful  reperfusion
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procedures.  Accordingly,  the  finding  of  mismatched  BMIPP  uptake  less  than  perfusion
tracers may be a predictor of functional recovery in acute myocardial infarction. For the
evaluation  of  area  at  risk  in  acute  myocardial  infarction,  BMIPP  imaging  in  subacute
phase is valuable. BMIPP defect size in subacute phase of myocardial infarction correlat‐
ed  well  with  the  risk  area  revealed  by  contrast  ventriculography  or  echocardiography
[47,60],  and the area with BMIPP reduction 1 week after the onset of myocardial infarc‐
tion corresponded well to the area with perfusion defect which was demonstrated before
revascularization therapy at admission [61].  These observations holds the concept of “is‐
chemic  memory imaging” because BMIPP imaging obtained in subacute phase of  myocar‐
dial infarction reflects prior ischemic damage or metabolically stunned myocardium even
after  the  restoration  of  perfusion  abnormality  [47-49].  Therefore,  BMIPP  imaging  may
contribute to improving the detection of culprit lesion of the small amount of acute myo‐
cardial infarction. In patients with non ST elevated and non serum creatinine kinase-MB
elevated  but  increased  cTnT  level,  BMIPP  SPECT  at  subacute  phase  can  detect  culprit
coronary lesions more sensitively than thallium [62].
Mismatched uptake of BMIPP less than thallium is not also an uncommon finding in chronic
phase of myocardial infarction. In 26 patients with prior myocardial infarction (>4 week af‐
ter onset) without revascularization therapy, resting BMIPP and exercise-redistribution thal‐
lium scintigraphies were studied. Sixty-seven % of the segments with discordant BMIPP
uptake less than redistribution thallium showed reversible thallium defects, 21% showed
fixed thallium defects and 12% showed normal thallium uptake, indicating that the myocar‐
dium with discordant BMIPP uptake less than redistribution thallium uptake were mostly
exposed to stress induced ischemia [37]. In subacute to chronic phase of infraction (>2 week
after onset), similar findings were reported, with most of the mismatched segments (22/27)
is associated with reversible thallium defect [63].
5.2. Acute coronary syndrome and unstable angina pectoris
Because oxygen extraction by the myocardium is nearly complete, reduction of coronary
flow against the myocardial oxygen demand evoke the metabolic switch from fatty acid
oxidation to anaerobic glucose metabolism. Thus the BMIPP uptake might be suppressed
in  ischemia.  In  a  study of  111 consecutive patients  with acute  chest  pain without  myo‐
cardial infarction, BMIPP SPECT at 2 days after the onset of chest pain showed regional
abnormality in 74% of coronary abnormalities,  while only 38% showed perfusion abnor‐
mality  demonstrated by tetrofosmin within 24  hr  after  the  onset  of  chest  pain [64].  Re‐
cently,  multicenter  trial  to  evaluate  the  performance of  BMIPP to  detect  acute  coronary
syndromes in  emergency department  patients  with chest  pain was conducted in  a  total
of  507 patients  without  history of  prior  myocardial  infarction [65].  BMIPP imaging was
performed within 30 hours of symptom cessation. Sensitivity of detecting acute coronary
syndrome increased from 43% in clinical diagnosis to 73% in BMIPP imaging alone. Both
negative and positive predictive values of a clinical diagnosis alone increased significant‐
ly  when  combined  BMIPP  imaging  from  62%  to  83%  and  41%  to  58%,  respectively.
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Figure 4. Schematic presentation of 123I-BMIPP metabolism in myocardium. Abbreviations: see Figure 1.
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These findings indicates that BMIPP imaging can detect prolonged metabolic abnormali‐
ty or stunning in patients with acute chest pain up to 2 days after cessation of symptom.
In  patients  with  unstable  angina,  discordant  BMIPP uptake  less  than  thallium has  also
been observed frequently [66-69]. In patients with unstable angina without prior myocar‐
dial infarction, comparison of BMIPP image and stress thallium scan performed after sta‐
bilization  of  their  condition  demonstrated  that  BMIPP  decrease  was  associated  with
stress perfusion abnormality in 44 of 57 (77%) segments and degree of BMIPP reduction
correlated with the degree of perfusion abnormality at stress,  degree of wall motion ab‐
normality, and severity of coronary artery stenosis [66]. In another study in patients with
unstable  angina  after  medication  and  elimination  of  chest  pain  disclosed  that  patients
with abnormal BMIPP uptake had more severe coronary artery stenosis and more collat‐
eral  opacification  than  patients  without  BMIPP  abnormality.  In  addition,  revasculariza‐
tion was performed in 82% of patients with abnormal BMIPP images, while in only 22%
of patients  with normal  BMIPP images,  accordingly,  BMIPP imaging may be helpful  in
decision-making regarding interventional  treatment [68].  These findings indicate that  re‐
duced BMIPP uptake in patients with unstable angina may represent persistent metabol‐
ic  abnormality  reflecting  prior  severe  ischemia  or  repetitive  ischemic  insults,  thus  the
concept  of  ischemic  memory  imaging  could  be  extended  and  applied  to  these  patients
population. In other words, BMIPP imaging could extend time window for detecting pre‐
vious ischemic event after the resolution of perfusion abnormality.
5.3. Chronic stable coronary artery disease
In  chronic  stable  coronary artery  disease  even without  history of  myocardial  infarction,
discordant BMIPP uptake less than perfusion tracer is also a common finding. Compari‐
son of BMIPP and stress-reinjection thallium SPECT in 45 patients with chronic coronary
artery disease demonstrated that most of the segments (118/124) with discordant BMIPP
uptake less than reinjection-thallium were associated with demand ischemia indicated by
reversible thallium defects [70]. When reversible thallium defects were analyzed, approxi‐
mately  half  of  the  segments  evidenced  discordant  BMIPP  uptake  less  than  reinjection
thallium.  On  the  other  hand,  around  80%  of  the  segments  with  fixed  thallium  defects
demonstrated  concordant  reduction  of  both  tracers,  suggesting  myocardium  with  re‐
duced or poor viability has metabolic abnormality similar to the degree of resting perfu‐
sion  abnormality.  When  reversible  thallium  defects  were  analyzed  with  respect  to  the
evidence of discordant BMIPP uptake less than thallium and regional wall motion abnor‐
mality, wall motion was more severely impaired in the segments with discordant BMIPP
uptake less than thallium than those without such discordance in both subset of patients
with and without old myocardial infarction. However, severity of coronary artery steno‐
sis  was similar  in the vascular  teritory with discordant BMIPP uptake less  than reinjec‐
tion  thallium  and  those  without  such  discordance.  Comparison  of  BMIPP  and  stress-
redistribution-reinjection  thallium  imaging  in  55  patients  with  stable  coronary  artery
disease revealed that discordant BMIPP uptake less than thallium was observed in only
37% of the segments with thallium redistribution after exercise, on the contrary, such dis‐
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cordance was observed in 82% of the segments with no redistribution but new fill-in af‐
ter thallium reinjection [71].  In addition,  such discordance was observed in only 19% of
the  segments  with  fixed  defects.  Previous  studies  with  stress-redistribution-reinjection
thallium demonstrated that the myocardium with new fill-in after thallium reinjection is
characterized as severely ischemic but viable myocardium with frequent wall motion ab‐
normalities  that  may recover  after  revascularization [72,73].  Accordingly,  these  observa‐
tion may indicate  that  discordant  BMIPP uptake less  than thallium is  suggestive  of  the
myocardium jeopardized by more severe ischemia.
The concept of ischemic memory imaging of BMIPP has been tested in 32 patients with exer‐
cise-induced ischemia on thallium SPECT. BMIPP imaging at rest within 30 hrs of ischemia,
which was induced and confirmed by exercise thallium SPECT, revealed reduction of
BMIPP uptake corresponding to the ischemic area detected by stress thallium study in more
than 90 % of patients [50]. Therefore, the authors concluded that BMIPP can identify sus‐
tained metabolic abnormality as a ischemic memory imaging at least until 30 hrs after stress
induced ischemic episodes. This finding was complemented by the studies assessing glucose
metabolism in patients undergoing exercise testing using FDG. Those have shown that a
metabolic switch from fatty acid to glucose use occurs promptly when myocardial ischemia
is induced during exercise and this metabolic switch to glucose may persist for 24hours, de‐
spite restoration of blood flow at rest [74,75].
Accumulated data in patients with chronic ischemic heart disease in Japan, however, dem‐
onstrated that reduced BMIPP uptake was frequently observed independent of prior radio‐
nuclide and ECG stress tests but related to severe ischemia and wall motion abnormality,
raise the possibility that BMIPP reduction reflects the substrate shift from fatty acid to glu‐
cose as a results of repeated myocardial ischemia rather than reflecting the single episode of
metabolic stunning. Myocardium exposed to repetitive ischemia or stunning is subsequently
adapted metabolically (metabolic remodeling) into chronic ischemic myocardium, so called
hibernation [76-78]. In hibernating myocardium, energy substrate is shifted from fatty acid
to glucose, contractility is impaired but with recruitable inotropic reserve, and myocardial
flow reserve is severely impaired. In relation to this issue, relationship between BMIPP up‐
take and absolute myocardial blood flow by PET was investigated in patients with chronic
stable angina without previous myocardial infarction. The results demonstrated that rest
myocardial blood flow was preserved independent of BMIPP uptake. However, hyperemic
myocardial blood flow was decreased in the area with reduced BMIPP uptake, resulting in
the severity of impaired myocardial flow reserve correlated to the reduction of BMIPP up‐
take [79]. Thus, reduced BMIPP uptake implies impaired myocardial flow reserve and may
reflects adaptive substrate shifts or metabolic remodeling in hibernating myocardium. Rep‐
resentative case with stable angina pectoris who underwent BMIPP and thallium SPECT be‐
fore and after coronary intervention (Fig 5).
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These findings indicates that BMIPP imaging can detect prolonged metabolic abnormali‐
ty or stunning in patients with acute chest pain up to 2 days after cessation of symptom.
In  patients  with  unstable  angina,  discordant  BMIPP uptake  less  than  thallium has  also
been observed frequently [66-69]. In patients with unstable angina without prior myocar‐
dial infarction, comparison of BMIPP image and stress thallium scan performed after sta‐
bilization  of  their  condition  demonstrated  that  BMIPP  decrease  was  associated  with
stress perfusion abnormality in 44 of 57 (77%) segments and degree of BMIPP reduction
correlated with the degree of perfusion abnormality at stress,  degree of wall motion ab‐
normality, and severity of coronary artery stenosis [66]. In another study in patients with
unstable  angina  after  medication  and  elimination  of  chest  pain  disclosed  that  patients
with abnormal BMIPP uptake had more severe coronary artery stenosis and more collat‐
eral  opacification  than  patients  without  BMIPP  abnormality.  In  addition,  revasculariza‐
tion was performed in 82% of patients with abnormal BMIPP images, while in only 22%
of patients  with normal  BMIPP images,  accordingly,  BMIPP imaging may be helpful  in
decision-making regarding interventional  treatment [68].  These findings indicate that  re‐
duced BMIPP uptake in patients with unstable angina may represent persistent metabol‐
ic  abnormality  reflecting  prior  severe  ischemia  or  repetitive  ischemic  insults,  thus  the
concept  of  ischemic  memory  imaging  could  be  extended  and  applied  to  these  patients
population. In other words, BMIPP imaging could extend time window for detecting pre‐
vious ischemic event after the resolution of perfusion abnormality.
5.3. Chronic stable coronary artery disease
In  chronic  stable  coronary artery  disease  even without  history of  myocardial  infarction,
discordant BMIPP uptake less than perfusion tracer is also a common finding. Compari‐
son of BMIPP and stress-reinjection thallium SPECT in 45 patients with chronic coronary
artery disease demonstrated that most of the segments (118/124) with discordant BMIPP
uptake less than reinjection-thallium were associated with demand ischemia indicated by
reversible thallium defects [70]. When reversible thallium defects were analyzed, approxi‐
mately  half  of  the  segments  evidenced  discordant  BMIPP  uptake  less  than  reinjection
thallium.  On  the  other  hand,  around  80%  of  the  segments  with  fixed  thallium  defects
demonstrated  concordant  reduction  of  both  tracers,  suggesting  myocardium  with  re‐
duced or poor viability has metabolic abnormality similar to the degree of resting perfu‐
sion  abnormality.  When  reversible  thallium  defects  were  analyzed  with  respect  to  the
evidence of discordant BMIPP uptake less than thallium and regional wall motion abnor‐
mality, wall motion was more severely impaired in the segments with discordant BMIPP
uptake less than thallium than those without such discordance in both subset of patients
with and without old myocardial infarction. However, severity of coronary artery steno‐
sis  was similar  in the vascular  teritory with discordant BMIPP uptake less  than reinjec‐
tion  thallium  and  those  without  such  discordance.  Comparison  of  BMIPP  and  stress-
redistribution-reinjection  thallium  imaging  in  55  patients  with  stable  coronary  artery
disease revealed that discordant BMIPP uptake less than thallium was observed in only
37% of the segments with thallium redistribution after exercise, on the contrary, such dis‐
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cordance was observed in 82% of the segments with no redistribution but new fill-in af‐
ter thallium reinjection [71].  In addition,  such discordance was observed in only 19% of
the  segments  with  fixed  defects.  Previous  studies  with  stress-redistribution-reinjection
thallium demonstrated that the myocardium with new fill-in after thallium reinjection is
characterized as severely ischemic but viable myocardium with frequent wall motion ab‐
normalities  that  may recover  after  revascularization [72,73].  Accordingly,  these  observa‐
tion may indicate  that  discordant  BMIPP uptake less  than thallium is  suggestive  of  the
myocardium jeopardized by more severe ischemia.
The concept of ischemic memory imaging of BMIPP has been tested in 32 patients with exer‐
cise-induced ischemia on thallium SPECT. BMIPP imaging at rest within 30 hrs of ischemia,
which was induced and confirmed by exercise thallium SPECT, revealed reduction of
BMIPP uptake corresponding to the ischemic area detected by stress thallium study in more
than 90 % of patients [50]. Therefore, the authors concluded that BMIPP can identify sus‐
tained metabolic abnormality as a ischemic memory imaging at least until 30 hrs after stress
induced ischemic episodes. This finding was complemented by the studies assessing glucose
metabolism in patients undergoing exercise testing using FDG. Those have shown that a
metabolic switch from fatty acid to glucose use occurs promptly when myocardial ischemia
is induced during exercise and this metabolic switch to glucose may persist for 24hours, de‐
spite restoration of blood flow at rest [74,75].
Accumulated data in patients with chronic ischemic heart disease in Japan, however, dem‐
onstrated that reduced BMIPP uptake was frequently observed independent of prior radio‐
nuclide and ECG stress tests but related to severe ischemia and wall motion abnormality,
raise the possibility that BMIPP reduction reflects the substrate shift from fatty acid to glu‐
cose as a results of repeated myocardial ischemia rather than reflecting the single episode of
metabolic stunning. Myocardium exposed to repetitive ischemia or stunning is subsequently
adapted metabolically (metabolic remodeling) into chronic ischemic myocardium, so called
hibernation [76-78]. In hibernating myocardium, energy substrate is shifted from fatty acid
to glucose, contractility is impaired but with recruitable inotropic reserve, and myocardial
flow reserve is severely impaired. In relation to this issue, relationship between BMIPP up‐
take and absolute myocardial blood flow by PET was investigated in patients with chronic
stable angina without previous myocardial infarction. The results demonstrated that rest
myocardial blood flow was preserved independent of BMIPP uptake. However, hyperemic
myocardial blood flow was decreased in the area with reduced BMIPP uptake, resulting in
the severity of impaired myocardial flow reserve correlated to the reduction of BMIPP up‐
take [79]. Thus, reduced BMIPP uptake implies impaired myocardial flow reserve and may
reflects adaptive substrate shifts or metabolic remodeling in hibernating myocardium. Rep‐
resentative case with stable angina pectoris who underwent BMIPP and thallium SPECT be‐
fore and after coronary intervention (Fig 5).
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Figure 5. Short axis and horizontal long axis slices of 201Tl, 123I- BMIPP and gated blood pool images. The patient with
angina pectoris underwent thallium and BMIPP SPECT. Discordant BMIPP uptake less than thallium in antero-lateral
wall was observed (arrows). Gated blood pool scintigraphy demonstrated mild hypokinesis in antero-lateral wall.
Stroke volume image showed reduced stroke volume in anterolateral wall (arrow). Coronary angiography showed se‐
vere stenosis of the first diagonal brunch of the left anterior descending coronary artery. Coronary angioplasty was
successfully performed and BMIPP uptake and wall motion abnormality improved 8 month later. The discordant
BMIPP uptake less than thallium depicted the dysfunctional but viable myocardium or hibernating myocardium in an‐
terolateral wall. ED = end-diastolic, ES = end-systolic, PTCA = percutaneous transluminal coronary angioplasty, SV =
stroke volume
5.4. Detection of coronary artery disease
Meta-analysis for the assessment of diagnostic accuracy of BMIPP imaging for the detection
of coronary artery disease was conducted with 7 studies between 1995 and 2004 [80]. A total
of 528 patients with a high prevalence of coronary artery disease who underwent both
BMIPP imaging and coronary angiography were analyzed using a random-effects model.
The overall sensitivity and specificity were 78% (95% confidence interval, 73% to 81%) and
84% (95% confidence interval, 77% to 89%). The summary receiver operating characteristic
curve analysis showed that the area under the curve was 0.91 (SE, 0.020), and the Q* index
was 0.84 (SE, 0.022), indicating excellent diagnostic accuracy. This diagnostic performance is
comparable with stress myocardial perfusion SPECT reported by meta-analysis; a sensitivity
and specificity of 88% and 73%, respectively [81]. Thus, stress SPECT imaging is a more sen‐
sitive test, whereas BMIPP imaging is a more specific test. Unlike stress myocardial perfu‐
sion imaging, BMIPP imaging is obtained without the use of exercise or pharmacologic
agents. Therefore, BMIPP imaging at rest may be an alternative imaging modality for those
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who are unable to perform adequate exercise testing or pharmacologic stress myocardial
perfusion imaging, such as those presenting with acute chest pain and patients with end
stage renal disease with hemodialysis.
5.5. Myocardial viability assessment and prediction of functional recovery
Improvement of  regional  or global  systolic  function can be achieved if  revascularization
of viable myocardium is successfully performed. Therefore,  assessment of residual myo‐
cardial  viability  in  the  setting of  dysfunctional  myocardium due to  significant  coronary
artery disease is a key issue in making clinical decisions with respect to revascularization
procedures.  In  this  respect,  stress  myocardial  perfusion SPECT has  been extensively  in‐
vestigated. The hallmarks of myocardial viability supplied by a stenosed or occluded cor‐
onary artery are the perfusion defect with thallium redistribution on stress-redistribution
or  rest-redistribution  images,  fill-in  of  thallium,  setamibi,  and  tetrofosmin  after  reinjec‐
tion, or significant uptake on resting or reinjection images (usually more than 50-60% up‐
take  of  normal  area).  However,  the  ability  of  perfusion  tracers  to  differentiate  viable
from non-viable myocardium is not completely satisfactory as evidenced by recent viabil‐
ity studies using perfusion tracers [82-84]. In terms of the hallmark of viability in BMIPP
imaging, there are several  substantial  evidences that discordant BMIPP uptake less than
perfusion  tracers  is  a  marker  of  viability;  1)  as  previously  described,  such  mismatch  is
associated  with  ischemic  myocardium  as  evidenced  by  stress  perfusion  studies,  2)  in‐
creased FDG uptake was observed in areas with discordant BMIPP uptake less than thal‐
lium  and  higher  oxidative  metabolism  by11C-acetate  PET  was  observed  in  mismatched
area  than the  area  with  concordant  reduction of  BMIPP and perfusion [85],  3)  myocar‐
dial areas with BMIPP uptake less than sestamibi were more likely to have a positive re‐
sponse to dobutamine than areas with matched defect  [86,87],  4)  histologic  examination
in  patients  with  bypass  surgery  demonstrated  that  BMIPP  uptake  reduction  against  %
fibrosis looked biphasic, with steep reduction of BMIPP uptake within 20% of fibrosis, al‐
though,  thallium  uptake  reduction  correlated  linearly  to  %  fibrosis,  implying  the  areas
with discordant BMIPP uptake less than thallium had less than 20% fibrosis [88].
Functional recovery after revascularization has been investigated in relation to BMIPP up‐
take abnormality in patients with chronic coronary artery disease. Discordant BMIPP uptake
less than thallium could predict functional recovery after revascularization more precisely
than exercise-reinjection thallium study. In addition, the extent of discordance were a good
predictor of global ejection fraction improvement after revascularization [89]. Similarly, area
with discordant BMIPP uptake less than sestamibi measured by quantitative analysis was
highly predictive of improvement of ejection fraction, wall motion and free fatty acid utiliza‐
tion after revascularization [87]. Interestingly, the comparison of FDG, BMIPP, and sestami‐
bi uptake in patients with old myocardial infarction and stable ischemic regional wall
motion abnormalities demonstrated that extent of discordant BMIPP uptake less than FDG
uptake before revascularization highly correlated with ejection fraction improvement after
revascularization (r = 0.74) and also the extent of discordant BMIPP uptake less than sesta‐
mibi correlated significantly with ejection fraction improvement (r = 0.50). However, no sig‐
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angina pectoris underwent thallium and BMIPP SPECT. Discordant BMIPP uptake less than thallium in antero-lateral
wall was observed (arrows). Gated blood pool scintigraphy demonstrated mild hypokinesis in antero-lateral wall.
Stroke volume image showed reduced stroke volume in anterolateral wall (arrow). Coronary angiography showed se‐
vere stenosis of the first diagonal brunch of the left anterior descending coronary artery. Coronary angioplasty was
successfully performed and BMIPP uptake and wall motion abnormality improved 8 month later. The discordant
BMIPP uptake less than thallium depicted the dysfunctional but viable myocardium or hibernating myocardium in an‐
terolateral wall. ED = end-diastolic, ES = end-systolic, PTCA = percutaneous transluminal coronary angioplasty, SV =
stroke volume
5.4. Detection of coronary artery disease
Meta-analysis for the assessment of diagnostic accuracy of BMIPP imaging for the detection
of coronary artery disease was conducted with 7 studies between 1995 and 2004 [80]. A total
of 528 patients with a high prevalence of coronary artery disease who underwent both
BMIPP imaging and coronary angiography were analyzed using a random-effects model.
The overall sensitivity and specificity were 78% (95% confidence interval, 73% to 81%) and
84% (95% confidence interval, 77% to 89%). The summary receiver operating characteristic
curve analysis showed that the area under the curve was 0.91 (SE, 0.020), and the Q* index
was 0.84 (SE, 0.022), indicating excellent diagnostic accuracy. This diagnostic performance is
comparable with stress myocardial perfusion SPECT reported by meta-analysis; a sensitivity
and specificity of 88% and 73%, respectively [81]. Thus, stress SPECT imaging is a more sen‐
sitive test, whereas BMIPP imaging is a more specific test. Unlike stress myocardial perfu‐
sion imaging, BMIPP imaging is obtained without the use of exercise or pharmacologic
agents. Therefore, BMIPP imaging at rest may be an alternative imaging modality for those
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who are unable to perform adequate exercise testing or pharmacologic stress myocardial
perfusion imaging, such as those presenting with acute chest pain and patients with end
stage renal disease with hemodialysis.
5.5. Myocardial viability assessment and prediction of functional recovery
Improvement of  regional  or global  systolic  function can be achieved if  revascularization
of viable myocardium is successfully performed. Therefore,  assessment of residual myo‐
cardial  viability  in  the  setting of  dysfunctional  myocardium due to  significant  coronary
artery disease is a key issue in making clinical decisions with respect to revascularization
procedures.  In  this  respect,  stress  myocardial  perfusion SPECT has  been extensively  in‐
vestigated. The hallmarks of myocardial viability supplied by a stenosed or occluded cor‐
onary artery are the perfusion defect with thallium redistribution on stress-redistribution
or  rest-redistribution  images,  fill-in  of  thallium,  setamibi,  and  tetrofosmin  after  reinjec‐
tion, or significant uptake on resting or reinjection images (usually more than 50-60% up‐
take  of  normal  area).  However,  the  ability  of  perfusion  tracers  to  differentiate  viable
from non-viable myocardium is not completely satisfactory as evidenced by recent viabil‐
ity studies using perfusion tracers [82-84]. In terms of the hallmark of viability in BMIPP
imaging, there are several  substantial  evidences that discordant BMIPP uptake less than
perfusion  tracers  is  a  marker  of  viability;  1)  as  previously  described,  such  mismatch  is
associated  with  ischemic  myocardium  as  evidenced  by  stress  perfusion  studies,  2)  in‐
creased FDG uptake was observed in areas with discordant BMIPP uptake less than thal‐
lium  and  higher  oxidative  metabolism  by11C-acetate  PET  was  observed  in  mismatched
area  than the  area  with  concordant  reduction of  BMIPP and perfusion [85],  3)  myocar‐
dial areas with BMIPP uptake less than sestamibi were more likely to have a positive re‐
sponse to dobutamine than areas with matched defect  [86,87],  4)  histologic  examination
in  patients  with  bypass  surgery  demonstrated  that  BMIPP  uptake  reduction  against  %
fibrosis looked biphasic, with steep reduction of BMIPP uptake within 20% of fibrosis, al‐
though,  thallium  uptake  reduction  correlated  linearly  to  %  fibrosis,  implying  the  areas
with discordant BMIPP uptake less than thallium had less than 20% fibrosis [88].
Functional recovery after revascularization has been investigated in relation to BMIPP up‐
take abnormality in patients with chronic coronary artery disease. Discordant BMIPP uptake
less than thallium could predict functional recovery after revascularization more precisely
than exercise-reinjection thallium study. In addition, the extent of discordance were a good
predictor of global ejection fraction improvement after revascularization [89]. Similarly, area
with discordant BMIPP uptake less than sestamibi measured by quantitative analysis was
highly predictive of improvement of ejection fraction, wall motion and free fatty acid utiliza‐
tion after revascularization [87]. Interestingly, the comparison of FDG, BMIPP, and sestami‐
bi uptake in patients with old myocardial infarction and stable ischemic regional wall
motion abnormalities demonstrated that extent of discordant BMIPP uptake less than FDG
uptake before revascularization highly correlated with ejection fraction improvement after
revascularization (r = 0.74) and also the extent of discordant BMIPP uptake less than sesta‐
mibi correlated significantly with ejection fraction improvement (r = 0.50). However, no sig‐
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nificant correlation was observed between the area with discordant FDG uptake more than
sestamib and ejection fraction recovery [90]. The results are quite intuitive because, in ische‐
mic and viable myocardium, substrate shift from fatty acid to glucose would take place,
hence, mismatch of FDG and BMIPP uptake should be prominent but mismatch between
BMIPP and sestamibi might be modest. These data suggest that discordant BMIPP uptake
less than perfusion may represent reversible ischemic myocardial injury or hibernating my‐
ocardium and that the regional and global dysfunction will improve after revascularization
in patients with chronic stable coronary artery disease. Metabolic stunning is also a good
marker of functional recovery. In acute myocardial infarction with emergency revasculariza‐
tion, BMIPP and tetrofosmin mismatch around 1 week after the revascularization predicted
recovery of ejection fraction and wall motion 3 month later [91,92].
5.6. Risk stratification and prediction of the prognosis
Assessment of prognostic value of BMIPP imaging over perfusion tracers in patients with
coronary artery disease is a matter of clinical importance. The initial study for the assess‐
ment of prognostic implications of BMIPP imaging was conducted in 50 consecutive pa‐
tients with myocardial infarction with a mean follow up period of 23 months [93]. During
the follow-up period, 9 patients had cardiac events; 8 of the 9 patients with cardiac events
showed discordant BMIPP uptake less than reinjection thallium, whereas only 20 of 41 pa‐
tients without cardiac events showed such mismatch. When all the clinical and radionuclide
variables were analyzed by Cox regression analysis, presence of discordant BMIPP uptake
was the best, and an independent, predictor of future cardiac events followed by the num‐
ber of coronary artery stenosis. BMIPP and thallium imaging performed within 1 month of
acute myocardial infarction demonstrated that impaired BMIPP uptake and mismatched
BMIPP uptake less than thallium are related to a high probability of fatal and non-fatal car‐
diac events [94] and the defect score of BMIPP and mismatched BMIPP uptake less than
thallium provided incremental predictive value for future cardiac events [95,96].
In the patients with chronic stage of myocardial infarction, clinical value of BMIPP imaging
for predicting prognosis is also demonstrated. BMIPP imaging performed before revascula‐
rization in 76 patients with chronic stable ischemia (including 61 patients with myocardial
infarction after at least 3 month of onset) with left ventricular dysfunction has been analyzed
[97]. Patients with large amount of discordant BMIPP uptake less than thallium demonstrat‐
ed greater ejection fraction improvement after revascularization and, interestingly, showed
significantly better event free survival than patients with small amount or no perfusion and
metabolic mismatch. These data indicate that patients with significant amount of discordant
BMIPP uptake less than thallium may benefit from revascularization.
In chronic coronary artery disease without old myocardial infarction, value of BMIPP imag‐
ing for risk stratification has been also demonstrated. In 270 patients, BMIPP defect score
was analyzed with respect to cardiac event during a median follow-up of 3.9 years [98]. Ka‐
plan-Meier survival estimates revealed that patients with a summed BMIPP defect score
lower than 5 showed a better prognosis than the patients with more defect of BMIPP (a hard
event-free survival rate at 3 years: 98% vs 93% (P = 0.03), all event-free survival rate at 3
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years: 92% vs 80% (P = 0.0003), respectively). More importantly, BMIPP was able to select a
high-risk subgroup among patients with diabetes mellitus as well as non-diabetic patients,
with 41% event rate in diabetic patients with BMIPP defect score 5 or more but only 4%
event rate in non-diabetic patients with BMIPP defect score lower than 5.
One of the strength of BMIPP imaging in daily clinical use is its simplicity since it offers
metabolic information without stress procedure. It is a matter of great interest whether rest‐
ing BMIPP imaging offers complementary or additional prognostic information to that pro‐
vided conventional stress perfusion imaging. One hundred and sity-seven consecutive
patients with angina pectoris but without prior myocardial infarction who had undergone
both BMIPP and stress thallium imaging were followed up for 48 months [99]. For overall
cardiac events (5 hard and 29 soft events), multivariate Cox’s analysis revealed that reduced
BMIPP uptake, stress perfusion score, diabetes, and left ventricular ejection fraction were
the significant predictors. No hard event was observed with normal BMIPP uptake, whereas
2 patients with nearly normal stress perfusion with impaired BMIPP uptake had a hard
event. The authors concluded that resting BMIPP imaging may provide significant prognos‐
tic information independent of stress myocardial perfusion imaging.
Recently meta-analysis on the prognostic value of BMIPP imaging in acute coronary syn‐
drome,  acute  myocardial  infarction,  and  stable  coronary  artery  disease  was  reported
[100].  In 3  studies  involving 541 patients  with suspected acute coronary syndrome who
were excluded for  acute  myocardial  infarction,  an abnormal  finding on BMIPP imaging
significantly  associated  with  future  hard  cardiac  events,  defined  as  cardiac  death  and
non-fatal  myocardial  infarction.  The negative predictive value of BMIPP imaging for fu‐
ture hard and soft events were 98.9% and 92.3% over 3.5 years, respectively. In 6 studies
which comprised 607 patients  with acute myocardial  infarction,  larger  defect  on BMIPP
imaging  was  significantly  associated  with  cardiac  death  and  hard  events  with  relative
risk  of  2.81  and  3.87,  respectively.  Two studies  included  166  patients  with  stable  coro‐
nary artery disease who underwent elective revascularization. Both studies evaluated the
prognostic value of mismatched BMIPP uptake less than perfusion, and showed contrast‐
ing  results  depending on the  timing of  BMIPP imaging to  relative  to  revascularization.
The  presence  of  mismatched  myocardium  before  revascularization,  which  suggested  a
jeopardized but viable myocardium, is  associated with fewer events  if  patients  undergo
successful  revascularization.  However,  the mismatch occurs after  revascularization,  indi‐
cating residual ischemia, the more hard events occur.
5.7. Chronic kidney disease
In chronic kidney disease (CKD), cardiovascular disease accounts for most of the morbid‐
ity  and  mortality  in  both  pre-dialysis  and  after  the  onset  of  end  stage  renal  disease.
Stress  myocardial  perfusion imaging has  become increasingly  recognized as  a  powerful
prognostic  tool  for  cardiovascular  outcomes  in  patents  with  known  or  suspected  coro‐
nary artery disease.  Abnormal stress myocardial  perfusion scan is  more common in pa‐
tients  with  CKD  and  stress  perfusion  imaging  is  confirmed  as  a  powerful  tool  for
predicting outcomes across entire spectrum of renal dysfunction. At the same time, pres‐
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ence of CKD itself  added prognostic value to perfusion imaging [101].  While stress per‐
fusion imaging is valuable method to assess coronary artery disease, stress test may not
be suitable for substantial number of CKD patients, especially in end stage renal disease.
Because  an  inability  to  exercise  enough due  to  multiple  comorbidity  including  obesity,
arthritis,  and deconditioning etc,  and suboptimal vasodilator stress testing due to an in‐
complete  vasodilator  response  due  to  endothelial  dysfunction.  In  this  context,  BMIPP
imaging can be performed safely and effectively at rest to detect metabolic alteration due
to ischemia without stress testing.
In addition to the high prevalence of coronary artery disease in patients with CKD, several
sequelae of renal failure also contribute to left ventricular metabolic remodeling, so-called
uremic cardiomyopathy. In this condition, myocyte capillary mismatch, with diminished
vascular supply relative to the number and volume of functioning myocytes is observed
[102,103]. These epicardial and microvascular disorder should induce ischemia when car‐
diac demand increases. For the detection of coronary artery disease in asymptomatic pa‐
tients undergoing hemodialysis, dual isotope SPECT with thallium and BMIPP was
investigated [104]. Significant coronary stenosis (>75%) was found in 72% of patients
(93/130). When a BMIPP summed score of 6 or more was defined as abnormal, sensitivity,
specificity, and accuracy for detecting coronary artery disease by BMIPP SPECT were 98.0%,
65.6%, and 90.0%, respectively. For the assessment of prognostic value of BMIPP in patients
with hemodialysis, 318 asymptomatic patients without prior myocardial infarction under‐
went dual isotope SPECT with thallium and BMIPP [105]. During a mean follow up period
of 3.6 ± 1.0 years, 50 died of cardiac event. Kaplan-Meier analysis showed that the cardiac
death-free survival rates at 3 years were 61% and 98% in patients with BMIPP summed
scores of >12 and <12, respectively. When the cutoff value of BMIPP–Tl mismatch score, a
marker of ischemia, was determined to be 7, the sensitivity and specificity of BMIPP–Tl mis‐
match for predicting cardiac death were 86% and 88%, respectively. Kaplan-Meier survival
estimates revealed that the event-free rates of cardiac death at 3 years were 53% in patients
with BMIPP–Tl mismatch of > 7, whereas 96% in patients with BMIPP–Tl mismatch < 7.
These finding suggested that significantly impaired myocardial fatty acid metabolism de‐
tected by BMIPP SPECT might predict the occurrence of cardiac death in asymptomatic he‐
modialysis patients. In addition, in patients with hemodialysis and complete coronary
revascularization, BMIPP imaging abnormality and BMIPP thallium mismatch can also pre‐
dict cardiac death [106]. Further more, prospectively enrolled 155 patients receiving hemo‐
dialysis after angiography had confirmed the absence of obstructive coronary lesions were
examined by BMIPP SPECT [107]. During a mean follow-up of 5.1 years, 42 patients died of
cardiac events. Stepwise Cox hazard analysis demonstrated that cardiac death asscociated
with reduced BMIPP uptake and increased insulin resistance. Thus, impaired myocardial
fatty acid metabolism and insulin resistance may be associated with cardiac death among
hemodialysis patients without obstructive coronary artery disease.
Accordingly, in patients with high risk CKD, BMIPP imaging at rest is highly valuable in
terms of the assessment of the myocardial metabolic abnormality, stratifying the patient’s
risk, and predicting cardiac death.
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6. Summary and conclusions
In normal condition approximately two-thirds or more of the total energy produced by my‐
ocardium is derived from fatty acid oxidation and myocardial substrates may change signif‐
icantly in various pathological conditions such as ischemia. Accordingly, many fatty acid
tracers for SPECT imaging have been introduced. Until now, 123I-BMIPP, one of the methyl
branched fatty acid analogues, is the only approved fatty acid tracer for daily clinical use.
The concept of BMIPP imaging is metabolic trapping, like FDG, by inhibiting β-oxidation by
introducing methyl branching at β-carbon position. Myocardial BMIPP uptake more likely
reflects activation of BMIPP into BMIPP-CoA with consumption of ATP, thus the uptake in‐
directly reflects cellular ATP production by fatty acid metabolism. Under the condition of
ischemia, the reduction of BMIPP uptake is observed by reflecting the reduction of ATP pro‐
duction due to depressed oxidative fatty acid metabolism and substrate shift from fatty
acids to glucose. Reduced uptake of BMIPP at rest is often observed in ischemic myocardi‐
um independent of the uptake of perfusion tracers, that is, discordant or mismatched BMIPP
uptake less than perfusion tracers. Through comparison with perfusion, BMIPP image can
detect previous myocardial ischemia as an ischemic memory imaging (stunned myocardium
or status of metabolic stunning) and viable but chronically dysfunctional myocardium (hi‐
bernating myocardium or status of metabolic remodeling). In addition, BMIPP image may
offer incremental prognostic information in ischemic heart diseases. Through the basic and
clinical studies, it has become clear that BMIPP imaging has a high potential utility in the
entire spectrum of ischemic heart diseases in evaluating the patients with acute chest pain,
acute myocardial infarction, unstable angina pectoris, chronic stable coronary artery diseas‐
es, in terms of diagnosis, risk stratification, and also for the prediction of prognosis.
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Cardiovascular disease (CVD) is ranked as the leading cause of death world wide, 
responsible for 17.1 million deaths globally each year. Such numbers are often difficult 
to comprehend. A coronary even occurs every 25 seconds and CVD kills one person 
every 34 seconds. 35 people under 65 years of age die prematurely every day due to 
CVD. The incidence of CVD has declined in recent years due to a better understanding 
of the pathology, implementation of lipid lowering therapy, new drug regimens and 
advances in acute surgical intervention. The disease burden has a great financial 
impact on global healthcare systems and major economic consequences for world 
economies. This text reviews the epidemiology, development, risk factors, diagnosis 
and treatment of ischemic heart disease.
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